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SUMMARY 
In the first chapter we have developed an enantioselective copper-catalyzed 
desymmetrization of meso-cyclobutenes for the synthesis of enantiomerically 
enriched cyclobutylboronates. This was the first catalytic enantioselective 
synthesis of this family of compounds. Through this methodology we have 
prepared a broad scope of cyclobutanes with high levels of diastereo- and 
enantioselectivity with up to four stereogenic centers.We have also developed 
some strategies to synthetize useful synthetic intermediates from the 
cyclobutylboronates.  
In the second chapter of this Doctoral Thesis we have developed a 
stereospecific copper-catalyzed substitution reaction of propargylic 
ammonium salts with aryl Grignard reagents. The reaction was completely -
regioselective and stereospecific. Also, the functional group tolerance of the 
reaction is excepcional. In addition, no added ligand was needed, and we 
simply used an inexpensive copper salt. In the second part of this chapter, we 
developed a strategy for the synthesis of enantiomerically enriched allenes 
using alkyl Grignard reagents instead of aryl Grignard reagents. With this 
strategy we bypassed the problem of the allene racemization when alkyl 
magnesium halides are used.  
In the last chapter of this thesis, we have developed a new methodology for 
the allyl-allyl cross-coupling reaction between allylic carbonates or 
ammonium salts and allyl boronates. The reaction was completely 
regioselective and stereospecific and we have observed complete inversion in 
the configuration of the chiral center.  We have also developed strategies for 
the selective functionalization of the different double bonds 
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RESUMEN 
En el segundo capítulo, se ha desarrollado el primer método 
enantioselectivo catalizado por cobre para la desimetrización de ciclobutenos, 
logrando la síntesis de ciclobutilboronatos quirales. Esta metodología fue la 
primera catalítica enantioselectiva de esta clase de compuestos. Los 
ciclobutilboronatos obtenidos presentaron altos niveles de diastereo- y 
enantioselectividad con hasta 4 centros estereogénicos en la molécula. 
También desarrollamos métodos para sintetizar valiosos intermedios sintéticos 
a partir de los productos obtenidos. 
En el tercer capítulo de la presente Tesis Doctoral hemos desarrollado una 
metodología para la sustitución nucleófila estereoespecífica con reactivos de 
Grignard arílicos de sales de amonio propargílicas catalizada por cobre. La 
reacción fue completamente regioselectiva y enantioespecífica. Además, la 
reacción presento una alta compatibilidad con diversos grupos funcionales sin 
la necesidad de añadir un ligando. En la segunda parte de este capítulo, 
utilizamos esta estrategia para la síntesis de alenos enantioméricamente 
enriquecidos usando reactivos de Grignard alquílicos en lugar de arílicos. 
Mediante esta estrategia conseguimos evitar la racemización que presentan 
este tipo de reacciones. 
En el último capítulo de esta Tesis Doctoral, hemos desarrollado una nueva 
metodología para el acoplamiento alilo-alilo entre carbonatos o sales de 
amonio alílicas y boronatos alílicos. La reacción fue completamente 
regioselectiva y enantioespecífica y observamos una inversión completa del 
centro quiral. También, hemos desarrollado estrategias para la 
funcionalización selectiva de los diferentes dobles enlaces que se forman en la 
reacción. 
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1. INTRODUCTION 
Chirality is defined as “The geometric property of a rigid object (or spatial 
arrangement of points or atoms) of being non-superposable on its mirror 
image; such an object has no symmetry elements of the second kind (a mirror 
plane, σ = S1, a centre of inversion, i = S2, a rotation-reflection axis, S2n). If the 
object is superposable on its mirror image the object is described as being 
achiral”.1 A French chemist and biologist known as Louis Pasteur discover 
chiral chemistry when he separated by hand the two enantiomers of sodium 
ammonium tartrate in 1848.2 An easy example of a chiral molecule could be 
the aminoacid alanine (Figure 1-1). These molecules are enantiomers and they 
have identical chemical and physical properties. However, if they are in a chiral 
environment there could be important differences in their properties. 
 
 
Figure 1-1: Mirror images of aminoacid alanine. 
 
Life depends on chiral recognition, because the interaction between living 
systems and enantiomers are usually different. Metabolic processes and 
biological responses occur because enzymes or other natural binding places 
 
1 McNaught, A.D.; Wilkinson, A. IUPAC, Compendium of Chemical Terminology, 2nd ed. 
Blackwell Scientific Publication, Oxford, 1997. 
2 Challener CA. Overview of chirality. In: Chiral drugs. 1st ed. Ashgate Publisher. Aldershot, 
2001; pp. 3-14. 
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only recognize a specific molecular geometry. This differences in the 
properties of two enantiomers in a chiral environment are the reason why 
asymmetric synthesis has become a main field inside organic chemistry during 
the last decades. Around 60% of the commercial drugs have at least one 
stereogenic center in their structure and sometimes the configuration of this 
center has a critical effect in the pharmaceutical properties of the drug. 
Pharmaceutical control agencies compel pharmaceuticals companies to 
synthetize all the possible stereoisomers of a drug to test for possible side effect 
and to determine which isomer is the biologically active.3 The case of 
Thalidomide is well-known because it caused ten thousand infants to born with 
limbs malformations between 1957 and 1963. Only half of them survived. The 
problem was that thalidomide was sold as a racemate, and one of the 
enantiomers did treat nauseas and morning sickness in pregnant women but the 
other one is a teratogenic agent and cause phocomelia in the babies. 
Dextropropoxyphene is a well-known analgesic, but his enantiomer is an 
anticough drug.4  
However, stereoisomers are not only important in the pharmaceutical field. 
(S)-carvone smells like caraway, but its enantiomer smells like spearmint, so 
this fact is really important for perfumes manufactures (Figure 1-2).3 
 
 
3 Nguyen, L.A.; He, H.; Pham-Huy, C. Int. J. Biomed. Science 2006, 85-100. 
4 Drayer, D.E. Clin. Pharmacol. Ther. 1986, 40, 125. 
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Figure 1-2: Different properties of enantiomers. 
 
There are two main methodologies to obtain enantiopure compounds. 
Traditionally, enantiomerically enriched compounds were obtained through 
the separation of both enantiomers from the corresponding racemate. This was 
achieved either by crystallization or kinetic resolution (Scheme 1-1¡Error! No 
se encuentra el origen de la referencia.).  
 
 
Scheme 1-1:Resolution of a racemate to obtain an enantiomerically 
enriched compound. 
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More recently, the advances in chiral chromatography allows for the 
separation of enantiomers by different techniques, as high-pressure liquid 
chromatography (HPLC) or gas chromatography (GC).5 However, the 
separation of the racemate, implies that at least 50% of the compound is lost. 
Because of this fact, asymmetric synthesis has arisen in the last decades as the 
preferred methodology to obtain enantiomerically enriched compounds. 
Asymmetric synthesis is a method for preparation of chemical compounds 
which aims to bias the synthesis in favor of producing one stereoisomer over 
another stereoisomer. Diastereomeric transition states must occur during the 
formation of the product in order to produce a different rate of reaction for the 
different stereoisomers. To form this diastereomeric transition states, a non-
racemic chiral compound must be involved in the reaction. This compound 
could be a reagent or a chiral catalyst. We can divide asymmetric catalytic 
synthesis on various groups: 
 
- The substrate is a non-racemic chiral compound. The formation of the 
new formed stereogenic center goes through a diastereomeric transition 
state where the different rates of reaction determine which isomer is 
formed preferentially (Scheme 1-2). In this section are included 
stereospecific reactions and asymmetric induction. By definition, 
stereospecificity is the property of a reaction mechanism that leads to 
different stereoisomeric reaction products from different 
stereoisomeric reactants, or which operates on only one (or a subset) of 
the stereoisomers.6 On the other hand, asymmetric induction describes 
the preferential formation in a chemical reaction of one enantiomer or 
diastereoisomer over the other as a result of the influence of a chiral 
 
5 Donald, T.H.; Bingyun, L. Chiral Drug Separation. In Encyclopedia of Chemical 
Processing. Lee, S. Taylor & Francis, New York, 2007. 
6 Eliel, E., "Stereochemistry of Carbon Compound", McGraw-Hill, 1962 pp 434-436. 
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feature present in the substrate, reagent, catalyst or environment. 
Usually, the removal of the asymmetric inductor is needed after the 
reaction. The main problem of this family of reaction is that an 
stochiometric non-racemic chiral reagent is needed in the reaction. 
 
 
Scheme 1-2: Asymmetric reaction using a non-racemic substrate. 
 
- The reagent is a non-racemic chiral compound. In this case is the 
reagent the one that carries the stereogenic center. This causes that 
diastereomeric transition states are formed and the isomers are formed 
at different rates (Scheme 1-3). This is a very similar case than the 
former one, and any explanation and definition described above, 
applies to this case 
 
 
Scheme 1-3: Asymmetric reaction using a non-racemic reagent. 
 
- Enantioselective catalyzed reactions, which we define as reactions in 
which there is selective formation of one enantiomer over the other as 
defined by a nonracemic chiral catalyst from achiral or racemic 
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substrates. Since the catalyst is not consumed in this process it may be 
used in a substoichiometric quantity potentially improving efficiency 
and avoiding waste. The catalyst could be metal-based catalyst or an 
organocatalyst. The importance of asymmetric catalysis could be 
hihjlighted for the 2011 Nobel Prize to Professors William R. Knowles 
and Ryoji Noyori “for their work on chirally catalyzed hydrogenation 
reactions” and K. Barry Sharpless “for their work on chirally catalyzed 
oxidation reactions” (Scheme 1-4). 
 
 
Scheme 1-4: Enantioselective catalyzed reactions. 
 
- Enantioselective catalyzed desymmetrization, which we defined as 
reaction where a prochiral starting material (meso-compound) is 
desymmetrized. The new bond formation is used to break the symmetry 
through a process controlled by the chiral catalyst (Scheme 1-5). I will 
detail this in the next section. 
 
 
Scheme 1-5: Catalized desymmetrization reactions. 
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A comprehensive review of the literature regarding asymmetric synthesis 
exceeds the scope of the introduction of this chapter. Therefore, only a brief 
section about metal catalyzed desymmetrization reactions will be explained. 
 
1.1. Metal-Catalyzed Desymmetrization Reactions. 
The first project of the present doctoral Thesis is the copper-catalyzed 
desymmetrization of meso-cyclobutenes. A meso molecule is defined as “an 
achiral member(s) of a set of diastereomers which also includes one or more 
chiral members”.7 Unlike prochiral compounds, they contain pairs of chiral 
elements, but remain achiral due to the existence of a symmetry element 
(Figure 1-3). 
 
 
Figure 1-3: Symmetry elements in meso-compounds. 
In a synthetic sequence, chiral compounds usually constitute the most 
expensive reagents. Therefore, the use of stochiometric amounts of 
enantiomerically enriched substrates or reagents is unfavored. Enantioselective 
catalysis solves this problem using only small amounts of the chiral component 
in the reaction. The use of meso-compounds in enantioselective catalytic 
desymmetrization reactions allows for the preparation of molecules with 
several stereogenic centers in only one step of synthesis.  
 
7 Moss, G. P. Pure Appl. Chem. 1996, 68, 2193-2222. 
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The desymmetrization step could be achieved by the use of enzymes8 or 
organocatalysis9 but in the following pages we will explain some illustrative 
examples of metal-catalyzed desymmetrizations.10 
In 2002, Overman and coworkers reported a concise synthesis of 
quadrigemine C.11 As key step of the synthesis they proposed a 
desymmetrization of a complex meso intermediate II-1. The strategy consisted 
in a double intramolecular heck reaction catalyzed by a palladium chiral 
complex (Scheme 1-6). 
 
 
8 For a review see: Garcia-Urdiales, E.; Alfonso, I.; Gotor, V. Chem. Rev. 2011, 111, PR110-
PR180. For illustrative examples in total synthesis see: a) Baran, P. S.; Li, K.; O’Malley, D.P.; 
Mitsos, C. Angew. Chem. Int. Ed. 2006, 45, 249-252. b) Göksel, H.; Stark, C.B.W. Org. Lett. 
2006, 8, 3433-3436. c) Candy, M.; Audran, G.; Bienaymé, H.; Bressy, C.; Pons, J.M. J. Org. 
Chem. 2010, 75, 1354-1359. 
9 For a review see: Borissov, A.; Davies, T.Q.; Ellis, S.R.; Fleming, T.A.; Richardson, M.S.W.; 
Dixon, D.J. Chem. Soc. Rev. 2016, 45, 5474-5540. For illustrative examples in total synthesis 
see: a) Chandler, C. L.; List, B. J. Am. Chem. Soc. 2008, 130, 6737-6739. b) Merad, J.; Borkar, 
P.; Bouyon-Yenda, T.; Roux, C.; Pons, J.M.; Parrain, J.L.; Chuzel, O.; Bressy, C. Org. Lett. 
2015, 17, 2118-2121. 
10 For a review see: a) Ward, R.S. Chem. Soc. Rev. 1990, 19, 1-19. b) Poss, C.S.; Schreiber, 
S.T. Acc. Chem. Res. 1994, 27, 9-17. c) Zeng, X.P.; Cao, Z.Y.; Wang, Y.H.; Zhou, F.; Zhou, J. 
Chem. Rev. 2016, 116, 7330-7396. d) Merad, J.; Candy, M.; Pons, J.M.; Bressy, C. Synthesis 
2017, 49, 1938-1954. 
11 Lebsack, A.D.; Link, J.T.; Overman, L.E.; Stearns, B.A. J. Am. Chem. Soc. 2002, 124, 9008-
9009. 
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Scheme 1-6: Desymmetrization step in the total synthesis of Quadrigemine 
C. 
 
In 2007, Lautens and coworkers reported the very first enantioselective 
synthesis of (+)-homochelidone.12 The key step of the synthesis was the 
enantioselective ring opening of the meso compound I-3 by cross-coupling 
with boronic acid I-4 using a chiral palladium complex (Scheme 1-7). 
 
 
Scheme 1-7: Palladium catalyzed desymmetrization in the synthesis of 
(+)-homochelidone. 
 
 
 
12 McManus, H.; Fleming, M.J.; Lautens, M. Angew. Chem. Int. Ed. 2007, 46, 433-436. 
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2. SYNTHESIS OF CYCLOBUTYLBORONATES. 
2.1.  Background. 
2.1.1. General Overview of Organoboron Compounds. 
Located in the fifth position of the periodic table, boron has a ground 
state electron configuration of 1s22s22p1 and therefore three valence 
electrons. Commonly, boron forms trivalent neutral compounds with and 
empty p-orbital. This kind of compounds are electron deficient, and as 
boron is sp2 hybridized, are isoelectronic with carbocations (Figure 2-1).1 
 
 
Figure 2-1: General structure of organoboron compounds. 
 
Organoboron compounds present a C-B bond in their structure. They 
must be synthetized in the laboratory, because C-B bonds do not exist in 
nature. It was mid XIX century when Frankland and Duppa,2 synthetized 
and isolated the first boronic acids, although organoboron compounds were 
not used until much later.  
 
1 Ingleson, M. J. Fundamental and Applied Properties of Borocations. En Synthesis and 
Application of Organoboron Compounds; Fernández, E., Whiting, A. Ed.; Springer 
International Publishing: Switzerland, 2015; pp 39-71.   
2 a) Frankland, E.; Duppa, B. F. Justus Liebigs Ann. Chem. 1860, 115, 319-322; b) 
Frankland, E.; Duppa, B. F. Proc. R. Soc. Lond. 1860, 10, 568-570; c) Frankland, E.; Duppa, 
B. F. J. Chem. Soc. 1862, 15, 363-381.   
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In the early XX century, Alfred Stock developed a series of vacuum 
techniques to prepare the very first boron hydrides, starting off the field of 
borane chemistry. They synthetize B2H6, B4H10, B5H9 and B6H10, which 
proved to be volatile and explosive.3 In 1972, fascinated by the nature of 
these compounds, Lipscomb studied by X-ray diffraction the structure of 
boranes, developing a new theory of chemical bonding, essential to 
understand the nature of boranes. His work was recognized with the Nobel 
Prize in 1976.4  
But it was the organic chemistry community the one that developed the 
first useful applications of organoboron compounds and also, take the 
challenge of developing boron chemistry. In 1956, Professor Herbert C. 
Brown published the very first hydroboration of alkenes.5 After the 
discovery of the so called “Brown Hydroboration”, a large number of 
reactions using organoboron compounds have been reported. In 1961, 
Brown also established one of the bases of asymmetric synthesis 
succeeding in the hydroboration of different olefins with 
diisopinocampheylborane. At that time, the stereoselectivities obtained in 
this reaction were only paired with some enzymatic processes (Scheme 
2-1).6  
 
 
 
 
 
3 Stock, A.; Massenez, C. Eur. J. Inorg. Chem. 1912, 45, 3539-3568.   
4 Lipscomb, W. N. Pure. Appl. Chem. 1972, 29, 493-511. 
5 a) Brown, H. C.; Subba Rao, B. C. J. Am. Chem. Soc. 1956, 78, 5694-5695. (b) Wang, 
Z. Brown Hydroboration. In Comprehensive Organic Name Reactions and Reagents; John 
Wiley & Sons: Hoboken, 2009; pp 536-543. 
6 Brown, H. C.; Zweifel, G. J. Am. Chem. Soc. 1961, 83, 486-487. 
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Scheme 2-1: First asymmetric hydroboration of alkenes. 
 
Professor Brown’s career was devoted to boron chemistry. He 
developed a large number of methodologies for the synthesis of C-B bonds, 
a highly versatile bond, which can be converted into C-O, C-N, C-C or C-
X bond afterwards.7 Herbert C. Brown was awarded with the Nobel Prize 
in Chemistry in 1979 for his contributions to this field.   
In the 70’s, with the development of palladium catalyzed cross-coupling 
reaction, several groups were trying to take advantage of the facile synthesis 
of alkenyl boranes from alkynes, to use them in cross-coupling reactions. 
But it was not until 1979, when Professor Akira Suzuki realized that organic 
groups in organoboranes have weak carbanion character. Because of this 
character, transmetalation between organoboranes and palladium 
complexes does not occur efficiently. He notice that, if organoborates, 
obtained from organoboranes and a base, were used instead, 
transmetalation took place smoothly.8 Afterwards, they realize that boronic 
acids and esters presented several advantages over boranes (Scheme 2-2). 
They are more stable and easier to handle, less polar and less reactive.9 In 
 
7 Brown, H. C. Organic Syntheses via Boranes; Wiley: New York, 1975. 
8 a) Miyaura, N.; Yamada, K.; Suzuki, A. Tetrahedron Lett. 1979, 36, 3437-3440. b) 
Miyaura, N.; Suzuki, A. J. Chem. Soc., Chem. Commun. 1979, 866-867 
9 a) Miyaura, N.; Suzuki, A. Chem. Rev. 1995, 95, 2457-2483. b) Suzuki, A. J. Organomet. 
Chem. 1999, 576, 147-168.  c) Martin, R.; Buchwald, S. L. Acc. Chem. Res. 2008, 41, 1461-
1473. d) Sun, H. Y.; Hall, D. G. At the Forefront of the Suzuki-Miyaura Reaction: Advances 
in Stereoselective Cross-Couplings. In Synthesis and Application of Organoboron 
Compounds; Fernández, E., Whiting, A. Ed.; Springer International Publishing: 
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2010, Professors Richard Heck, EiiChi Negishi and Akira Suzuki were 
awarded with the Nobel Prize of Chemistry for their contribution to cross-
coupling reactions.  
 
 
Scheme 2-2: Suzuki cross-coupling reaction. 
 
In the last two decades, the increasing number of publications about 
boron chemistry, may indicate a reborn of this chemistry. Boron have found 
many interesting applications beyond the organic synthesis field. It plays a 
new role in drug discovery with the approval of anticancer agent Velcade 
® and fungicide Kerydin® (Figure 2-2), the first drugs in the market with 
a boron atom in their structure. Also, boron chemistry is presented in 
polymers,10 nanotubes11 and neutron capture therapy (10B). This renaissance 
of boron chemistry demonstrates that Professor Brown’s words are not old 
 
Switzerland, 2015; pp 221-242. e) Hussain, I.; Capricho, J.; Yawer, M. A. Adv. Synth. Catal. 
2016, 358, 3320-3349. f) Das, P.; Linert, W. Coord. Chem. Rev. 2016, 311, 1-23. g) Almond-
Thynne, J.; Blakemore, D. C.; Prydeb, D. C.; Spivey, A. C. Chem. Sci. 2017, 8, 40-62. h) 
Sydnes, M. O. Catalysts 2017, 7, 35-48. i) Hooshmand, S. E.; Heidari, B.; Sedghi, R.; 
Varma, R. S. Green Chem. 2019, 21, 381-405. 
10 a) Matsumi, N.; Naka, K.; Chujo Y. J. Am. Chem. Soc. 1998, 120, 5112-5113. b) 
Matsumi, N.; Naka, K.; Chujo Y. J. Am. Chem. Soc. 1998, 120, 10776-10777. c) Entwistle, 
C. D.; Marder, T. B. Angew. Chem. Int. Ed. 2002, 41, 2927-2931. d) Brooks, W. L. A.; 
Sumerlin, B. S. Chem. Rev. 2016, 116, 1375-1397. 
11 a) Barth, R. F.; Soloway, A. H.; Brugger, R. M. Cancer Invest. 1996, 14, 534-550. b) 
Yura, Y.; Fujita, Y. Oral Science International 2013, 10, 9-14. 
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fashioned: “a new continent has been discovered – it requires settlers to 
develop its riches to contribute to mankind.” 
 
 
Figure 2-2: Boron-containing drugs in the market. 
 
2.1.2. Boronic Acids and Derivatives. 
Trivalent boron-containing molecules that possess one carbon-based 
substituent and two hydroxyl groups are known as boronic acids and they 
are important intermediates in organic synthesis.12 If instead of two 
hydroxyl groups they have two alkoxides, they are known as boronic esters 
or boronates. The later are generally easier to handle and less polar than 
boronic esters, but they are less reactive. A wide selection of boronic esters 
can be found in organic synthesis. In fact, some of them, bearing a chiral 
alkoxide, can be used as inductors in stereoselective transformations.13 
Among the most widely used boronic esters are ethylenglycol (Beg), 
pinacol (Bpin), neopentylglycol (Bnep), hexyleneglycol (Bheg), pinanediol 
(Bpnd) and cathecol (Bcat) derivatives. Usually, stability of this species 
increases in hindered cyclic boronates as Bpin. A special case is Bcat, 
which is very sensible and prone to hydrolysis. The reason behind this 
behavior is the conjugation between the oxygen atom and the benzene ring. 
 
12 a) Meng, F.; McGrath, K. P.; Hoveyda, A. H. Nature 2014, 513, 367-374. b) Antonio, 
J. P. M.; Russo, R.; Carvalho, C. P.; Cal, P. M. S. D.; Gois, P. M. P. Chem. Soc. Rev. 2019, 
48, 3513-3536. 
13 a) Ramachandran, P. V.; Brown, H. C. Recent Advances in Borane Chemistry. In 
Organoboranes for Syntheses, ACS Symposium Series 783; American Chemical Society: 
Washington, DC, 2001; pp 1-15. b) Matteson, D. S. Tetrahedron 1998, 54, 10555-10607. 
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That confers the boron atom a higher Lewis acidity. Beyond these, recently 
diethanolamine (BDEA) and N-methyliminodiacetic acid (BMIDA) have 
been employed as alternative protecting groups. Moreover, 1,8-
diaminonaphthalene (Bdan) has also been used, providing a less Lewis 
acidic boron atom (Figure 2-3).14  
 
 
Figure 2-3: Most commonly used boronic esters. 
 
The partial donation of the oxygen electron pairs to the empty p-orbital 
of the boron atom confers the B-O bond a partial double bond character and 
thus, making it around 40 Kcal/mol stronger than C-O bond (130 versus 92 
Kcal/mol).15 In boronic esters, with two oxygen atoms attached to the boron 
center, the vacant orbital of boron only can accept one π dative bond, so the 
electronic structure can be explained by two resonance forms (Figure 
2-4).14 
 
 
 
14 Hall, D. G. Boronic Acids: Preparation and Application in Organic Synthesis, Medicine 
and Materials, 2nd ed.; Wiley-VCH: Boston, 2011. 
15 Sana, M.; Leroy, G.; Wilante, C. Organometallics 1991, 10, 264-270. 
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Figure 2-4: Resonance forms of π dative bond intermediates. 
 
Traditional approaches to synthetize boronic esters are based on 
organometallic reagents such as lithium compounds16 or Grignard 
reagents.17 However, the lack of compatibility of these reagents with several 
functional groups make this approach impossible in some cases. It was not 
until 1995 that Professor Miyaura finally solved this problem. He described 
the palladium catalyzed cross-coupling of bis(pinacolato)diboron with aryl 
bromides or iodines, obtaining the correspondent aryl boronates (Scheme 
2-3).18 The Miyaura borylation possesses a broad scope and the 
compatibility of functional groups is no longer an issue. The reaction can 
also be performed with vinyl,19 aryl,20 allyl21 or benzyl22 halides or triflates. 
 
 
 
16 Brown, H. C.; Cole, T. E. Organometallics 1983, 2, 1316-1319.   
17 a) Gilman, H.; Vernon, C. J. Am. Chem. Soc. 1926, 48, 1063-1066; b) Clary, J. W.; 
Rettenmaier, T. J.; Snelling, R.; Bryks, W.; Banwell, J.; Wipke, W. T.; Singaram, B. J. Org. 
Chem. 2011, 76, 9602-9610.   
18 a) Ishiyama, T.; Murata, M.; Miyaura, N. J. Org. Chem. 1995, 60, 7508-7510. b) 
Ishiyama, T.; Itoh, Y.; Kitano, T.; Miyaura, N. Tetrahedron Lett. 1997, 38, 3447-3450. c) 
Ishiyama, T.; Miyaura, N. J. Organomet. Chem. 2000, 611, 392-402. d) Ishiyama, T.; 
Miyaura, N. Chem. Rec. 2004, 3, 271-280. e) Kürti, L.; Czakó, B. Miyaura Boration In 
Strategic Applications of Named Reactions in Organic Synthesis. 1st edition, Elsevier, 
London, 2005. pp 296-297. f) Miyaura, N. Bull. Chem. Soc. Jpn. 2008, 81, 1535-1553. 
19 (a) Takahashi, K.; Takagi, J.; Ishiyama, T.; Miyaura, N. Chem. Lett. 2000, 126-127. (b) 
Takagi, J.; Takahashi, K.; Ishiyama, T.; Miyaura, N. J. Am. Chem. Soc. 2002, 124, 8001-
8006. 
20 (a) Ishiyama, T.; Itoh, Y.; Kitano, Y.; Miyaura, N. Tetrahedron Lett. 1997, 38, 3447-
3450. (b) Fürstner, A.; Seidel, G. Org. Lett. 2002, 4, 541-543. (c) Billingsley, K. L.; Barder, 
T. E.; Buchwald, S. L. Angew. Chem. Int. Ed. 2007, 46, 5359-5363. 
21 Zhang, P.; Roundtree, I. A.; Morken, J. P. Org. Lett. 2012, 14, 1416-1419. 
22 Ishiyama, T.; Oohashi, Z.; Ahiko, T. -A.; Miyaura, N. Chem. Lett. 2002, 780-781. 
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Scheme 2-3: Miyaura Borylation. 
 
The metal-catalyzed hydroboration has become another useful strategy 
to introduce boronic ester groups in unsaturated compounds, as well as the 
addition of diboron compounds.23 Platinum is usually the best performing 
metal in the addition of diboron compounds;24 however, other metals such 
palladium,25 gold,26 iridium27 or rhodium28 have proven themselves equally 
useful. The reaction is quite general and all alkynes,29 alkenes,30 allenes,31 
carbonyls32 and imines33 are feasible substrates for the transformation. 
 
23 a) Beletskaya, I.; Pelter, A. Tetrahedron 1997, 53, 4957-5026. b) Crudden, C. M.; 
Edwards, D. Eur. J. Org. Chem. 2003, 4695-4712.  c) Chow, W. K.; Yuen, O. Y.; Choy, P. 
Y.; So, C. M.; Lau, C. P.; Wong, W. T.; Kwong, F. Y. RSC Adv. 2013, 3, 12518-12539. d) 
Neeve, E. C.; Geier, S. J.; Mkhalid, I. A. I.; Westcott, S. A.; Marder, T. B. Chem. Rev. 2016, 
116, 9091-9161. e) Hemmings, D.; Fritemeier, R.; Westcott, S. A.; Santos, W. L.; Steel, P.  
G. Chem. Soc. Rev. 2018, 47, 7477-7494. 
24 Ishiyama, T.; Matsuda, N.; Murata, M.; Ozawa, F.; Suzuki, A.; Miyaura, N. 
Organometallics 1996, 15, 713-720. 
25 Yang, F. -Y.; Cheng, C. -H. J. Am. Chem. Soc. 2001, 123, 761-762.   
26 Baker, R. T.; Nguyen, P.; Marder, T. B.; Westcott, S. A. Angew. Chem., Int. Ed. 1995, 
34, 1336-1338.   
27 Xu, L.; Zhang, S.; Li, P. Chem. Soc. Rev. 2015, 44, 8848-8858.   
28 Nguyen, P.; Coapes, R. B.; Woodward, A. D.; Taylor, N. J.; Burke, J. M.; Howard, J. 
A. K.; Marder, T. B. J. Organomet. Chem. 2002, 652, 77-85.   
29 Ishiyama, T.; Matsuda, N.; Miyaura, N.; Suzuki, A. J. Am. Chem. Soc. 1993, 115, 
11018-11019.   
30 a) Ishiyama, T.; Yamamoto, M.; Miyaura, N. Chem. Commun. 1996, 2073-2074. b) 
Ishiyama, T.; Yamamoto, M.; Miyaura, N. Chem. Commun. 1997, 689-690. c) Iverson, C. 
N.; Smith, M. R. Organometallics 1997, 16, 2757-2759.   
31 Ishiyama, T.; Kitano, T.; Miyaura, N. Tetrahedron Lett. 1998, 39, 2357-2360.   
32 Lawson, Y. G.; Lesley, M. J. G.; Norman, N. C.; Rice, C. R.; Marder, T. B. Chem. 
Commun. 1997, 2051-2052.   
33 Cameron, T. M.; Baker, R. T.; Westcott, S. A. Chem. Commun. 1998, 2395-2396.   
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C-H borylation catalyzed by transition metals has become recently a 
convenient strategy to prepare aryl boronates.34 This methodology is quite 
elegant, due to the fact than the use of aryl halides or triflates is no longer 
require and simple arenes can be used instead. Rhodium,35 palladium36 or 
rhenium37 are metals that perform well in this transformation, but iridium 
is the most commonly used catalyst in this borylation.38 Previously inert 
bonds such C-F39 bonds or C-OR40 bonds can also be activated by metal-
catalyzed borylations (Scheme 2-4).  
 
34 a) Ishiyama, T.; Miyaura, N. J. Organomet. Chem. 2003, 680, 3-11. b) Mkhalid, I. A. 
I.; Barnard, J. H.; Marder, T. B.; Murphy, J. M.; Hartwig, J. F. Chem. Rev. 2010, 110, 890-
931. c) Ros, A.; Fernández, R.; Lassaletta, J. M. Chem. Soc. Rev. 2014, 43, 3229-3243.   
35 a) Chen, H. Y.; Schlecht, S.; Semple, T. C.; Hartwig, J. F. Science 2000, 287, 1995-
1997.  b) Kawamorita, S.; Miyazaki, T.; Ohmiya, H.; Iwai, T.; Sawamura, M. J. Am. Chem. 
Soc. 2011, 133, 19310-19313. 
36 a) Ishiyama, T.; Ishida, K.; Takagi, J.; Miyaura, N. Chem. Lett. 2001, 30, 1082-1083.  
b) Dai, H. X.; Yu, J. Q. J. Am. Chem. Soc. 2012, 134, 134-137. c) Kuninobu, Y.; Iwanaga, 
T.; Omura, T.; Takai, K. Angew. Chem. Int. Ed. 2013, 52, 4431-4434. 
37 Chen, H.; Hartwig, J. F. Angew. Chem. Int. Ed. 1999, 38, 3391-3393.   
38 a) Iverson, C. N.; Smith, M. R., III. J. Am. Chem. Soc. 1999, 121, 7696-7697. b) Cho, 
J. Y.; Iverson, C. N.; Smith, M. R. III. J. Am. Chem. Soc. 2000, 122, 12868-12869. c) Cho, 
J. -Y.; Tse, M. K.; Holmes, D.; Maleczka, R. E., Jr.; Smith, M. R., III. Science 2002, 295, 
305-308. d) Ishiyama, T.; Takagi, J.; Ishida, K.; Miyaura, N.; Anastasi, N. R.; Hartwig, J. F. 
J. Am. Chem. Soc. 2002, 124, 390-391. e) Coventry, D. N.; Batsanov, A. S.; Goeta, A. E.; 
Howard, J. A. K.; Marder, T. B.; Perutz, R. N. Chem. Commun. 2005, 2172-2174. f) 
Kawamorita, S.; Ohmiya, H.; Hará, K.; Fukuoka, A.; Sawamura, M. J. Am. Chem. Soc. 2009, 
131, 5058-5059. g) Ros, A.; Estepa, B.; Lopez-Rodriguez, R.; Alvarez, E.; Fernandez, R.; 
Lassaletta, J. M. Angew. Chem. Int. Ed. 2011, 50, 11724 -11728. h) Roosen, P. C.; Kallepalli, 
V. A.; Chattopadhyay, B.; Singleton, D. A.; Maleczka, R. E. Jr.; Smith III, M. R. J. Am. 
Chem. Soc. 2012, 134, 11350-11353. i) Crawford, K. M.; Ramseyer, T. R.; Daley, C. J. A.; 
Clark, T. B. Angew. Chem. Int. Ed. 2014, 53, 7589-7593. j) Kuninobu, Y.; Ida, H.; Nishi, 
M.; Kanai, M. Nat. Chem. 2015, 7, 712–717. k) Bisht, R.; Chattopadhyay, B. J. Am. Chem. 
Soc. 2016, 138, 84-87. l) Wang, G.; Liu, L.; Ding, Y. S.; Zhou, J.; Mao, S.; Li, P. J. Am. 
Chem. Soc. 2017, 139, 91-94. m) Li, H. L.; Kuninobu, Y.; Kanai, M. Angew. Chem. Int. Ed. 
2017, 56, 1495- 1499. n) Su, B.; Hartwig, J. F. Angew. Chem. Int. Ed. 2018, 57, 10163-
10167. 
39 a) Liu, X. W.; Echavarren, J.; Zarate, C.; Martin, R. J. Am. Chem. Soc. 2015, 137, 12470-
12473. b) Zhang, J.; Dai, W.; Liu, Q.; Cao, S. Org. Lett. 2017, 19, 3283−3286. c) Niwa, T.; 
Ochiai, H.; Hosoya, T. ACS Catal. 2017, 7, 4535−4541. d) Sakaguchi, H.; Uetake, Y.; 
Ohashi, M.; Niwa, T.; Ogoshi, S.; Hosoya, T. J. Am. Chem. Soc. 2017, 139, 12855-12862. 
e) Tian, Y. M.; Guo, X. N.; Kuntze-Fechner, M. W.; Krummenacher, I.; Braunschweig, H.; 
Radius, U.; Steffen, A.; Marder, T. B. J. Am. Chem. Soc. 2018, 140, 17612-17623. 
40 a) Kinuta, H.; Tobisu, M.; Chatani, N. J. Am. Chem. Soc. 2015, 137, 1593-1600. b) 
Zarate, C.; Manzano, R.; Martin, R. J. Am. Chem. Soc. 2015, 137, 6754-6757. c) Mao, L.; 
Szabó, K. J.; Marder, T. B. Org. Lett. 2017, 19, 1204-1207.   
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Scheme 2-4: C-H, C-F and C-OMe borylations. 
 
More recently, different methodologies have emerged to introduce 
boronic ester moieties without the use of any metals, simply using a 
catalytic amount of base (Figure 2-5).41  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
41 a) Cid, J.; Gulyas, H.; Carbo, J. J.; Fernandez, E. Chem. Soc. Rev. 2012, 41, 3558-3570. 
b) Cuenca, A. B.; Shishido, R.; Ito, H.; Fernandez, E. Chem. Soc. Rev. 2017, 46, 415-430.  
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Figure 2-5: Different strategies for the synthesis of boronic esters. 
 
Despite the large number of existing methodologies for the synthesis of 
boronic esters, most of them are based in the electrophilic nature of the 
boron atom. Nonetheless, in 2006, Segawa, Yamashita and Nozaki 
discovered that there are some boryl complexes that could act as 
nucleophiles. They succeeded in the synthesis, isolation and 
characterization by X-Ray crystallography of the first boryl lithium 
compound. Moreover, they also studied its reactivity in the presence of a 
variety of electrophiles. The results demonstrated that this boryl complex is 
indeed a strong nucleophile and opened a new window in boron organic 
chemistry. However, despite the breakthrough, the synthetic application of 
the boryl lithium species has been hampered by their instability (Scheme 
2-5).42 Following these investigations, the group of Nozaki, and later 
 
42 a) Segawa, Y.; Yamashita, M.; Nozaki, K. Science 2006, 314, 113-115. b) Marder, T. 
B. Science 2006, 314, 69-70. c) Braunschweig, H. Angew. Chem. Int. Ed. 2007, 46, 1946-
1948. d) Segawa, Y.; Suzuki, Y.; Yamashita, M.; Nozaki, K. J. Am. Chem. Soc. 2008, 130, 
16069- 16079. e) For a more theoretical study, see: Cheung, M. S.; Marder, T. B.; Lin, Z. 
Organometallics 2011, 30, 3018-3028.   
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Weetman, were able to transform this boryl lithium reagent into boryl 
magnesium compounds, increasing the stability by treating it with 
magnesium bromide.43 
 
 
Scheme 2-5: Reactivity of boryl lithium compounds. 
 
Nucleophilic boron species opened a completely new pathway to the 
formation of carbon-boron bonds.44 Several methodologies have been 
published to generate nucleophilic boron species,45 but among them, 
 
43 a) Yamashita, M.; Suzuki, Y.; Segawa, Y.; Nozaki K. J. Am. Chem. Soc. 2007, 129, 
9570-9571. b) Pécharman, A. -F.; Colebatch, A. L.; Hill, M. S.; McMullin, C. L.; Mahon, 
M. F.; Weetman, C. Nature Commun. 2017, 8, 15022-15029.   
44 a) Dang, L.; Lin, Z.; Marder, T. B. Chem. Commun. 2009, 3987-3995; b) Cid, J.; Gulyás, 
H.; Carbó, J. J.; Fernández, E. Chem. Soc. Rev. 2012, 41, 3558-3570; c) Yamashita, M.; 
Nozaki K. Boryl Anions. In Synthesis and Application of Organoboron Compounds; 
Fernández, E., Whiting, A. Ed.; Springer International Publishing: Switzerland, 2015; pp 1-
38.   
45 a) Lee, K. S.; Zhugralin, A. R.; Hoveyda, A. H. J. Am. Chem. Soc. 2009, 131, 7253-
7255. b) Bonet, A.; Gulyás, H.; Fernández, E. Angew. Chem. Int. Ed. 2010, 49, 5130-5134. 
c) Bonet, A.; Pubill-Ulldemolins, C.; Bo, C.; Gulyás, H.; Fernández, E. Angew. Chem. Int. 
Ed. 2011, 50, 7158-7161. d) Wu, H.; Radomkit, S.; O’Brien, J. M.; Hoveyda, A. H. J. Am. 
Chem. Soc. 2012, 134, 8277-8285. e) Kleeberg, C.; Crawford, A. G.; Batsanov, A. S.; 
Hodgkinson, P.; Apperley, D. C.; Cheung, M. S.; Lin, Z.; Marder, T. B. J. Org. Chem. 2013, 
77, 785-789. f) Sanz, X.; Lee, G. M.; Pubill-Ulldemolins, C.; Bonet, A.; Westcott, S. A.; 
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copper-catalyzed borylations have proven to be the most versatile and will 
be discussed in the next section. 
 
2.1.3. Copper-Catalyzed Borylations. 
It was 2000, when Hosomi reported the copper-catalyzed hydroboration 
of α,β-unsaturated ketones with B2pin2.
46 This breakthrough discovery led 
to a completely new area of research in organometallic chemistry. It was at 
this point when the catalytic activity of copper(I) salts was disclosed and 
how the addition of phosphines dramatically improved the results. The 
outcome of the reaction was even better than the one obtained with more 
expensive transition metals, such as platinum or rhodium. The use of copper 
allowed for the reaction to take place at room temperature. They tested the 
methodology with different enones, and they successfully converted the 
products into the correspondent β-hydroxy ketones by means of a simple 
oxidation (Scheme 2-6). 
 
Scheme 2-6: Copper-catalyzed borylation by Hosomi.  
 
 Following the work of Hosomi, Professor Miyaura reported the 
hydroboration of different unsaturated compounds using copper(I) chloride, 
lithium chloride and potassium acetate as base. Mixing these reagents with 
B2pin2, provoked the B-B bond cleavage and the in situ formation of 
copper-boryl species, which could undergo β-borylation of α,β-unsaturated 
 
Gulyás, H.; Bo, C.; Fernández, E. Org. Biomol. Chem. 2013, 11, 7004-7010. g) Cuenca, A. 
B.; Shishido, R.; Ito, H.; Fernández, H. Chem. Soc. Rev. 2017, 46, 415-430.   
46 Ito, H.; Yamanaka, H.; Tateiwa, J.; Hosomi, A. Tetrahedron Lett. 2000, 41, 6821-6825. 
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carbonyl compounds, hydroboration of alkynes and allylic substitution 
(Scheme 2-7).47 They proposed that the reaction between CuCl and KOAc 
in the presence of LiCl generate the active specie [CuClOAc]K. After 
transmetalation with the diboron compound, the copper-boryl nucleophile 
is generated.  
 
 
Scheme 2-7: Copper-catalyzed borylation by Miyaura.  
 
While both reports used slightly different conditions, they agreed that 
copper-boryl complexes are formed in situ, and that these complexes 
behaved as formal boron nucleophiles. 
It was also in Japan, when five years later Sawamura published the 
stereospecific copper-catalyzed borylation of allylic carbonates. With this 
contribution, the potential of copper-catalyzed borylations was revealed.48 
 
47 a) Takahashi, K.; Ishiyama, T.; Miyaura, N. Chem. Lett. 2000, 29, 982-983. b) 
Takahashi, K.; Ishiyama, T.; Miyaura, N. J. Organomet. Chem. 2001, 625, 47-53. 
48 Ito, H.; Kawakami, C.; Sawamura, M. J. Am. Chem. Soc. 2005, 127, 16034-16035. 
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They proposed that the in situ formed boryl-complex catalyzed the SN2’ 
borylation of allylic carbonates, affording allylboron compounds via a γ-
selective and stereospecific substitution reaction. This methodology yielded 
enantiomerically enriched allyl boronates with excellent results (Scheme 
2-8).  
 
 
Scheme 2-8: Copper-catalyzed borylation of allylic carbonates by 
Sawamura. 
 
At the same time, Sadighi reported the copper-catalyzed reduction of 
CO2 to CO by B2pin2. They also reported the isolation and X-Ray 
characterization of copper(I) boryl complex [(IPr)Cu-Bpin], the reductant 
of the reaction, and the resulting borate complex [(IPr)Cu(OBpin)] formed 
after deoxygenation of carbon dioxide. The copper-boryl complex could be 
regenerated by reaction of the borate with the diboron compound forming 
the stable product pinB-O-Bpin (Scheme 2-9).49 Later, the same authors 
reported the reduction of aldehydes through a 1,2-diboration.50 
 
 
 
49 Laitar, D. S.; Mueller, P.; Sadighi, J. P. J. Am. Chem. Soc. 2005, 127, 17196-17197. 
50 Laitar, D. S.; Tsui, E. Y.; Sadighi, J. P. J. Am. Chem. Soc. 2006, 128, 11036-11037. 
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Scheme 2-9: Reduction of CO2 and X-Ray images of both the copper-
boryl complex and the borate-copper complex. 
 
After these two publications, an important contribution was reported by 
Yun for the copper-catalyzed borylation of α,β-unsaturated carbonyl 
compounds with B2pin2 (Scheme 2-10).
51 In this work, there were two 
important discoveries that were crucial in the subsequent development of 
the field. First, Yun reported the importance of using alcohols in the 
reaction to improve the rate of the reaction. The reason behind this is that 
after the insertion step, the formation of copper methoxide is needed to 
regenerate the catalytic cycle from the recently formed copper enolate. 
Without a proton source, this transformation is really slow. Therefore, 
methanol protonates the copper enolate, forming copper methoxide, which 
can start again the catalytic cycle. Previously, Sawamura and Sadighi used 
highly sensitive CuOt-Bu and, therefore, the use of a glovebox was 
necessary. However, Yun demonstrated that the in situ formation of the 
copper alkoxide by reaction of copper(I) chloride and sodium tert-butoxide 
 
51 Mun, S.; Lee, J. E.; Yun, J. Org. Lett. 2006, 8, 4887-4889. 
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worked equally well, making the experimental process easier and more 
convenient.  
 
 
Scheme 2-10: Borylation of α,β-unsaturated carbonyl compounds by 
Yun. 
 
In the last fifteen years, the number of publications on copper-catalyzed 
borylation reactions have exponentially increased. Many groups around the 
globe have successfully demonstrated that most of the organocopper 
chemistry known to form carbon-carbon bonds, can now be applied to the 
formation of carbon-boron bonds (Scheme 2-11). Nucleophilic copper-
boryl complex can react with a broad variety of electrophiles such as 
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aldehydes,52 imines,53 α,β-unsaturated compounds,54 alkynes,55 alkenes and 
allenes.56 A comprehensive review of the literature exceeds the scope of the 
introduction of this chapter. Therefore, only selective examples about 
copper-catalyzed borylations of non-polarized alkenes will be included in 
the next sections. 
 
 
 
 
 
52 For selected examples see: a) Molander, G. A.; Wisniewski, S. R. J. Am. Chem. Soc. 
2012, 134, 16856-16868. b) Kubota, K.; Yamamoto, E.; Ito, H. J. Am. Chem. Soc. 2015, 
137, 420-424. c) Wang, L.; Zhang, T.; Sun, W.; He, Z.; Xia, C.; Lan, Y.; Liu, C. J. Am. 
Chem. Soc. 2017, 139, 5257-5264. d) Tagichi, J.; Takeuchi, T.; Takahashi, R.; Masero, F.; 
Ito, H. Angew. Chem. Int. Ed. 2019, 58, 7299-7303. 
53 For selected examples see: a) Beenen, M. A.; An, C.; Ellman, J. A. J. Am. Chem. Soc. 
2008, 130, 6910-6911. b) Hong, K.; Morken, J. P. J. Am. Chem. Soc. 2013, 135, 9252-9254. 
c) Wang, D.; Cao, P.; Wang, B.; Jia, T.; Lou, Y.; Wang, M.; Liao, J. Org. Lett. 2015, 17, 
2420-2423. d) Li, Z.; Zhang, L.; Nishiura, M.; Hou, Z. ACS Catal. 2019, 9, 4388-4393. 
54 For selected examples see: a) Lee, J. E.; Yun, J. Angew. Chem. Int. Ed. 2008, 47, 145-
147. b) Lillo, V.; Prieto, A.; Bonet, A.; Díaz-Requejo, M. M.; Ramıírez, J.; Pérez, P. J.; 
Fernández, E. Organometallics 2009, 28, 659-662. c) Chen, I. H.; Yin, L.; Itano, W.; Kanai, 
M.; Shibasaki, M. J. Am. Chem. Soc. 2009, 131, 11664-11665. e) O’Brien, J. M; Lee, K. S.; 
Hoveyda, A. H. J. Am. Chem. Soc. 2010, 132, 10630-10633. f) Chen, I. H.; Kanai, M.; 
Shibasaki, M. Org. Lett. 2010, 12, 4098-4101. g) Moure, A. L.; Gomez-Arrayas, R.; 
Carretero, J. C. Chem. Commun. 2011, 47, 6701-6703. 
55 For selected examples see: a) Lee, J. -E.; Kwon, J.; Yun, J. Chem. Commun. 2008, 733-
734. b) Jang, H.; Zhugralin, A. R.; Lee, Y.; Hoveyda, A. H.; J. Am. Chem. Soc. 2011, 133, 
7859-7871. c) Moure, A. L.; Arrayás, R. G.; Cárdenas, D. J.; Alonso, I.; Carretero, J. C. J. 
Am. Chem. Soc. 2012, 134, 7219-7222. d) Moure, A. L.; Mauleón, P.; Arrayás, R. G.; 
Carretero, J. C. Org. Lett. 2013, 15, 2054-2057. e) Moon, J. H.; Jung, H. -Y.; Lee, Y. J.; Lee, 
S. W.; Yun, J.; Lee, J. Y. Organometallics 2015, 34, 2151-2159. f) Kojima, C.; Lee, K. H.; 
Lin, Z.; Yamashita, M. J. Am. Chem. Soc. 2016, 138, 6662-6669.  For carboboration of 
alkynes, see: Alfaro, R.; Parra, A.; Aleman, J.; García-Ruano, J. L.; Tortosa, M. J. Am. Chem 
Soc. 2012, 134, 15165-15168. 
56 For selected examples see: a) Yuan, W.; Ma, S. Adv. Synth. Catal. 2012, 354, 1867-
1872. b) Meng, F.; Jung, B.; Haeffner, F.; Hoveyda, A. H. Org. Lett. 2013, 15, 1414-1417. 
c) Semba, K.; Shinomiya, M.; Fujihara, T.; Terao, J.; Tsuji, Y. Chem. Eur. J. 2013, 19, 7125-
7132. d) Semba, K.; Fujihara, T.; Terao, J.; Tsuji, Y. Angew. Chem. Int. Ed. 2013, 52, 12400-
12403. e) Yuan, W.; Zhang, X.; Yu, Y.; Ma, S. Chem. Eur. J. 2013, 19, 7193-7202. f) Meng, 
F. K.; Jang, H.; Jung, B.; Hoveyda, A. H. Angew. Chem. Int. Ed. 2013, 52, 5046-5051. g) 
Jang, H.; Jung, B.; Hoveyda, A. H. Org. Lett. 2014, 16, 4658-4661. h) Yuan, W.; Song, L.; 
Ma, S. Angew. Chem. Int. Ed. 2016, 55, 3140-3143.  
 Synthesis of cyclobutylboronates. 
31 
 
 
Scheme 2-11: Copper-boryl complex as tool in organic synthesis. 
 
2.1.3.1. Copper-Catalyzed Borylation of Non-Polarized Alkenes. 
Sadighi’s group isolated, in 2006, the complex formed after the insertion 
of the double bound of styrene into a (NHC)-copper-boryl complex 
(Scheme 2-12). This insertion is highly regioselective, however, this 
complex could be rearranged to the other regioisomer upon heating 
(elimination/reinsertion).57 
 
 
Scheme 2-12: Insertion of an alkene into a copper-boron bond. 
One year later, Marder and coworkers, reported a computational study 
about the insertion reaction of alkenes into copper-boryl(I) complexes. DFT 
 
57 Laitar, D. S.; Tsui, E. Y.; Sadighi, J. P. Organometallics 2006, 25, 2405-2408. 
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calculations supported that this insertion implies a nucleophilic attack of 
copper-boryl species to the alkene.58 
In 2009, Hoveyda’s group reported that enantiomerically pure (NHC)-
copper(I) complexes were able to catalyzed the borylation reaction of 
styrenes not only with complete regioselectivity, as reported by Sadighi, 
but also with excellent enantioselectivities (Scheme 2-13).59 Some years 
later, the same group reported the hydroboration of vinylsilanes to obtain 
enantiomerically enriched borosilanes.60 
 
 
Scheme 2-13: Copper(I) Catalyzed Asymmetric Hydroboration. 
 
Similar studies were carried out by the group of Xiong. They reported 
an asymmetric formal hydroboration of ,-diaryl substituted alkenes and 
-alkyl styrenes in excellent yields and enantiomeric excesses (Scheme 
2-14).61 More recently, Hong and Meng published the same reaction with 
 
58 Dang, L.; Zhao, H.; Lin, Z.; Marder, T. B. Organometallics 2007, 26, 2824-2832.   
59 a) Lee, Y.; Hoveyda, A. H. J. Am. Chem. Soc. 2009, 131, 3160-3161. b) Corberán, R.; 
Mszar, N. W.; Hoveyda, A. H. Angew. Chem. Int. Ed. 2011, 50, 7079-7082.   
60 Meng, F. K.; Jang, H. J.; Hoveyda, A. H. Chem. Eur. J. 2013, 19, 3204-3214.   
61 Wang, Z.; He, X.; Zhang, R.; Zhang, G.; Xu, G.; Zhang, Q.; Xiong, T.;  Zhang, Q. Org. 
Lett. 2017, 19, 3067-3070. 
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comparable result, however they provided some insight into the 
stereodetermining step through DFT calculations.62 
 
 
Scheme 2-14: Copper(I) catalyzed asymmetric hydroboration of ,-
disubstituted alkenes. 
 
Ito and coworkers were the first to show that the borylation of alkyl 
substituted alkenes was also possible (Scheme 2-15).63 The reaction is 
highly regioselective towards the anti-Markovnikov product and they 
concluded that the nature of the ligand played a crucial role in the observed 
regioselectivity. They applied this new methodology to the exo-cyclization 
of alkenyl halides, running the reaction in the absence of methanol.64 
 
 
 
 
62 Wen, L.; Cheng, F.; Li, H.; Zhang, S.; Hong, X.; Meng, F. Asian J. Org. Chem. 2018, 
7, 103-106. 
63 Kubota, K.; Yamamoto, E.; Ito, H. J. Am. Chem. Soc. 2013, 135, 2635−2640. 
64 a) Kubota, K.; Yamamoto, E.; Ito, H. J. Am. Chem. Soc. 2013, 135, 2635-2640. b) 
Yamamoto, E.; Kojima, R.; Ito, H. Synlett 2016, 27, 272-276. c) Kubota, K.; Iwamoto, H.; 
Ito, H. Org. Biomol. Chem. 2017, 15, 285-300. 
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Scheme 2-15: Anti-Markovnikov hydroboration of alkyl-substituted 
alkenes. 
 
Ito demonstrated later how important the election of the ligand was, 
publishing the Markovnikov copper-catalyzed borylation of alkyl 
substituted alkenes (Scheme 2-16).65 Both methodologies together are two 
complementary approaches to these alkenyl boronates. 
 
 
 
 
 
 
 
 
 
65 Iwamoto, H.; Kubota, K.; Ito, H. Chem. Commun. 2016, 52, 5916-5919. 
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Scheme 2-16: Markovnikov Hydroboration of Alkyl-Substituted Alkenes. 
 
More related to the present chapter is the copper-catalyzed borylation of 
strained alkenes. Tortosa and coworkers reported, in 2014, the synthesis of 
enantioenriched cyclopropylboronates through a copper-catalyzed 
desymmetrization of cyclopropenes (Scheme 2-17).66 In order to obtain 
high levels of stereoselectivities, a bulky bidentate phosphine ligand was 
required. This ligand also played a key role avoiding the cyclopropane 
dimerization. At the same time, Lin and coworkers reported the same 
transformation. They use a different ligand but, to achieve high levels of 
stereocontrol, an ester moiety was needed in the cyclopropene.67 
 
 
 
 
 
 
66 Parra, A.; Amenos, L.; Guisan-Ceinos, M.; Lopez, A.; Garcia-Ruano, J. L.; Tortosa, M. 
J. Am. Chem. Soc. 2014, 136, 15833-15836. 
67 Tian, B.; Liu, Q.; Tong, X.; Lin, G. Q. Org. Chem. Front. 2014, 1, 1116-1122. 
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Scheme 2-17: Enantioselective desymmetrization of cyclopropenes. 
 
In 2015, Yun and coworkers introduced the enantiodivergent borylation 
of strained bicyclic olefins.68 They obtained high levels of stereocontrol 
using the bidentate phosphine (R,R)-Taniaphos. They succeeded in 
obtaining both possible enantiomers by simply tuning the boron source 
from B2pin2 to HBpin (Scheme 2-18). In the same year, Tortosa and 
coworkers studied the relative reactivity of different strained alkenes in 
copper-catalyzed borylations.69 
 
 
 
 
 
 
68 Lee, H.; Lee, B. Y.; Yun, J. Org. Lett. 2015, 17, 764-766.   
69 Parra, A.; López, A.; Díaz-Tendero, S.; Amenós, L.; Garcia-Ruano, J. L.; Tortosa, M. 
Synlett 2015, 26, 494-500. 
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Scheme 2-18: Enantioselective hydroboration of strained alkenes. 
 
The results regarding copper-catalyzed borylation of cyclobutenes will 
be explained in the following pages of this chapter.70 
 
2.1.4. Importance of Cyclobutanes in Organic Chemistry. 
Small and strained molecules have attracted the interest of chemists 
throughout history. If we compare cyclopropane and its homologue the 
cyclobutane, the former has drawn much more interest than the latter. 
Cyclopropane ring have a strain energy of 27.5 Kcal/mol, while the 
cyclobutane ring have 26.7 Kcal/mol. Both rings have almost the same 
strain energy. When strain energies are calculated, you can dissect the result 
between C-C and C-H contributions. While the C-C energy in 
cyclopropanes is 10 Kcal/mol higher, this is compensated by the difference 
in C-H energy (8 Kcal/mol).71 Cyclobutanes are present in both synthetic 
and natural products. Among the most well-known cyclobutane containing 
molecules we have cubane, a non-natural high strained molecule.72 But not 
 
70 Guisan-Ceinos, M.; Parra, A.; Martin-Heras, V.; Tortosa, M. Angew. Chem. Int. Ed. 
2016, 55, 6969-6972. 
71 Khoury, P. R.; Goddard, J. D.; Tam, W. Tetrahedron 2004, 60, 8103-8112. 
72 Eaton, P. E.; Cole, T. W. J. Am. Chem. Soc. 1964, 86, 962–964. 
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only synthetic molecules contain cyclobutanes in its structure. A wide 
number of natural products have this peculiar moiety in their framework. 
We can find it in simple terpenes as -pinene or the sex attractant 
pheromone grandisol. But also, this structure exists in more complex 
molecules such as (-)-Bielschowskysin or Penitrem A (Figure 2-6).73 
 
 
Figure 2-6: Cyclobutane containing molecules. 
 
 
73 For some examples of natural products and pharmaceuticals containing cyclobutanes, 
see a) Hansen, T. V., Stenstrom, Y. (2001) Naturally occurring cyclobutanes. Organic 
Synthesis: Theory and Applications, Volume 5, 1-38. b) Sinninghe Damste, J. S.; Strous, 
M.; Rijpstra, W. I. C.; Hopmans, E. C.; Geenevasen, J. A. J.; van Duin, A. C. T.; van Niftrik, 
L. A.; Jetten, M. S. M.; Nature 2002, 419, 708-712. c) Vilaine, J. P.; Thollon, C.; Villeneuve, 
N.; Peglion, J. L. Eur. Heart J. Suppl. 2003, 5, G26. c) Mascitti, V.; Corey, E. J.  J. Am. 
Chem. Soc. 2006, 128, 3118-3119. d) Nouri, D. H.; Tantillo, D. J. Curr. Org. Chem. 2006, 
10, 2055-2074. e) Dembitsky, V. M. J. Nat. Med. 2008, 62, 1-33. f) Sergeiko, A.; Poroikov, 
V. V.; Hanus, L. O.; Dembitsky, V. M. Open Med. Chem. J. 2008, 2, 26-37. g) Blakemore, 
D. C.; Bryans, J. S.; Carnell, P.; Carr, C. L.; Chessum, N. E. A.; Field, M. J.; Kinsella, N.; 
Osborne, S. A.; Warren, A. N.; Williams, S. C. Bioorg. Med. Chem. Lett. 2010, 20, 461-464. 
h) Cipres, A.; O’Malley, D. P.; Li, K.; Finlay, D.; Baran, P. S.; Vuori, K. ACS Chem. Biol. 
2010, 5, 195. i) Bach, T.; Hehn, J. P. Angew. Chem. Int. Ed. 2011, 50, 1000-1045. j) Mercer, 
J. A. M.; Cohen, C. M.; Shuken, S. R.; Wagner, A. M.; Smith, M. W.; Moss III, F. R.; Smith, 
M. D. Vahala, R.; Gonzalez-Martinez, A.; Boxer, S. G.; Burns. N. Z. J. Am. Chem. Soc. 
2016, 138, 15845-15848. 
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Furthermore, cyclobutanes have proved to be valuable synthetic 
intermediates for several transformations. Due to the strain energy in the 
ring (25.6 kcal/mol), cyclobutanes are prone to ring-opening reaction as 
well as ring expansions. Also, they can be used to synthetize cyclopropanes 
through ring-contraction reactions (Scheme 2-19).74 Therefore, the 
preparation of this strained cycles has become a really active area.75 They 
provide unique rigidity and three dimensionality which could be crucial in 
drug discovery.76 
 
 
Scheme 2-19: Applications of cyclobutanes. 
 
 
74 a) Namyslo, J. C.; Kaufmann, D. E. Chem. Rev. 2003, 103, 1485-1537. b) Hoffmann, 
N. Chem. Rev. 2008, 108, 1052-1103. c) Seiser, T.; Saget, T.; Tran, D. N.; Cramer, N. 
Angew. Chem. Int. Ed. 2011, 50, 7740-7752. 
75 For some reviews on synthesis of cyclobutanes, see a) Lee-Ruff, E.; Mladenova, G. 
Chem. Rev. 2003, 103, 1449-1483. b) Yoon, T. P. ACS Catal. 2013, 3, 895-902. c) Poplata, 
S.; Tröster, A.; Zou, Y. -Q.; Bach, T. Chem. Rev. 2016, 116, 9748-9815. 
76 a) Ruzyllo, W.; Tendera, M.; Ford, I.; Fox, K. M. Drugs 2007, 67, 393-405. b) Carreira, 
E. M.; Fessard, T. C. Chem. Rev. 2014, 114, 8257-8322. 
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2.1.5. Synthesis of Cyclobutanes. 
Among the classical methodologies to prepare chiral cyclobutanes 
stands out the [2+2] cycloadditions (Scheme 2-20).77 In this reaction, two 
double bonds reacts in a photochemical electrocyclic reaction to form a 
cyclobutane. 
 
 
Scheme 2-20: [2+2] cycloaddition reaction to form cyclobutanes. 
 
Another known methodology is the acyclic ring closure (Scheme 
2-21).78 This included the 1,4-cyclization reaction of functionalized alkyl 
halides or pseudohalides. 
 
 
 
 
77 Recent selected work on [2+2] cycloadditions for the synthesis of cyclobutanes: a) Zhu, 
M.; Zheng, C.; Zhang, X.; You, S. -L. J. Am. Chem. Soc. 2019, 141, 2636-2644. b) Wiest, 
J. M.; Conner, M. L.; Brown, M. K. J. Am. Chem. Soc. 2018, 140, 15943-15949. c) Poplata, 
S.; Bach, T. J. Am. Chem. Soc. 2018, 140, 3228−3231. d) Kramm, F.; Teske, J.; Ullwer, F.; 
Frey, W.; Plietker, B. Angew. Chem. Int. Ed. 2018, 57, 13335-13338. e) Zhou, C.; Lei, T.; 
Wei, X. Z.; Liu, Z.; Chen, B.; Ramamurthy, V.; Tung, C. H.; Wu, L. Z. Org. Lett. 2018, 20, 
6808−6811. f) Conner, M. L.; Xu, Y.; Brown, M. K. J. Am. Chem. Soc. 2015, 137, 
3482−3485. g) Du, J.; Skubi, K. L.; Schultz, D. M.; Yoon, T. P. Science 2014, 344, 392-
396. 
78 a) Shu, C.; Noble, A.; Aggarwal, V. K. Angew. Chem. Int. Ed. 2019, 58, 3870-3874. b) 
Hazra, C. K.; Jeong, J.; Kim, H.; Baik, M. -H.; Park, S.; Chang, S. Angew. Chem. Int. Ed. 
2018, 57, 2692-2696. c) Wang, Y. M.; Bruno, N. C.; Placeres, A. L.; Zhu, S.; Buchwald, S. 
L. J. Am. Chem. Soc. 2015, 137, 10524-10527. d) Johnson, T.; Choo, K. L.; Lautens, M. 
Chem. Eur. J. 2014, 20, 14194-14197. e) Panish, R.; Chintala, S. R.; Boruta, D. T.; Fang, 
Y.; Taylor, M. T.; Fox, J. M. J. Am. Chem. Soc. 2013, 135, 9283-9286. f) Kubota, K.; 
Yamamoto, E.; Ito, H. J. Am. Chem. Soc. 2013, 135, 2635-2640. 
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Scheme 2-21: Acyclic ring closure to form cyclobutanes. 
 
The catalytic Wagner–Meerwein shifts of cyclopropanols is a useful 
strategy for the synthesis of cyclobutanones (Scheme 2-22).79 The reaction 
involves the 1,2-alkyl shift into an olefin moiety or carbonyl group to afford 
the corresponding cyclobutanone.  
 
 
Scheme 2-22: Catalytic Wagner-Meerwein shift for the synthesis of 
cyclobutanones. 
 
A straightforward strategy to prepare funtionalized cyclobutanes is the 
direct functionalization of cyclobutanes or cyclobutenes (Scheme 2-23).80  
 
79 a) Shim, S. Y.; Choi, Y.; Ryu, D. H. J. Am. Chem. Soc. 2018, 140, 11184-11188. b) 
Kleinbeck, F.; Toste, F. D. J. Am. Chem. Soc. 2009, 131, 9178-9179. c) Trost, B. M.; 
Yasukata, T. J. Am. Chem. Soc. 2001, 123, 7162-7163.  
80 a) Fawcett, A.; Biberger, T.; Aggarwal, V. K. Nat. Chem. 2019, 11, 117-122. b) Chen, 
Y. J.; Hu, T. J.; Feng, C. G.; Lin, G. Q. Chem. Commun. 2015, 51, 8773-8776. c) Xiao, K. 
J.; Lin, D. W.; Miura, M.; Zhu, R. Y.; Gong, W.; Wasa, M.; Yu, J. Q. J. Am. Chem. Soc. 
2014, 136, 8138-8142. d) Aitken, D. J.; Caboni, P.; Eijsberg, H.; Frongia, A.; Guillot, R.; 
Ollivier, J.; Piras, P. P.; Secci, F. Adv. Synth. Catal. 2014, 356, 941-945. e) Reeves, C. M.; 
Eidamshaus, C.; Kim, J.; Stoltz, B. M. Angew. Chem. Int. Ed. 2013, 52, 6718-6721. f) 
Audisio, D.; Luparia, M.;  Oliveira, M. T.; Klütt, D.; Maulide, N. Angew. Chem. Int. Ed. 
2012, 51, 7314-7317. 
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Scheme 2-23: Direct functionalization of cyclobutanes and cyclobutenes. 
 
Almost completely unexplored, there is a fifth strategy, the 
desymmetrization of meso-cyclobutenes. Regarding this strategy, at the 
time of this Doctoral Thesis, there was only one example of catalytic 
desymmetrization of meso-cyclobutenes. Rajanbabu and Liu, reported the 
enantioselective desymmetrization of strained alkenes catalyzed by nickel 
and a chiral phosphoramidite ligand. (Scheme 2-24).81 In one of the 
examples, they succeeded in the enantioselective desymmetrization of a 
meso-cyclobutene with moderate yield and enantioselectivity.  
 
 
Scheme 2-24: Hydrovinylation of meso-cyclobutenes. 
 
 
81 Liu, W.: Rajanbabu, T. V. J. Org. Chem. 2010, 75, 7636-7643. 
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2.1.6. Synthesis of Cyclobutylboronates. 
Cyclobutanes with multiple stereocenters are important synthetic 
intermediates as mentioned above. In the context of the synthesis of 
functionalized cyclobutanes, cyclobutylboronates are promising synthetic 
intermediates due to the configurational stability of the C-B bond. The boryl 
moiety provides a handle for further functionalization through 
stereospecific transformations of the C-B bond (Scheme 2-25),82 such as 
protodeborylation,83 oxidation,84 homologation,85 Suzuki-Miyaura cross-
coupling,86 amination,87 potassium trifluoroborates (Molander Salts)88 or 
fluorination.89 Therefore, different functionalized cyclobutanes can be 
envisioned from a common synthetic intermediate. 
 
 
82 a) Boronic Acids: Preparation and Applications in Organic Synthesis and Medicine; 
Hall, D., Ed.; Wiley-VCH: Weinheim, 2005. b) Brown, H. C.; Basavaiah, D.; Kulkarni, S. 
U.; Bhat, N. G.; Vara Prasad, J. V. N. J. Org. Chem. 1988, 53, 239-246. c) Brown, H. C.; 
Singaram, B. Acc. Chem. Res. 1988, 21, 287-293. d) Matteson, D. S. Chem. Rev. 1989, 89, 
1535-1551 e) Mlynarski, S. N.; Schuster, C. H.; Morken, J. P. Nature 2013, 505, 386-390. 
f) Neeve, E. C.; Geier, S. J.; Mkhalid, I. A. I.; Westcott, S. A.; Marder, T. B. Chem. Rev. 
2016, 116, 9091. 
83 a) Zweifel, G.; Arzoumanian, H.; Whitney, C. C. J. Am. Chem. Soc. 1967, 89, 3652-
3653. b) Roesner, S.; Blair, D. J.; Aggarwal, V. K. Chem. Sci. 2015, 6, 3718-3723. c) Cox, 
P. A.; Leach, A. G.; Campbell, A. D.; Lloyd-Jones, G. C. J. Am. Chem. Soc. 2016, 138, 
9145-9157. 
84 a) Brown, H. C.; Zweifel, G. J. Am. Chem. Soc. 1959, 81, 247. b) Kabalka, G. W.; 
Shoup, T. M.; Goudagon, N. M. J. Org. Chem. 1989, 54, 5930-5933. c) Fang, L.; Yan, L.; 
Haeffner, F.; Morken, J. P. J. Am. Chem. Soc. 2016, 138, 2508-2511. 
85 a) Matteson, D. S.; Mah, R. W. H. J. Am. Chem. Soc. 1963, 85, 2599-2603. b) Matteson, 
D. S.; Majumdar, D. J. Am. Chem. Soc. 1980, 102, 7588-7590. c) Brown, H. C.; Singh, S. 
M.; Rangaishenvi, M. V. J. Org. Chem. 1986, 51, 3150-3155. 
86 a) Miyaura, N.; Suzuki, A. Chem. Rev. 1995, 95, 2457-2483. b) Kirchhoff, J. H.; 
Netherton, M. R.; Hills, I. D.; Fu, G. C. J. Am. Chem. Soc. 2002, 124, 13662-13663. c) Jana, 
R.; Pathak, T. P.; Sigman, M. S. Chem. Rev. 2011, 111, 1417-1492. d) Li, L.; Zhao, S.; Joshi-
Pangu, A.; Diane, M.; Biscoe, M. R. J. Am. Chem. Soc. 2014, 136, 14027-14030. 
87  a) Hupe, E.; Marek, I.; Knochel, P. Org. Lett. 2002, 4, 2861-2863. b) Mlynarski, S. N.; 
Karns, A. S.; Morken, J. P. J. Am. Chem. Soc. 2012, 134, 16449-16451. 
88  a) Darses, S.; Genet, J. P. Chem. Rev. 2008, 108, 288-325. b) Sandrock, D. L.; Jean-
Gerard, L.; Chen, C. Y.; Dreher, S. D.; Molander, G. A. J. Am. Chem. Soc. 2010, 132, 17108-
17110. c) Lee, J. C. H.; McDonald, R.; Hall, D.G. Nat. Chem. 2011, 3, 894-899. d) Tellis, J. 
C.; Primer, D. N.; Molander, G. A. Science 2014, 345, 433-436. 
89 a) Furuya, T.; Ritter, T. Org. Lett. 2009, 11, 2860-2863. b) Li, Z.; Wang, Z.; Zhu, L.; 
Tan, X.; Li, C. J. Am. Chem. Soc. 2014, 136, 16439-16443. 
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Scheme 2-25: Versatility of the C-B bond in cyclobutylboronates. 
 
Despite their potential, the stereoselective synthesis of 
cyclobutylboronates is still a great challenge.90 In this section we will cover 
the stereoselective methodologies to synthetize cyclobutylboronates. This 
topic is divided into two sections. The first one describes synthetic methods 
that are just diastereoselective, that is, those that do not allow for the 
preparation of enantiomerically enriched compounds. The second section 
compiles the existing asymmetric methodologies for the preparation of 
cyclobutylboronates, that is, those that allow for the preparation of 
enantiomerically enriched compounds. 
 
2.1.6.1. Diastereoselective Synthesis of Cyclobutylboronates. 
Comparing the number of different methodologies to prepare 
cyclopropylboronates, cyclobutyl derivatives have received considerably 
less attention. In 2010, Ito and coworkers, in a very elegant work, developed 
the stereospecific synthesis of cyclobutylboronates through a copper-
 
90 Martin-Heras, V.; Parra, A.; Tortosa, M. Synthesis, 2018, 50, 470-484. 
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catalyzed borylation of homoallylic sulfonates (Scheme 2-26).91 The initial 
insertion of the double bond into the copper-boron complex allows for the 
formation an alkylcopper intermediate that cyclized to form a 
cyclobutylboronate. Both syn and anti-derivatives could be obtained by 
switching the double bond geometry. The limitation of this method is that 
either a phenyl or a silyl group in the alkene is necessary for the reaction to 
occur.  
 
 
Scheme 2-26: Copper catalyzed stereospecific synthesis of 
cyclobutylboronates. 
 
Sawamura and coworkers reported a diastereoselective method for the 
C-H borylation of cyclobutanes (Scheme 2-27).92 Nitrogen-containing 
substituents in the cyclobutane ring, such as pyridyl or benzoxazolyl, are 
required as directing groups to obtain high diastereoselectivities. As 
catalyst they used a silica-supported monophosphane-Ir complex and 
 
91 Ito, H.; Toyoda, T.; Sawamura, M. J. Am. Chem. Soc. 2010, 132, 5990-5992. 
92 Murakami, R.; Tsunoda, K.; Iwai, T.; Sawamura, M. Chem. Eur. J. 2014, 20, 13127-
13131. 
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B2pin2 as boron source. The pinacolborane produced after the borylation 
also worked as borylating agent, therefore yields could be up to 200%.   
 
 
Scheme 2-27: Stereoselective C-H borylation of cyclobutanes catalyzed 
by silica supported Ir catalyst. 
 
It was in 2016, when Yu and coworkers reported the Pd-catalyzed -
borylation of amides (Scheme 2-28).93 The reaction is promoted by 
quinoline-based ligands and among the wide range of compounds 
compatible with this methodology, cyclobutylamides afforded excellent 
results. Cyclobutylboronates were synthetized with excellent yields as 
single diastereomers. 
 
 
 
 
 
93 He, J.; Jiang, H.; Takise, R.; Zhu, R. Y.; Chen, G.; Dai, H. X.; Dhar, T. G. M.; Shi, J.; 
Zhang, H.; Cheng, P. T. W.; Yu, J. Q. Angew. Chem. Int. Ed. 2016, 55, 785-789. 
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Scheme 2-28: Pd-catalyzed C-H borylation of cyclobutanes. 
 
Recently, Aggarwald and coworkers published a palladium catalyzed 
cross-coupling where they succeeded into the carbopalladation of a strained 
-bond of bicyclo[1.1.0]butyl boronate complexes, introducing at the same 
time an aryl unit and a boronic ester across the mentioned -bond. With this 
methodology they synthetized arylcyclobutylboronates with excellent 
diastereocontrol (Scheme 2-29).94  
 
 
 
 
 
 
 
 
94 Fawcett, A.; Biberger, T.; Aggarwal, V. K. Nat. Chem. 2019, 11, 117-122. 
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Scheme 2-29: Carbopalladation of -bonds to synthesize substituted 
cyclobutylboronates. 
 
The mechanism they proposed started by the oxidative addition of the 
aryl triflate to the palladium(0) complex. Then, the palladium(II) complex 
attacked from the exo face of the bicyclo[1.1.0]butyl moiety inducing a 1,2-
metallate rearrangement, where there is a simultaneous cleavage of the C-
C bond, 1,2-migration of the substituent in the boronate complex to the -
carbon and formation of the C-Pd bond at the -carbon. The last step is the 
reductive elimination to give the desired cyclobutylboronate and start again 
the catalytic cycle (Scheme 2-30). 
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Scheme 2-30: Mechanism for the carbopalladation of C-C -bonds in 
strained boronate complexes. 
 
Recently, Aggarwal and Silvi, reported the radical addition of different 
alkyl iodines to strained -bonds of bicyclo[1.1.0]butyl boronate 
complexes. They succeeded in the diastereoselective synthesis of 
cyclobutylboronates with moderate to excellent results without the use of 
any metal catalyst (Scheme 2-31).95 The mechanism is similar to that 
explained in Scheme 2-30. They proposed that the radical formed from the 
alkyl iodine under visible light irradiation added to the central bond of the 
bicyclo[1.1.0]butyl unit leading to a radical anion. This radical anion 
underwent a SET process with another molecule of alkyl iodine forming a 
 
95 Silvi, M.; Aggarwal, V. K. J. Am. Chem. Soc. 2019, 141, 9511-9515. 
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zwitterionic specie, which underwent a 1,2-metalate rearrangement to form 
the desired cyclobutylboronate. 
 
 
Scheme 2-31: Radical addition to strained -bonds to synthesis 
cyclobutylboronates. 
 
2.1.6.2. Asymmetric Synthesis of Cyclobutylboronates. 
Similarly, the asymmetric synthesis of cyclobutylboronates has been 
much less studied than the asymmetric synthesis of cyclopropylboronates. 
The first example was reported in 1999, when Matteson and coworkers 
published the first synthesis of enantiomerically enriched boron-containing 
cyclobutanes (Scheme 2-32).96 Deprotonation of an enantiopure -cyano 
-chloroboronate with LDA provided a cyclic boronate that evolved to the 
desired cyclobutylboronate upon treatment with MgBr2. 
 
 
 
 
96 Man, H. W.; Hiscox, W. C.; Matteson, D. S. Org. Lett. 1999, 1, 379-381. 
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Scheme 2-32: Stereoselective synthesis of cyclobutylboronates. 
 
Making good use of the opportunities offered by photochemistry, Bach 
and coworkers developed an enantioselective [2+2] cycloaddition. They 
used an innovative chiral template for the reaction, and under 300 nm 
wavelength light the desired cyclobutylboronate is formed with excellent 
results and almost perfect stereocontrol (Scheme 2-33).97 The drawbacks 
of this reaction is that 2.5 equivalents of chiral template are needed, as well 
as 10 equivalents of vinylboronate. 
 
 
 
 
97 Coote, S. C.; Bach, T. J. Am. Chem. Soc. 2013, 135, 14948-14951. 
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Scheme 2-33: Enantioselective [2+2] photochemical synthesis of 
cyclobutylboronate. 
 
Recently, after the results presented in this chapter were reported, Logan 
and Brown used Pd-Ruphos G3 and a copper(I) complex in combination to 
create a catalytic system capable of perform the enantioselective 
arylboration of alkenes. Concerning this thesis, they reported the formation 
of a bicyclic cyclobutylboronate with good yield and moderate 
enantioselectivity (Scheme 2-34).98 
 
 
 
 
 
 
 
 
98 Logan, K. M.; Brown, M. K. Angew. Chem. Int. Ed. 2017, 56, 851-855. 
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Scheme 2-34: Pd/Cu catalyzed enantioselective arylborylation of 
alkenes. 
 
In the same year, Yu and coworkers reported the enantioselective Pd-
catalyzed C-H activation of cyclobutylamides. As in their previous report 
(Scheme 2-28),93 the amide moiety worked as directing group. In the 
present case, they used a chiral bidentate ligand to obtain the desired 
cyclobutylboronates with excellent yields and enantioselectivities (Scheme 
2-35).99 
 
 
 
 
 
 
 
 
99 He, J.; Shao, Q.; Wu, Q.; Yu, J. Q. J. Am. Chem. Soc. 2017, 139, 3344-3347. 
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Scheme 2-35: Enantioselective C-H borylation of cyclobutylamides. 
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2.2.  Enantioselective Synthesis of Cyclobutylboronates via a 
Copper-Catalyzed Desymmetrization Approach. 
2.2.1. Objectives. 
At the beginning of this Doctoral Thesis there were only two reports for 
the synthesis of enantiomerically enriched cyclobutylboronates (Scheme 
2-32 and Scheme 2-33)96,97, none of them using a catalytic amount of a 
chiral source. Eager to broad the toolbox to prepare these useful, 
nevertheless difficult-to-prepare compounds, we decided to explore an 
entirely new approach. We thought to apply our experience in copper-
catalyzed borylations66,69,100 and envisioned the possibility of access 
cyclobutylboronates through a desymmetrization of meso-cyclobutenes. If 
successful, our method would be the first catalytic enantioselective 
approach for the synthesis of cyclobutylboronates. Beside the importance 
of the products, we were also intrigued about the behavior of cyclobutenes 
under copper-catalyzed borylation conditions. Our idea was supported by 
the successful copper-catalyzed borylation of cyclopropenes previously 
resported in our group.66  However, reactivity, diastereoselectivity and 
enantioselectivity were not obvious parameters to control when moving 
from a three to a four-membered alkene. Indeed, the evidence that shows 
that meso-cyclobutenes are challenging substrates is that they had been 
scarcely used in metal-catalyzed transformations, and virtually unexplored 
in asymmetric catalysis. With these ideas in mind, we proposed the 
following objectives for this chapter (Scheme 2-36): 
- To develop a diastero- and enantioselective copper-catalyzed 
borylation of meso-cyclobutenes to produce cyclobutylboronates 
with three stereogenic centers.  
 
100 a) Lopez, A.; Parra, A.; Jarava-Barrera, C.; Tortosa, M. Chem. Comm. 2015, 51, 17684-
17687. b) Jarava-Barrera, C.; Parra, A.; Lopez, A; Cruz-Acosta, F.; Collado-Sanz, D.; 
Cárdenas, D. J.; Tortosa, M. ACS Catal. 2016, 6, 442-446.  
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- To explore the possibility of trapping the cyclobutylcopper 
intermediate with electrophiles different than proton. If this 
approach is successful, we could access cyclobutylboronates with 
up to four contiguous stereogenic centers. 
 
 
Scheme 2-36: Objectives of this chapter. 
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2.2.2. Synthesis of Starting Materials. 
First, we prepared a series of meso-cyclobutenes II-1a-l (Figure 2-7) to 
study the copper-catalyzed borylation. To do so, we followed different 
reported procedures depending on the substituents attached to the ring. 
 
 
Figure 2-7: Prepared meso-cyclobutenes. 
 
Cyclobutene II-1a, with two benzyloxy substituents, was synthetized 
from commercially available cis-dichlorocyclobutene in only one step, 
making this synthesis very convenient (Scheme 2-37).101 We used the same 
procedure to synthetize cyclobutene II-1b, with to benzylthionyl 
substituents in the structure. 
 
 
 
 
101 A. H.; Lombardi, P. J.; O’Brien, R. V.; Zhugralin, A. R. J. Am. Chem. Soc. 2009, 131, 
8378-8379. 
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Scheme 2-37: Synthesis of cyclobutenes II-1a and II-1b. 
 
Cyclobutenes II-1d, II-1f, II-1g and II-1h were prepared following a 
modified reported procedure.102 The sequence started with the in situ 
formation of dichloroketene from trichloroacetyl chloride and zinc. [2+2] 
cycloaddition between the corresponding Z-alkene and dichloroketene 
formed compounds II-3. The ketone was reduced with NaBH4, forming 
alcohols II-4. By a sequence of mesylation and elimination with Na/NH3, 
cyclobutenes II-1 were finally formed (Scheme 2-38). Only one 
purification step was needed, and the yields indicated are global yields. 
 
 
 
 
 
 
102 Baldwin, J. E.; Gallagher, S. S.;  Leber, P. A.; Raghavan, A. S.; Shukla, R. J. Org. 
Chem. 2004, 69, 7212-7219. 
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Scheme 2-38: Synthesis of Cyclobutenes II-1d, II-1f, II-1g and II-1h. 
 
Compounds II-1c and II-1e (Scheme 2-39), were prepared following a 
reported procedure.103 The sequence started as before with the in situ 
formation of the dichloroketene from trichloroacetyl chloride and zinc. 
Alkynes reacted with the in situ formed dichloroketene, forming the 
corresponding dichlorocyclobutenones II-5, which were oxidized to 
diketones II-6 with H2SO4. Then, by Luche reduction with NaBH4/CeCl3 
the cis diols II-7 were formed diastereoselective, and the double bond was 
reduced by Pd/H2 to form cyclobutanediols II-8. To form the desired 
cyclobutenes II-1, a Corey-Hopkins elimination was performed.104 
 
 
 
 
103 Hasegawa, M.; Murakami, M. J. Org. Chem. 2007, 72, 3764. 
104 Corey, E. J.; Hopkins, P. B. Tetrahedron Lett. 1982, 23, 1979-1982.   
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Scheme 2-39: Synthesis of cyclobutenes II-1c and II-1e. 
 
Cyclobutenes II-1j, II-1k and II-1i were synthetized following a reported 
procedure (Scheme 2-40).105 From 5-heptadienol, obtained from reduction 
of tropone, cyclobutenes II-1j and II-1k were prepared, as a separable 
mixture of diastereoisomers, through a intramolecular photochemical 
disrotatory cyclization. This mixture could be oxidized to obtain 
cyclobutene II-1i.  
 
 
 
 
 
105 Zhang, Z.; Song, Q. P.; Wang, G. W.; Luh, T.Y. ARKIVOC, 2009, 7, 229-236. 
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Scheme 2-40: Synthesis of cyclobutene II-1i, II-1j and II-1k. 
 
Finally, cyclobutene II-1l was prepared through diastereoselective attack 
of phenylmagnesium bromide to II-1i (Scheme 2-41). 
 
 
Scheme 2-41: Synthesis of cyclobutene II-1l. 
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2.2.3. Copper-Catalyzed Borylation of Cyclobutenes: Preliminary 
Results. 
We chose cyclobutene II-1a as the model substrate for the 
enantioselective synthesis of cyclobutylboroantes. Before studying the 
enantioselective approach, we first explored the reactivity of cyclobutene 
II-1a under copper-catalyzed conditions using a non-chiral ligand. 
Treatment of cyclobutene II-1a  with 1.3 equivalents of B2pin2 in the 
presence of Cu(CH3CN)4PF6 (10 mol%) as copper source, xantphos (11 
mol%) as ligand, NaOt-Bu (50 mol%) as base in THF, led to a 
diastereomeric mixture of cyclobutylboronates (d.r. = 85:15) in low yield 
(Scheme 2-42). Although the result was not as good as expected, this 
experiment allowed us to obtain samples of both diastereoisomers, 
determined the relative configuration through NOE analysis and 
encouraged us to search for conditions to develop the enantioselective 
version. 
 
 
Scheme 2-42: Diastereoselective copper-catalyzed borylation of 
cyclobutene II-1a. 
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2.2.4. Copper-Catalyzed Borylation of Cyclobutenes: Screening of 
Conditions. 
To test the feasibility of the enantioselective version of the reaction, we 
selected a set of chiral commercially available phosphines with different 
steric and electronic properties (Table 2-1). 
In the first attempt, we were delighted to see that the reaction of 
cyclobutene II-1a and 2 equivalents of bis(pinacolato)diboron under 10 
mol% of Cu(CH3CN)4PF6 as copper source, (R)-BINAP (11 mol%) as 
ligand and t-BuONa (50 mol%) as base in THF, lead to cyclobutylboronate 
II-2a with high yield and excellent diastereomeric (93:7) and enantiomeric 
ratio (96:4) (Table 2-1, entry 1). We soon realized that although results with 
BINAP were good, Segphos derivatives provided superior results (Table 
2-1, entries 2-4). With ferrocene derivative L5 and quinoline ligand 
QuinoxP*, we observed a significant drop in the enantioselectivity and 
lower diastereoselectivity. With these results in hand, we chose (R)-DM-
Segphos as the ligand of choice, which provide cyclobutylboronate II-2a  
with 96% isolated yield and excellent stereocontrol (Table 2-1, entry 3, d.r. 
> 98:2, e.r. = 99:1). 
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Table 2-1: Ligand Optimization. 
 
Entry L* d.r.
[b] e.r.[c] Yield (%)[d] 
1 L1 93:7 96:4 76 
2 L2 >98:2 94:6 93 
3 L3 >98:2 99:1 96 
4 L4 >98:2 96:4 90 
5 L5 95:5 15:85 84 
6 L6 90:10 82:18 81 
[a] Reaction conditions: II-1a (0.1 mmol), B2pin2 (0.20 mmol), NaOt-Bu (50 mol%), 
Cu(CH3CN)4PF6 (10 mol%), L* (11 mol%), MeOH (0.2 mmol), THF (0.2 M). 
[b]d.r. 
determined by 1H-NMR analysis. [c]e.r. determined by chiral SFC. [d] Yield of isolated 
II-2a. 
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Attempts to change the base did not provide better results (Table 2-2). 
KOt-Bu gave the desired product with good yield (81%) and excellent 
enantioselectivity (99:1), but with a diastereoselectivity of 80:20 (Table 
2-2, entry 2). NaOMe afforded the product with an excellent 
enantioselectivity of 98:1, but the yield and diastereoselectivity were 
significantly lower (Table 2-2, entry 3). 
 
Table 2-2: Base Optimization. 
 
Entry Base d.r.
[b] e.r.[c] Yield (%)[d] 
1 NaOt-Bu >98:2 99:1 96 
2 KOt-Bu 80:20 99:1 81 
3 NaOMe 80:20 98:2 44 
[a] Reaction conditions: II-1a (0.1 mmol), B2pin2 (0.20 mmol), Base (50 mol%), 
Cu(CH3CN)4PF6 (10 mol%), (R)-DM-SEGPHOS (11 mol%), MeOH (0.2 mmol), THF 
(0.2 M). [b]d.r. determined by 1H-NMR analysis. [c]e.r. determined by chiral SFC. [d] 
Yield of isolated II-2a. 
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Copper(I) chloride provided similar results, however the diastereomeric 
ratio and the yield were slightly lower than when using Cu(CH3CN)PF6 
(Table 2-3, entry 2). Carrying out the reaction with 5 mol% of Cu(I), 
provided inferior results (Table 2-3, entry 3). Finally, reducing the 
equivalents of B2pin2 to 1.1, provided the product with excellent 
stereocontrol but only 60% yield (Table 2-3, entry 4). 
 
Table 2-3: Reaction Optimization. 
 
Entry 
Change in other 
parameters 
d.r.[b] e.r.[c] Yield (%)[d] 
1 - >98:2 99:1 96 
2 CuCl (10 mol%) 94:6 98:2 90 
3 Cu(CH3CN)PF6 (5 mol%) 90:10 95:5 70 
4 1.1 equiv B2pin2 >98:2 99:1 60 
[a] Reaction conditions: II-1a (0.1 mmol), B2pin2 (0.20 mmol), NaOt-Bu (50 mol%), 
Cu(CH3CN)4PF6 (10 mol%), (R)-DM-SEGPHOS (11 mol%), MeOH (0.2 mmol), THF 
(0.2 M). [b]d.r. determined by 1H-NMR analysis. [c]e.r. determined by chiral SFC. [d] 
Yield of isolated II-2a. 
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2.2.5. Scope of the Reaction. 
To study the scope of the reaction, a variety of disubstituted meso-
cyclobutenes (II-1) were tested with the optimized copper-catalyzed 
borylation conditions (Scheme 2-43).  
When we applied the optimal conditions to cyclobutane II-1b, we 
observed a significant decrease in the yield (22%) but the stereocontrol was 
still excellent. We reasoned that sulfur atoms could coordinate to the copper 
catalyst, poisoning it and stopping the catalytic cycle. We reasoned that a 
ligand bulkier than DM-Segphos, could provide better results, minimizing 
the coordination of the sulfur atoms. Gratifyingly, when we used (R)-
DTBM-Segphos (L4) as ligand, cyclobutylboronate II-2b was obtained 
with excellent stereocontrol and better yield (52%). Aromatic substituents 
were compatible with the reaction conditions and compound II-2c, was 
prepared with excellent results. Cyclobutenes II-1d and II-1e, with alkyl 
groups as substituents, yielded the borylation products with excellent 
stereocontrol and yield, independently of the steric hindrance of the alkyl 
chain. Moreover, alkyl chains with coordinating alkoxy groups, produced 
the corresponding cyclobutylboronate II-2f with any erosion of the yield or 
the stereoselectivity. 
Bicyclic compounds were compatible with the reaction conditions and 
a variety of bicyclic cyclobutenes were tested. Cyclohexyl and cycloheptyl 
rings fused with the cyclobutene (compounds II-1g and II-1h) were 
suitable substrates for the borylation. We were pleased to see that the 
presence of unprotected ketones did not affect the reaction, yielding the 
borylated product II-2i with 91% yield and excellent stereocontrol, without 
traces of the borylated ketone.106 Cyclobutylboronates II-2j and II-2k, were 
prepared from the correspondent cyclobutenes, with excellent results. The 
 
106 McIntosh, M. L.; Moore, C. M.; Clark, T. B. Org. Lett. 2010, 12, 1996-1999. 
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presence of a free alcohol in the bicyclic structure, did not affect the 
outcome of the reaction. Compound II-2l, with a quaternary center, yielded 
the borylated product with almost perfect stereocontrol and excellent yield. 
In the last three examples, the creation of four stereogenic centers in the 
molecule was achieved in only one step of synthesis, with complete 
stereoselectivity. 
 
 
Scheme 2-43: Scope of the enantioselective copper-catalyzed 
borylation of meso-cyclobutenes. 
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The absolute configuration of (R,S,R)-II-2c and (S,R,S,R)-II-2l  were 
determined from single crystal X-ray crystallography of p-bromobenzoates 
(R,R,R)-II-10107 and (S,R,R,R)-II-11108 derivatives (Scheme 2-44). 
Oxidation of the carbon-boron bond with sodium perborate, followed by 
benzoylation with 4-bromobenzoyl chloride afforded compounds (R,R,R)-
II-10 and (S,R,R,R)-II-11. The absolute configuration of all the other 
cyclobutylboronates was assigned by analogy. 
 
 
Scheme 2-44: Determination of the absolute configuration by X-ray 
crystallography. 
 
107 CCDC 1442992 contains the supplementary crystallographic data. These data can be 
obtained free of charge at www.ccdc.cam.ac.uk/conts/retrieving.html 
108 CCDC 1441995 contains the supplementary crystallographic data. These data can be 
obtained free of charge at www.ccdc.cam.ac.uk/conts/retrieving.html 
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2.2.6. Derivatizations. 
Tu further demonstrate the utility of the synthetized cyclobutylboronates 
we designed a series of transformations, in order to converted them in useful 
intermediates. 
First, we successfully transformed cyclobutylboronate II-2g into the 
correspondent trifluoroborate salt II-12. These salts have been successfully 
employed in a variety of cross-coupling reactions, as more stable 
equivalents of boronic acids (Scheme 2-45).109 
 
 
Scheme 2-45: Formation of trifluoroborate salt II-12. 
 
Secondly, we have transformed cyclobutylboronate II-2j, into 
enantiomerically enriched cyclobutanone II-14 by protection of the alcohol 
with tert-butyldimethylsilyl chloride and double oxidation of the C-B bond 
to the ketone II-14 (Scheme 2-46). We have used ketone II-14 as 
intermediate for the preparation of some valuable compounds. 
 
 
 
109 a) Fang, G. -H.; Yan Z. -J.; Deng, M. -Z. Org. Lett. 2004, 6, 357-360. b) Molander, G. 
A.; Ellis, N. Acc. Chem. Res. 2007, 40, 275-286. c) Darses, S.; Genet, J. P. Chem. Rev. 2008, 
108, 288-325. d) Molander, G. A., Gormisky, P. E. J. Org. Chem. 2008, 73, 7481-7485. 
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Scheme 2-46: Synthesis of cyclobutanone II-14. 
 
We have transformed cyclobutanone II-14 into diol II-16, in only two 
steps (Scheme 2-47), being this synthesis the very first catalytic 
enantioselective synthesis of this compound. Previous synthesis of this 
compounds depended on kinetic resolution of the racemic compound. This 
diol is a precursor of the chiral ligand FLEXIphosO,110 useful in rhodium-
catalyzed asymmetric hydrogenations111 and 1,6-diene cycloisomerization 
catalyzed by palladium.112 
 
 
 
 
 
 
110 Fairlamb, I. J. S.; Tommasi, S.; Moulton, B. E.; Zheng, W.; Lin, Z.; Whitwood, A. C. 
Eur. J. Inorg. Chem. 2007, 3173-3178. 
111 a) Adger, B.; Berens, U.; Griffiths, M. J.; Kelly, M. J.; McCague, R.; Miller, J. A.; 
Palmer, C. F.; Roberts, S. M.; Selke, R.; Vitinius, U.; Ward, G. Chem. Commun. 1997, 1713-
1714. b) Derrien, N.; Dousson, C. B.; Roberts, S. M.; Berens, U.; Burk, M. J.; Ohff, M. 
Tetrahedron: Asymmetry 1999, 10, 3341-3352. 
112 a) Fairlamb, I. J. S.; Grant, S.; Whitwood, A. C.; Whitthall, J.; Batsanov, A. S.; 
Collings, J. C.  J. Organomet. Chem. 2005, 690, 4462-4477. b) Fairlamb, I. J. S.; Grant, S.; 
Tommasi, S.; Lynam, J. M.; Bandini, M.; Dong, H.; Lin, Z.; Whitwood, A. Adv. Synth. 
Catal. 2006, 348, 2515-2530. 
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Scheme 2-47: Synthesis of diol II-16. 
 
We also have performed the regioselective Baeyer-Villiger oxidation of 
cyclobutanone II-14 to obtain Corey lactone II-17 (Scheme 2-48).113 In a 
first attempt, we tried to perform the Baeyer-Villiger oxidation using 
mCPBA, but we observed that although the conversion was complete the 
regioselectivity was not good enough (r.r. = 2.8:1). We also tried using 
SbCl5 along with ethyl diazoacetate, but a complicated mixture was formed. 
Finally, using H2O2 in trifluoroethanol, we achieved the desired 
transformation with excellent regioselectivity (r.r. = 9:1).114 Lactone II-17 
is an intermediate in the synthesis of the HIV-1 protease inhibitor GRL-
06579A.115 
 
 
 
113 Corey, E. J.; Weinshenker, N. M.; Schaaf, T. K.; Huber, W. J. Am. Chem. Soc. 1969, 
91, 5675-5677. 
114 Depre, D.; Chen, L. Y.; Ghosez, L. Tetrahedron, 2003, 59, 6797-6812. 
115 Ghosh, A. K.; Takayama, J. Tetrahedron Lett. 2008, 49, 3409-3412. 
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Scheme 2-48: Synthesis of Corey lactone II-17. 
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2.2.7. Mechanistic Proposal. 
A plausible mechanism for the copper(I)-catalyzed borylation of 
cyclobutenes is proposed in Scheme 2-49. First, the reaction between 
copper(I) salt, the ligand and sodium tert-butoxide formed a copper 
alkoxide. This alkoxide (L*Cu-Ot-Bu) could undergo a σ-bond metathesis 
reaction with bis(pinacolato)diboron to form a chiral copper-boryl complex 
(L*Cu-Bpin). Then, insertion of the cyclobutene into the copper-boryl 
complex would afford cyclobutyl copper intermediate II-A. Reaction with 
MeOH would provide the hydroboration product and copper-methoxide 
(L*Cu-OMe) that would regenerate the catalytic cycle.  
 
 
Scheme 2-49: Mechanism for the copper-catalyzed borylation of 
cyclobutenes. 
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 This methodology has been used by Burns and co-workers as key step 
in the synthesis of [5]-ladderanoic acid (Scheme 2-50).116 
 
 
Scheme 2-50: Synthesis of [5]-ladderanoic acid. 
  
 
116 Mercer, J. A. M; Cohen, C. M.; Shuken, S. R.; Wagner, A. M.; Smith, M. W.; Moss 
III, F. R.; Smith, M. D.; Vahala, R.; Gonzalez-Martinez, A.; Boxer, S. G.; Burns, N. Z. J. 
Am. Chem. Soc. 2016, 138, 15845-15848. 
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2.3. Enantioselective Carboboration of Cyclobutenes. 
2.3.1. Introduction and Objectives. 
Looking back at the proposed mechanism (Scheme 2-49), we thought 
about the possibility of trapping the cyclobutylcopper intermediate II-A 
with an electrophile different than proton (Scheme 2-51). If we succeeded 
in this endeavor, we would have developed a borylation of the double bond 
in combination with another bond-forming process.117 Previously, in our 
group, the copper-catalyzed carboboration of alkynes was successfully 
performed.118 Other groups have also performed the copper-catalyzed 
carboboration of diverse motifs.119 But this transformation, as well as with 
the hydroboration, has never been performed in cyclobutenes. The expected 
products would be cyclobutylboronates with four contiguous stereocenters. 
The creation of four new stereocenters in a single step would be an 
important contribution to the field. The objective of this chapter is to 
perform an enantioselective copper-catalyzed carboboration of meso-
 
117 For reviews see: a) Cuenca, A. B.; Shishido, R.; Ito, H.; Fernandez, E.  Chem. Soc. Rev. 
2017, 46, 415-430. b) Fyfe, J. W. B.; Watson, A. J. B. Chem. 2017, 3, 31-55. c) Collins, B. 
S. L.; Wilson, C. M.; Myers, E. L.; Aggarwal, V. K. Angew. Chem., Int. Ed. 2017, 56, 11700-
11733. 
118 Alfaro, R.; Parra, A.; Alemán, J; Ruano, J. L. G.; Tortosa, M. J. Am. Chem. 
Soc. 2012, 134, 15165-15168.  
119 For selected examples of copper-catalyzed carboborations of alkynes see: a) Liu, P.; 
Fukui, Y.; Tian, P.; He, Z. -T.; Sun, C. -Y.; Wu, N. -Y.; Lin, G. -Q. J. Am. Chem. Soc. 2013, 
135, 11700−11703. b) Zhou, Y.; You, W.; Smith, B. K.; Brown, M. K. Angew. Chem. Int. 
Ed. 2014, 53, 3475−3479. c) Itoh, T.; Shimizu, Y.; Kanai, M. J. Am. Chem. Soc. 2016, 138, 
7528−7531. d) Cheng, L. J.; Mankad, N. P. Angew. Chem. Int. Ed. 2018, 57, 10328-10332. 
For selected examples of copper-catalyzed carboborations of alkenes see: a) Ito, H.; Kosaka, 
Y.; Nonoyama, K.; Sasaki, Y.; Sawamura, M. Angew. Chem. Int. Ed. 2008, 47, 7424-7427. 
b) Zhong, C.; Kunii, S.; Kosaka, Y.; Sawamura, M.; Ito, H. J. Am. Chem. Soc. 2010, 132, 
11440-11442. c) Meng, F.; McGrath, K. P.; Hoveyda, A. H. Nature 2014, 513, 367-374. d) 
Semba, K.; Nakao, Y. J. Am. Chem. Soc. 2014, 136, 7567-7570. e) Whyte, A.; Burton, K. 
I.; Zhang, J.; Lautens, M. Angew. Chem. Int. Ed. 2018, 57, 13927-13930. For selected 
examples of copper-catalyzed carboborations of allenes see: a) Meng, F.; Jang, H.; Jung, B.; 
Hoveyda, A. H. Angew. Chem. Int. Ed. 2013, 52, 5046-5051. b) Semba, K.; Bessho, N.; 
Fujihara, T.; Terao, J.; Tsuji, Y. Angew. Chem. Int. Ed. 2014, 53, 9007-9011. For selected 
examples of cooperative Cu/Pd catalyzed arylborations see: a) Semba, K.; Nakao, Y. J. Am. 
Chem. Soc. 2014, 136, 7567-7570. b) Logan, K. M.; Smith, K. B.; Brown, M. K. Angew. 
Chem. Int. Ed. 2015, 54, 5228-5231. c) Logan, K. M.; Brown, M. K. Angew. Chem. Int. Ed. 
2017, 56, 851-855. d) Bergmann, A. M.; Dorn, S. K.; Smith, K. B.; Logan, K. M. Angew. 
Chem. Int. Ed. 2019, 58, 1719-1723. 
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cyclobutenes controlling the diastereo- and the enantioselectivity by 
choosing the appropriate catalytic system. 
 
 
Scheme 2-51: Objectives of this section. 
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2.3.2. Screening of Conditions. 
Intrigued by this result, we selected a set of chiral phosphines to test the 
feasibility of this reaction under our copper-catalyzed conditions. We tested 
different ligands and we found that Segphos derivatives, although best 
suited for the hydroboration, did not give good results in the carboboration 
reaction. The desired product II-27d was formed with poor yields and low 
enantioselectivities (Table 2-4, entries 2 to 4). Ferrocenyl type ligand L5 
did not give the desired product II-27d (Table 2-4, entry 5). Quinoline 
based ligand, QuinoxP* (L6), was the best performing ligand, forming 
cyclobutane II-27d with good yield, complete control of the 
diastereoselectivity and good enantioselectivity (Table 2-4, entry 6). The 
best performing ligand controlling the enantioselectivity was BenzP* 
(Table 2-4, entry 10), but unfortunately the yield was low. (R)-Difluorphos 
gave also good results (Table 2-4, entry 11), but QuinoxP* was superior. 
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Table 2-4: Ligand Optimization. 
 
Entry L* d.r.
[b] e.r.[c] Yield (%)[d] 
1 L1 98:2 64:36 18 
2 L2 >98:2 57:43 22 
3 L3 95:5 59:41 12 
4 L4 94:6 67:33 10 
5 L5 - - <5 
6 L6 98:2 92:8 71 
7 L7 92:8 77:23 35 
8 L8 98:2 82:18 8 
10 L10 98:2 96:4 26 
11 L11 98:2 88:12 47 
[a] Reaction conditions: II-1d (0.2 mmol), B2pin2 (0.20 mmol), NaOt-Bu (1.5 equiv), 
Cu(CH3CN)4PF6 (10 mol%), L* (11 mol%), MeI (0.8 mmol), THF (0.2 M). 
[b]d.r. 
determined by 1H-NMR analysis. [c]e.r. determined by chiral SFC. [d] Yield of isolated II-
27d. 
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With the optimal ligand in hand, we proceeded to the optimization of 
the base (Table 2-5). KOt-Bu afforded cyclobutylboronate II-27d with 
poor yield and the lower stereoselectivity (Table 2-5, entry 2). NaOMe did 
not provide the desired product in appreciable yield (Table 2-5, entry 3). 
 
Table 2-5: Base Optimization. 
 
Entry Base d.r.
[b] e.r.[c] Yield (%)[d] 
1 NaOt-Bu 98:2 92:8 71 
2 KOt-Bu 95:5 82:18 17 
3 NaOMe - - <5 
[a] Reaction conditions: II-1d (0.2 mmol), B2pin2 (0.20 mmol), Base (1.5 equiv), 
Cu(CH3CN)4PF6 (10 mol%), QuinoxP* (11 mol%), MeI (0.8 mmol), THF (0.2 M). 
[b]d.r. determined by 1H-NMR analysis. [c]e.r. determined by chiral SFC. [d] Yield of 
isolated II-27d. 
 
We also tested different electrophiles to see the possible scope of the 
reaction (Table 2-6). Unfortunately, other electrophiles failed to form the 
desired product. 
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Table 2-6: Electrophile optimization. 
 
Entry Electrophile d.r.
[b] e.r.[c] Yield (%)[d] 
1 MeI 98:2 92:8 71 
2 MeOMs - - <5 
3 MeOTs - - <5 
4 MeOTf - - <5 
5 BnCl - - <5 
6 AllylI - - <5 
[a] Reaction conditions: II-1d (0.2 mmol), B2pin2 (0.20 mmol), Base (1.5 equiv), 
Cu(CH3CN)4PF6 (10 mol%), QuinoxP* (11 mol%), EX (0.8 mmol), THF (0.2 M). 
[b]d.r. determined by 1H-NMR analysis. [c]e.r. determined by chiral SFC. [d] Yield of 
isolated product. 
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2.3.3. Scope of the Reaction. 
With the optimal condition in hand, we proceeded to test them with a 
variety of cyclobutenes (Figure 2-8). 
 
 
Figure 2-8: Disubstituted cyclobutenes. 
 
When we applied the optimal condition to cyclobutene II-1c, we were 
surprised that the reaction did not give the desired product II-27c. Analysis 
of the 1H-NMR concluded that under the carboboration conditions, 
cyclobutene II-1c is not stable, and it opened to the correspondent diene. 
Cyclobutene bearing an alkyl chain with alkoxy groups II-1f gave the 
desired product with good yield and stereoselectivities (66%, d.r. > 98:2; 
e.r. = 91:9). Methyl substituted cyclobutylboronate II-27g was obtained 
from bicyclic cyclobutene II-1g with excellent diastereoselectivity and 
slightly lower enantiocontrol (78%, d.r. > 98:2; e.r. = 88:12). When we 
tested cyclobutenes II-1i, II-1j and II-1k we obtained complicated 
mixtures of products. We reasoned that the ketone and the alcohols were 
interfering with the outcome of the reaction. We decided to protect 
cyclobutene II-1j with a silyl group, and we were happy to see that the 
correspondent cyclobutylboronate II-27m was formed in moderate yield 
and complete diastereoselectivity (55%). Unfortunately, the benzoylated 
product prepared through oxidation-protection of the C-B bond was not 
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stable under HPLC conditions and we obtained complicated 
chromatograms that did not allow us to measure the enantiomeric ratio of 
the product. Although the study of the scope is not complete, these 
preliminary results are a proof of concept to show that the enantioselective 
carboboration of cyclobutenes is a feasible transformation.  
 
 
Scheme 2-52: Scope of the enantioselective carboboration of meso-
cyclobutenes. 
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2.3.4. Mechanistic Proposal. 
Although we do not have a model capable of explaining the differences 
observed between the carboboration and the hydroboration events,  a 
plausible mechanism for the copper(I)-catalyzed carboboration of 
cyclobutenes is proposed in Scheme 2-53. First, the reaction of copper(I) 
salt, the ligand and sodium tert-butoxide formed a copper alkoxide. This 
alkoxide (L*Cu-OtBu) could undergo a σ-bond metathesis reaction with 
bis(pinacolato)diboron to form a chiral copper-boryl complex (L*Cu-
Bpin). Then, insertion of the cyclobutene into the copper-boryl complex 
would afford cyclobutyl copper intermediate A, being this the most 
plausible stereodetermining step of the borylation. Reaction with MeI, 
likely through an oxidative addition-reductive elimination sequence, would 
provide the carboboration product and copper-iodine (L*Cu-I) that would 
regenerate the catalytic cycle after reaction with another equivalent of the 
alkoxide. We cannot rule out the activation of the boron atom in 
intermediate II-A with the alkoxide to promote the formation of an “ate” 
complex, facilitating the C-C bond formation event, as proposed by 
Mauleón, Gómez-Arrayás and Carretero in the intramolecular 
carboboration of alkynes.120 
 
 
 
 
 
 
 
120 Kim-Lee, S. H.; Alonso, I.; Mauleon, P.; Gomez-Arrayas, R.; Carretero, J. C. ACS 
Catal. 2018, 8, 8993-9005. 
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Scheme 2-53: Mechanism for the enantioselective carboboration of 
cyclobutenes. 
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2.4. Conclusions. 
In this chapter we have described the diastero- and enantioselective 
copper-catalyzed hydroboration of meso-cyclobutenes. Our method 
represents the first catalytic enantioselective synthesis of 
cyclobutylboronates. Through a desymmetrization approach, 
functionalized cyclobutanes with up to four stereocenters have been 
prepared (Scheme 2-54). 
A combination of a commercially available Segphos derivative along 
with an inexpensive copper(I) catalyst provided the enantiomerically 
enriched cyclobutylboronates in high yield and almost perfect sterocontrol. 
Further functionalization of the C-B bond gave access to different valuable 
intermediates.  
Furthermore, we have also successfully trapped the cyclobutylcopper 
intermediate with methyl iodide, synthetizing cyclobutylboronates with 
four contiguous stereocenters. In this case, chiral ligand QuinoxP* afforded 
the best results.  
 
 
Scheme 2-54: Copper-catalyzed hydro- and carboboration of 
cyclobutenes. 
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2.5. Conclusiones. 
En este capítulo, hemos descrito la primera hidroboración diastero- y 
enantioselectiva catalizada por cobre de ciclobutenos meso. Hemos 
sintetizado con éxito ciclobutilboronatos con hasta cuatro centros 
estereogénicos en la estructura siguiendo una estrategia de desimetrización 
(Esquema 2-55). 
Utilizando una fosfina bidentada comercial de la familia Segphos y un 
catalizador de cobre(I), hemos preparado ciclobutilboronatos 
enantioméricamente enriquecidos con rendimientos elevados y excelente 
esterocontrol. El enlace C-B se ha derivatizado a través de distintas 
transformaciones para preparar importantes intermedios sintéticos. 
Finalmente, hemos conseguido atrapar el intermedio de ciclobutilcobre 
con ioduro de metilo, preparando ciclobutilboronatos con cuatro centros 
estereogénicos contiguos. En este caso, el ligando quiral QuinoxP* 
proporcionó los mejores resultados. 
 
 
Esquema 2-55: Hidro- y carboboración de ciclobutenos catalizada por 
cobre. 
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2.6. Supplementary Data. 
2.6.1. General Experimental Details. 
Tetrahydrofuran and dichloromethane were purified by passing through 
a Pure Solv™ column drying system from Innovative Technology, Inc. 
Additionally, THF and methanol were degassed through three consecutive 
freeze-pump-thaw cycles. Diethyl ether, chloroform, dimethoxyethane and 
ethyl acetate were dried using activated 4Å molecular sieves and stored 
under argon. Unless indicated otherwise, all reactions were conducted 
under an argon atmosphere using flame-dried glassware with standard 
vacuum-line techniques. NMR spectra were acquired on a Bruker 300 
spectrometer, running at 300, and 75 MHz for 1H and 13C, respectively. 
Chemical shifts (δ) are reported in ppm relative to residual solvent signals 
(CDCl3, 7.26 ppm for 
1H NMR and 77.2 ppm for 13C NMR respectively). 
13C NMR spectra were acquired on a broad band decoupled mode. The 
following abbreviations are used to describe peak patterns when 
appropriate: s (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), 
sex (sextet), sept (septuplet), m (multiplet), br (broad). Analytical thin layer 
chromatography (TLC) was performed using pre-coated aluminum-backed 
plates (Merck Kieselgel 60 F254) and visualized by ultraviolet irradiation 
or phosphomolybdic acid dip, potassium permanganate dip, vanillin dip or 
cerium ammonium molybdate dip. Purification of reaction mixtures was 
carried out by flash chromatography (FC) using silica gel Merck-60 or 
Florisil® 60-100 mesh from Aldrich. Optical rotations were measured on a 
Perkin-Elmer 241 polarimeter. The enantiomeric ratio (er) of the products 
was determined by stationary phase SFC or UHPLC using chiral columns. 
Mass Spectrometry (MS) and High-Resolution Mass Spectrometry 
(HRMS) were registered in a spectrometer GCT Agilent Technologies 
6890N using Electronic Impact (E.I.) techniques at 70 eV and electrospray 
(ESI+ or ESI-). Melting points were determined in a GallenKamp apparatus 
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in open capillary tubes. All ligands, [Cu(CH3CN)4]PF6 and NaOt-Bu (2.0 
M solution in THF), were acquired from commercial sources and were used 
without further purification. Bis(pinacolato)diboron was recrystallized in n-
pentane before used. 
3,5-Cycloheptadienol was prepare following a reported procedure.105 
 
2.6.2. Synthesis of Starting Materials. 
2.6.2.1. Synthesis of (3R*,4S*)-3,4-bis(benzyloxy)cyclobut-1-ene, II-1a 
and (3R*,4S*)-3,4-bis(benzylthio)cyclobut-1-ene, II-1b. 
Compound II-1a and II-1b were prepared following a similar procedure 
reported in the bibliography.101 
 
To an oven-dried flask was added NaH (2.24 equiv) and THF (0.25 M). 
The solution was vigorously stirred at 0 ºC and the correspondent 
nucleophile (5.25 equiv) was added dropwise to the mixture. It was stirred 
for 15 min and 3,4-dichlorocyclobut-1-ene (1 equiv) was added. It was 
stirred at 65 ºC for 12 h. The reaction was cool down at room temperature 
and water was added. To the solution was added ether and the phases were 
separated. Aqueous phase was extracted with ether (x2). The combined 
organic phases were dried over MgSO4 and the solvent removed under 
reduced pressure. Crude was purified by flash column chromatography 
using hexanes/ethyl acetate 95:5 as eluent.  
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(3R*,4S*)-3,4-bis(Benzyloxy)cyclobut-1-ene, II-1a. 
 From 3,4-dichlorocyclobut-1-ene (0.768 
g, 6.3 mmol), following the general procedure 
described above, compound II-1a (1.0 g, 3.8 
mmol) was obtained in 60% yield as yellow 
oil.  
1H-NMR, 13C-NMR and MS data were consistent with literature 
values.101 1H-NMR (300 MHz, CDCl3) δ 7.30 (t, J = 6.8 Hz, 4H), 7.27 – 
7.21 (m, 4H), 7.21 – 7.16 (m, J = 3.7 Hz, 2H), 6.34 – 6.28 (m, 2H), 4.70 
(dd, J = 33.8, 11.6 Hz, 6H), 4.68 – 4.67 (m, 2H). 
 
(3R*,4S*)-3,4-bis(Benzylthio)cyclobut-1-ene, II-1b. 
 From 3,4-dichlorocyclobut-1-ene (0.500 
g, 4.06 mmol), following the general 
procedure described above, compound II-1b 
(0.8 g, 2.7 mmol) was obtained in 66% yield 
as yellow oil.  
1H NMR (300 MHz, CDCl3): δ 7.31 – 7.23 (m, 10H), 5.87 (s, 2H), 4.06 
(s, 2H), 3.79 (d, J = 3.5 Hz, 4H). 13C NMR (75 MHz, CDCl3): δ 138.7, 
138.6, 129.2, 128.6, 127.0, 52.2, 36.2. HRMS-ESI+ m/z calculated for 
C18H18S2Na [M+Na]
+: 321.0742, found 321.0731. 
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2.6.2.2. General procedure for synthesis of cyclobutenes II-1d, II-1f, II-1g, 
II-1h. 
Compounds II-1d, II-1f, II-1g and II-1h were prepared following a 
similar procedure reported in the bibliography.102 
 
 
 
To a mixture of activated zinc (2 equiv), the corresponding cis-alkene 
(1 equiv), and anhydrous ether (2.5 mL/mmol of alkene), placed in a 
sonication bath maintained at 15-20 °C, was added a solution of 
trichloroacetyl chloride (1.44 equiv) in ether (1.2 mL/mmol of alkene) over 
a 90 min period. Sonication of the reaction mixture at 15 °C was continued 
for another 6.5 h. The mixture was quenched with wet ether and filtered 
through a sintered glass funnel; the zinc was rinsed with wet ether, and the 
total filtrate was washed with water (x2), NaHCO3 (aq) (x5), and brine. The 
organic phase was dried over MgSO4 and the solvent removed under 
reduced pressure. The crude product was used in the next step without 
further purification. 
The corresponding dichloroketone (1 equiv) and methanol (5 mL/mmol 
of dichloroketone) were cooled to 0 ºC and sodium borohydride (2.5 equiv) 
was added portionwise over 2 h. The reaction mixture was allowed to warm 
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to room temperature and was stirred for 2 h, and then it was re-cooled to 0 
ºC and diluted with a cold mixture of NH4Cl (aq) and ether. The layers were 
separated, and the aqueous phase was extracted with ether (x3). The 
ethereal extract was washed with saturated solution of NaHCO3, water, and 
brine, and then it was dried over MgSO4 and filtered. Concentration 
afforded the crude product, which was used in the next step without further 
purification. 
A solution of the corresponding alcohol (1 equiv) in CH2Cl2 (2.3 
mL/mmol of alcohol) was cooled to 0 ºC, and then triethylamine (4.5 equiv) 
was added. Methanesulfonyl chloride (3.5 equiv) was placed in an addition 
funnel and added slowly over 1.5 h. The bath ice was allowed to melt, thus 
allowing the reaction mixture to slowly warm to room temperature. After 
being stirred for 3 h, the reaction mixture was again cooled to 0 ºC for work- 
up. A mixture of cold water (2.3 mL/mmol of alcohol) and CH2Cl2 (2.3 
mL/mmol of alcohol) was added to the reaction mixture. It was stirred for 
30 min and cold 1N HCl was added to acidify the mixture. The layers were 
separated, and the aqueous phase was extracted three times with CH2Cl2. 
The organic extract was washed twice with cold water, twice with cold 1N 
HCl, and with a saturated solution of NaHCO3 and brine, and then dried 
over MgSO4, and filtered. The resulting dark orange solution was 
concentrated by rotary evaporation, affording a dark orange liquid. This 
crude mesylate was used without further purification in the synthetic 
transformation that follows. 
Ammonia (24 mL/mmol of mesylate) was condensed at -78 ºC in a 
three-necked flask fitted with a magnetic stirrer, a dry ice/acetone 
condenser, and an addition funnel. Sodium (15 equiv) was added in small 
pieces, producing a deep blue color as cooling was maintained at -78 ºC. A 
solution of crude dichloro mesylate (1 equiv) in dry tetrahydrofuran (4.5 
mL/mmol of mesylate) was placed in the addition funnel and added to the 
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Na/NH3 over 30 min, and then the reaction mixture was allowed to warm 
to -40 to -35 ºC and stirred for 2 h. To destroy the excess sodium, NH4Cl 
was added until the blue color was gone. The dry ice/acetone condenser and 
the addition funnel were removed. The reaction mixture was slowly 
allowed to warm to 0 ºC, allowing the NH3 to evaporate. Water (12 
mL/mmol of mesylate) was added to dissolve the remaining salts and then, 
pentane (4 mL/mmol of mesylate) was added. The layers were separated, 
and the aqueous phase was extracted three times with pentane. The pentane 
extract was washed with water, 1N HCl, water, saturated NaHCO3, water, 
and brine. The organic phase was dried over MgSO4 and the solvent 
removed under reduced pressure. Crude was purified by flash column 
chromatography over silica gel using n-pentane as eluent. 
 
(3R*,4S*)-3,4-Dibenzylcyclobut-1-ene, II-1d. 
From (Z)-1,4-diphenylbut-2-ene (2 g, 9.6 mmol), 
following the general procedure described above, 
compound II-1d (0.35 g, 1.5 mmol) was obtained in 
16% overall yield (4 steps) as an orange oil.  
1H RMN (300 MHz, CDCl3): δ 7.42 – 7.35 (m, 4H), 7.32 – 7.25 (m, 
6H), 6.23 (s, 2H), 3.41 – 3.28 (m, 2H), 3.01 (dd, J = 13.5, 5.6 Hz, 2H), 2.82 
(dd, J = 13.4, 10.5 Hz, 2H). 13C RMN (75 MHz, CDCl3): δ 141.2, 139.7, 
128.8, 128.4, 125.8, 47.7, 36.5. HRMS-EI+ m/z calculated for C18H18 [M]
+: 
234.1409, found 234.1407. 
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(3R*,4S*)-3,4-bis(Methoxymethyl)cyclobut-1-ene, II-1f. 
From (Z)-1,4-dimethoxybut-2-ene (4 g, 34.5 mmol), 
following the general procedure described above, 
compound II-1f (1.3 g, 9.2 mmol) was obtained in 27% 
overall yield (4 steps) as a colorless oil after a flash column 
chromatography over silica gel using n-pentane/ethyl ether 80:20 as eluent. 
1H RMN (300 MHz, CDCl3): δ 6.16 (s, 2H), 3.58 – 3.50 (m, 2H), 3.50 
– 3.42 (m, 2H), 3.33 (s, 6H), 3.22 – 3.14 (m, 2H). 13C RMN (75 MHz, 
CDCl3): δ 138.6, 72.9, 58.9, 45.7. HRMS-EI+ m/z calculated for C8H14O2 
[M]+: 142.0994, found 142.0995. 
 
(1R*,7S*)-Bicyclo[5.2.0]non-8-ene, II-1g. 
From cycloheptene (4 g, 41.6 mmol), following the general 
procedure described above, compound II-1g (1.44 g, 11.8 
mmol) was obtained in 28% yield overall yield (4 steps) as a 
colorless oil.  
1H RMN (300 MHz, CDCl3): δ 6.07 (s, 2H), 2.97 – 2.86 (m, 2H), 1.82 
– 1.71 (m, 5H), 1.44 – 1.15 (m, 5H). 13C RMN (75 MHz, CDCl3): δ 139.7, 
48.9, 32.3, 30.7, 28.5. HRMS-EI+ m/z calculated for C9H14 [M]
+: 122.1096, 
found 122.1098. 
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(1R*,6S*)-Bicyclo[4.2.0]oct-7-ene, II-1h. 
From cycloheptene (5 g, 59.4 mmol), following the general 
procedure described above, compound II-1h (1.41 g, 13 mmol) 
was obtained in 22% yield overall yield (4 steps) as a colorless 
oil.  
1H-NMR, 13C-NMR and MS data were consistent with literature 
values.102 1H RMN (300 MHz, CDCl3): δ 6.17 (s, 2H), 2.89 (dd, J = 8.3, 
4.1 Hz, 2H), 1.80 – 1.63 (m, 4H), 1.48 – 1.38 (m, 2H), 1.38 – 1.27 (m, 2H). 
 
2.6.2.3. Synthesis of (3R*,4S*)-3,4-diphenylcyclobut-1-ene, II-1c and 
(3R*,4S*)-3,4-dipropylcyclobut-1-ene, II-1e. 
Compounds II-1c and II-1e were prepared by following a similar 
reported procedure in the bibliography.103 
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To a suspension of activated Zn (3.0 equiv.) in anhydrous ether (0.15 
M) was added alkyne (1.0 equiv). Later, trichloroacetyl chloride (1.3 
equiv), dissolved in dimethoxyethane (2 M), was added dropwise with 
vigorous agitation. The mixture was stirred at room temperature for 36 h. 
The reaction mixture was filtered over celite and washed with saturated 
NaHCO3 (x3) and saturated NaCl (x3). The organic phase was dried over 
MgSO4 and the solvent removed under reduced pressure. The reaction 
crude was used without further purification in the next step. 
To concentrated H2SO4 (2 mL/mmol X) at 55 ºC, was added II-18 (1 
equiv). The solution was stirred for 12 min, and then quenched with ice. 
The solution was extracted with ether (x3) and the combined organic phases 
were washed with saturated NaHCO3 (x3) and saturated NaCl (x3). The 
organic phase was dried over MgSO4 and the solvent removed under 
reduced pressure. The reaction crude was used without further purification 
in the next step.  
To a solution of II-19 (1 equiv) in methanol (0.05M) was added cerium 
trichloride heptahidrate (2.2 equiv) and the solution was vigorously stirred 
at 0 ºC for 15 min. Sodium borohydride (2.7 equiv) was added in small 
portions and the mixture was stirred at 0 ºC until full conversion by TLC (2 
h). The reaction was quenched with saturated NH4Cl and the aqueous phase 
was extracted with AcOEt (x10). The combined organic phases were dried 
over MgSO4 and the solvent removed under reduced pressure. The resulting 
diol was used without further purification in the next step.  
A mixture of diol II-20 (1 equiv) and Pd(C) (0.1 equiv) in ethanol (0.2 
M) was vigorously stirred under a hydrogen atmosphere at -20 ºC until full 
conversion by TLC (2 h). The reaction mixture was filtered over celite® and 
the solvent was removed under reduced pressure. The reaction crude was 
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purified by flash column chromatography using cyclohexane/ethyl acetate 
50:50 as eluent.  
 
(1R*,2S*,3S*,4R*)-3,4-Diphenylcyclobutane-1,2-diol, II-21c. 
 From diphenylacetilene (2.2 g, 12.1 mmol), 
following the general procedure described above, 
compound II-21c (0.931 mg, 3.9 mmol) was obtained in 
32% yield overall yield (4 steps) as a white solid.  
1H NMR (300 MHz, CDCl3) δ 7.16 – 7.01 (m, 6H), 6.89 (d, J = 7.8 Hz, 
4H), 4.70 (s, 2H), 3.92 (d, J = 3.3 Hz, 2H), 3.14 – 2.91 (m, 2H). 13C NMR 
(75 MHz, CDCl3) δ 138.5, 128.2, 126.2, 71.6, 51.1. mp = 144-145 ºC.  
 
(1R*,2S*,3R*,4S*)-3,4-Dipropylcyclobutane-1,2-diol, II-21e. 
 From 4-octyne (860 mg, 7.8 mmol), following the general 
procedure described above, compound II-21e (375 mg, 2.18 
mmol) was obtained in 28% yield overall yield (4 steps) as a 
colorless oil.  
1H NMR (300 MHz, CDCl3): δ 3.90 (d, J = 2.8 Hz, 2H), 2.31 (s, 2H), 
2.17 (br, 2H), 1.46 – 1.34 (m, 4H), 1.34 – 1.24 (m, 4H), 0.92 (m, 6H). 13C 
NMR (75 MHz, CDCl3): δ 72.5, 43.4, 30.6, 21.2, 14.4. mp = 56 - 57 ºC. 
HRMS-EI+ m/z calculated for C10H16O2 [M-4H]
+: 168.1150, found 
168.1157. 
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To a solution of II-21 (1 equiv) and DMAP (2.45 equiv) in anhydrous 
CH2Cl2 (0.2M) at 0 ºC was added dropwise thiophosgene (1.2 equiv). The 
mixture was vigorously stirred at 0 ºC until full conversion by TLC (2 h). 
The reaction was quenched adding silica gel and the reaction crude was 
purified by flash column chromatography over Florisil® using 
hexanes/ethyl acetate 90:10 as eluent.  
 
(1R*,5S*,6S*,7R*)-6,7-Diphenyl-2,4-dioxabicyclo[3.2.0]heptane-3-
thione, II-22c. 
From diol II-21c (956 mg, 4.0 mmol), following the general 
procedure described above, compound II-22c (880 mg, 3.1 
mmol) was obtained in 80% yield as yellow oil. 
1H NMR (300 MHz, CDCl3) δ 7.20 – 7.08 (m, 6H), 6.85 (d, 
J = 7.8 Hz, 4H), 5.60 (d, J = 1.6 Hz, 2H), 4.45 (s, 2H). 13C NMR (75 MHz, 
CDCl3) δ 192.5, 135.2, 128.6, 127.9, 127.2, 83.8, 50.5. 
 
(1R*,5S*,6R*,7S*)-6,7-Dipropyl-2,4-dioxabicyclo[3.2.0]heptane-3-
thione, II-22e. 
From diol II-21e (750 mg, 4.4 mmol), following the 
general procedure described above, compound II-22e  
(0867 mg, 4 mmol) was obtained in 93% yield as yellow 
oil. 
1H NMR (300 MHz, CDCl3): δ 4.89 – 4.80 (s, 2H), 2.80 – 2.66 (m, 2H), 
1.47 – 1.26 (m, 8H), 0.93 (t, J = 7.0 Hz, 6H). 13C NMR (75 MHz, CDCl3): 
δ 193.4, 84.6, 43.4, 29.2, 20.5, 14.0. HRMS-EI+ m/z calculated for 
C11H18O2S [M]
+: 214.1028, found 214.1037.  
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To a solution of tiocarbonate II-22 (1 equiv) in benzene (0.5 M) at room 
temperature, Corey-Hopkins reagent (3 equiv) was added. The mixture was 
vigorously stirred at room temperature until full conversion by TLC (4-6h). 
Crude was purified by flash column chromatography using n-pentane as 
eluent.  
 
(3R*,4S*)-3,4-Dipropylcyclobut-1-ene, II-1c. 
From compound II-22c (1.0 g, 3.5 mmol), following 
the general procedure described above, compound II-1c 
(430 mg, 2.1 mmol) was obtained in 60% yield as colorless 
oil. 
1H-NMR, 13C-NMR and MS data were consistent with literature 
values.121 1H RMN (300 MHz, CDCl3) δ 7.04 – 6.87 (m, 10H), 6.53 (s, 
2H), 4.51 (s, 2H). 
 
 (3R*,4S*)-3,4-Dipropylcyclobut-1-ene, II-1e. 
From compound II-22e (400 mg, 1.9 mmol), following 
the general procedure described above, compound II-1e 
(135 mg, 1.0 mmol) was obtained in 52% yield as colorless 
oil. 
1H NMR (300 MHz, CDCl3): δ 6.17 (s, 2H), 2.89 – 2.76 (m, 2H), 1.53 
– 1.35 (m, 4H), 1.34 – 1.28 (m, 4H), 0.92 (t, J = 7.0 Hz, 6H).13C NMR (75 
MHz, CDCl3): δ 140.2, 46.8, 32.3, 21.6, 14.5. HRMS-EI+ m/z calculated 
for C10H18 [M]
+: 138.1409, found 138.1410.  
 
121 Miyashi, T.; Wakamatsu, K.; Akiya, T.; Kikuchi, K.; Mukai, T. J. Am. Chem. 
Soc., 1987, 109, 5270-5271. 
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2.6.2.4. Synthesis of (1R*,3s,5S*)-bicyclo[3.2.0]hept-6-en-3-ol, II-1j and 
(1R*,3r,5S*)-bicyclo[3.2.0]hept-6-en-3-ol, II-1k. 
Compounds II-1j and II-1k were prepared by following a similar 
procedure reported in the bibliography.105 
 
 
 
A solution of 3,5-cycloheptadienol (2.2 g, 20.0 mmol) in anhydrous 
ether (800 mL) was bubbled with nitrogen for 30 min and then irradiated 
for 4 h with a quartz jacketed Hanovia immersion lamp. The solvent was 
removed under reduced pressure affording a mixture of both endo and exo 
bicyclo[3.2.0]hept-6-en-3-ol with a ratio of 2:1 (based on 1H NMR 
analysis). The reaction crude was purified by flash column chromatography 
using cyclohexane/ethyl acetate 80:20 as eluent. 
 
(1R*,3s,5S*)-Bicyclo[3.2.0]hept-6-en-3-ol, II-1j. 
From 3,5-cycloheptadienol (2.2 g, 20 mmol), following the 
general procedure described above, compound II-1j (580 mg, 
5.3 mmol) was obtained in 26% yield as colorless oil. 
1H-NMR, 13C-NMR and MS data were consistent with 
literature values.105 1H RMN (300 MHz, CDCl3) δ 6.33-6.35 (d, 2H), 4.25-
4.36 (m, 1H), 3.30-3.35 (d, 2H), 1.95-2 (m, 2H), 1.70-1.75 (m, 2H). 
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(1R*,3r,5S*)-Bicyclo[3.2.0]hept-6-en-3-ol, II-1k. 
From 3,5-cycloheptadienol (2.2 g, 20 mmol), following the 
general procedure described above, compound II-1k (650 mg, 
5.9 mmol) was obtained in 30% yield as colorless oil. 
1H-NMR, 13C-NMR and MS data were consistent with 
literature values.105 1H RMN (300 MHz, CDCl3) δ 5.94-5.92 (s, 2H), 4.42-
4.38 (m,1H), 3.26-3.24 (m, 2H), 1.35-1.2 (m, 4H). 
 
2.6.2.5. Synthesis of (1R*,5S*)-bicyclo[3.2.0]hept-6-en-3-one, II-1i. 
 Compound II-1i was prepared by following a similar procedure 
reported in the bibliography.105 
 
 
To a suspension of pyridinium chlorochromate (2.5 g, 11.0 mmol, 1.1 
equiv) in CH2Cl2 (12 mL) at 0 ºC was added a solution of the above mixture 
of endo and exobicyclo[3.2.0]hept-6-en-3-ol dissolved in CH2Cl2 (7 mL). 
After 2 h stirring at room temperature, the supernatant liquid was poured 
into ether (50 mL) and the residual in the flask was extracted with ether (2 
× 20 mL). The combined organic phases were filtered over a pad of silica 
and rinsed with ether. The solvent was removed under reduced pressure and 
the crude product was purified by distillation (75 ºC, 14 mbar). 
1H-NMR, 13C-NMR and MS data were consistent with literature 
values.105 1H RMN (300 MHz, CDCl3) δ 6.10 (s, 2 H), 3.47 (d, J = 7.6 Hz, 
2 H), 2.35–2.41 (m, 2 H), 2.15–2.23 (m, 2 H). 
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2.6.2.6. Synthesis of (1R*,3S*,5S*)-3-phenylbicyclo[3.2.0]hept-6-en-3-ol, 
II-1l. 
 
 
To a solution of II-1i (0.4 g, 3.7 mmol, 1 equiv) in THF (1.8 mL/mmol 
ketone), phenylmagnesium bromide (1.34 g, 7.4 mmol, 2 equiv) was added 
at -78 ºC. The mixture was stirred vigorously at -78 ºC until full conversion 
by TLC (4 h). The solution was extracted with AcOEt (x3) and the 
combined organic phases were washed with saturated NaCl (x3). The 
organic phase was dried over MgSO4 and the solvent removed under 
reduced pressure. Crude was purified by flash column chromatography 
using hexanes/ethyl acetate 80:20 as eluent. Compound II-1l (0.214 g, 1.15 
mmol) was obtained in 31% yield as colorless oil.  
 1H RMN (300 MHz, CDCl3): δ 7.48 (d, J = 7.8 Hz, 2H), 7.35 (t, J = 7.8 
Hz, 2H), 7.23 (d, J = 7.8 Hz, 1H), 6.47 (d, J = 0.7 Hz, 2H), 3.57 (d, J = 7.1 
Hz, 2H), 2.89 (s, 1H), 2.21 (d, J = 14.2 Hz, 2H), 2.10 (dd, J = 14.2, 7.1 Hz, 
2H). 13C RMN (75 MHz, CDCl3): δ 146.5, 144.2, 128.2, 126.7, 125.2, 86.8, 
49.3, 44.3. HRMS-ESI+ m/z calculated for C13H14ONa [M+Na]
+: 
209.0936, found 209.0938. 
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2.6.2.7. Synthesis of (((1R,3s,5S)-bicyclo[3.2.0]hept-6-en-3-yl)oxy) 
trimethylsilane. 
 
 
To a solution of II-1j (283 mg, 2.57 mmol, 1 equiv), DMAP (47 mg, 
0.38 mmol, 0.15 equiv) and triethylamine (290 mg, 3.85 mmol, 1.5 equiv) 
in DMF (1 mL) was added TMSCl (328, 3.1 mmol, 1.2 equiv) at room 
temperature. The reaction mixture was stirred at room temperature until full 
conversion is observed by TLC (1 h). Et2O and water were added, and the 
layers were separated. The combined organic phases were washed with 
brine, dried over Na2SO4, filtered and concentrated in vacuum. Solvent was 
removed under reduced pressure and crude was purified by flash column 
chromatography over silica gel using n-hexanes/ethyl ether 95:5 as eluent. 
Compound II-1m (228 mg, 1.25 mmol) was obtained in 49% yield as 
colorless oil. 
1H-NMR (300 MHz, CDCl3) δ 6.10 (s, 2 H,), 4.47-4.33 (m, 1 H), 3.24–
3.16 (m, 2 H), 1.82-1.55 (m, 4 H), 0.08 (s, 9H). 13C-NMR (75 MHz, CDCl3) 
δ 141.4, 78.9, 47.2, 37.7, 0.4. HRMS-ESI+ m/z calculated for C13H14ONa 
[M+Na]+: 209.0936, found 209.0938. 
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2.6.3. General procedure for synthesis of racemic 
cyclobutylboronates. 
 
 
An oven-dried vial was charged with [Cu(CH3CN)4]PF6 (7.5 mg, 0.02 
mmol, 10.0 mol%), Xantphos (0.022 mmol, 11.0 mol%) and B2pin2 (2 
equiv) and sealed with a septum. The vial was connected to an argon-
vacuum line, evacuated and backfilled with argon (x3). THF (1 mL) was 
added and the mixture was stirred for 15 min at room temperature. A 0.2 M 
NaOt-Bu solution in THF (50 µL, 0.1 mmol, 0.5 equiv) was then added 
dropwise and the dark brown solution was stirred for 10 min. The reaction 
mixture was cooled at –78 C for 10 min and cyclobutene II-1a (0.2 mmol, 
1.0 equiv) was added followed by methanol (16 µL, 0.4 mmol, 2.0 equiv). 
Then, the reaction mixture was stirred overnight (16 h) at room temperature. 
Hexanes was added to the mixture and solvent was removed under reduced 
pressure. Crude was purified by flash column chromatography using n-
hexane/ether 80:20 as eluent. 
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(±)-2-((1R,2S,3R)-2,3-bis(Benzyloxy)cyclobutyl)-4,4,5,5-tetramethyl-
1,3,2-dioxaborolane, (±)-II-2a. 
From II-1a (53.2 mg, 0.2 mmol), following the general procedure 
described above, compound (±)-II-2a (26 mg, 0.066 mmol) was obtained 
in 33% yield as colorless oil.  
1H RMN (500 MHz, CDCl3) δ 7.30 (d, J = 7.3 Hz, 
2H), 7.28 (s, 2H), 7.24 (t, J = 7.3 Hz, 4H), 7.18 (t, J = 7.1 
Hz, 2H), 4.57 – 4.42 (m, 4H), 4.12 – 4.06 (m, 2H), 2.26 – 
2.10 (m, 1H), 1.98 – 1.90 (m, 2H), 1.15 (s, 6H), 1.15 (s, 
6H).13C RMN (126 MHz, CDCl3) δ 138.8, 138.8, 128.4, 
128.3, 127.9, 127.9, 127.5, 127.5, 83.4, 77.5, 75.6, 71.0, 70.6, 26.9, 24.9, 
24.8. [note: the carbon attached to boron was not observed due to 
quadrupole broadening caused by the 11B nucleus]. HRMS-EI+ m/z 
calculated for C23H28BO4 [M-CH3]
+: 379.2081, found 379.2078. 
 
(±)-2-[(1R,2R,3S)-2,3-bis(Benciloxi)ciclobutil]-4,4,5,5-tetrametil-
1,3,2-dioxaborolano, (±)-II-9. 
From II-1a (53.2 mg, 0.2 mmol), following the general 
procedure described above, compound (±)-II-9 (4.7 mg, 
0.012 mmol) was obtained in 6% yield as colorless oil.  
1H RMN (500 MHz, CDCl3) δ 7.41 – 7.38 (m, 2H), 
7.34 – 7.29 (m, 6H), 7.27 – 7.23 (m, 2H), 4.76 (d, J = 12.2 Hz, 1H), 4.62 
(d, J = 12.2 Hz, 1H), 4.53 – 4.46 (m, 2H), 4.39 – 4.35 (m, 1H), 4.03 (dd, J 
= 10.9, 8.2 Hz, 1H), 2.25 – 2.16 (m, 1H), 1.75 – 1.67 (m, 1H), 1.22 (s, 6H), 
1.22 (s, 6H). 13C RMN (126 MHz, CDCl3) δ 139.4, 138.8, 128.4, 128.2, 
127.7, 127.7, 127.5, 127.2, 83.5, 80.3, 74.5, 72.1, 70.2, 29.3, 25.1, 25.0. 
[note: the carbon attached to boron was not observed due to quadrupole 
broadening caused by the 11B nucleus]. 
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2.6.4. General procedure for the synthesis of chiral 
cyclobutylboronates II-2. 
 
 
An oven-dried vial was charged with [Cu(CH3CN)4]PF6 (7.5 mg, 0.02 
mmol, 10.0 mol%) and ligand ((R)-DTBM-Segphos or (R)-DM-Segphos) 
(0.022 mmol, 11.0 mol%) and sealed with a septum. The vial was connected 
to an argon-vacuum line, evacuated and backfilled with argon (x3). THF 
(0.7 mL) was added and the mixture was stirred for 15 min at room 
temperature. With the vial still connected to the double line, the solvent was 
removed to dryness. Then, a solution of B2pin2 (2 equiv) in THF (1 mL) 
was added and the mixture was stirred for 15 min. A 0.2 M NaOt-Bu 
solution in THF (50 µL, 0.1 mmol, 0.5 equiv) was then added dropwise and 
the dark brown solution was stirred for 10 min. The reaction mixture was 
cooled at –78 C for 10 min and the corresponding cyclobutene II-1 (0.2 
mmol, 1.0 equiv) was added followed by methanol (16 µL, 0.4 mmol, 2.0 
equiv). Then, the reaction mixture was stirred overnight (16 h) at the 
optimal temperature for each case (–20 or 0 ºC). Hexanes was added to the 
mixture and solvent was removed under reduced pressure. Crude was 
purified by flash column chromatography over Florisil® (Eluent is indicated 
in each case). 
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(–)-2-[(1R,2S,3R)-2,3-bis(Benzyloxy)cyclobutyl]-4,4,5,5-tetramethyl-
1,3,2-dioxaborolane, II-2a. 
From II-1a (53.2 mg, 0.2 mmol), following 
the general procedure described above ((R)-DM-
Segphos, 0 C) and purifying crude by flash 
column chromatography over Florisil® using n-
pentane/ethyl ether 65:35 as eluent, compound 
II-2a (75.6 mg, 0.192 mmol) was obtained in 96% yield as a colorless oil.  
Compound II-2a was obtained with a 99:1 enantiomeric ratio 
determined by SFC using Chiralpak-ID column [CO2/MeOH (90:10)], 1.0 
mL/min, major= 8.8 min, minor= 9.7 min. [α]20D= –15.0 (c = 1.0, CHCl3). 1H 
RMN (500 MHz, CDCl3): δ 7.32 – 7.27 (m, 4H), 7.24 (t, J = 7.3 Hz, 4H), 
7.20 – 7.16 (m, 2H), 4.57 – 4.42 (m, 4H), 4.12 – 4.06 (m, 2H), 2.22 – 2.13 
(m, 1H), 1.97 – 1.90 (m, 2H), 1.15 (s, 6H), 1.15 (s, 6H).13C RMN (126 
MHz, CDCl3): δ 138.8, 138.8, 128.4, 128.3, 127.9, 127.9, 127.5, 127.5, 
83.4, 77.5, 75.6, 71.0, 70.6, 26.9, 24.9, 24.8. [note: the carbon attached to 
boron was not observed due to quadrupole broadening caused by the 11B 
nucleus]. HRMS-EI+ m/z calculated for C23H28BO4 [M-CH3]
+: 379.2081, 
found 379.2078. 
(–)-2-[(1R,2S,3R)-2,3-bis(Benzylthio)cyclobutyl]-4,4,5,5-tetramethyl-
1,3,2-dioxaborolane, II-2b. 
 From II-1b (59.6 mg, 0.2 mmol), following 
the general procedure described above ((R)-
DTBM-Segphos, 0 C) and purifying crude by 
flash column chromatography over Florisil® 
using n-pentane/ethyl ether 97:3 as eluent, 
compound II-2b (44.3 mg, 0.104 mmol) was 
obtained in 52% yield as a colorless oil.  
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Compound 2b was obtained with a 99:1 enantiomeric ratio determined 
by SFC using Chiralpak-ID column [CO2/MeOH (90:10)], 1.0 mL/min, 
major= 11.6 min, minor= 13.0 min. [α]20D= –29.0 (c = 1.0, CHCl3). 1H NMR 
(300 MHz, CDCl3): δ 7.35 – 7.20 (m, 10H), 3.74 (s, 2H), 3.73 (s, 2H), 3.66 
– 3.59 (m, 2H), 2.31 – 2.13 (m, 2H), 2.09 – 1.99 (m, 1H), 1.24 (s, 6H), 1.23 
(s, 6H). 13C NMR (75 MHz, CDCl3): δ 138.8, 138.6, 129.2, 129.1, 128.5, 
128.5, 127.0, 126.9, 83.6, 46.3, 44.0, 36.2, 35.9, 28.7, 24.9, 24.8. [note: the 
carbon attached to boron was not observed due to quadrupole broadening 
caused by the 11B nucleus].
 
HRMS-ESI+ m/z calculated for 
C24H31BO2S2Na [M+Na]
+: 449.1750 found, 449.1764. 
 
(–)-2-[(1R,2S,3R)-2,3-Diphenylcyclobutyl]-4,4,5,5-tetramethyl-1,3,2-
dioxaborolane,  II-2c. 
 From II-1c (41.3 mg, 0.2 mmol), following the 
general procedure described above ((R)-DM-Segphos, 0 
C) and purifying crude by flash column 
chromatography over Florisil® using n-pentane/ethyl 
ether  90:10 as eluent, compound II-2c (47 mg, 0.14 
mmol) was obtained in 70% yield as white solid.  
Compound II-2c was obtained with a 97:3 enantiomeric ratio 
determined by SFC using Chiralpak-IC column [CO2/MeOH (99:1)], 1.0 
mL/min, major= 10.7 min, minor= 11.6 min. mp = 75-77 ºC. [α]20D = –59.4 
(c = 1.0, CHCl3). 1H RMN (300 MHz, CDCl3): δ 7.03 (m, 10H), 4.07 (d, J 
= 5.5 Hz, 2H), 2.64 – 2.44 (m, 2H), 2.44 – 2.27 (m, 1H), 1.31 (s, 12H). 13C 
RMN (75 MHz, CDCl3): δ 141.9, 141.7, 128.0, 127.9, 127.6, 125.5, 125.5, 
83.3, 46.5, 45.0, 25.9, 24.9, 24.8. [note: the carbon attached to boron was 
not observed due to quadrupole broadening caused by the 11B nucleus]. 
HRMS-EI+ m/z calculated for C22H27BO2 [M]
+: 334.2104, found 334.2089. 
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(–)-2-[(1R,2S,3S)-2,3-Dibenzylcyclobutyl]-4,4,5,5-tetramethyl-1,3,2-
dioxaborolane, II-2d. 
From II-1d (46.9 mg, 0.2 mmol), following the 
general procedure described above ((R)-DM-
Segphos, -20 C) and purifying crude by flash 
column chromatography over Florisil® using n-
pentane/ethyl ether 90:10 as eluent, compound II-
2d (65.9 mg, 0.18 mmol) was obtained in 91% yield as a colorless oil. 
 [α]20D= –22.6 (c = 1.0, CHCl3). 1H NMR (300 MHz, CDCl3): δ 7.33 – 
7.25 (m, 4H), 7.24 – 7.14 (m, 6H), 2.99 – 2.67 (m, 6H), 2.05 – 1.91 (m, 
1H), 1.86 – 1.70 (m, 2H), 1.12 (s, 6H), 1.10 (s, 6H). 13C NMR (75 MHz, 
CDCl3): δ 141.5, 141.1, 129.0, 128.8, 128.3, 128.3, 125.7, 125.7, 82.9, 40.5, 
39.0, 37.7, 35.9, 25.1, 24.8, 24.7. [note: the carbon attached to boron was 
not observed due to quadrupole broadening caused by the 11B nucleus]. 
HRMS-EI+ m/z calculated for C24H31BO2 [M]
+: 362.2417, found 362.2411. 
Compound II-2d was transformed into II-23 through oxidation 
followed by benzoylation to determine the enantiomeric ratio (See 
compound II-23). 
 
(–)-2-[(1R,2S,3R)-2,3-Dipropylcyclobutyl]-4,4,5,5-tetramethyl-1,3,2-
dioxaborolane, II-2e. 
From II-1e (27.6 mg, 0.2 mmol), following the 
general procedure described above ((R)-DM-Segphos, 
-20 C) and purifying crude by flash column 
chromatography over Florisil® using n-pentane/ethyl 
ether 95:5 as eluent, compound II-2e (45.2 mg, 0.17 
mmol) was obtained in 85% yield as a colorless oil. 
Chapter 2 
110 
 
[α]20D= –28.0 (c = 1.0, CHCl3). 1H NMR (300 MHz, CDCl3): δ 2.35 – 
2.13 (m, 2H), 1.92 (m, 1H), 1.62 – 1.38 (m, 1H), 1.41 – 0.91 (m, 21H), 0.80 
(m, 6H). 13C NMR (75 MHz, CDCl3): δ 82.9, 39.5, 37.5, 33.7, 32.3, 26.1, 
24.9, 24.8, 20.8, 20.7, 14.6, 14.4. [note: the carbon attached to boron was 
not observed due to quadrupole broadening caused by the 11B nucleus]. 
HRMS-ESI+ m/z calculated for C16H31BO2 [M]
+: 266.2417, found 
266.2405. 
Compound II-2e was transformed into II-24e through oxidation 
followed by benzoylation to determine the enantiomeric ratio (See 
compound II-24e). 
 
(–)-2-[(1R,2S,3R)-2,3-bis(Methoxymethyl)cyclobutyl]-4,4,5,5-
tetramethyl-1,3,2-dioxaborolane, II-2f. 
From II-1f (28.4 mg, 0.2 mmol), following the 
general procedure described above ((R)-DM-Segphos, -
20 C) and purifying crude by flash column 
chromatography over Florisil® using n-pentane/ethyl 
ether 70:30 as eluent, compound II-2f (50.3 mg, 0.19 mmol) was obtained 
in 93% yield as a yellowish oil.  
[α]20D= –28.4 (c = 1.0, CHCl3). 1H NMR (300 MHz, CDCl3): δ 3.55 – 
3.43 (m, 2H), 3.43 – 3.31 (m, 2H), 3.29 (s, 3H), 3.27 (s, 3H), 2.74 – 2.60 
(m, 2H), 2.08 – 1.96 (m, 1H), 1.78 (td, J = 10.3, 5.0 Hz, 1H), 1.54 (dt, J = 
10.3, 6.7 Hz, 1H), 1.21 (s, 12H). 13C NMR (75 MHz, CDCl3): δ 83.2, 73.9, 
73.5, 58.9, 58.7, 37.8, 36.1, 24.9, 24.8, 23.9. [note: the carbon attached to 
boron was not observed due to quadrupole broadening caused by the 11B 
nucleus]. HRMS-ESI+ m/z calculated for C14H27BO4Na [M+Na]
+: 
293.1894, found 293.1898.  
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Compound II-2f was transformed into II-24f through oxidation 
followed by benzoylation to determine the enantiomeric ratio (See 
compound II-24f). 
 
(–)-2-[(1R,7S,8R)-Bicyclo[5.2.0]nonan-8-yl)]-4,4,5,5-tetramethyl-
1,3,2-dioxaborolane, II-2g. 
From II-1g (24.4 mg, 0.2 mmol), following the general 
procedure described above ((R)-DM-Segphos, -20 C) and 
purifying crude by flash column chromatography over 
Florisil® using n-pentane/ethyl ether 90:10 as eluent, 
compound II-2g (39.0 mg, 0.156 mmol) was obtained in 
78% yield as a yellowish oil. 
 [α]20D= –25.0 (c = 1.0, CHCl3). 1H NMR (300 MHz, CDCl3): δ 2.51 – 
2.36 (m, 2H), 2.12 – 1.98 (m, 1H), 1.84 – 1.71 (m, 3H), 1.71 – 1.35 (m, 
7H), 1.25 (s, 6H), 1.25 (s, 6H), 1.12 – 1.01 (m, 2H). 13C NMR (75 MHz, 
CDCl3): δ 82.9, 40.6, 38.7, 34.6, 33.3, 32.6, 29.8, 29.5, 25.7, 24.9, 24.8. 
[note: the carbon attached to boron was not observed due to quadrupole 
broadening caused by the 11B nucleus]. HRMS-EI+ m/z calculated for 
C15H29BO2 [M]
+: 250.2104, found 250.2113. 
Compound II-2g was transformed into II-24g through oxidation 
followed by benzoylation to determine the enantiomeric ratio (See 
compound II-24g). 
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(–)-2-[(1R,6S,7R)-Bicyclo[4.2.0]octan-7-yl]-4,4,5,5-tetramethyl-1,3,2-
dioxaborolane, II-2h. 
From II-1h (21.6 mg, 0.2 mmol), following the general 
procedure described above ((R)-DM-Segphos, -20 C) and 
purifying crude by flash column chromatography over 
Florisil® using n-pentane/ethyl ether 95:5 as eluent, 
compound II-2h (44.9 mg, 0.19 mmol) was obtained in 95% 
yield as a yellowish oil. 
 [α]20D= –25.2  (c = 1.0, CHCl3). 1H NMR (300 MHz, CDCl3): δ 2.42 – 
2.22 (m, 2H), 1.98 – 1.85 (m, 1H), 1.74 – 1.66 (m, 2H), 1.65 – 1.51 (m, 
2H), 1.52 – 1.29 (m, 6H), 1.24 (s, 12H). 13C NMR (75 MHz, CDCl3): δ 
82.9, 35.4, 33.4, 28.8, 28.4, 26.8, 24.9, 24.9, 23.2, 22.7. [note: the carbon 
attached to boron was not observed due to quadrupole broadening caused 
by the 11B nucleus]. HRMS-EI+ m/z calculated for C14H25BO2 [M]
+: 
236.1948, found 236.1947. 
Compound II-2h was transformed into II-24h through oxidation 
followed by benzoylation to determine the enantiomeric ratio (See 
compound II-24h). 
 
(–)-(1S,5S,6R)-6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-
yl)bicyclo[3.2.0]heptan-3-one, II-2i. 
From II-1i (21.6 mg, 0.2 mmol), following the general 
procedure described above ((R)-DM-Segphos, 0 C) and 
purifying crude by flash column chromatography over 
Florisil® using n-pentane/ethyl ether 90:10 as eluent, 
compound II-2i (43.0 mg, 0.18 mmol) was obtained in 91% 
yield as a yellowish oil. 
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 [α]20D= –24.0 (c = 1.0, CHCl3). 1H NMR (300 MHz, CDCl3): δ 3.07 – 
2.92 (m, 2H), 2.57 – 2.40 (m, 2H), 2.38 – 2.25 (m, 1H), 2.19 (d, J = 19.2 
Hz, 2H), 1.84 – 1.72 (m, 1H), 1.63 – 1.51 (m, 1H), 1.25 (s, 12H). 13C NMR 
(75 MHz, CDCl3): δ 221.5, 83.2, 45.9, 45.0, 35.9, 34.1, 27.7, 24.7. [note: 
the carbon attached to boron was not observed due to quadrupole 
broadening caused by the 11B nucleus]. HRMS-EI+ m/z calculated for 
C13H21BO3 [M]
+: 236.1584, found 236.1577. 
Compound II-2i was transformed into II-24i through oxidation 
followed by benzoylation to determine the enantiomeric ratio (See 
compound II-24i). 
 
(–)-(1S,3R,5S,6R)-6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-
yl)bicyclo[3.2.0]heptan-3-ol, II-2j. 
From II-1j (22.0 mg, 0.2 mmol), following the general 
procedure described above ((R)-DM-Segphos, -20 C) and 
purifying crude by flash column chromatography over 
Florisil® using n-pentane/ethyl ether 80:20 as eluent, 
compound II-2j (34.8 mg, 0.15 mmol) was obtained in 73% 
yield as a yellowish oil.  
[α]20D= –33.0 (c = 1.0, CHCl3). 1H NMR (300 MHz, CDCl3): δ 4.52 – 
4.38 (m, 1H), 2.75 (m, 2H), 2.29 – 2.14 (m, 1H), 2.04 – 1.89 (m, 3H), 1.89 
– 1.79 (m, 1H), 1.75 (d, J = 12.5 Hz, 2H), 1.52 (s, 1H), 1.26 (s, 12H). 13C 
NMR (75 MHz, CDCl3): δ 83.0, 77.9, 44.3, 43.4, 39.3, 37.6, 27.1, 24.9. 
[note: the carbon attached to boron was not observed due to quadrupole 
broadening caused by the 11B nucleus]. HRMS-ESI+ m/z calculated for 
C13H23BO3Na [M+Na]
+: 261.1632, found 261.1637. 
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Compound II-2j was transformed into II-25j through benzoylation 
followed by oxidation to determine the enantiomeric ratio (See compound 
II-25j). 
 
(–)-(1S,3S,5S,6R)-6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-
yl)bicyclo[3.2.0]heptan-3-ol, II-2k. 
From II-1k (22.0 mg, 0.2 mmol), following the general 
procedure described above ((R)-DM-Segphos, -20 C) and 
purifying crude by flash column chromatography over 
Florisil® using n-pentane/ethyl ether 80:20 as eluent, 
compound II-2k (36.2 mg, 0.15 mmol) was obtained in 
76% yield as a colorless oil.  
[α]20D= –32.3 (c = 1.0, CHCl3). 1H NMR (300 MHz, CDCl3): δ 4.85 – 
4.70 (m, 1H), 2.85 – 2.72 (m, 2H), 2.23 – 2.11 (m, 1H), 1.95 – 1.84 (m, 
2H), 1.72 – 1.49 (m, 5H), 1.24 (s, 12H). 13C NMR (75 MHz, CDCl3): δ 
83.2, 74.2, 43.2, 42.5, 37.9, 36.0, 26.4, 25.0, 24.9. [note: the carbon attached 
to boron was not observed due to quadrupole broadening caused by the 11B 
nucleus]. HRMS-ESI+ m/z calculated for C13H23BO3Na [M+Na]
+: 
261.1632, found 261.1637. 
Compound II-2k was transformed into II-25k through benzoylation 
followed by oxidation to determine the enantiomeric ratio (See compound 
II-25k). 
 
 Synthesis of cyclobutylboronates. 
115 
 
(–)-(1S,3R,5S,6R)-3-Phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
2-yl)bicyclo[3.2.0]heptan-3-ol, II-2l. 
From II-1l (37.26 mg, 0.2 mmol), following the general 
procedure described above ((R)-DTBM-Segphos, 0 C) 
and purifying crude by flash column chromatography over 
Florisil® using n-pentane/ethyl ether 80:20 as eluent, 
compound II-2l (57.2 mg, 0.18 mmol) was obtained in 
91% yield as a yellowish solid. 
 Compound II-2l was obtained with a 98:2 enantiomeric ratio 
determined by SFC using Chiralpak-ID column [CO2/MeOH (95:5)], 3.0 
mL/min, major= 5.1 min, minor= 6.4 min. mp = 87-89 ºC. [α]20D= –35.2 (c = 
1.0, CHCl3). 
1H NMR (300 MHz, CDCl3): δ 7.48 (d, J = 7.2 Hz, 2H), 7.34 
(t, J = 7.5 Hz, 2H), 7.22 (t, J = 7.2 Hz, 1H), 3.05 – 2.93 (m, 2H), 2.35 – 
2.16 (m, 4H), 2.17 – 2.01 (m, 3H), 1.80 (s, 1H), 1.28 (s, 12H). 13C NMR 
(75 MHz, CDCl3): δ 148.0, 128.2, 126.7, 125.0, 87.0, 82.9, 49.8, 49.3, 40.0, 
38.3, 26.5, 24.8. [note: the carbon attached to boron was not observed due 
to quadrupole broadening caused by the 11B nucleus]. HRMS-ESI+ m/z 
calculated for C19H27BO3Na [M+Na]
+: 337.1945, found 337.1961. 
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2.6.5. Derivatizations to determine the enantiomeric excess of 
cyclobutylboronates II-2d, II-2e, II-2f, II-2g, II-2h, II-2i, II-
2j, II-2k. 
 
2.6.5.1. Synthesis of (–)-(1R,2R,3R)-2,3-dibenzylcyclobutan-1-ol, II-23. 
 
NaBO3·4H2O (4 equiv) was added to a solution of II-2d (65 mg, 0,174 
mmol, 1 equiv) in THF/H2O (1:1, 10.8 mL/mmol cyclobutylboronate). The 
reaction mixture was stirred overnight at room temperature and then 
quenched with H2O and extracted with Et2O (x3). The combined organic 
phases were washed with brine, dried over Na2SO4, filtered and 
concentrated in vacuum to afford the alcohol. The residue was purified by 
flash column chromatography on silica gel using hexanes/ether 80:20 as 
eluent. Compound II-23 (41 mg, 0.162 mmol) was obtained in 93% global 
yield as a yellow oil. 
[α]20D= –78.8 (c = 1.0, CHCl3). Compound II-23 was obtained with a 
96:4 enantiomeric ratio determined by SFC using Chiralpak-IB column 
[CO2/MeOH (80:20)], 2.0 mL/min, major= 3.9 min, minor= 4.4 min.1H NMR 
(300 MHz, CDCl3) δ 7.37 – 7.13 (m, 10H), 4.24 (q, J = 7.5 Hz, 1H), 2.97 
(d, J = 9.5 Hz, 1H), 2.88 (d, J = 7.5 Hz, 2H), 2.70 – 2.53 (m, 3H), 2.11 (dd, 
J = 11.6, 7.5 Hz, 1H), 1.90 – 1.77 (m, 1H), 1.58 (br, 1H). 13C NMR (75 
MHz, CDCl3) δ 141.1, 140.8, 128.8, 128.7, 128.6, 128.5, 126.1, 126.0, 71.5, 
49.5, 36.6, 35.1, 34.1, 31.0. HRMS-ESI+ m/z calculated for C18H20ONa 
[M+Na]+: 275.1406, found 275.1413. 
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2.6.5.2. Procedure for synthesis of benzoates II-24. 
 
NaBO3·4H2O (4 equiv) was added to a solution of the corresponding 
cyclobutylboronate II-2 (1 equiv) in THF/H2O (1:1, 10.8 mL/mmol 
cyclobutylboronate). The reaction mixture was stirred overnight at room 
temperature and then quenched with H2O and extracted with Et2O (x3). The 
combined organic phases were washed with brine, dried over Na2SO4, 
filtered and concentrated in vacuum to afford the alcohol. This compound 
was used in the next step without further purification.  
To a solution of corresponding alcohol in CH2Cl2, 4-
dimethylaminopyridine (DMAP) (2.1 equiv), triethylamine (3 equiv) and 
the corresponding benzyl chloride (2.0 equiv) were added. The reaction 
mixture was stirred for 30 min at room temperature and then quenched with 
H2O. The aqueous layer was extracted with Et2O (x3) and the combined 
organic phases were washed with brine, dried over Na2SO4, filtered and 
concentrated under reduced pressure. The residue was purified by flash 
column chromatography on silica gel. 
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(–)-(1R,2R,3R)-2,3-Dipropylcyclobutyl benzoate, II-24e. 
From II-2e (50 mg, 0.188 mmol), following the 
general procedure described above, purifying crude by 
flash column chromatography over silica gel using n-
pentane/ethyl ether 90:10 as eluent, compound II-24e (42 
mg, 0.161 mmol) was obtained in 86% global yield as a 
colorless oil.  
 Compound II-24e was obtained with a 97:3 enantiomeric ratio 
determined by UHPLC using Chiralpak-IC-3 [Hexane/2-propanol 
(99.6:0.4)], 1.0 mL/min, major= 3.5 min, minor= 4.0 min. [α]20D= –75.6 (c = 
1.0, CHCl3). 1H NMR (300 MHz, CDCl3) δ 8.04 (d, J = 7.5 Hz, 2H), 7.55 
(t, J = 7.5 Hz, 1H), 7.43 (t, J = 7.5 Hz, 2H), 5.02 (q, J = 7.5 Hz, 1H), 2.66 
– 2.51 (m, 1H), 2.30 – 2.12 (m, 2H), 2.12 – 2.01 (m, 1H), 1.61 – 1.39 (m, 
4H), 1.34 – 1.25 (m, 4H), 0.94 (t, J = 7.0 Hz, 3H), 0.90 (t, J = 7.3 Hz, 
3H).13C NMR (75 MHz, CDCl3) δ 166.3, 132.9, 130.8, 129.7, 128.4, 74.3, 
44.9, 32.7, 32.6, 30.8, 30.4, 21.2, 21.0, 14.4, 14.3. HRMS-EI+ m/z 
calculated for C17H24O2Na [M]
+: 283.1668 found 283.1680. 
 
(–)-(1R,2S,3R)-2,3-Bis(methoxymethyl)cyclobutyl benzoate, II-24f. 
From II-2f (50 mg, 0.18 mmol), following the general 
procedure described above, purifying crude by flash 
column chromatography over silica gel using n-
pentane/ethyl ether 65:35 as eluent, compound II-24f (37 
mg, 0.14 mmol) was obtained in 78% global yield as a 
yellow oil.  
[α]20D= –67.1 (c = 1.0, CHCl3). Compound II-24f was obtained with a 
97:3 enantiomeric ratio determined by SFC using Chiralpak-ID column 
[CO2/MeOH (95:5)], 1.0 mL/min, major= 10.5 min, minor= 10.0 min. 1H 
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NMR (300 MHz, CDCl3) δ 8.04 (d, J = 7.4 Hz, 2H), 7.55 (t, J = 7.4 Hz, 
1H), 7.43 (t, J = 7.4 Hz, 2H), 5.18 (q, J = 7.6 Hz, 1H), 3.62 – 3.46 (m, 4H), 
3.37 (s, 3H), 3.34 (s, 3H), 2.96 – 2.84 (m, 1H), 2.69 – 2.55 (m, 1H), 2.40 – 
2.17 (m, 2H).13C NMR (75 MHz, CDCl3) δ 166.3, 133.0, 130.4, 129.7, 
128.4, 73.0, 71.3, 70.6, 59.0, 58.9, 44.5, 30.4, 30.1. HRMS-ESI+ m/z 
calculated for C15H20O4Na [M+Na]
+: 287.1253, found 287.1255. 
 
(–)-(1R,7R,8R)-Bicyclo[5.2.0]nonan-8-yl benzoate, II-24g. 
From II-2g (39 mg, 0.156 mmol), following the general 
procedure described above, purifying crude by flash column 
chromatography over silica gel using n-pentane/ethyl ether 
90:10 as eluent, compound II-24g (34 mg, 0.14 mmol) was 
obtained in 90% global yield as a yellowish oil. 
 [α]20D= –51.4 (c = 1.0, CHCl3). Compound II-24g was 
obtained with a 97:3 enantiomeric ratio determined by SFC using 
Chiralpak-IC column [CO2/MeOH (99:1)], 1.0 mL/min, major= 20.0 min, 
minor= 22.8 min. 1H NMR (300 MHz, CDCl3) δ 8.04 (d, J = 7.5 Hz, 2H), 
7.55 (t, J = 7.5 Hz, 1H), 7.43 (t, J = 7.5 Hz, 2H), 5.02 (q, J = 7.5 Hz, 1H), 
2.66 – 2.51 (m, 1H), 2.30 – 2.12 (m, 2H), 2.12 – 2.01 (m, 1H), 1.61 – 1.39 
(m, 4H), 1.34 – 1.25 (m, 4H), 0.94 (t, J = 7.0 Hz, 3H), 0.90 (t, J = 7.3 Hz, 
3H).13C NMR (75 MHz, CDCl3) δ 166.5, 132.9, 130.7, 129.7, 128.4, 74.9, 
46.0, 33.3, 33.1, 32.5, 32.1, 31.4, 30.5, 28.3. HRMS-EI+ m/z calculated for 
C16H20O2 [M]
+: 244.1463, found 244.1469. 
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(–)-(1R,6R,7R)-Bicyclo[4.2.0]octan-7-yl benzoate, II-24h. 
From II-2h (57 mg, 0.24 mmol), following the general 
procedure described above, purifying crude by flash column 
chromatography over silica gel using n-pentane/ethyl ether 
90:10 as eluent, compound II-24h (50.6 mg, 0.22 mmol) was 
obtained in 96% global yield as a yellowish oil.  
 
[α]20D= –39.5 (c = 1.0, CHCl3). Compound II-24h was obtained with a 
96:4 enantiomeric ratio determined by SFC using Chiralpak-IC column 
[CO2/MeOH (99:1)], 1.0 mL/min, major= 17.7 min, minor= 19.6 min. 1H 
NMR (300 MHz, CDCl3) δ 8.04 (d, J = 7.4 Hz, 2H), 7.55 (t, J = 7.4 Hz, 
1H), 7.43 (t, J = 7.4 Hz, 2H), 5.31 (q, J = 7.5 Hz, 1H), 2.60 – 2.49 (m, 1H), 
2.26 – 2.14 (m, 1H), 2.15 – 2.06 (m, 2H), 2.04 – 1.92 (m, 1H), 1.86 – 1.77 
(m, 1H), 1.70 – 1.58 (m, 2H), 1.48 – 1.39 (m, 2H), 1.34 – 1.22 (m, 1H), 
1.17 – 1.01 (m, 1H).13C NMR (75 MHz, CDCl3) δ 166.4, 132.8, 130.6, 
129.6, 128.3, 70.7, 40.7, 34.4, 30.0, 25.2, 24.8, 23.7, 22.5. HRMS-EI+ m/z 
calculated for C15H18O2 [M]
+: 230.1307, found 230.1304. 
 
 (–)-(1S,5R,6R)-3-Oxobicyclo[3.2.0]heptan-6-yl benzoate, II-24i. 
From II-2i (43 mg, 0.18 mmol), following the general 
procedure described above, purifying crude by flash column 
chromatography over silica gel using n-pentane/ethyl ether 
90:10 as eluent, compound II-24i (30 mg, 0.13 mmol) was 
obtained in 72% global yield as a yellowish oil.  
[α]20D= –7.9 (c = 1.0, CHCl3). Compound II-24i was 
obtained with a 96:4 enantiomeric ratio determined by SFC using 
Chiralpak-IC column [CO2/MeOH (90:10)], 1.0 mL/min, major= 18.4 min, 
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minor= 15.6 min. 1H NMR (300 MHz, CDCl3) δ 8.04 (d, J = 7.3 Hz, 2H), 
7.56 (t, J = 7.3 Hz, 1H), 7.45 (t, J = 7.3 Hz, 2H), 4.96 (q, J = 7.1 Hz, 1H), 
3.26 – 3.13 (m, 1H), 3.12 – 2.97 (m, 1H), 2.70 – 2.46 (m, 4H), 2.37 – 2.20 
(m, 2H).13C NMR (75 MHz, CDCl3) δ 218.0, 166.1, 133.3, 130.0, 129.7, 
128.5, 74.6, 44.3, 43.7, 43.1, 34.2, 28.3. HRMS-EI+ m/z calculated for 
C14H14O3 [M]
+: 230.0943, found 230.0941. 
 
2.6.5.3. Procedure for synthesis of benzoates II-25. 
 
To a solution of alcohol in CH2Cl2, 4-dimethylaminopyridine (DMAP) 
(2.1 equiv), triethylamine (3 equiv) and the benzyl chloride (2.0 equiv) were 
added. The reaction mixture was stirred for 30 min at room temperature and 
then quenched with H2O. The aqueous layer was extracted with Et2O (x3) 
and the combined organic phases were washed with brine, dried over 
Na2SO4, filtered and concentrated under reduced pressure. The residue was 
purified by flash column chromatography on Florisil® using n-
pentane/ethyl ether 90:10 as eluent. 
NaBO3·4H2O (4 equiv) was added to a solution of cyclobutylboronate 
(1 equiv) in THF/H2O (1:1, 10.8 mL/mmol cyclobutylboronate). The 
reaction mixture was stirred overnight at room temperature and then 
quenched with H2O and extracted with Et2O (x3). The combined organic 
phases were washed with brine, dried over Na2SO4, filtered and 
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concentrated in vacuum to afford the alcohol. The residue was purified by 
flash column chromatography on silica gel using hexanes/ethyl acetate 
70:30 as eluent. 
(–)-(1S,3R,5R,6R)-6-Hydroxybicyclo[3.2.0]heptan-3-yl benzoate, II-
25j. 
From II-2j (30 mg, 0.125 mmol), following the general 
procedure described above, compound II-25j (15 mg, 
0.065 mmol) was obtained in 52% overall yield as a yellow 
oil.  
 [α]20D= –18.7 (c = 1.0, CHCl3). Compound II-25j was 
obtained with a 97:3 enantiomeric ratio determined by SFC using 
Chiralpak-IC column [CO2/MeOH (95:5)], 3.0 mL/min, major= 6.0 min, 
minor= 6.9 min. 1H NMR (300 MHz, CDCl3) δ 8.02 (d, J = 7.3 Hz, 2H), 
7.56 (t, J = 7.3 Hz, 1H), 7.44 (t, J = 7.3 Hz, 2H), 5.62 (t, J = 5.1 Hz, 1H), 
4.42 – 4.29 (m, 1H), 2.96 – 2.82 (m, 1H), 2.81 – 2.70 (m, 1H), 2.42 – 2.28 
(m, 1H), 2.21 – 1.92 (m, 5H), 1.88 (br, 1H). 13C NMR (75 MHz, CDCl3) δ 
166.3, 133.1, 130.8, 129.6, 128.6, 80.7, 72.6, 49.9, 39.4, 38.4, 36.4, 31.8. 
HRMS-ESI+ m/z calculated for C14H16O3Na [M+Na]
+: 255.0991, found 
255.0994. 
 
(–)-(1S,3S,5R,6R)-6-Hydroxybicyclo[3.2.0]heptan-3-yl benzoate, II-25k. 
From II-2k (39 mg, 0.164 mmol), following the general 
procedure described above, compound II-25k (30.4 mg, 
0.131 mmol) was obtained in 78% global yield as a yellow 
oil. 
[α]20D= –12.0 (c = 1.0, CHCl3). Compound II-25k was 
obtained with a 97:3 enantiomeric ratio determined by SFC using 
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Chiralpak-ID column [CO2/MeOH (95:5)], 3.0 mL/min, major= 11.1 min, 
minor= 10.0 min.1H NMR (300 MHz, CDCl3) δ 8.02 (d, J = 7.5 Hz, 2H), 
7.55 (t, J = 7.5 Hz, 1H), 7.43 (t, J = 7.5 Hz, 2H), 5.62 – 5.47 (m, 1H), 4.15 
– 4.01 (m, 1H), 2.93 – 2.81 (m, 1H), 2.81 – 2.69 (m, 1H), 2.21 (m, 1H), 
2.11 (m, 2H), 2.08 – 2.00 (m, 1H), 1.94 – 1.79 (m, 2H), 1.71 (br, 1H).13C 
NMR (75 MHz, CDCl3) δ 166.6, 133.0, 130.6, 129.7, 128.5, 77.2, 72.4, 
47.7, 37.7, 36.8, 36.0, 29.5. HRMS-ESI+ m/z calculated for C14H16O3Na 
[M+Na]+: 255.0991, found 255.0991. 
 
2.6.6. Procedure for the synthesis of potassium (+)-((1R,7S,8R)-
bicyclo[5.2.0]nonan-8-yl)trifluoroborate, II-12.  
 
 
To a solution of II-2g (175 mg, 0.700 mmol, 1.00 equiv) in MeOH (3 
mL) in a 20 mL vial containing a stir bar. An aqueous solution of KHF2 
(4.5M, 4.5 equiv) was added to the vial. The solution was stirred at room 
temperature for 6 h. After the evaporation of the solvent under vacuum, the 
residual pinacol was removed by adding three portions of Et2O, retiring the 
resulting solution. The solid obtained was triturated with acetone (x7) and 
filtered through a plug of Celite®. The acetone solution was evaporated to 
yield compound II-12 (129 mg, 0.56 mmol) in 80% yield as white solid. 
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[α]20D= +46.8 (c = 1.0, (CH3)2CO). 1H NMR (300 MHz, Acetone) δ 2.42 
– 2.19 (m, 2H), 1.97 – 1.84 (m, 1H), 1.84 – 1.69 (m, 3H), 1.67 – 1.49 (m, 
3H), 1.48 – 1.15 (m, 3H), 1.14 – 0.98 (m, 2H), 0.95 – 0.75 (m, 1H). 13C 
NMR (75 MHz, Acetone) δ 41.3, 41.2, 38.8, 35.9, 34.8, 33.5, 30.8, 26. 9, 
26.9. HRMS-ESI- m/z calculated for C9H15BF3 [M-K]-: 191.1224, found 
191.1238. 
 
2.6.7. Synthesis of (–)-(1R,3R,5R,6S)-Bicyclo[3.2.0]heptane-3,6-
diol, II-16. 122 
 
 
(–)-tert-Butyldimethyl[((1S,3R,5S,6R)-6-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl]bicyclo[3.2.0]heptan-3-yl)oxy)silane, II-26. 
To a solution of II-2j (104 mg, 0.44 mmol, 1 equiv) and imidazole (39 
mg, 0.57 mmol, 1.2 equiv) in CH2Cl2 (2 mL) was added TBSCl (76.9, 0.51 
mmol, 1.1 equiv) at room temperature. The reaction mixture was stirred at 
 
122 Derrien, N; Dousson, C. B.; Roberts, S. M.; Berens, U.; Burk M. J.; Ohff, M. 
Tetrahedron: Asymmetry, 1999, 10, 3341. 
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room temperature until full conversion is observed by TLC (4 h). Et2O and 
water were added, and the layers were separated. The combined organic 
phases were washed with brine, dried over Na2SO4, filtered and 
concentrated in vacuum. Solvent was removed under reduced pressure and 
crude was purified by flash column chromatography over Florisil® using 
hexanes/ethyl ether 95:5 as eluent. Compound II-26 (132 mg, 0.375 mmol) 
was obtained in 87% yield as colorless oil. 
 [α]20D= –28.2 (c = 1.0, CHCl3). 1H NMR (300 MHz, 
CDCl3) δ 4.45 – 4.34 (m, 1H), 2.80 – 2.63 (m, 2H), 2.17 – 
2.02 (m, 2H), 1.89 – 1.79 (m, 2H), 1.80 – 1.64 (m, 3H), 1.26 
(s, 12H), 0.89 (s, 9H), 0.06 (s, 6H). 13C NMR (75 MHz, 
CDCl3) δ 82.9, 77.8, 44.1, 43.4, 39.3, 37.5, 26.7, 26.1, 24.9, 
24.9, 18.2, -4.7. HRMS-ESI+ m/z calculated for 
C19H37BO3SiNa [M+Na]
+: 375.2497, found 375.2482. 
 
(–)-(1S,3R,5R,6R)-3-((tert-butyldimethylsilyl)oxy)bicyclo 
[3.2.0]heptan-6-ol, II-13. 
NaBO3·4H2O (231 mg, 1.5 mmol, 4 equiv) was added to a solution of 
cyclobutylboronate II-26 (132 mg, 0.375 mmol, 1 equiv) in THF/H2O (1:1, 
4.5 mL). The reaction mixture was stirred overnight at room temperature 
and then quenched with H2O and extracted with Et2O (x3). The combined 
organic phases were washed with brine, dried over Na2SO4, filtered and 
concentrated in vacuum to afford the alcohol. The residue was purified by 
flash column chromatography on silica gel using hexanes/ethyl acetate 4:1 
as eluent. Compound II-13 (90.5 mg, 0.375 mmol) was obtained in 
quantitative yield as colorless oil. 
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 [α]20D= –14.7 (c = 1.0, CHCl3). 1H NMR (300 MHz, 
CDCl3) 4.43 – 4.32 (m, 2H), 2.80 – 2.67 (m, 1H), 2.67 – 2.55 
(m, 1H), 2.41 – 2.25 (m, 1H), 2.07 – 1.90 (m, 1H), 1.84 – 1.73 
(m, 3H), 1.68 – 1.56 (m, 2H), 0.89 (s, 9H), 0.06 (s, 6H). 13C 
NMR (75 MHz, CDCl3) δ 77.3, 73.0, 50.0, 42.3, 41.2, 36.5, 
31.7, 26.0, 18.1, -4.7, -4.8. HRMS-ESI+ m/z calculated for C13H26O2SiNa 
[M+Na]+: 265.1594, found 265.1587. 
 
(–)-(1R,3R,5R)-3-((tert-Butyldimethylsilyl)oxy)bicyclo[3.2.0]heptan-
6-one, II-14. 
DMSO (55 mg, 0.7 mmol, 2 equiv) and (COCl)2 (53 mg, 0.42 mmol, 1,2 
equiv) were added to a stirred flask with CH2Cl2 (2 mL) at -78 ºC and the 
mixture was stirred at -78 ºC for 30 minutes. Alcohol II-13 (86 mg, 0,35 
mmol, 1 equiv) dissolved in CH2Cl2 (2 mL) was added slowly to the mixture 
and it was stirred for 1 hour at -78 ºC. Et3N (142 mg, 1.4 mmol, 4 equiv) 
was added at -78 ºC and the reaction was stirred at room temperature until 
full conversion is observed by TLC (2h). The reaction was quenched with 
H2O and extracted with Et2O (x3). The combined organic phases were 
washed with brine, dried over Na2SO4, filtered and concentrated in vacuum 
to afford the alcohol. The residue was purified by flash column 
chromatography on silica gel using hexanes/Ethyl acetate 90:10 as eluent. 
Compound II-14 (74 mg, 0.306 mmol) was obtained in 87% yield as 
colorless oil.  
 [α]20D= –71.6 (c = 1.0, CHCl3). 1H NMR (300 MHz, CDCl3) 
4.44 (br, 1H), 3.63 – 3.51 (m, 1H), 3.23 – 2.98 (m, 2H), 2.94 – 
2.80 (m, 1H), 2.15 (d, J = 13.6 Hz, 1H), 1.95 – 1.88 (m, 2H), 
1.86 – 1.73 (m, 1H), 0.84 (s, 9H), 0.04 (s, 3H), 0.03 (s, 3H). 13C 
NMR (75 MHz, CDCl3) δ 213.6, 76.0, 63.6, 53.3, 41.4, 41.3, 28.7, 25.7, 
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17.9, -4.9. HRMS-EI+ m/z calculated for C13H24O2Si [M]
+: 240.1546, 
found 240.1553. 
 
(–)-(1R,3R,5R)-3-Hydroxybicyclo[3.2.0]heptan-6-one, II-15. 
TBAF (65.3 mg, 0.250 mmol, 1,2 equiv) was added slowly to a solution 
of II-14 (50 mg, 0.208 mmol, 1 equiv) in THF (1 mL). The reaction is 
stirred at room temperature until full conversion is observed by TLC (4 h). 
The reaction was quenched with H2O and extracted with Et2O (x3). The 
combined organic phases were washed with brine, dried over Na2SO4, 
filtered and concentrated in vacuum to afford the alcohol. The residue was 
purified by flash column chromatography on silica gel using hexanes/Ethyl 
acetate 80:20 as eluent. Compound II-15 (61 mg, 0.254 mmol) was 
obtained in 80% yield as colorless oil. 
 The spectral data for II-15 matched those previously 
reported.122 1H NMR (CDCl3, 300 MHz) 4.54 (br, 1H), 3.67 – 
3.54 (m, 1H), 3.20 (ddd, J = 18.0, 9.6, 3.7 Hz, 1H), 3.08 – 2.97 
(m, 1H), 2.96 – 2.85 (m, 1H), 2.19 (d, J = 14.2 Hz, 1H), 2.02 – 
1.93 (m, 2H), 1.92 – 1.84 (m, 1H), 1.82 (s, 1H). [α]20D= –108.0  (c = 1.0, 
CHCl3). 
 
(–)-(1R,3R,5R,6S)-Bicyclo[3.2.0]heptane-3,6-diol, II-16. 
Compound II-16 was synthetized following a previously reported 
procedure.122 
To a MeOH (0.5 mL) solution containing NaBH4 (8 mg, 0.2 
mmol, 1.3 equiv.) at -78 ºC was added a MeOH (0.1 mL) 
solution of II-15 (19 mg, 0.15 mmol, 1 equiv.) dropwise over 
0.5 h. The mixture was allowed to stir at this temperature for 3 
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h, after which time TLC analysis indicated the complete disappearance of 
the starting material and the appearance of a new product. The reaction was 
quenched with water (0.3 mL), followed by dilute hydrochloric acid (1 M, 
1 mL/mmol of ketone). The aqueous mixture was extracted with ether (x3), 
which were combined, washed with saturated aqueous NaCl, dried 
(MgSO4) and concentrated in vacuum to yield a pale yellow oil. The residue 
was purified by flash column chromatography on silica gel using 
hexanes/Ethyl acetate 1:1 as eluent. Compound II-16 (14 mg, 0.109 mmol) 
was obtained in 73% yield as colorless oil. 
 The spectral data for II-16 matched those previously reported.122 1H 
NMR (300 MHz, C6D6) δ 4.53 (br, 1H), 4.26 (br, 1H), 4.17 (t, J = 4.5 Hz, 
1H), 3.36 (br, 1H), 2.98 (q, J = 8.0 Hz, 1H), 2.66 (dtd, J = 13.2, 9.0, 1.2 Hz, 
1H), 2.28 – 2.19 (m, 1H), 2.15 (d, J = 15.1 Hz, 1H), 1.87 (dt, J = 13.3, 4.7 
Hz, 1H), 1.54 – 1.38 (m, 3H). [α]20D= –34.90 (c = 1.0, CHCl3). 
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2.6.8. Procedure for the Baeyer-Villiger Oxidation. Synthesis of 
(3aR,5R,6aR)-5-((tert-butyldimethylsilyl)oxy)hexahydro-
2H-cyclopenta[b]furan-2-one, II-17. 
 
Compound II-17 was synthetized following a previously reported 
procedure.123 Aqueous 35% hydrogen peroxide (40 mg, 4 equiv) was added 
at 0 ºC to a 0.4 M solution of cyclobutanone II-14 (20 mg, 0.083 mmol) in 
trifluoroethanol (0.3 mL). The resulting reaction mixture was then stirred 
at 0 ºC until complete conversion of the starting material (96 h). The solvent 
was removed under vacuum and the residue was dissolved in ether and 
extracted with 1 M aqueous Na2S2O3. The organic layer was dried over 
MgSO4, concentrated in vacuo and purified by flash column 
chromatography on silica gel using n-hexane/ethyl acetate 4:1 as eluent.  
Compound II-17 (16.8 mg, 0.066 mmol) was obtained in 80% yield as 
yellow oil (9:1 r.r.). Only the major regioisomer was characterized. 1H 
NMR (300 MHz, CDCl3) δ 5.05 (t, J = 7.0 Hz, 1H), 4.41 – 4.34 (m, 1H), 
3.06 – 2.97 (m, 1H), 2.79 (dd, J = 18.1, 11.4 Hz, 1H), 2.52 (dd, J = 18.1, 
3.9 Hz, 1H), 2.14 (d, J = 14.9 Hz, 1H), 1.95 – 1.80 (m, 2H), 1.79 – 1.72 (m, 
1H), 0.86 (s, 9H), 0.05 (s, 3H), 0.05 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 
177.7, 85.3, 74.2, 43.0, 42.6, 37.2, 37.0, 25.8, 18.1, -4.8, -5.0. HRMS-ESI+ 
m/z calculated for C13H24O3SiNa [M+Na]
+: 279.1386, found 279.1378. 
 
123 Depré, D; Chen, L; Ghosez, L. Tetrahedron, 2003, 59, 6797. 
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2.6.9. General procedure for the carboboration of meso-
cyclobutenes. 
 
 
An oven-dried vial was charged with [Cu(CH3CN)4]PF6 (7.5 mg, 0.02 
mmol, 10.0 mol%) and QuinoxP* (7.4 mg, 0.022 mmol, 11.0 mol%) and 
sealed with a septum. The vial was connected to an argon-vacuum line, 
evacuated and backfilled with argon (x3). THF (0.7 mL) was added and the 
mixture was stirred for 15 min at room temperature. With the vial still 
connected to the double line, the solvent was removed to dryness. Then, a 
solution of B2pin2 (2 equiv) in THF (1 mL) was added and the mixture was 
stirred for 15 min. A 0.2 M NaOt-Bu solution in THF (150 µL, 0.3 mmol, 
1.5 equiv) was then added dropwise and the dark brown solution was stirred 
for 10 min. The reaction mixture was cooled at –78 C for 10 min and the 
corresponding cyclobutene II-1 (0.2 mmol, 1.0 equiv) was added followed 
by methyl iodine (50 µL, 0.8 mmol, 4.0 equiv). Then, the reaction mixture 
was stirred overnight (16 h) at the room temperature. Hexanes was added 
to the mixture and solvent was removed under reduced pressure. Crude was 
purified by flash column chromatography over silica gel (Eluent is 
indicated in each case). 
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(–)-2-((1R,2S,3R,4S)-2,3-Dibenzyl-4-methylcyclobutyl)-4,4,5,5-
tetramethyl-1,3,2-dioxaborolane, II-27d. 
From II-1d (46.9 mg, 0.2 mmol), following the 
general procedure described above  and purifying 
crude by flash column chromatography over silica 
gel using n-pentane/ethyl ether 95:5 as eluent, 
compound II-27d (53 mg, 0.14 mmol) was obtained 
in 71% yield as a colorless oil. 
 [α]20D= –12.5 (c = 1.0, CHCl3). 1H NMR (300 MHz, CDCl3): δ 7.15-
7.35 (m,10H), 2.68-3 (m, 4H), 2.34-2.43 (m, 2H), 1.70-1.75 (m,1H), 1.30-
1.35 (m, 1H), 1.16 (s, 6H), 1.12 (s, 6H), 0.9-0.94 (d, J= 6 Hz 3H). 13C NMR 
(75 MHz, CDCl3): δ 141.2, 128.78, 128.75, 128.18, 128.15, 125.6, 125.5, 
82.8, 45.7, 37.4, 36.2, 36.2, 33.9, 24.9, 24.8, 20.1 [note: the carbon attached 
to boron was not observed due to quadrupole broadening caused by the 11B 
nucleus]. HRMS-EI+ m/z calculated for C25H33BO2 [M+Na]+: 399.2450, 
found 399.2465. 
Compound II-27d was transformed into II-28 through oxidation 
followed by benzoylation to determine the enantiomeric ratio (See 
compound II-28). 
 
(–)-2-((1R,2S,3R,4S)-2,3-bis(Methoxymethyl)-4-methylcyclobutyl)-
4,4,5,5-tetramethyl-1,3,2-dioxaborolane, II-27f. 
From II-1f (28.4 mg, 0.2 mmol), following the 
general procedure described above and purifying crude 
by flash column chromatography over silica gel using 
n-pentane/ethyl ether 80:20 as eluent, compound II-27f 
(30 mg, 0.113 mmol) was obtained in 66% yield as a 
yellowish oil.  
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[α]20D= –14.1 (c = 1.0, CHCl3). 1H NMR (300 MHz, CDCl3): δ 3.52 – 
3.45 (m, 2H), 3.40 – 3.31 (m, 2H), 3.29 (s, J = 1.8 Hz, 3H), 3.28 (s, 3H), 
2.74 – 2.59 (m, 1H), 2.38 – 2.23 (m, 2H), 1.64 – 1.54 (m, 1H), 1.23 (s, J = 
2.7 Hz, 6H), 1.22 (s, 6H), 1.10 (d, J = 6.6 Hz, 3H).13C NMR (75 MHz, 
CDCl3): δ 83.6, 83.2, 74.1, 73.3, 58.8, 58.6, 43.3, 34.1, 32.8, 25.1, 25.1, 
25.0, 19.7. [note: the carbon attached to boron was not observed due to 
quadrupole broadening caused by the 11B nucleus]. HRMS-ESI+ m/z 
calculated for C15H30BO4 [M+H]+: 285.2244, found 285.2237.  
Compound II-27f was transformed into II-29f through oxidation 
followed by benzoylation to determine the enantiomeric ratio (See 
compound II-29f). 
 
(–)-4,4,5,5-Tetramethyl-2-((1R,7S,8R,9S)-9-methylbicyclo[5.2.0] 
nonan-8-yl)-1,3,2-dioxaborolane, II-27g. 
From II-1g (24.4 mg, 0.2 mmol), following the general 
procedure described above and purifying crude by flash 
column chromatography over silica gel using n-
pentane/ethyl ether 90:10 as eluent, compound II-27g 
(35.4 mg, 0.13 mmol) was obtained in 67% yield as a 
yellowish oil. 
 [α]20D= –15.9 (c = 1.0, CHCl3). 1H NMR (300 MHz, CDCl3): δ 2.49 – 
2.35 (m, 1H), 2.17 – 1.94 (m, 2H), 1.77 (m, 3H), 1.64 (m, 2H), 1.54 – 1.31 
(m, 3H), 1.26 (s, 6H), 1.25 (s, 6H), 1.19 – 1.11 (m, 1H), 1.06 (m, 5H). 13C 
NMR (75 MHz, CDCl3): δ 83.0, 46.4, 36.7, 34.7, 34.2, 32.6, 29.9, 29.3, 
25.2, 25.1, 24.9, 20.0. [note: the carbon attached to boron was not observed 
due to quadrupole broadening caused by the 11B nucleus]. HRMS-EI+ m/z 
calculated for C16H29BO2 [M+Na]+: 287.2162, found 287.2152. 
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Compound II-27g was transformed into II-29g through oxidation 
followed by benzoylation to determine the enantiomeric ratio (See 
compound II-29g). 
 
(–)-(1S,3R,5S,6R)-6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-
yl)bicyclo[3.2.0]heptan-3-ol, II-2j. 
From II-1m (36.4 mg, 0.2 mmol), following the general 
procedure described above by flash column 
chromatography over silica gel using n-pentane/ethyl ether 
90:10 as eluent, compound II-27m (35.7 mg, 0.11 mmol) 
was obtained in 55% yield as a yellowish oil.  
[α]20D= –11.7 (c = 1.0, CHCl3). 1H-NMR (300 MHz, CDCl3) δ 4.35 – 
4.24 (m, 1H), 2.72 – 2.62 (m, 1H), 2.57 – 2.41 (m, 1H), 2.21 (m,1H), 2.00 
– 1.82 (m, 3H), 1.72 – 1.59 (m, 2H), 1.28 (s, 6H), 1.27 (s, 6H), 1.17 – 1.05 
(d, J = 7 Hz, 3H), 0.10 (s, 9H). 13C-NMR (75 MHz, CDCl3) δ 77.3, 45.5, 
43.5, 42.6, 35.6, 34.6, 25.3, 25.1, 21.2, 0.3. HRMS-EI+ m/z calculada para 
C17H33O3Si [M+Na]+: 347.2188, encontrada 347.2145. 
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2.6.10. Derivatizations to determine the enantiomeric excess of 
cyclobutylboronates II-27d, II-27f and II-27g. 
 
2.6.10.1. Synthesis of (–)-(1R,2R,3R,4R)-2,3-dibenzyl-4-
methylcyclobutan-1-ol, II-28. 
 
NaBO3·4H2O (4 equiv) was added to a solution of II-27d (38 mg, 0.1 
mmol, 1 equiv) in THF/H2O (1:1, 10.8 mL/mmol cyclobutylboronate). The 
reaction mixture was stirred overnight at room temperature and then 
quenched with H2O and extracted with Et2O (x3). The combined organic 
phases were washed with brine, dried over Na2SO4, filtered and 
concentrated in vacuum to afford the alcohol. The residue was purified by 
flash column chromatography on silica gel using hexanes/ Et2O 80:20 as 
eluent. Compound II-28 (23 mg, 0.9 mmol) was obtained in 87% yield as 
a yellow oil. 
[α]20D= –31.6 (c = 1.0, CHCl3). Compound II-28 was obtained with a 
92:8 enantiomeric ratio determined by SFC using Chiralpak-IB column 
[CO2/MeOH (80:20)], 2.0 mL/min, major= 3.5 min, minor= 3.9 min. 1H 
NMR (300 MHz, CDCl3) δ 7.28-7.05 (m, 10H), 4.18-4.09 (m, 1H), 2.89-
2.82 (m, 1H), 2.82-2.76 (m, 2H), 2.71-2.50 (m, 2H), 2.25-2.11 (m, 2H), 
1.36 (s, 1H), 0.91-0.89 (d, J = 6 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 
141.0, 140.9, 128.6, 128.5, 128.5, 128.3, 125.9, 125.8, 71.2, 46.5, 39.6, 
37.9, 36.3, 34.8, 13.5. HRMS-ESI+ m/z calculated for C19H22O [M+Na]+: 
289.1574, found 289.1572. 
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2.6.10.2. Procedure for synthesis of benzoates II-29. 
 
NaBO3·4H2O (4 equiv) was added to a solution of the corresponding 
cyclobutylboronate II-27 (1 equiv) in THF/H2O (1:1, 10.8 mL/mmol 
cyclobutylboronate). The reaction mixture was stirred overnight at room 
temperature and then quenched with H2O and extracted with Et2O (x3). The 
combined organic phases were washed with brine, dried over Na2SO4, 
filtered and concentrated in vacuum to afford the alcohol. This compound 
was used in the next step without further purification.  
To a solution of corresponding alcohol in CH2Cl2, 4-
dimethylaminopyridine (DMAP) (2.1 equiv), triethylamine (3 equiv) and 
the corresponding benzyl chloride (2.0 equiv) were added. The reaction 
mixture was stirred for 30 min at room temperature and then quenched with 
H2O. The aqueous layer was extracted with Et2O (x3) and the combined 
organic phases were washed with brine, dried over Na2SO4, filtered and 
concentrated under reduced pressure. The residue was purified by flash 
column chromatography on silica gel. 
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(–)-(1R,2S,3R,4R)-2,3-bis(Methoxymethyl)-4-methylcyclobutyl 
benzoate, II-29f. 
From II-27f (31 mg, 0.11 mmol), following the 
general procedure described above, purifying crude by 
flash column chromatography over silica gel using n-
pentane/ethyl ether 70:30 as eluent, compound II-29f (21 
mg, 0.08 mmol) was obtained in 73% global yield as a 
yellow oil.  
[α]20D= –46.1 (c = 1.0, CHCl3). Compound II-29f was obtained with a 
91:9 enantiomeric ratio determined by SFC using Chiralpak-IA column 
[CO2/MeOH (95:5)], 1.0 mL/min, major= 8.8 min, minor= 7.9 min. 1H NMR 
(300 MHz, CDCl3) δ 8.11 – 7.87 (m, 1H), 7.55 – 7.42 (m, 1H), 7.40 – 7.29 
(m, 1H), 5.22 – 5.01 (m, 1H), 3.58 – 3.39 (m, 4H), 3.29 (s, 3H), 3.27 (s, 
3H), 2.98-2.83 (m, 1H), 2.53 (m, 1H), 2.28 – 1.99 (m, 1H), 1.08 (d, J = 7.3 
Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 166.3, 133.0, 130.4, 129.7, 128.5, 
72.8, 71.7, 71.3, 62.9, 58.9, 58.9, 41.5, 38.7, 35.5, 14.5. HRMS-ESI+ m/z 
calculated for C16H23O4 [M+H]+: 279.1595, found 279.1596. 
 
(–)-(1R,7R,8R,9R)-9-Methylbicyclo[5.2.0]nonan-8-yl benzoate, II-29g. 
From II-27g (29 mg, 0.11 mmol), following the general 
procedure described above, purifying crude by flash column 
chromatography over silica gel using n-pentane/ethyl ether 
90:10 as eluent, compound II-29g (23 mg, 0.09 mmol) was 
obtained in 82% global yield as a yellowish oil. 
 [α]20D= –31.6 (c = 1.0, CHCl3). Compound II-29g was 
obtained with a 88:12 enantiomeric ratio determined by SFC using 
Chiralpak-IA column [CO2/MeOH (99:1)], 1.0 mL/min, major= 20.7 min, 
minor= 24.9 min. 1H NMR (300 MHz, CDCl3) δ 8.14 – 7.99 (m, 2H), 7.62 
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– 7.51 (m, 1H), 7.48 – 7.40 (m, 2H), 5.00 (m, 1H), 2.71 (m, 1H), 2.43 – 
2.27 (m, 1H), 2.08 – 1.96 (m, 2H), 1.92 – 1.72 (m, 4H), 1.65 – 1.45 (m, 
2H), 1.47 – 1.22 (m, 3H), 1.23 – 1.15 (m, 1H), 1.17 – 0.92 (m, 5H). 13C 
NMR (75 MHz, CDCl3) δ 166.5, 132.9, 130.8, 129.7, 128.4, 75.8, 43.3, 
42.4, 37.3, 32.5, 32.5, 31.1, 30.3, 28.6, 14.8. HRMS-EI+ m/z calculated for 
C17H22O2 [M+Na]+: 281.1525, found 281.1512. 
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2.7. NMR Spectra. 
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2.8. HPLC chromatograms. 
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3. STEREOSPECIFIC COPPER-CATALYZED 
SUBSTITUTION REACTION OF PROPARGYLIC 
AMMONIUM SALTS. 
3.1. Background. 
3.1.1. Transition-Metal Catalyzed Reaction of Nitrogen-Containing 
Molecules. 
In the last decades, transition-metal catalyzed reactions have emerged as 
one of the most powerful strategies for the formation of carbon-carbon 
bonds.1 Much recently, powerful efforts have been made through the 
discovery of more stable and easily available electrophiles for cross-
coupling reactions (Scheme 3-1).  
 
 
Scheme 3-1: New electrophiles in cross-coupling reaction. 
 
1 a) Beller, M.; Bolm, C. Transition Metals for Organic Synthesis: Building Blocks and 
Fine Chemicals. WILEY‐VCH Verlag GmbH; Weinheim, 1998. b) Bates, R. Organic 
Synthesis Using Transition Metals, Second Edition.  John Wiley & Sons, Ltd; Weinheim, 
2012. c) Colacot, T. New Trends in Cross-Coupling: Theory and Applications. Royal 
Society of Chemistry, 2015. d) Johansson-Seechurn, C. C. C.; Kitching, M. O.; Colacot, T. 
J.; Snieckus, V. Angew. Chem. Int. Ed. 2012, 51, 5062-5085. e) Cherney, A. H.; Kadunce, 
N. T.; Reisman, S. E. Chem. Rev. 2015, 115, 9587-9652. 
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Several approaches for the activation of C-H,2 C-O3 and C-C4 bonds have 
been developed through the last years. These advances have provided to the 
organic chemistry community with a completely new toolbox for making 
new molecules and design new synthetic strategies. 
However, reaction involving transition-metal C-N cleavage is far less 
explored.5 This is not surprising, taking account of the high dissociation 
energy of the C-N bond (356 KJ/mol).6  
Nevertheless, the high number of nitrogen-containing molecules in 
pharmaceuticals and natural products, makes strategies to activate C-N 
bonds extremely desirable for the synthesis community, because late stage 
functionalization of molecules is key to the discovery of new leads in the 
early drug discovery stage.7 In addition, strategies aiming for the activation 
of C-N bonds, would benefit of the large variety of methods to prepare 
amine-containing molecules.8 
 
2 a) Colby, D. A.; Bergman, R. G.; Ellman, J. A. Chem. Rev. 2010, 110, 624-655. b) 
Wencel-Delord, J.; Dröge, T.; Liu, F.; Glorius, F. Chem. Soc. Rev. 2011, 40, 4740-4761. c) 
Yang, L.; Huang, H. Chem. Rev. 2015, 115, 3468-3517. d) He, J.; Wasa, M.; Chan, K. S. L.; 
Shao, Q.; Yu, J. Q. Chem. Rev. 2017, 117, 8754-8786. e) Yang, Y.; Lan, J.; You, J. Chem. 
Rev. 2017, 117, 8787-8863. f) Wei, Y.; Hu, P.; Zhang, M.; Su, W. Chem. Rev. 2017, 117, 
8864-8907. 
3 Quasdorf, K. W.; Tian, X.; Garg, N. K. J. Am. Chem. Soc. 2008, 130, 14422-14423. b) 
Li, W. N.; Wang, Z. L. RSC Adv. 2013, 3, 25565-25575. c) Cornella, J.; Zarate, C.; Martin, 
R. Chem. Soc. Rev. 2014, 43, 8081-8097. d) Tobisu, M.; Chatani, N. Acc. Chem. Res. 2015, 
48, 1717-1726. e) Tollefson, E. J.; Hanna, L. E.; Jarvo, E. R. Acc. Chem. Res. 2015, 48, 
2344-2353. f) Su, B.; Cao, Z. C.; Shi, Z. J. Acc. Chem. Res. 2015, 48, 886-896.  
4 a) Jun, C. H. Chem. Soc. Rev. 2004, 33, 610-618. b) Park, Y. J.; Park, J. W.; Jun, C. H. 
Acc. Chem. Res. 2008, 41, 222-234. c) Xia, Y.; Lu, G.; Liu, P.; Dong, G. Nature 2016, 539, 
546-550. 
5 a) Ouyang, K.; Hao, W.; Zhang, W. X.; Xi, Z. Chem. Rev. 2015, 115, 12045-12090. b) 
Wang, Q.; Su, Y.; Li, L.; Huang, H. Chem. Soc. Rev. 2016, 45, 1257-1272. 
6 Luo, Y. R. Comprehensive Handbook of Chemical Bond Energies, CRC Press, Boca 
Raton, FL, 2007. 
7 a) Vitaku, E.; Smith, D. T.; Njardarson, J. T. J. Med. Chem. 2014, 57, 10257-10274. b) 
Blakemore, D. C.; Castro, L.; Churcher, I.; Rees, D. C.; Thomas, A. W.; Wilson, D. M.; 
Wood, A. Nat. Chem. 2018, 10, 383-394. 
8 a) Nugent, T. C. Chiral Amine Synthesis; Wiley-VCH Verlag GmbH & Co. KGaA: 
Weinheim, 2010. b) Ruiz-Castillo, P.; Buchwald, S. L. Chem. Rev. 2016, 116, 12564-12649. 
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However, a comprehensive review of the literature regarding C-N 
activation exceeds the scope of the introduction in this chapter. Therefore, 
only literature concerning ammonium salts will be included in the next 
sections. 
 
3.1.2. Cross-Coupling Reactions of Ammonium Salts. 
As we have mentioned earlier in this chapter, C-N bonds possess a high 
dissociation energy. An interesting way to bypass this problem is to convert 
the corresponding amine into an ammonium salt. This functional group is 
easily prepared from amines and the dissociation energy of the C-N bond 
drop significantly. In this section, different methodologies to activate C-N 
bond using ammonium salts will be explained.  
 
3.1.2.1. Arylic Ammonium salts. 
In a pioneering work, Wenkert and co-workers, succeeded in the 
development of the first metal-catalyzed cross-coupling of arylic 
ammonium salts as electrophiles. They envisioned a Kumada-type cross-
coupling using Grignard reagents as nucleophiles in the presence of a nickel 
catalyst (Scheme 3-2).9 The best results were obtained using alkyl Grignard 
reagents, but the use of arylic compounds was also compatible. Although 
the results were not excellent, this seminal publication served as inspiration 
to other groups.   
 
 
 
9 Wenkert, E.; Han, A. -L.; Jenny, C. -J. J. Chem. Soc., Chem. Commun. 1988, 975-976. 
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Scheme 3-2: Kumada-type cross-coupling of ammonium salts with 
Grignard reagents. 
 
It was not until 2003, that Macmillan and co-workers, discovered that 
aryltrimethylammonium salts could be used as partners in Suzuki cross-
coupling reactions with aryl boronic acids, using a Ni(0) catalyst and a 
bulky ligand (Scheme 3-3).10 MacMillan was also the first that introduced 
triflate as a critical counteranion in these reactions. The scope of the 
transformation was fairly broad, both the anilinium and the boronic acid, 
obtaining excellent yields in all reported examples. 
 
 
 
 
 
 
 
 
10 Blakey, S. B.; MacMillan, D. W. C. J. Am. Chem. Soc. 2003, 125, 6046-6047. 
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Scheme 3-3: First Suzuki cross-coupling of ammonium salts with aryl 
boronic acids. 
 
In 2010, Reeves and co-workers discovered a palladium-catalyzed 
Kumada cross-coupling of aryl trimethylammonium salts with Grignard 
reagents (Scheme 3-4).11 Using triflate as counteranion and a commercially 
available palladium complex, they obtained excellent results, improving 
those obtained previously by Wenkert.9   
 
 
 
 
 
 
11 Reeves, J. T.; Fandrick, D. R.; Tan, Z.; Song, J. J.; Lee, H.; Yee, N. -K.; Senanayake, 
C. H. Org. Lett. 2010, 12, 4388-4391. 
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Scheme 3-4: Kumada-type palladium catalyzed cross-coupling of 
aryltrimethylammonium salts. 
 
In 2014, Wang and co-workers reported the Buchwald-Hartwig type 
cross-coupling reaction between aryl ammonium salts and simple amines 
(Scheme 3-5).12 As catalyst, they used the commercially available 
Ni(COD)2 and a N-heterocyclic carbene turned out to be the best ligand for 
the transformation. Both primary and secondary amine worked well with 
the reaction conditions. They succeeded in the one-pot amino group 
exchange of a dimethylamine into a morpholine moiety.  
 
 
 
 
12 Zhang, X. -Q.; Wang, Z. -X. Org. Biomol. Chem., 2014, 12, 1448-1453. 
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Scheme 3-5: Nickel catalyzed cross-coupling between 
aryltrimethylammonium salts and amines. 
 
The same group, in 2015, published the C-H arylation of various 
heterocycles catalyzed by palladium, using aryl trimethylammonium salts 
as electrophiles (Scheme 3-6).13 Both (benzo)oxazoles and 
(benzo)thiazoles worked well in the reaction conditions, obtaining 
moderate to excellent yields. They proposed a catalytic cycle where the key 
step was the C-H palladation in the presence of NaOt-Bu. 
 
 
 
 
13 Zhu, F.; Tao, J. -L.; Wang, Z. -X. Org. Lett. 2015, 17, 4926-4929. 
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Scheme 3-6: Palladium catalyzed C-H arylation of heterocycles. 
 
Itami and co-workers realized that there were a wide repertoire of 
functionalization methods using dimethylamine as directing group. 
However, the methodologies to transform this group were still scarce. They 
envisioned the transformation of the dimethylamino group into 
trimethylammonium salts to make a C-N nickel-catalyzed borylation and 
later take advantage of the wide amount of C-B functionalization methods 
(Scheme 3-7). Both aryl and benzyl ammonium salts were suitable for the 
borylation and they succeeded with the transformation of the C-B bond.14 
Simultaneously, Shi and co-workers reported the same transformation.15 
 
 
 
 
 
 
 
14 Zhang, H.; Hagihara, S.; Itami, K. Chem. Eur. J. 2015, 21, 16796-16800. 
15 Hu, J.; Sun, H.; Cai, W.; Pu, X.; Zhang, Y.; Shi, Z. J. Org. Chem. 2016, 81, 14-24. 
Stereospecific Copper-Catalyzed Substitution Reaction Of Propargylic 
Ammonium Salts. 
 
195 
 
 
Scheme 3-7: Nickel-catalyzed borylation of ammonium salts. 
 
In 2016, Wang, Uchiyama and co-workers, reported a methodology for 
the cross-coupling of aryl ammonium salts with organolithium reagents 
(Scheme 3-8). Their conclusion included that the best catalytic system for 
this transformation was the commercially available PdCl2(PPh3)2 and that 
the counteranion played a key role in the transformation. In this case, iodine 
was superior to other counteranion such as triflate or tetrafluoroborate.16 
 
 
Scheme 3-8: Cross-coupling of aryl trimethylammonium salts and 
organolithium reagents catalyzed by palladium. 
 
16 Yang, Z. K.; Wang, D. -Y.; Minami, H.; Ogawa, H.; Ozaki, T.; Saito, T.; Miyamoto, 
K.; Wang, C.; Uchiyama, M. Chem. Eur. J. 2016, 22, 15693-15699. 
Chapter 3 
 
196 
 
The same group published a methodology for the Stille cross-coupling 
of aryl ammonium salts catalyzed by nickel (Scheme 3-9).17 This was the 
first Stille coupling using this kind of electrophiles, which opened the door 
to further investigations. The functional group tolerance was very high and 
the mechanism they proposed was the typical for a Stille coupling, although 
some interesting conclusion could be obtained from their mechanism 
experiments. Despite of CsF seemed to act only as a base to free the ICy 
ligand, and allowed the oxidative addition step, it was crucial in the 
transmetalation. DFT calculations showed that the barrier was lowered by 
a substantial amount if fluorine anions were attached to the metal centre 
during the reaction.  
 
 
Scheme 3-9: Stille Cross-coupling of aryl ammonium salts. 
 
Wang and co-workers published in 2016, a method for the -arylation 
of ketones, taking advantage of the unique reactivity of aryl ammonium 
salts (Scheme 3-10).18 The choice of catalyst was nickel and after a large 
 
17 Wang, D. Y.; Kawahata, M.; Yang, Z. K.; Miyamoto, K.; Komagawa, S.; Yamaguchi, 
K.; Wang, C.; Uchiyama, M. Nat. Commun. 2016, 7, 12937-12945. 
18 Li, J.; Wang, Z. X. Org. Biomol. Chem. 2016, 14, 7579-7584. 
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screening of ligands and bases they found that IPr·HCl and LiOt-Bu 
excelled in this reaction. 
  
 
Scheme 3-10: Nickel catalyzed -arylation of ketones. 
 
In 2017, Wang, Uchiyama and co-workers, reported a very interesting 
procedure for the transition metal-free cross-coupling of 
aryltrimethylammonium triflates with diarylzinc compounds. The most 
interesting fact in this work was the proposed mechanism. They proposed 
that aryl ammonium compounds could suffer a SET process generating the 
corresponding radical anion.  This radical anion propagated with another 
molecule of diarylzinc, forming another radical anion, which in the final 
step reacted with another aryl ammonium molecule to generate the desired 
product and restarted the catalytic cycle (Scheme 3-11).19 
 
 
 
19 Wang, D. Y.; Morimoto, K.; Yang, Z. -K.; Wang, C.; Uchiyama, M. Chem. Asian. J. 
2017, 12, 2554-2557. 
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Scheme 3-11: Mechanism for the metal-free cross-coupling of 
aryltrimethylammonium salts. 
 
3.1.2.2. Benzylic Ammonium salts. 
In 1995, Zhuangyu succeeded in perform the very first metal catalyzed 
cross-coupling of benzylic ammonium salts. The vinylation of the 
substrates took place in the presence of low amounts of palladium(II) 
acetate with moderate yields. Mechanistic experiments showed evidences 
of a radical mechanism (Scheme 3-12).20 They proposed that the radical is 
formed by reductive cleavage of the quaternary ammonium salt in the 
presence of palladium(0). 
 
 
 
 
 
20 Yi, P.; Zhuangyu, Z.; Hongwen, H. Synthesis 1995, 3, 245-247. 
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Scheme 3-12: Vinylation of benzylic ammonium salts catalyzed by 
palladium. 
 
In an inspiring work, Watson and co-workers reported the stereospecific 
nickel-catalyzed Suzuki cross-coupling between benzylic 
trimethylammonium salts and boronic acids (Scheme 3-13).21 Both primary 
and secondary benzylic compounds could be used, and they obtained high 
levels of stereospecificity starting from enriched benzylic ammonium salts. 
This publication represents the first stereospecific cross-coupling reaction 
using a secondary ammonium salt as electrophile. Also, the importance of 
the triflate as counteranion is highlighted. They proposed that the reaction 
started with the oxidative addition of the electron rich Ni(0) complex into 
the C-N bond. Transmetalation with the boronic acid and then reductive 
elimination produce the desired product. A year later, they reported the 
same transformation with improved reaction conditions. They bypass the 
need of a ligand in the cross-coupling reaction and they only used 
Ni(COD)2 as catalyst.
22 Also in 2016, they reported the stereospecific 
borylation of benzylic ammonium salts catalyzed by nickel with excellent 
results.23 Itami and coworkers also reported a similar borylation.14 
 
 
 
21 Maity, P.; Shacklady-McAtee, D. M.; Yap, G. P. A.; Sirianni, E. R.; Watson, M. P. J. 
Am. Chem. Soc. 2013, 135, 280-285. 
22 Shacklady-McAtee, D. M.; Roberts, K. M.; Basch, C. H.; Song, Y. G.; Watson, M. P. 
Tetrahedron 2014, 70, 4257-4263. 
23 Basch, C. H.; Cobb, K. M.; Watson, M. P. Org. Lett. 2016, 18, 136-139. 
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Scheme 3-13: Cross-coupling of benzylic ammonium salts catalyzed 
by nickel. 
 
After Watson, there have been several reports on the Suzuki cross-
coupling of benzylic ammonium salts. In 2017, the group of Tu, published 
the Suzuki cross-coupling between benzylic ammonium salts with aryl 
boronic acids using a N-heterocyclic carbene nickel pincer complexes as 
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catalyst and the groups of Zhao and Phipps reported the same 
transformation using palladium.24  
The groups of Chatani and Wei, published the C-H activation of 
aromatic amides with benzylic ammonium salts catalyzed by nickel 
(Scheme 3-14).25 
 
 
Scheme 3-14: Nickel-catalyzed benzylation of aromatic amides. 
 
In 2016, Martin and co-workers reported the formal cross-electrophile 
coupling between benzylic ammonium salts and carbon dioxide, leading to 
-substituted phenylacetic acids (Scheme 3-15).26 They used commercially 
available nickel salts, along with phenanthroline type ligands to obtain the 
desired products with good results. They also completely avoided the 
common problems of cross-electrophile reactions, such as 
homodimerization and -hydride elimination. 
 
 
 
 
24 a) Liu, X. Y.; Zhu, H. B.; Shen, Y. J.; Jiang, J.; Tu, T. Chinese Chemical Letters 2017, 
28, 350-353. b) Wang, T.; Yang, S.; Xu, S.; Han, C.; Guo, G.; Zhao, J. RSC Adv. 2017, 7, 
15805-15808. c) Türtscher, P. L.; Davis, H. J.; Phipps, R. J. Synthesis 2018, 50, 793–802. 
25 a) Sasagawa, A.; Yamaguchi, M.; Ano, Y.; Chatani, N. Isr. J. Chem. 2017, 57, 964-967. 
b) Li, J.; Zheng, Z.; Xiao, T.; Xu, P.F.; Wei, H. Asian J. Org. Chem. 2018, 7, 133-136. 
26 Moragas, T.; Gaydou, M.; Martin, R. Angew. Chem. Int. Ed. 2016, 55, 5053-5057. 
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Scheme 3-15: Carboxylation of benzylic ammonium salts catalyzed by 
nickel. 
 
In 2019, Shu and coworkers have reported a procedure for the nickel-
catalyzed cross-electrophile reaction between benzyl or 
aryltrimethylammonium salts and C-O electrophiles.27 In this way, the 
ammonium salts could be coupled either with a range of vinyl acetates or 
aryl triflates. Mechanistic experiments suggest a radical mechanism 
(Scheme 3-16). 
 
 
 
 
 
27 He, R. D.; Li, C. L.; Pan, Q. Q.; Guo, P.; Liu, X. Y; Shu, X. Z. J. Am. Chem. Soc. 2019, 
141, 12481-12486. 
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Scheme 3-16: Nickel-catalyzed cross-electrophile reaction of 
trimethylammonium salts. 
 
3.1.2.3. Allylic Ammonium Salts. 
In 1980, Langlois and Dressaire reported the allylic substitution of 
ammonium salts with Grignard reagents in the presence of dilithium 
dichlorocuprate (Scheme 3-17).28 In 1987, the groups of Hosomi and 
Gupton published the same transformation.29 In 1982, Hirao and 
coworkers reported the Pd-catalyzed Tsuji-Trost reaction of allylic 
ammonium salts with carbon nucleophiles. In most cases, they obtained 
almost no regioselectivity.30 
 
 
Scheme 3-17: Allylic substitution of ammonium salts. 
 
28 Dressaire, G.; Langlois, Y. Tetrahedron Lett. 1980, 21, 67-70. 
29 a) Hosomi, A.; Hoashi, K.; Tominaga, Y. J. Org. Chem. 1987, 52, 2947-2948. b) 
Gupton, J. T.; Layman, W. J. J. Org. Chem. 1987, 52, 3683-3686. 
30 Hirao, T.; Yamada, N.; Oshiro, Y.; Agawa, T. J. Organomet. Chem. 1982, 236, 409-
411. 
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3.1.2.4. Pyridinium Salts. 
It was Katritzky and co-workers in 1976 who discovered the potential 
of pyridinium salts as leaving groups.31 It was an easy way to transform 
amines into good leaving groups (Scheme 3-18). 
 
 
Scheme 3-18: Pyridinium salts as leaving group. 
 
However, it was not until 2007 when Buszek and Brown reported the 
use of pyridinium salts as partners in cross-coupling reaction. They reported 
the palladium-catalyzed Suzuki cross-coupling reaction of N-
vinylpyridinium and ammonium tetrafluoroborate salts with boronic acids 
(Scheme 3-19).32  
 
 
Scheme 3-19: Suzuki cross-coupling of vinylpyridinium salts. 
 
 
31 a) Bapat, J. B.; Blade, R. J.; Boulton, A. J.; Espztajn, J.; Katritzky, A. R.; Lewis, J.; 
Molina-Buendia, P.; Nie, P. L.; Ramsden, C. A. Tetrahedron Lett. 1976, 31, 2691-2694. b) 
Katritzky, A. R.; Marson, C. M. Angew. Chem. Int. Ed. Engl. 1984, 23, 420-429. c) 
Katritzky, A. R.; Brycki, B. Can. J. Chem. 1986, 64, 1161-1169.  
32 Buszek, K. R.; Brown, N. Org. Lett. 2007, 9, 707-710. 
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In 2016, Watson and co-workers reported the sp3-sp2 Suzuki cross-
coupling of alkylpyridinium salts with boronic acids (Scheme 3-20).33 With 
this strategy, normal alkylamines could be used as alkylating agents, being 
the first example of this kind of transformation. They proposed a radical 
mechanism based on mechanistic experiments. The pyridinium underwent 
a SET process with a Ni(I) complex to produce an alkyl radical and a Ni(II) 
complex. Both molecules reacted to form a Ni(III) complex which after 
reductive elimination produce the desired product and regenerate the Ni(I) 
complex. The same group extended this methodology to benzylic amines 
for the synthesis of diarylmethanes.34 
 
 
 
 
 
 
 
 
 
 
 
33 Basch, C. H.; Liao, J.; Xu, J.; Piane, J. J.; Watson, M. P. J. Am. Chem. Soc. 2017, 139, 
5313-5316. 
34 a) Liao, J.; Guan, W.; Boscoe, B. P.; Tucker, J. W.; Tomlin, J. W.; Garnsey, M. R.; 
Watson, M. P. Org. Lett. 2018, 20, 3030-3033. b) Guan, W.; Liao, J.; Watson, M. P. 
Synthesis 2018, 50, 3231-3237. 
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Scheme 3-20: Nickel-catalyzed cross-coupling of alkylammonium 
salts. 
 
In the same year, Glorius and co-workers, reported a photocatalytic 
strategy to carry out a similar transformation. Using an iridium 
photocatalyst, under visible-light conditions, they performed the cross-
coupling between alkylpyridinium salts and a variety of heterocycles 
(Scheme 3-21).35 They also could use protected amino acids as starting 
 
35 Klauck, F. J. R.; James, M. J.; Glorius, F. Angew. Chem. Int. Ed. 2017, 56, 12336-12339. 
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materials with excellent results. They proposed a SET process to produce a 
radical from the alkylpyridinium salt. Recently, Watson and coworkers 
have reported a nickel-catalyzed Suzuki cross-coupling between 
alkylpyridinium salts from aminoacids and boronic acids or boroxines.36  
 
 
Scheme 3-21: Visible-light mediated cross-coupling of 
alkylammonium salts. 
 
Glorius and coworkers have reported this year a procedure for the 
dicarbofuntionalization of styrenes using benzylic radicals from 
benzylpyridinium salts.37 
Also in 2019, Watson and co-workers have reported the alkyl-alkyl 
cross-coupling of pyridinium salts with alkylzinc reagents catalyzed by 
nickel (Scheme 3-22).38 This is the very first sp3-sp3 bond formation using 
alkyl amine derivatives with inactivated alkyl groups. It worked for both 
 
36 Hoerner, M. E.; Baker, K. M.; Basch, C. H.; Bampo, E. M.; Watson, M. P. ASAP. DOI: 
10.1021/acs.orglett.9b02643 
37 Klauck, F. J. R.; Yoon, H.; James, M. J.; Lautens, M.; Glorious, F. ACS Catal. 2019, 9, 
236-241. 
38 Plunkett, S.; Basch, C. H.; Santana, S. O.; Watson, M. P. J. Am. Chem. Soc. 2019, 141, 
2257-2262. 
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primary and secondary amines and presented very good functional group 
tolerance. 
 
 
Scheme 3-22: Alkyl-alkyl Negishi cross-coupling of pyridinium salts. 
 
Recently, Martin and co-workers have reported the reductive 
deaminative arylation of alkylpyridinium salts with aromatic halides 
catalyzed by nickel (Scheme 3-23).39 Mechanistic experiments suggested 
that nickel is not involved into the C-N cleavage. Watson, Molander and 
Rueping have reported similar transformation.40 
 
 
 
 
 
39 Martin-Montero, R.; Yatham, V. R.; Yin, H.; Davies, J.; Martin, R. Org. Lett. 2019, 21, 
2947-2951. 
40 a) Yi, J.; Badir, S. O.; Kammer, L. M.; Ribagorda, M.; Molander, G. A. Org. Lett. 2019, 
21, 3346-3351. b) Liao, J.; Basch, C. H.; Hoerner, M. E.; Talley, M. R.; Boscoe, B. P.; 
Tucker, J. W.; Garnsey, M. R.; Watson, M. P. Org. Lett. 2019, 21, 2941-2946. c) Yue, H.; 
Zhu, C.; Shen, L.; Geng, Q.; Hock, K. J.; Yuan, T.; Cavallo, L.; Rueping, M. Chem. Sci. 
2019, 10, 4430-4435. 
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Scheme 3-23: Reductive deaminative arylation catalyzed by nickel. 
 
Recently, Xiao, Lu and coworkers have reported an alkyl-heck reaction 
using alkylpyridinium salts as electrophiles via a radical mechanism.41 The 
reaction is catalyzed by iridium and they were able to perform also the 
carbonylative heck reaction adding CO (80 atm) to the reaction mixture. 
 
 
 
 
 
 
 
 
41 Jiang, X.; Zhang, M. M.; Xiong, W.; Lu, L. Q.; Xiao, W. J. Angew. Chem. Int. Ed. 2019, 
58, 2402-2406. 
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Scheme 3-24: Iridium catalyzed Heck-type reaction using 
alkylpyridinium salts as electrophiles. 
 
3.1.2.5. Propargylic ammonium salts. 
When we started the project presented in this chapter, there was only 
one example of propargylic ammonium salts used as electrophiles. In 2007, 
Murai and co-workers, reported the reaction between 1-
methylthiopropargylammonium salts with a variety of organometallic 
reagents (Scheme 3-25).42 When they used aryl Grignard reagents, they 
obtained a mixture of propargyl sulfides or allenyl sulfides, being the mayor 
product the first one. However, when they used organocopper reagents they 
obtained allenyl sulfides as single regioisomer. Finally, when they used an 
organolithium reagent, the salts undergo dimerization. 
 
 
Scheme 3-25: Substitution reaction of 1-methylthiopropargyl 
ammonium salts. 
 
 
42 Murai, T.; Fukushima, K.; Mutoh, Y. Org. Lett. 2007, 9, 5295-5298. 
Stereospecific Copper-Catalyzed Substitution Reaction Of Propargylic 
Ammonium Salts. 
 
211 
 
During the development of the work presented in this chapter, Ma and 
co-workers reported the synthesis of tetrasubstituted allenes using 
propargylic ammonium salts as starting materials (Scheme 3-26).43 They 
used copper(II) bromide as catalyst and the propose an SN2’ pathway for 
the reaction. The sterospecificity of the transformation was not studied. 
 
 
Scheme 3-26: Copper-catalyzed allene synthesis from propargylic 
ammonium salts. 
 
3.1.3. Cross-Coupling of Propargylic compounds. 
The catalytic propargylic substitution reaction is a powerful method to 
synthetize new chiral propargylic compounds. In addition, the alkyne 
moiety is an extremely versatile functional group.44 Furthermore, there are 
a wide number of natural products, pharmaceuticals and fine chemicals 
containing propargylic moieties in their structure (Figure 3-1).45  
 
43 Ma, S.; Liu, Q.; Tang, X.; Cai, Y. Asian J. Org. Chem. 2017, 6, 1209-1212. 
44 a) Diederich, F., Stang, P. J., Tykwinski, R. R. Acetylene Chemistry, Wiley-VCH: New 
York, 2005. b) The Chemistry of Triple-Bonded Functional Groups. Patai, S. Wiley: New 
York, 1994. 
45 a) Konishi, M.; Ohkuma, H.; Matsumoto, K.; Tsuno, T.; Kamei, H.; Miyaki, T.; Oki, 
T.; Kawaguchi, H.; Van Duyne, G. D.; Clardy, J. J. Antibiot. 1989, 42, 1449-1452. b) 
Thompson, A. S.; Corley, E. G.; Huntington, M. F.; Grabowski, E. J. J. Tetrahedron Lett. 
1995, 36, 8937-8940. c) Wright, J. L.; Gregory, T. F.; Kesten, S. P.; Boxer, P. A.; Serpa, K. 
Chapter 3 
 
212 
 
 
Figure 3-1: Alkyne containing natural products and pharmaceuticals. 
 
However, when internal propargylic electrophiles are treated with 
nucleophiles in the presence of a metal-catalyst, there are two different 
reactive places, making the regioselectivity difficult to control (Scheme 
3-27).46 
 
 
 
A.; Meltzer, L. T.; Wise, L. D.; Espitia, S. A.; Konkoy, C. S.; Whittemore, E. R.; Woodward, 
R. M. J. Med. Chem. 2000, 43, 3408-3419. d) Zhu, X.; Liu, J.; Zhang, W. Nature Chemical 
Biology 2015, 11, 115-120. e) Chai, Q. Y.; Yang, Z.; Lin, H. W.; Han, B. N.; Mar. Drugs 
2016, 14, 216-233. 
46 a) Miyake, Y.; Uemura, S.; Nishibayashi, Y. ChemCatChem 2009, 1, 342-356. b) Detz, 
R. J.; Hiemstra, H.; van Maarseveen, J. H. Eur. J. Org. Chem. 2009, 6263-6276. c) Zhang, 
D. Y.; Hu, X. P. Tetrahedron Lett. 2015, 56, 283-295. 
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Scheme 3-27: Propargylic substitution. 
 
In 1977, Nicholas and co-workers reported that dicobalt hexacarbonyl-
stabilized propargylic cations from propargylic alcohols could be trapped 
with a variety of nucleophiles. This reaction is known as Nicholas Reaction 
(Scheme 3-28).47 Diastereoselective Nicholas reactions are possible, but 
the drawback of this transformation is that a full equivalent of Co2(CO)8 is 
needed. 
 
 
Scheme 3-28: Nicholas reaction. 
 
The asymmetric propargylic substitution is an important challenge in 
synthetic chemistry. Although there are reports where the asymmetric 
propargylic substitution of terminal alkynes is achieved,48 a comprehensive 
review of the literature exceeds the scope of the introduction of this chapter. 
Therefore, only literature concerning asymmetric propargylic substitution 
of internal alkynes will be included in this section. 
 
47 a) Lockwood, R. F.; Nicholas, K. M. Tetrahedron Lett. 1977, 4163-4166. b) Kurti, L.; 
Czako, B. Strategic Applications of Named Reactions in Organic Synthesis. 2005, Elsevier 
Academic Press, London. 
48 a) Zhang, D. -Y.; Hu, X. P. Tetrahedron Lett. 2015, 56, 283-295. b) Roy, R.; Saha, S. 
RSC Adv. 2018, 8, 31129-31193. 
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Despite the fact that palladium-catalyzed propargylic substitution 
usually gives the allenyl compound,49 in 1996 Marshall and Wolf reported 
the propargylic substitution of enantiomerically pure mesylates with 
arylamines. The stereospecificity of the reaction was good and the reaction 
occurred with retention of the configuration (Scheme 3-29).50 
 
 
Scheme 3-29: Palladium-catalyzed propargylic substitution. 
 
In 2008, Smith and Fu reported the very first enantioselective Negishi 
cross-coupling of propargylic halides with arylzinc reagents using a chiral 
nickel/Pybox complex. The reaction worked well with both propargyl 
bromides and chlorides and the enantiomeric excesses were good to 
excellent (Scheme 3-30).51 
 
 
49 a) Keinan, E.; Bosch, E. J. Org. Chem. 1986, 51, 4006-4016. b) Tsuji, J.; Mandai, T. 
Angew. Chem. Int. Ed. Engl. 1995, 34, 2589-2612. 
50 Marshall, J. A.; Wolf, M. A. J. Org. Chem. 1996, 61, 3238-3239. 
51 Smith, S. W.; Fu, G. C. J. Am. Chem. Soc. 2008, 130, 12645-12647. 
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Scheme 3-30: Nickel-catalyzed Negishi cross-coupling of propargylic 
halides. 
 
In 2012, the same group reported the enantioselective nickel-catalyzed 
Negishi cross-coupling of different propargylic compounds bearing a 
carbonate as leaving group. They used the same pybox ligand and readily 
available arylzinc reagents (Scheme 3-31).52 This was the first report that 
performed an enantioselective sp3-sp2 cross-coupling using oxygen based 
electrophiels excluding allylic compounds.  
 
 
 
 
52 Oelke, A. J.; Sun, J.; Fu, G. C. J. Am. Chem. Soc. 2012, 134, 2966-2969. 
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Scheme 3-31: Nickel-catalyzed Negishi cross-coupling of propargylic 
carbonates. 
 
Nishibayashi and co-workers reported in 2011 a cooperative catalytic 
system for the propargylic substitution of alcohols with aldehydes. They 
used indium(III) bromide as Lewis acid and a chiral organocatalyst to 
achieve high levels of enantiocontrol. However, the diastereocontrol was 
not as high, and they obtained mixtures of the syn and the anti-isomers 
almost in equal proportion (Scheme 3-32).53 The same year, Cozzi and co-
workers reported the same transformation with slightly better results using 
indium(III) triflate and Macmillan catalyst. However, diastereoselectivity 
remained a problem.54 
 
 
 
53 Motoyama, K.; Ikeda, M.; Miyake, Y.; Nishibayashi, Y. Eur. J. Org. Chem. 2011, 2239–
2246. 
54 Sinisi, R.; Vita, M. V.; Gualandi, A.; Emer, E.; Cozzi, P. G. Chem. Eur. J. 2011, 17, 
7404-7408. 
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Scheme 3-32: Cooperative catalytic propargylic substitution of 
alcohols with aldehydes. 
 
In 2016, Trost and co-workers reported the stereospecific propargylic 
substitution of propargylic bromides with hetereoaryl diorganocuprates 
(Scheme 3-33).55 They obtained excellent yields and stereospecificities. 
However, a full equivalent of copper(I) salt was needed. 
 
 
 
 
 
 
55 Trost, B. M.; Debien, L. Chem. Sci. 2016, 7, 4985-4989. 
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Scheme 3-33: Stereospecific substitution of propargylic bromides. 
 
Recently, Tsuji, Kawatsura and co-workers have reported the 
enantioselective propargylic amination of carbonates catalyzed by a chiral 
nickel-complex with excellent yields and enantioselectivities (Scheme 
3-34).56 
 
 
 
 
 
 
 
 
 
56 Watanabe, K.; Miyazaki, Y.; Okubo, M.; Zhou, B.; Tsuji, H.; Kawatsura, M. Org. Lett. 
2018, 20, 5448−5451. 
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Scheme 3-34: Nickel-catalyzed enantioselective amination of 
propargylic carbonates. 
 
3.1.4. Stereospecific Copper-Catalyzed Synthesis of Allenes. 
Although in 1875 Van’t Hoff predicted the correct structure of allenes,57 
they were considered mere curiosities for a long period of time and its 
chemistry did not really starting to develop until the 50’s.58 Advances in the 
synthesis, characterization and isolation of this unique structures, especially 
in their enantiomerically pure form, have opened the door to the 
development of a huge variety of procedures to take advantage of their 
unique reactivity.59 
Now, more than 150 natural products are known to have an allene in 
their structure, most of them enantiomerically enriched. There are 
important moieties in a wide variety of compounds. Some of the most 
 
57 Van't Hoff, J. H. La Chimie dans L'Espace, Bazendijk, Rotterdam, 1875. 
58 Taylor, D. R. Chem. Rev. 1967, 67, 317-359. 
59 a) Zimmer, R.; Dinesh, C. U.; Nandanan E.; Khan, F. A. Chem. Rev. 2000, 100, 3067-
3125. b) Hashmi, A. S. K. Angew. Chem. Int. Ed. 2000, 39, 3590-3593. c) Ma, S. Acc. Chem. 
Res. 2003, 36, 701-712. d) Modern Allene Chemistry, Krause, N.; Hashmi, A. S. K. ed. 
Wiley-VCH, Weinheim, Germany, 2004. e) Hoffmann-Röder A.; Krause, N. Angew. Chem. 
Int. Ed. 2004, 43, 1196-1216. f) Ma, S. Chem. Rev. 2005, 105, 2829-2872. g) Ma, S. Acc. 
Chem. Res. 2009, 42, 1679-1688. h) Yu, S.; Ma, S. Angew. Chem. Int. Ed. 2012, 51, 3074-
3112. i) Pullis, A. P.; Yeung, K.; Procter, D. J. Chem. Sci. 2017, 8, 5240-5247. 
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known allene-containing natural product and pharmaceuticals are 
fucoxanthin (the most abundant carotinoid), isolated from algae and 
diatomees,60 grasshoper ketone, a metabolite of many carotinoids,61 
laurallene, a bromoallene isolated from red algae,62 and Enprostil, a 
commercially marketed drug which is a highly potent inhibitor of gastric 
HCl secretion (Figure 3-2).63 
 
 
Figure 3-2: Natural products and drugs with an allene in their 
structure. 
 
 
60 a) Willstätter, R.; Page, H. J. Justus Liebigs Ann. Chem. 1914, 404, 237-271. b) Bonnett, 
R.; Spark, A. A.; Tee, J. L.; Weedon, B. C. L. Proc. Chem. Soc. London 1964, 419. 
61 a) Meinwald, J.; Erickson, K.; Hartshorn, M.; Meinwald, Y. C.; Eisner, T.; Tetrahedron 
Lett. 1968, 2959-2962. b) DeVille, T. E.; Hursthouse, M. B.; Russell, S. W.; Weedon, B. C. 
L. J. Chem. Soc. Chem. Commun. 1969, 754-755. 
62 a) Fukuzawa, A.; Kurosawa, E. Tetrahedron Lett. 1979, 2797-2800. b) Suzuki, M.; 
Koizumi, K.; Kikuchi, H.; Suzuki, T.; Kurosawa, E. Bull. Chem. Soc. Jpn. 1983, 56, 715-
718. c) Wright, A. D.; Koenig, G. M.; Sticher, O. J. Nat. Prod. 1991, 54, 1025-1033. 
63 Collins, P.W.; Djuric, S. W. Chem. Rev. 1993, 93, 1533-1564. 
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Among the methodologies to prepare allenes, one of the most 
convenient and straightforward strategies is the reaction of organocuprates 
generated from organolithium or organomagnesium reagents.64   
Most of the existing procedures used stochiometric amounts of copper 
in the reaction, and there are few reported catalytic strategies.65 This 
methodology presents several limitations, especially in catalytic 
asymmetric synthesis. Enantioselective methodologies do not offer a broad 
scope and minimum variation in the stereoelectronic properties of the 
propargylic compounds could lead to problems in the regio- and the 
stereoselectivity.66 Also, the chirality transfer in stereospecific reaction is 
usually poor and the loss of enantiomeric purity is reported in the 
literature.67 
In 2011, Sawamura and coworkers overcame these problems. They 
reported the synthesis of enantiomerically enriched allenes by a 
stereospecific copper-catalyzed -selective coupling of propargylic 
phosphonates and alkylboranes.68 They did not need any ligand and had a 
wide scope. They demonstrated the transfer of chirality on 3 examples, 
obtaining excellent results (Scheme 3-35, top). A year later, they extended 
this methodology to alkenyl- and arylboronates (Scheme 3-35, bottom).69 
 
64 a) Hoffmann-Röder, A.; Krause, N. Angew. Chem. Int. Ed. 2002, 41, 2933-2935. b) Yu, 
S.; Ma, S. Chem. Commun. 2011, 47, 5384-5418. c) Neff, R. K.; Frantz, D. E. ACS Catal. 
2014, 4, 519-528.  
65 For selected examples: a) Friel, D. F.; Snapper, M. L.; Hoveyda, A. H. J. Am. Chem. 
Soc. 2008, 130, 9942-9951. b) Cerat, P.; Gritsch, P. J.; Goudreau, S. R.; Charette, A. B. Org. 
Lett. 2010, 12, 564-567. 
66 For selected examples: a) Alexakis, A.; Marek, I.; Mangeney, P.; Normant, J. F. J. Am. 
Chem. Soc. 1990, 112, 8042-8047. b) Li, H.; Grassi, D.; Guenee, L.; Bürgi, T.; Alexakis, A. 
Chem. Eur. J. 2014, 20, 16694-16706. c) Li, H.; Müller, D.; Guenee, L.; Alexakis, A. Org. 
Lett. 2012, 14, 5880-5883. d) Han, J. T.; Yun, J. Chem. Commun. 2019, 55, 9813-9816. 
67 a) Claesson, A.; Olsson, L. I.; J. Chem. Soc. Chem. Commun. 1979, 524-525. b) Chenier, 
J. H. B.; Howard, J. A.; Mile, B. J. Am. Chem. Soc. 1985, 107, 4190-4191. 
68 Ohmiya, H.; Yokobori, U.; Makida, Y.; Sawamura, M. Org. Lett. 2011, 13, 6312-6315. 
69 Yang, M.; Yokokawa, N.; Ohmiya, H.; Sawamura, M. Org. Lett. 2012, 14, 816-819. 
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Scheme 3-35: Stereospecific copper-catalyzed coupling of propargylic 
phosphonates with boron reagents. 
 
In the same year, Lalic and coworkers, develop a similar strategy where 
they performed the copper-catalyzed cross-coupling of propargylic 
phosphates and boron reagents to synthetize enantiomerically pure allenes 
(Scheme 3-36).70 They used aryl boronates and alkyl boranes along a N-
heterocyclecarbene copper-complex to obtain trisubstituted allenes with 
excellent results in yield and stereospecificity. They demonstrated by a 
stochiometric experiment with ICyCuMe, that the formal nucleophile is an 
organocopper reagent. 
 
 
 
 
 
70 Uehling, M. R.; Marionni, S. T.; Lalic, G. Org. Lett. 2012, 14, 362-365. 
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Scheme 3-36: Stereospecific copper-catalyzed cross-coupling  reaction 
of propargylic phosphonates and boron reagents. 
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3.2. Regio- and Stereospecific Copper-Catalyzed 
Substitution Reaction of Propargylic Ammonium Salts 
with Aryl Grignard Reagents. 
3.2.1. Introduction and objectives. 
At the outset of our investigation, there were only three examples in the 
literature of a stereospecific transformation using ammonium salts as 
eletrophiles.21,22,23 Additionally, only aryl and benzylic ammonium salts had 
been used in cross-coupling reactions. Moreover, most of the reported 
examples required the use of the air-sensitive and thermally unstable 
Ni(COD)2 while the use of copper as catalyst was virtually unexplored.
28,29 
With these precedents, we decided to contribute to the field with two 
objectives in mind: to expand the scope of the ammonium salts, with special 
interest in stereospecific transformations, and to introduce copper-catalysis 
in the arena.  
We envisioned that propargylic ammonium salts would be good 
candidates to explore a stereospecific copper-catalyzed transformation 
(Scheme 3-37). To prepare these electrophiles, we could take advantage of 
the variety of methodologies existing in the literature to synthesize 
enantiomerically enriched propargylic amines, either from propargylic 
alcohols71 or through different asymmetric catalytic methods.72 The specific 
objective of this chapter is to develop a stereospecific Kumada type cross-
coupling of propargylic ammonium salts with Grignard reagents, finding 
 
71 a) Matsumura, K.; Hashiguchi, S.; Ikariya, T.; Noyori, R. J. Am. Chem. Soc. 1997, 119, 
8738-8739. b) Anand, N.K.; Carreira, E.M. J. Am. Chem. Soc. 2001, 123, 9687-9688. c) 
Takita, R.; Yakura, K.; Ohshima, T.; Shibasaki, M. J. Am. Chem. Soc. 2005, 127, 13760-
13761. 
72 a) Gommermann, N.; Koradin, C.; Polborn, K.; Knochel, P. Angew. Chem., Int. Ed. 
2003, 42, 5763-5766. b) Akullian, L.C.; Snapper, M.L.; Hoveyda, A.H. Angew. Chem., Int. 
Ed. 2003, 42, 4244-4247. c) Knöpfel, T.F.; Aschwanden, P.; Ichikawa, T.; Watanabe, T.; 
Carreira, E.M. Angew. Chem., Int. Ed. 2004, 43, 5971-5973. d) Klauber, E.G.; De, C.K.; 
Shah, T.K.; Seidel, D. J. Am. Chem. Soc. 2010, 132, 13624-13626. e) Paioti, P.H.S.; 
Abboud, K.A.; Aponick, A. J. Am. Chem. Soc. 2016, 138, 2150-2153. 
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the optimal catalytic system to control the stereospecificity and the 
regioselectivity. 
 
Scheme 3-37: Objectives of this chapter. 
 
3.2.2. Synthesis of Starting Materials. 
First, we prepared a series of propargylic ammonium salts III-1 (Figure 
3-3). We prepare them by different procedures and in the next pages we 
will explain each of the corresponding methodologies. 
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Figure 3-3: Prepared propargylic ammonium salts. 
 
We choose propargylic ammonium salt (R)-III-1a as model substrate to 
study the reaction. This compound could be synthetized starting with a 
Sonogashira reaction between (S)-3-butyn-2-ol and phenyl iodine. After 
that, a one-pot mesylation/amination with dimethylamine, followed by 
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treatment with methyl triflate yielded the enantiomerically enriched 
ammonium salt with 76% of global yield (Scheme 3-38). We use the same 
procedure to prepare III-1c-l. 
 
 
Scheme 3-38: Synthesis of propargylic ammonium salt starting by 
Sonogashira reaction. 
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The absolute configuration of (R)-III-1i was determined from single 
crystal X-ray crystallography (Figure 3-4).73 The absolute configuration of 
all the other propargylic ammonium salts was assigned by analogy. 
 
           
Figure 3-4: Single X-ray structure of (R)-III-1i. 
 
To synthetize III-1m, we started with the commercially available -
(Trimethylsilyl)-3-butyn-2-ol and then proceeded with the same route of 
one-pot mesylation/amination, followed by treatment with methyl triflate 
(Scheme 3-39). 
 
 
Scheme 3-39: Synthesis of III-1m. 
 
For the synthesis of III-1n, III-1o, III-1p and III-1w we started with a 
nucleophilic attack of a lithium acetylide to an aldehyde, followed by the 
 
73 CCDC 1546939 contains the supplementary crystallographic data. These data can be 
obtained free of charge at www.ccdc.cam.ac.uk/conts/retrieving.html 
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same sequence as before (Scheme 3-40). In the case of III-1w, we made a 
kinetic resolution to obtain the enantiomerically enriched alcohol. 
 
 
Scheme 3-40: Synthesis of III-1n, III-1o, III-1p and (R)-III-1w. 
 
Primary propargylic ammonium salt III-1q was prepared from 
corresponding commercially available alcohol, through one-pot 
mesylation/amination, followed by treatment with methyl triflate (Scheme 
3-41). 
 
 
Scheme 3-41: Synthesis of III-1q. 
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Finally, ammonium salt III-1r, was synthesized by treatment of the 
commercially available dimethylamine with methyl triflate (Scheme 3-42). 
 
 
Scheme 3-42: Synthesis of III-1r. 
 
3.2.3. Copper-Catalyzed Substitution Reaction of Propargylic 
Ammonium Salts. Screening of Conditions. 
Motivated by the possibilities of this reaction, we choose the previously 
reported conditions for palladium catalyzed Kumada coupling of aryl 
trimethylammonium salts as a starting point. When we treated compound 
(R)-III-1a with 4-methoxyphenylmagnesium bromide and Pd(PPh3)2Cl2 
we observed the formation of a 40:60 mixture of III-2a and III-3a in 12% 
yield (Table 3-1, entry 1). Far from assuming that the desired reaction did 
not work, we got more motivated about finding the right catalytic system 
for our reaction.  
We started our screening by changing the catalyst to [Ni(dppe)]Cl2 and 
surprisingly the formation of the allenyl product is completely avoided, 
although the yield was low and we observed the formation of the 
corresponding propargylic bromide (Table 3-1, entry 2). Based on our 
previous experience in copper catalysis we decided to use Cu(CH3CN)4PF6 
along with the phosphine Xanthphos. Surprisingly, the desired product was 
formed in good yield and good stereoselectivity with no trace of the allenyl 
product (Table 3-1, entry 3). With this result in hand, we decided to try a 
battery of different ligands. All ligands tested gave the -product with good 
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to excellent yields and good stereospecificity (Table 3-1, entries 4-14). 
Surprisingly, when we tried the reaction without any added ligand, the -
product was formed with 98% yield and 98% of enantiomeric ratio (Table 
3-1, entry 15). Changing the copper source to copper(I) chloride yield the 
product with inferior result (Table 3-1, entry 16). We could reduce the 
catalytic loading to 5 mol% with a slight decrease in the yield (Table 3-1, 
entry 17), but switching the solvent to CH2Cl2 gave 98% yield again with 
only 5 mol% of copper (Table 3-1, entry 18). Finally, the reaction did not 
work without catalyst at -40 ºC. Interestingly, at room temperature the -
product was obtained inlow yield and almost complete erosion of the 
stereospecificity (Table 3-1, entry 19). 
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Table 3-1: Influence of the metal source and the ligand. 
 
Entry [M] (mol%) L 
T 
(ºC) 
Yieldc 
(%) 
e.r.d 
1a Pd(PPh3)Cl2 (10) ---- rt 12 ---- 
2b [Ni(dppe)]Cl2 (10) ---- rt 22 ---- 
3 Cu(CH3CN)4PF6 (10) Xantphos -40 80 93:7 
4 Cu(CH3CN)4PF6 (10) PCy3 -40 85 97.5:2.5 
5 Cu(CH3CN)4PF6 (10) Sphos -40 89 98.2 
7 Cu(CH3CN)4PF6 (10) IMes -40 89 97:3 
8 Cu(CH3CN)4PF6 (10) Bathophenanthroline -40 93 98:2 
9 Cu(CH3CN)4PF6 (10) PPh3 -40 80 98:2 
10 Cu(CH3CN)4PF6 (10) dppe -40 80 97:3 
11 Cu(CH3CN)4PF6 (10) dppp -40 63 97.5:2.5 
13 Cu(CH3CN)4PF6 (10) dppf -40 61 88:12 
14 Cu(CH3CN)4PF6 (10) 4-4’-ditBu-bpy -40 72 96:4 
15 Cu(CH3CN)4PF6 (10) ----- -40 98 99:1 
16 CuCl (10) ----- -40 80 85:15 
17 Cu(CH3CN)4PF6 (5) ----- -40 95 99:1 
18e Cu(CH3
CN)
4
PF
6
 (5) ----- -40 98 99:1 
19e ----- ----- rt 22 54:46 
Reaction condition: (R)-III-1a (0.1 mmol, 1.0 equiv), ArMgX (1.1 equiv), CuX (10 
mol%), THF (0.1 M), −40 °C, 5 min, unless otherwise noted. aReaction conditions: 
Pd(PPh3)2Cl2 (10 mol%), 4 h. 40:60 mixture of III-2a and III-3a was obtained. b 
[Ni(dppe)]Cl2 (10 mol%), 4 h. cIsolated yield after column chromatography. 
dDetermined by chiral SFC. e CH2Cl2 was used instead of THF. 
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Next, we tested the influence of the temperature (Table 3-2). We 
observed that increasing the temperature caused a decrease in both the yield 
and the enantiomeric excess (Table 3-2, entries 2 and 3). 
 
Table 3-2: Influence of the temperature. 
 
Entry T (ºC) Yielda (%) e.r.b 
1 -40 98 99:1 
2 -20 96 95:5 
3 0 94 94:6 
Reaction conditions: (R)-III-1a (0.1 mmol, 1.0 equiv), ArMgX (1.1 
equiv), Cu(CH
3
CN)
4
PF
6
  (5 mol%), CH2Cl2 (0.1 M), 5 min, unless 
otherwise noted. aIsolated yield after column chromatography. 
bDetermined by chiral SFC.  
 
We next explored the influence of the counteranion in the outcome of 
the transformation (Table 3-3). Switching from triflate to mesylate the 
yield dropped significantly and the enantiomeric excess decreased slightly 
(Table 3-3, entry 2). The use of tetrafluoroborate or iodine afforded similar 
results as those observed with the mesylate (Table 3-3, entries 3-4). Finally, 
the use of tosylate as counteranion preserved the enantiomeric excess but 
with lower yield (Table 3-3, entry 5). 
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Table 3-3: Influence of the nature of the counteranion. 
 
Entry X Yield (%)a e.r.b 
1 OTf 90 99:1 
2 OMs 58 94:6 
3 BF4 68 94:6 
4 I 58 96:4 
5 OTs 56 98:2 
Reaction conditions: (R)-III-1a (0.1 mmol, 1.0 equiv), ArMgX (1.1 equiv), 
Cu(CH
3
CN)
4
PF
6
  (5 mol%), CH2Cl2 (0.1 M), 5 min, unless otherwise noted. 
aIsolated yield after column chromatography. bDetermined by chiral SFC.  
 
We next checked if the nature of the leaving group had any influence in 
the reaction (Table 3-4). Starting from a mesylate derivative we observed 
lower yield and some erosion of the stereospecificity (Table 3-4, entry 2). 
Phosphates provided an inseparable 95:5 mixture the  -product and the 
allenyl derivative (-product) (Table 3-4, entry 3). Finally, a propargylic 
acetate did not react under the optimized conditions (Table 3-4, entry 4).  
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Table 3-4: Influence of the leaving group. 
 
 
Reaction conditions: (R)-III-1a (0.1 mmol, 1.0 equiv), ArMgX (1.1 equiv), 
Cu(CH
3
CN)
4
PF
6
  (5 mol%), CH2Cl2 (0.1 M), 5 min, unless otherwise noted. 
aIsolated yield after column chromatography. bDetermined by 1H-NMR. 
cDetermined by chiral SFC. 
 
These preliminary results were interesting for different reasons. The 
products are very attractive synthetic intermediates. They contain a 
benzylic stereocenter, present in a wide number of biologically active 
compounds,74 and an alkyne which is an extremely versatile functional 
 
74 For selected examples, see: (a) Yu, K. -L.; Spinazze, P.; Ostrowski, J.; Currier, S. J.; 
Pack, E. J.; Hammer, L.; Roalsvig, T.; Honeyman, J. A.; Tortolani, D. R.; Raczek, P. R.; 
Mansuri, M. M.; Starrett, J. E., Jr. J. Med. Chem. 1996, 39, 2411. (b) Johnson, D. S.; Ahn, 
K.; Kesten, S.; Lazerwith, S. E.; Song, Y.; Morris, M.; Fay, L.; Gregory, T.; Stiff, C.; 
Dunbar, J. B., Jr.; Liimatta, M.; Beidler, D.; Smith, S.; Nomanbhoy, T. K.; Cravatt, B. F. 
Bioorg. Med. Chem. Lett. 2009, 19, 2865. (c) Pereira, A. R.; Strangman, W. K.; Marion, F.; 
Feldberg, L.; Roll, D.; Mallon, R.; Hollander, I.; Andersen, R. J. J. Med. Chem. 2010, 53, 
8523. (d) Mihalic, J. T.; Chen, X.; Fan, P.; Chen, X.; Fu, Y.; Liang, L.; Reed, M.; Tang, L.; 
Chen, J.-L.; Jaen, J.; Li, L.; Dai, K. Bioorg. Med. Chem. Lett. 2011, 21, 7001. 
Entry X Yield (%)a / b e.r.c 
1 NMe3OTf 90 ≥98:2 99:1 
2 OMs 75 ≥98:2 92:8 
3 OP(O)(OEt)2 84 95:5 98:2 
4 OAc NR 
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group.75 Moreover, the selective attack at the -position is very unusual in 
copper-catalyzed cross-coupling reactions of propargylic electrophiles, in 
which the -carbon is usually the reactive site. Additionally, the reaction is 
extremely fast (5 min) at −40 ºC and only 1.1 equivalents of the Grignard 
reagent is needed. Therefore, it was reasonable to predict a broad functional 
group compatibility, despite the high reactivity of the nucleophiles. 
  
 
75 (a) Acetylene Chemistry; Diederich, F., Stang, P. J., Tykwinski, R. R., Eds.; Wiley-
VCH: New York, 2005. (b) The Chemistry of Triple-Bonded Functional Groups; Patai, S., 
Ed.; Wiley: New York, 1994. 
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3.2.4. Scope of the Reaction. 
With the optimal conditions in hand, we next prepared a series of 
racemic secondary propargylic ammonium salts to determine the structural 
scope of the reaction (Scheme 3-43 and Scheme 3-44). Using phenyl 
magnesium bromide, we obtained compound III-2b with excellent results. 
The optimal conditions allowed a wide variety of functional groups in the 
aromatic ring (III-2c-k). Electron-withdrawing groups worked well with 
the reaction conditions (III-2c-f). The fact that the reaction was so fast at 
low temperature, using only 1.1 equivalents of the Grignard reagent, 
allowed the introduction of functional groups that are not usually 
compatible with strong nucleophiles. Ester groups were introduced in both 
para (III-2d) and orto positions (III-2e) without observing side reactions. 
Even ammonium salt III-1f with a ketone substituent in the aromatic ring 
was compatible with the reaction conditions. In this case, however, the 
chemoselectivity was not complete and we detected products derived from 
the attack of the Grignard reagent to the ketone in the crude mixture.  
Propargylic ammonium salts containing aryl fluorides (III-1g), aryl 
chlorides (III-1h) and aryl bromides (III-1i) reacted exclusively at the 
propargylic position (compounds III-2g, III-2h and III-2i). Importantly, 
we performed the reaction with III-1h at gram scale with any significant 
decrease in the yield or the chemoselectivity.  
We also carried out the reaction using propargylic compound with 
electron-donating groups in the aromatic ring. Methoxy substituents did not 
affect the yield neither at para (III-2j) or meta position (III-2k). Finally, 
heterocycles were also compatible with the reaction conditions and 
compound III-2l was obtained in excellent yield. 
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Scheme 3-43: Scope of the propargylic substitution of racemic 
ammonium salts. 
 
Silyl (III-2m) and alkyl substitution (III-2n) in the acetylene moiety are 
also allowed under the reaction conditions. For compound III-2n we had to 
increase the catalytic loading to 10 mol% and decrease the concentration of 
the reaction to achieve good conversions. We also tried different alkyl 
chains in the propargylic position. We were delighted to see that 
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compounds III-2o and III-2p were obtained with excellent results. For this 
last two examples, we also had to increase the catalytic loading to 10 mol% 
and decrease the concentration. This lower reactivity could be caused by a 
subtle difference in the stereoelectronic effects of the substituent in the 
alkyne and the propargylic position.   
Primary ammonium salts afforded only moderate results (III-2q and III-
2r) and a competition experiment between ammonium salt III-1a and III-
1q under the standard reaction conditions suggested that they are much less 
reactive than the secondary ones (see section 3.2.6). The yield observed for 
compound III-2q increased from 50% to 69% yield when the reaction was 
carried out at room temperature.  
The propargylic substitution also worked with different aryl magnesium 
bromides. Using aryl magnesium bromides with electron-withdrawing 
groups the desired products were prepared in good yields (III-2s and III-
2t). The same was valid when we used a Grignard reagent with an electron-
donating group (III-2u).  
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Scheme 3-44: Scope of the propargylic substitution of racemic 
ammonium salts. 
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3.2.5. Stereospecific Substitution. 
During the optimization of the reaction conditions, we observed 
complete stereospecificity for compound (R)-III-2a. Therefore, the next 
step was to check if the chirality transfer was general for different 
ammonium salts and Grignard reagents. Ammonium salts with different 
aryl substitution such as, an ester group ((R)-III-2d), a ketone ((R)-III-2f) 
or a methoxy group ((R)-III-2d) gave the desired product with excellent 
results. Different Grignard reagents also gave good stereospecificity. 
Interestingly, we could prepare the enantiomerically enriched compound 
(R)-III-2v, with two different halides groups on the aromatic ring, which 
would be difficult to prepare using other transition metals. 
Silyl substituted propargylic compound with an alkyl chain in the 
propargylic position were also suitable susbtrates for the reaction and 
compounds (R)-III-2w, (R)-III-2x and (R)-III-2y were prepared with 
excellent results. 
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Scheme 3-45: Scope of the propargylic substitution of 
enantiomerically enriched ammonium salts.76 
 
 
76 Enantiospecifity (es) = (e.e.product / e.e.starting material) * 100.  
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3.2.6. Competition experiment. 
To test the different reactivity between primary and secondary 
ammonium salts we did a competition experiment (Scheme 3-46). We 
observed that secondary propargylic ammonium salts are much more 
reactive than the primary ones. Although we do not have a mechanism that 
explain the selectivity and reactivity observed, this result suggested that 
there could be a considerable amount of C-N bond cleavage in the transition 
state of the reaction.77 
 
 
Scheme 3-46: Competition experiment between secondary and 
primary ammonium salts. 
  
 
77 Westaway, K. C.; Poirier, R. A. Can. J. Chem. 1975, 53, 3216-3226. 
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3.3. Regio- and Stereospecific Copper-Catalyzed 
Substitution Reaction of Propargylic Ammonium Salts 
with Aryl Grignard Reagents. 
3.3.1. Introduction and Objectives. 
When we tested for the first time our methodology but using an alkyl 
Grignard reagent, we were surprise to see that the regioselectivity change 
completely (Scheme 3-47). We obtained the corresponding allene with no 
trace of the propargylic compound in the reaction mixture.  
 
 
Scheme 3-47: First attempt on the propargylic substitution of propargylic 
ammonium salts with alkyl Grignard reagents. 
 
We only knew one example of this kind of transformation. In 1979, 
Claeson and coworkers reported that an enantiomerically enriched 
propargylic ammonium bromide reacted with an alkyl Grignard reagent in 
an SN
2’ fashion (Scheme 3-48).78 It was an isolated example and they 
observe a significant erosion in the enantiomeric purity. During the 
development of this work, Ma and coworkers reported the synthesis of 
tetrasubstituted allenes using propargylic ammonium salts as starting 
 
78 Claesson, A.; Olsson, L. I. Acta Chem. Scand. 1979, B33, 679-684. 
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materials.43 However, they did not explore the possibilities of a 
stereospecific reaction. 
 
 
Scheme 3-48: Copper-catalyzed substitution of propargylic 
ammonium salt. 
 
With these precedents, we decided to contribute to the field with an 
objective in mind: to expand the scope of the ammonium salts, with special 
interest in stereospecific transformations. 
The specific objective of this chapter is to develop a stereospecific SN
2’ 
substitution of propargylic ammonium salts with alkyl Grignard reagents, 
to form trisubstituted allenes. Also, we will have to find the optimal 
catalytic system to control the stereospecificity and the regioselectivity. 
 
 
 
 
 
 
 
 
 
Chapter 3 
 
246 
 
3.3.2. Copper-Catalyzed SN2’ Substitution Reaction of Propargylic 
Ammonium Salts. Screening of Conditions. 
With the first result in hand (Scheme 3-47 and Table 3-5, entry 1), we 
decided to try different ligands to check for the best condition for this 
reaction (Table 3-5). First, we tried to use copper(I) chloride instead of 
Cu(CH3CN)4PF6, however, the obtained result were inferior (Table 3-5, 
entry 2). Based on our previous experience in copper catalysis we decided 
to use the phosphine Xanthphos. We were happy to see that the results were 
better and we obtained allene (R)-III-3a with 86% yield and 96% of 
stereospecificity (Table 3-5, entry 3). With this result in hand, we decided 
to try a battery of different ligands. All ligands tested gave the -product 
with good to excellent yields and good stereospecificity (Table 3-5, entries 
4-9). The best result was obtained using the phosphine Sphos. With this 
ligand, (R)-III-3a was obtained in 86% yield and 98% stereospecificity 
(Table 3-5, entry 9). We could reduce the catalytic loading to 5 mol%, 
obtaining the same result (Table 3-5, entry 10), and switching the solvent 
to CH2Cl2 gave slightly better result and rising the yield to 92% (Table 3-5, 
entry 11). Finally, the reaction did not work without catalyst at -40 ºC. 
Interestingly, at room temperature the -product was obtained in low yield 
and stereospecificity (Table 3-5, entry 13). 
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Table 3-5: Influence of the metal source and the ligand. 
 
 
Entry [M] (mol%) L 
T 
(ºC) 
Yieldc 
(%) 
erd 
1 Cu(CH3CN)4PF6 (10) ----- -40 95 94:6 
2 CuCl (10) ----- -40 82 86:14 
3 Cu(CH3CN)4PF6 (10) Xantphos -40 86 97:3 
4 Cu(CH3CN)4PF6 (10) PCy3 -40 70 96:4 
5 Cu(CH3CN)4PF6 (10) (±)-BINAP -40 94 97:3 
6 Cu(CH3CN)4PF6 (10) Bathophenanthroline -40 88 97:3 
7 Cu(CH3CN)4PF6 (10) (±)-DTBM-Segphos -40 94 97:3 
8 Cu(CH3CN)4PF6 (10) dppf -40 82 96:4 
9 Cu(CH3CN)4PF6 (10) Sphos -40 86 98.2 
10a Cu(CH3CN)4PF6 (5) Sphos -40 86 98.2 
11a,b Cu(CH3CN)4PF6 (5) Sphos -40 92 98.2 
12 ----- ----- -40 ---- ---- 
13 ----- ----- rt 24 78:22 
Reaction condition: (R)-III-1a (0.2 mmol, 1.0 equiv), AlkylMgX (1.1 equiv), CuX (10 
mol%), Ligand (12 mol%), THF (0.1 M), −40 °C, 5 min, unless otherwise noted. aUsing 
6 mol% of ligand. bUsing CH2Cl2 (0.1 M) as solvent. cIsolated yield after column 
chromatography. dDetermined by chiral SFC. 
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Next, we tested the influence of the temperature (Table 3-6). We 
observed that increasing the temperature caused a decrease in both the yield 
and the enantiomeric excess (Table 3-6, entries 2 and 3). 
 
Table 3-6: Influence of the temperature. 
 
Entry T (ºC) Yielda (%) e.r.b 
1 -40 92 98:2 
2 0 70 95:5 
3 rt 77 94:6 
Reaction condition: (R)-III-1a (0.2 mmol, 1.0 equiv), AlkylMgX (1.1 
equiv), Cu(CH
3
CN)
4
PF
6
  (5 mol%), SPhos (6 mol%), CH2Cl2 (0.1 M), 5 
min, unless otherwise noted. aIsolated yield after column 
chromatography. bDetermined by chiral SFC.  
 
We next explored the influence of the counteranion in the outcome of 
the transformation (Table 3-7). Switching from triflate to mesylate the 
yield and the enantiomeric excess dropped significantly (Table 3-7, entry 
2). The use of tetrafluoroborate, iodine or tosylate afforded similar results 
as those observed with the mesylate (Table 3-7, entries 3-5).  
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Table 3-7: Influence of the nature of the counterion. 
 
Entry X Yield (%)a e.r.b 
1 OTf 92 98:2 
2 OMs 57 71:29 
3 BF4 63 66:34 
4 I 51 88:12 
5 OTs 51 65:35 
Reaction condition: (R)-III-1a (0.2 mmol, 1.0 equiv), AlkylMgX (1.1 equiv), 
Cu(CH
3
CN)
4
PF
6
  (5 mol%), SPhos (6 mol%), CH2Cl2 (0.1 M), 5 min, unless 
otherwise noted. aIsolated yield after column chromatography. bDetermined by 
chiral SFC.  
 
We next checked if the nature of the leaving group had any influence 
in the reaction (Table 3-8Table 3-4). We tried the reaction with the 
mesylate derivative, and we observed lower yield and some erosion 
of the stereospecificity (Table 3-8, entry 2).  
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Table 3-8: Influence of the leaving group. 
 
 
Reaction conditions: (R)-III-1a (0.2 mmol, 1.0 equiv), AlkylMgX (1.1 equiv), 
Cu(CH
3
CN)
4
PF
6
  (5 mol%), SPhos (6 mol%), CH2Cl2 (0.1 M), 5 min, unless 
otherwise noted. aIsolated yield after column chromatography. bDetermined by 
chiral SFC. 
  
Entry X Yield (%)a e.r.b 
1 NMe3OTf 92 98:2 
2 OMs 55 87:13 
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3.3.3. Scope of the Reaction. 
With the optimal conditions in hand, we first proceeded to study the 
scope of the transformation with a series of racemic propargylic ammonium 
salts. We chose starting materials with different substituents on the alkyne 
and at the propargylic position (Scheme 3-49 and Scheme 3-50). In some 
cases, we observed low solubility of the ammonium salt in THF, therefore, 
we decided to carry out the study using CH2Cl2 as solvent. Using (1,3-
dioxan-2-ylethyl)magnesium bromide, we prepared a broad range of 
trisubstituted allenes (compounds III-3a-p). The reaction worked well with 
aromatic substituents bearing electron withdrawing groups (III-3c-f). The 
fact that the reaction last only for five minutes allowed us to use esters (III-
3d-e) and a ketone (III-3f) as substituent. This groups are not usually 
compatible with the use of Grignard reagents. With the more reactive 
ketone group, we observed formation of the product in 40% yield 
(compound III-3f) due to lower chemoselectivity. Aromatic substituent 
with halides (III-3g-i) reacted only through the C–N bond giving excellent 
results. We further modified the substitution on the alkyne with a thiophene 
ring (compound III-3l) with excellent results. 
 
 
 
 
 
 
 
 
Chapter 3 
 
252 
 
 
Scheme 3-49: Scope of the SN
2' substitution of propargylic ammonium 
salts. 
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Alkyl chain on the alkyne also worked with good results (compounds 
III-3n). We also modified the propargylic position introducing alkyl chains 
other than methyl (compounds III-3o and III-3p). The use of different 
primary alkyl Grignard reagents gave the corresponding allenes with good 
yields (compounds III-3q-u). We also used secondary alkyl Grignard 
reagent with different substitution on the alkyne (compounds III-3v-x and 
III-3z). Even the use of tert-butylmagnesium bromide was compatible with 
the reaction conditions (compound III-3y). Unfortunately, silyl substituted 
alkynes did not react under the optimized conditions. 
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Scheme 3-50: Scope of the SN
2' substitution of propargylic ammonium 
salts. 
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3.3.4. Stereospecific Substitution. 
During the optimization of the reaction conditions, we observed 
complete stereospecificity for compound (R)-III-3a. Therefore, the next 
step was to check if the chirality transfer was general for different 
ammonium salts and alkyl Grignard reagents. Ammonium salts with 
different aryl substitution such as fluorine ((R)-III-3g) or a methoxy group 
((R)-III-3k) gave the desired product using (1,3-dioxan-2-ylethyl) 
magnesium bromide with excellent results. Compound (R)-III-3o, with a 
six-carbon chain on the propargylic position, was obtained also with 
excellent results. Changing the Grignard reagent to a different primary 
magnesium bromide (compounds (R)-III-3t and (R)-III-3u) did not affect 
the obtained results. The use of secondary ((R)-III-3w-x and (R)-III-3z) 
and even tertiary Grignard reagents ((R)-III-3y) was compatible with the 
reaction conditions with different substitution on the aromatic ring. 
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Scheme 3-51: Scope for the stereospecific SN
2' substitution of 
propargylic ammonium salts. 
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3.4. Conclusions. 
In this chapter we have described the regioselective and stereospecific 
copper-catalyzed Kumada cross-coupling of propargylic ammonium salts 
with Grignard reagents. Our method represents the first stereospecific 
copper-catalyzed cross-coupling of propargylic substrates (Scheme 3-52). 
We could control the regioselectivity of the reaction by the nature of the 
Grignard reagent. Aryl magnesium halides formed exclusively the -
regioisomer whereas alkyl magnesium halides formed the allene with 
complete regioselectivity.  
A combination of a commercially available, stable and inexpensive 
copper-salt and a simple phosphine in the case of alkyl Grignard reagents 
provided the enantiomerically enriched propargylic compounds or the 
allenes in high yield and almost perfect stereospecificity.  
 
 
Scheme 3-52: Copper-catalyzed Kumada cross-coupling of 
propargylic ammonium salts. 
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3.5. Conclusiones. 
En este capítulo, hemos descrito la reacción de acoplamiento cruzado de 
tipo Kumada catalizada por cobre entre sales de amonio propargílicas y 
reactivos de Grignard de manera regioselectiva y estereoespecífica. Esta 
metodologia representa la primera reacción de acoplamiento cruzado 
estereoespecífica y catalizada por cobre de sustratos propargílicos 
(Esquema 3-53). La regioselectividad de la reacción está controlada por la 
naturaleza de reactivo de Grignard. Haluros de arilmagnesio forman 
exclusivamente el regioisomero , mientras que los haluros de 
alkilmagnesio forman el correspondiente aleno de manera totalmente 
regioselectiva.  
Utilizando un catalizador comercial de cobre(I), y una fosfina en el caso 
de los haluros de alkilmagnesio, la reacción da lugar a compuestos 
propargílicos o alenos enantioméricamente enriquecidos con buenos 
rendimientos y una estereoespecificidad prácticamente total.  
 
 
Esquema 3-53: Reacción de acoplamiento cruzado de tipo Kumada 
catalizado por cobre de sales de amonio propargílicas. 
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3.6. Supplementary Data. 
Tetrahydrofuran and dichloromethane were purified by passing through 
a Pure Solv™ column drying system from Innovative Technology, Inc. 
Additionally, tetrahydrofuran and dichloromethane were degassed passing 
argon through them for 15 min. Diethyl ether was dried using activated 4Å 
molecular sieves and stored under argon. Unless indicated otherwise, all 
reactions were conducted under an argon atmosphere using flame-dried 
glassware with standard vacuum-line techniques. NMR spectra were 
acquired on a Bruker 300 spectrometer, running at 300, and 75 MHz for 1H 
and 13C NMR respectively. Chemical shifts (δ) are reported in ppm relative 
to residual solvent signals (CDCl3, 7.26 ppm for 
1H NMR and 77.2 ppm for 
13C NMR respectively). 13C NMR spectra were acquired on a broad band 
decoupled mode. The following abbreviations are used to describe peak 
patterns when appropriate: s (singlet), d (doublet), t (triplet), q (quartet), 
quint (quintet), sex (sextet), sept (septuplet), m (multiplet), br (broad). 
Analytical thin layer chromatography (TLC) was performed using pre-
coated aluminum-backed plates (Merck Kieselgel 60 F254) and visualized 
by ultraviolet irradiation or phosphomolybdic acid dip or potassium 
permanganate dip. Purification of reaction mixtures was carried out by flash 
chromatography (FC) using silica gel Merck-60. Optical rotations were 
measured on a Perkin-Elmer 241 polarimeter. The enantiomeric ratio (e.r.) 
of the products was determined by stationary phase SFC, HPLC or GC 
using chiral columns. Mass Spectrometry (MS) and High Resolution Mass 
Spectrometry (HRMS) were registered in a spectrometer GCT Agilent 
Technologies 6890N using Electronic Impact (E.I.) techniques at 70 eV, 
Fast Atom Bombardment and electrospray (ESI+ or ESI-). 4-
(Trimethylsilyl)-3-butyn-2-ol, 3-phenyl-2-propyn-1-ol, 1-dimethylamino-
3-(trimethylsilyl)-2-propyne were acquired from commercial sources. 
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Grignard reagents were acquired from commercial sources and were 
titrated prior to use.79 
 
3.6.1. Synthesis of starting materials. 
3.6.1.1. Synthesis of propargylic alcohols, III-4.  
 
 
 
To an oven-dried round bottom flask was added the corresponding aryl 
iodine (1.2 equiv), Pd(PPh3)2Cl2 (0.04 equiv) and copper(I) iodine (0.08 
equiv). The flask was connected to an argon-vacuum line, evacuated and 
backfilled with argon (x3). Diisopropylamine (2.8 mL/mmol alcohol) was 
added and the reaction mixture was stirred at 0 ºC for 5 min. 3-Butyn-2-ol 
(1 equiv) was added dropwise at 0 ºC and the reaction mixture was stirred 
for 16 h at room temperature. Silica gel was added to the mixture and the 
solvent was removed under reduced pressure. The crude product was 
purified by flash column chromatography using the appropriate mixture of 
solvents. 
 
 
79 Krasovskiy, A.; Knochel, P. Synthesis-Stuttgart, 2006, 5, 890-891. 
Stereospecific Copper-Catalyzed Substitution Reaction Of Propargylic 
Ammonium Salts. 
 
261 
 
(−)-(S)-4-Phenylbut-3-yn-2-ol, (S)-III-4a. 
From (S)-3-butyn-2-ol (0.50 g, 7.2 mmol), following 
the general procedure described above, compound (S)-
III-4a (0.97 g, 6.6 mmol) was obtained in 92% yield as 
an orange oil after flash column chromatography 
(Cy/EtOAc, 95/5).  
Compound (S)-III-4a was obtained in 99:1 enantiomeric ratio 
determined by SFC using Chiralpak-ID column [CO2/MeOH (95:5)], 1.0 
mL/min, major= 15.7 min, minor= 10.5 min. 
1H NMR, 13C NMR and MS data 
were consistent with literature values.80 1H NMR (300 MHz, CDCl3) δ 7.48 
– 7.37 (m, 2H), 7.37 – 7.28 (m, 3H), 4.77 (m, 1H), 1.90 (d, J = 5.3 Hz, 1H), 
1.56 (d, J = 6.6 Hz, 3H). [α]20D= −33.6 (c = 1.0, CHCl3). 
 
(±)-4-(4-(Trifluoromethyl)phenyl)but-3-yn-2-ol, III-4c. 
From 3-butyn-2-ol (0.50 g, 7.2 mmol), following 
the general procedure described above, compound 
III-4c (1.34 g, 6.3 mmol) was obtained in 87% yield 
as an orange oil after flash column chromatography 
(Cy/EtOAc, 90/10).  
1H NMR, 13C NMR and MS data were consistent with literature values.81 
1H NMR (300 MHz, CDCl3) δ 7.56 (m, 4H), 4.79 (q, J = 6.6 Hz, 1H), 1.89 
(s, 1H), 1.58 (d, J = 6.6 Hz, 3H). 
 
 
80 Zhang, X., Lu, Z., Fu, C., Ma, S. Org. Biomol. Chem. 2009, 7, 3258-3263. 
81 Shatskiy, A., Kivijärvi, T., Lundberg, H., Tinnis, H., Adolfsson, H. ChemCatChem, 
2015, 7, 3818-3821. 
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(−)-Methyl (S)-4-(3-hydroxybut-1-yn-1-yl)benzoate, (S)-III-4d. 
From (S)-3-butyn-2-ol (0.50 g, 7.2 mmol), 
following the general procedure described above, 
compound (S)-III-4d (1.09 g, 5.3 mmol) was 
obtained in 74% yield as an orange oil after flash 
column chromatography (Cy/EtOAc, 90/10).  
Compound (S)-III-4d  was obtained in 99:1 enantiomeric ratio 
determined by SFC using Chiralpak-ID column [CO2/MeOH (95:5)], 1.0 
mL/min, major= 20.3 min, minor= 19.8 min. 
1H NMR, 13C NMR and MS data 
were consistent with literature values.82 1H NMR (300 MHz, CDCl3) δ 7.97 
(d, J = 8.6 Hz, 2H), 7.47 (d, J = 8.6 Hz, 2H), 4.84 – 4.70 (m, 1H), 3.91 (s, 
3H), 1.99 (d, J = 5.4 Hz, 1H), 1.56 (d, J = 6.6 Hz, 3H). [α]20D= −28.2 (c = 
1.0, CHCl3). 
 
(±)-Methyl 2-(3-hydroxybut-1-yn-1-yl)benzoate, III-4e. 
From 3-butyn-2-ol (0.50 g, 7.2 mmol), following the 
general procedure described above, compound III-4e 
(1.04 g, 5.1 mmol) was obtained in 71% yield as an orange 
oil after flash column chromatography (Cy/EtOAc, 
90/10).  
1H NMR, 13C NMR and MS data were consistent with literature values.83 
1H NMR (300 MHz, CDCl3) δ 7.94 (d, J = 7.7 Hz, 1H), 7.54 (d, J = 6.6 Hz, 
1H), 7.47 (td, J = 7.5, 1.3 Hz, 1H), 7.37 (td, J = 7.6, 1.3 Hz, 1H), 4.82 (q, J 
= 6.6 Hz, 1H), 3.93 (s, 3H), 2.48 (s, 1H), 1.59 (d, J = 6.6 Hz, 3H). 
 
82 Harris, R. J., Nakafuku, K., Widenhoefer, R. A. Chem. Euro. J., 2014, 20, 12245-12254. 
83 Gangadhararao, G.; Kotikalapudi, R.; Reddy, M. N.; Swamy, K. C. K. Beilstein J. Org. 
Chem. 2014, 10, 996-1005. 
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(−)-(S)-1-[4-(3-Hydroxybut-1-yn-1-yl)phenyl]ethan-1-one, (S)-III-4f. 
 From (S)-3-butyn-2-ol (0.50 g, 7.2 mmol), 
following the general procedure described above, 
compound (S)-III-4f (1.22 g, 6.5 mmol) was obtained 
in 90% yield as an orange oil after flash column 
chromatography (Cy/EtOAc 90/10).  
Compound (S)-III-4f was obtained in 99:1 enantiomeric ratio 
determined by SFC using Chiralpak-ID column [CO2/MeOH (95:5)], 1.0 
mL/min, major= 24.9 min, minor= 23.5 min.
 1H NMR, 13C NMR and MS data 
were consistent with literature values.84 1H NMR (300 MHz, CDCl3) δ 7.90 
(d, J = 8.5 Hz, 2H), 7.50 (d, J = 8.5 Hz, 2H), 4.85 – 4.71 (m, 1H), 2.60 (s, 
3H), 1.97 (d, J = 5.4 Hz, 1H), 1.57 (d, J = 6.6 Hz, 3H). [α]20D= −32.4 (c = 
1.0, CHCl3). 
 
(±)-4-(4-Fluorophenyl)but-3-yn-2-ol, III-4g. 
From 3-butyn-2-ol (0.89 g, 12.7 mmol), following 
the general procedure described above, compound 
III-4g (1.8 g, 10.9 mmol) was obtained in 86% yield 
as an orange oil after flash column chromatography 
using (Cy/EtOAc, 90/10).  
1H NMR, 13C NMR and MS data were consistent with literature values.85 
1H NMR (300 MHz, CDCl3) δ 7.51 – 7.32 (m, 2H), 7.07 – 6.94 (m, 2H), 
4.84 – 4.64 (m, 1H), 2.12 (s, 1H), 1.56 (d, J = 6.6 Hz, 3H).  
 
84 Dutta, P.; Sarkar, A. Adv. Synth. Catal. 2011, 353, 2814-2822. 
85 Wang, Q., Kobayashi, Y. Tetrahedron Lett., 2010, 51, 5592-5595. 
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(±)-4-(4-Chlorophenyl)but-3-yn-2-ol, III-4h. 
From 3-butyn-2-ol (0.50 g, 7.2 mmol), following 
the general procedure described above, compound 
III-4h (1.24 g, 6.8 mmol) was obtained in 95% yield 
as an orange oil after flash column chromatography 
using (Cy/EtOAc, 90/10).  
1H NMR, 13C NMR and MS data were consistent with literature values.80 
1H NMR (300 MHz, CDCl3) δ 7.37 (d, J = 8.6 Hz, 2H), 7.29 (d, J = 8.7 Hz, 
2H), 4.76 (q, J = 6.6 Hz, 1H), 1.91 (s, 1H), 1.56 (d, J = 6.6 Hz, 3H). 
 
(−)-(S)-4-(3-Bromophenyl)but-3-yn-2-ol, (S)-III-4i. 
From (S)-3-butyn-2-ol (0.50 g, 7.2 mmol), following 
the general procedure described above, compound (S)-
III-4i (1.34 g, 6.0 mmol) was obtained in 83% yield as 
an orange oil after flash column chromatography using 
(Cy/EtOAc, 90/10).  
Compound (S)-III-4i was obtained in 99:1 enantiomeric ratio 
determined by SFC using Chiralpak-IB column [CO2/MeOH (95:5)], 1.0 
mL/min, major= 17.3 min, minor= 14.2 min.
 1H NMR, 13C NMR and MS data 
were consistent with literature values.86 1H NMR (300 MHz, CDCl3) δ 7.59 
(s, 1H), 7.46 (d, J = 8.0 Hz, 1H), 7.36 (d, J = 7.7 Hz, 1H), 7.19 (t, J = 7.9 
Hz, 1H), 4.76 (q, J = 6.6 Hz, 1H), 1.89 (s, 1H), 1.56 (d, J = 6.6 Hz, 3H). 
[α]20D= −22.7 (c = 1.0, CHCl3).  
 
86 Schubert, T., Hummel, W., Kula, M., Müller, M. Eur. J. Org. Chem. 2001, 22, 4181-
4187. 
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(±)-4-(4-Methoxyphenyl)but-3-yn-2-ol, III-4j. 
From 3-butyn-2-ol (0.50 g, 7.2 mmol), 
following the general procedure described above, 
compound III-4j (0.78 g, 4.4 mmol) was obtained 
in 62% yield as an orange oil after flash column 
chromatography using (Cy/EtOAc, 90/10).  
1H NMR, 13C NMR and MS data were consistent with literature values.87 
1H NMR (300 MHz, CDCl3) δ 7.36 (d, J = 8.9 Hz, 2H), 6.83 (d, J = 8.9 Hz, 
2H), 4.81 – 4.65 (m, 1H), 3.81 (s, 3H), 1.87 (d, J = 5.3 Hz, 1H), 1.54 (d, J 
= 6.6 Hz, 3H). 
 
(−)-(S)-4-(3-Methoxyphenyl)but-3-yn-2-ol, (S)-III-4k. 
From (S)-3-butyn-2-ol (0.50 g, 7.2 mmol), following 
the general procedure described above, compound (S)-
III-4k (1.08 g, 6.1 mmol) was obtained in 84% yield as 
an orange oil after flash column chromatography using 
(Cy/EtOAc, 90/10).  
Compound (S)-III-4k was obtained in 99:1 enantiomeric ratio 
determined by SFC using Chiralpak-IB column [CO2/MeOH (95:5)], 1.0 
mL/min, major= 20.4 min, minor= 13.3 min. 1H NMR (300 MHz, CDCl3) δ 
7.21 (t, J = 8.0 Hz, 1H), 7.02 (dt, J = 7.6, 1.1 Hz, 1H), 6.96 (m, 1H), 6.87 
(ddd, J = 8.0, 2.6, 1.1 Hz, 1H), 4.83–4.68 (m, 1H), 3.79 (s, 3H), 2.00 (d, J 
= 5.1 Hz, 1H), 1.55 (d, J = 6.6 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 
159.3, 129.4, 124.3, 123.7, 116.5, 115.0, 91.0, 83.9, 58.8, 55.3, 24.4. 
 
87 Saravanan, T.; Jana, S.; Chadha, A. Org. Biomol. Chem, 2014, 12, 4682-4690. 
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[α]20D= −26.5 (c = 1.0, CHCl3). HRMS-ESI+ m/z calculated for 
C11H12O2Na [M+Na]
+:199.0729, found 199.0732. 
(±)-4-(Thiophen-2-yl)but-3-yn-2-ol, III-4l. 
From 3-butyn-2-ol (0.50 g, 7.2 mmol), following the 
general procedure described above, compound III-4l 
(0.75 g, 4.9 mmol) was obtained in 68% yield as an 
orange oil after flash column chromatography using 
(Cy/EtOAc, 90/10).  
1H NMR, 13C NMR and MS data were consistent with literature values.88 
1H NMR (300 MHz, CDCl3) δ 7.27 (d, J = 5.4 Hz, 1H), 7.21 (d, J = 3.4 Hz, 
1H), 7.04 – 6.91 (m, 1H), 4.78 (d, J = 4.8 Hz, 1H), 1.96 (s, 1H), 1.56 (d, J 
= 6.6 Hz, 3H). 
 
3.6.1.2. Synthesis of alcohols III-4n, III-4o, III-4p and III-4w. 
 
To a solution of the corresponding acetylene (1 equiv) in THF (0.7M) at 
-78 °C was added n-butyllithium (2.5M in hexane, 0.9 equiv). After stirring 
30 min, the corresponding aldehyde (1.1 equiv) was added and the mixture 
was warmed to room temperature. Water was added to quench the reaction 
and the layers were separated. The aqueous phase was extracted with ether 
(3x) and the combined extracts were dried over magnesium sulfate. The 
solvent was evaporated under reduced pressure and the crude product was 
purified by flash column chromatography. 
 
88 Panteleev, J.; Huang, R. Y.; Lui, E. K. J.; Lautens, M. Org. Lett. 2011, 13, 5314-5317. 
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(±)-6-Phenylhex-3-yn-2-ol, III-4n. 
From but-3-yn-1-ylbenzene (2.60 g, 20 mmol), 
following the general procedure described above, 
compound III-4n (2.51 g, 14.4 mmol) was obtained 
in 72% yield as a yellow oil after flash column 
chromatography using (Cy/EtOAc, 90/10).  
1H NMR, 13C NMR and MS data were consistent with literature values.89 
1H NMR (300 MHz, CDCl3) δ 7.31 (m, 2H), 7.25 – 7.18 (m, 3H), 4.56 – 
4.41 (m, 1H), 2.82 (t, J = 7.6 Hz, 2H), 2.49 (td, J = 7.5, 1.8 Hz, 2H), 1.68 
(m, 1H), 1.41 (d, J = 6.5 Hz, 3H). 
 
(±)-1-Phenylnon-1-yn-3-ol, III-4o. 
From phenylacetylene (3.72 g, 36 mmol), 
following the general procedure described above, 
compound III-4o (7.14 g, 33.1 mmol) was 
obtained in 92% yield as a yellow oil after flash 
column chromatography using (Cy/EtOAc, 90/10).  
1H NMR, 13C NMR and MS data were consistent with literature values.90 
1H NMR (300 MHz, CDCl3) δ 7.51 – 7.37 (m, 2H), 7.31 (m, 3H), 4.60 (m, 
1H), 1.86 (d, J = 5.6 Hz, 1H), 1.80 (m, 2H), 1.56 – 1.45 (m, 2H), 1.33 (m, 
6H), 0.89 (t, J = 6.5 Hz, 3H). 
 
89 Jiang, B.; Chen, Z.; Xiong, W.  Chem. Comm. 2002, 14, 1524-1525. 
90 Boussonniere, A.; Beneteau, R.; Zimmermann, N.; Lebreton, J.; Denes, F. Chem. Eur. 
J. 2011, 17, 5613-5627. 
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(±)-1,5-Diphenylpent-1-yn-3-ol, III-4p. 
From phenylacetylene (3.3 g, 30 mmol), 
following the general procedure described above, 
compound III-4p (5.32 g, 22.5 mmol) was 
obtained in 75% yield as a yellow oil after flash 
column chromatography using (Cy/EtOAc, 90/10).  
1H NMR, 13C NMR and MS data were consistent with literature values.91 
1H NMR (300 MHz, CDCl3) δ 7.50 – 7.38 (m, 2H), 7.36 – 7.21 (m, 8H), 
4.61 (q, 6.4 Hz, 1H), 2.95 – 2.79 (m, 2H), 2.21 – 2.03 (m, 2H), 1.94 – 1.84 
(m, 1H). 
 
 
(±)-1-(Trimethylsilyl)hept-1-yn-3-ol, III-4w. 
From trimethylsilylacetylene (4.91 g, 50 mmol), 
following the general procedure described above, 
compound III-4w (7.5 g, 40.5 mmol) was obtained in 
81% yield as a yellow oil after flash column 
chromatography using (Cy/EtOAc, 90/10).  
1H NMR, 13C NMR and MS data were consistent with literature values.92 
1H NMR (300 MHz, CDCl3) δ 4.35 (q, 6.5 Hz, 1H), 1.80 (d, J = 5.4 Hz, 
1H), 1.74 – 1.64 (m, 2H), 1.40 (m, 4H), 0.91 (t, J = 7.1 Hz, 3H), 0.17 (s, 
9H). 
 
 
 
91 Kapeller, D. C.; Kocienski, P. J. Synthesis 2010, 22, 3811-3821. 
92 Ivanov, I. V.; Romanov, S. G.; Groza, N. V.; Nigam, S.; Kuhn, H.; Myagkova, G. I. 
Bioorgan. Med. Chem. 2002, 10, 2335-2343. 
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3.6.1.3. Synthesis of enantiomerically enriched alcohol (S)-III-4 through 
kinetic resolution. 
 
To an oven-dried round bottom flask was added III-4 (1 equiv), 
molecular sieves (50% w/w) and Amano Lipase from Pseudomonas 
fluorescens (50 % w/w). The flask was connected to an argon-vacuum line, 
evacuated and backfilled with argon (x3). n-Hexane (6 mL/mmol of 
alcohol) was added to the mixture. After that, vinyl acetate (3 equiv) was 
added and the mixture was stirred at room temperature for 24 h. After 
completion (checked by chiral SFC) the reaction was filtered, and the 
solvent was removed under reduced pressure.  
(−)-(S)-6-Phenylhex-3-yn-2-ol, (S)-III-4n. 
From (±)-6-Phenylhex-3-yn-2-ol (1.9 g, 10.9 
mmol), following the general procedure described 
above, compound (S)-III-4n (0.85 g, 4.9 mmol) was 
obtained in 45% yield as a yellow oil after flash 
column chromatography using (Cy/EtOAc, 90/10).  
Compound (S)-III-4n  was obtained in 99:1 enantiomeric ratio 
determined by HPLC using Chiralpak-IBN column [CO2/MeOH (95:5)], 
1.0 mL/min, major= 11.2 min, minor= 6.4 min. [α]20D= −33.1 (c = 1.0, 
CHCl3). 
(−)-(S)-1-(trimethylsilyl)hept-1-yn-3-ol, (S)-III-4w. 
From 1-(trimethylsilyl)hept-1-yn-3-ol (5.0 g, 27.1 
mmol), following the general procedure described 
above, compound (S)-III-4w (2.3 g, 12.5 mmol) was 
obtained in 46% yield as a yellowish oil after flash 
column chromatography (Cy/EtOAc, 95/5). 1H NMR, 13C NMR and MS 
data were consistent with literature values.92 [α]20D= −6.2 (c = 1.0, CHCl3). 
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Compound (S)-III-4w was transformed into (S)-III-6w through 
desilylation and benzoylation to determine the enantiomeric ratio (See 
compound (S)-III-6w). 
 
3.6.1.4. Synthesis of dimethylamines, III-5.  
 
 
 
To a solution of the alcohol (1 equiv) and triethylamine (5 equiv) in 
THF (2.5 mL/mmol of alcohol) was added methanesulfonyl chloride (2 
equiv) at 0 ºC. The reaction was stirred for 1h at room temperature and then, 
a solution of dimethylamine (2 M in THF, 5 equiv) was added to the 
mixture. The temperature was raised to 50 ºC and the reaction mixture was 
stirred for 16 h. The reaction mixture was filtered through a short pad of 
Celite® and rinsed with Et2O. The solvent was removed under reduced 
pressure and the crude product was purified by flash column 
chromatography (From Cy/EtOAc 2:1 to EtOAc gradient).  
The complete transfer of chirality in the SN2 reaction was 
demonstrated for compound (R)-III-5i using chiral GC analysis (see 
below). The inversion of the stereochemistry in (R)-III-5i was proved for 
its ammonium salt derivative (R)-III-1i, through single crystal X-ray 
crystallography (see section 3.2.2). For the other propargylic amines, we 
assumed complete chirality transfer and inversion of the stereochemistry in 
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the SN2 reaction.
93 This assumption is supported by the high fidelity 
between the enantiomeric excess of the propargylic alcohol and the 
enantiomeric excess of the coupling products. This is only possible if the 
SN2 reaction to form the dimethylamine takes place with complete chirality 
transfer.  
 
(+)-(R)-N,N-Dimethyl-4-phenylbut-3-yn-2-amine, (R)-III-5a. 
From (S)-4-phenylbut-3-yn-2-ol (450 mg, 3 mmol), 
following the general procedure described above, 
compound (R)-III-5a (442 mg, 2.6 mmol) was obtained in 
85% yield as an orange oil.  
1H NMR (300 MHz, CDCl3) δ 7.46 – 7.39 (m, 2H), 7.33 – 7.25 (m, 3H), 
3.69 (q, J = 7.0 Hz, 1H), 2.33 (s, 6H), 1.40 (d, J = 7.0 Hz, 3H). 13C NMR 
(75 MHz, CDCl3) δ 131.8, 128.3, 128.0, 123.5, 87.8, 85.3, 52.9, 41.4, 20.1.  
[α]20D= +33.4 (c = 1.0, CHCl3). HRMS-ESI+ m/z calculated for C12H16N 
[M+H]+: 174.1277, found 174.1275. 
 
()-N,N-Dimethyl-4-[4-(trifluoromethyl)phenyl]but-3-yn-2-amine, III-
5c. 
From ()-4-[4-(trifluoromethyl)phenyl]but-3-yn-
2-ol (1.1 g, 5 mmol), following the general procedure 
described above, compound III-5c (1.1 g, 4.5 mmol) 
was obtained in 89% yield as an orange oil. 
 
93 For similar SN2 reactions, see: (a) Davidson, M. H.; McDonald, F. E. Org. Lett. 2004, 
6, 1601-1603. (b)  Hanamoto, T.; Shimomoto, N.; Kikukawa, T.; Inanaga, J. Tetrahedron: 
Asymmetry 1999, 10, 2951-2959. 
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1H NMR (300 MHz, CDCl3) 7.66 – 7.40 (m, 4H), 3.71 (q, J = 7.0 Hz, 
1H), 2.34 (s, 6H), 1.41 (d, J = 7.0 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 
132.1, 129.9 (q, JC-F = 32 Hz), 127.3 (q, JC-F = 1.4 Hz), 125.3 (q, JC-F = 3.9 
Hz), 124.1 (q, JC-F = 271.8 Hz), 90.7, 84.2, 52.9, 41.5, 19.9. HRMS-EI
+ 
m/z calculated for C13H14NF3 [M]
+: 241.1078, found 241.1068. 
 
(+)-Methyl (R)-4-[3-(dimethylamino)but-1-yn-1-yl]benzoate, (R)-III-
5d. 
From methyl (S)-4-(3-hydroxybut-1-yn-1-
yl)benzoate (600 mg, 2.94 mmol), following the 
general procedure described above, compound (R)-
III-5d (564.2 mg, 2.4 mmol) was obtained in 83% 
yield as an orange oil. 
1H NMR (300 MHz, CDCl3) δ 7.97 (d, J = 8.3 Hz, 2H), 7.48 (d, J = 8.3 
Hz, 2H), 3.91 (s, 3H), 3.71 (q, J = 7.0 Hz, 1H), 2.33 (s, 6H), 1.41 (d, J = 
7.0 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 166.5, 131.6, 129.4, 129.2, 
128.1, 91.1, 84.7, 52.8, 52.2, 41.3, 19.8.  [α]20D= +38.1 (c = 1.0, CHCl3). 
HRMS-ESI+ m/z calculated for C14H18NO2 [M+H]
+: 232.1332, found 
232.1324. 
 
()-Methyl 2-[3-(dimethylamino)but-1-yn-1-yl]benzoate, III-5e. 
From ()-methyl 2-(3-hydroxybut-1-yn-1-yl)benzoate 
(816 mg, 4.0 mmol), following the general procedure 
described above, compound III-5e (693 mg, 3.0 mmol) 
was obtained in 75% yield as an orange oil. 
1H NMR (300 MHz, CDCl3) δ 7.86 (dd, J = 7.8, 1.3 Hz, 1H), 7.52 (dd, 
J = 7.7, 1.3 Hz, 1H), 7.40 (td, J = 7.6, 1.4 Hz, 1H), 7.30 (td, J = 7.6, 1.4 Hz, 
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1H), 3.88 (s, 3H), 3.73 (q, J = 7.0 Hz, 1H), 2.35 (s, 6H), 1.41 (d, J = 7.0 Hz, 
3H). 13C NMR (75 MHz, CDCl3) δ 166.8, 134.4, 132.1, 131.4, 130.2, 
127.5, 123.6, 93.3, 83.9, 53.0, 52.1, 41.3, 19.9. HRMS-ESI+ m/z calculated 
for C14H18NO2 [M+H]
+: 232.1332, found 232.1327. 
 
 
(+)-(R)-1-(4-(3-(Dimethylamino)but-1-yn-1-yl)phenyl)ethan-1-one, 
(R)-III-5f. 
From (S)-1-(4-(3-hydroxybut-1-yn-1-
yl)phenyl)ethan-1-one (750 mg, 4 mmol), 
following the general procedure described above, 
compound (R)-III-5f (613 mg, 2.8 mmol) was 
obtained in 71% yield as an orange oil. 
1H NMR (300 MHz, CDCl3) δ 7.88 (d, J = 8.5 Hz, 2H), 7.50 (d, J = 8.5 
Hz, 2H), 3.71 (q, J = 7.0 Hz, 1H), 2.58 (s, 3H), 2.33 (s, 6H), 1.41 (d, J = 
7.0 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 197.3, 136.0, 131.8, 128.3, 
128.2, 91.5, 84.6, 52.8, 41.3, 26.5, 19.7.  [α]20D= +35.5 (c = 1.0, CHCl3). 
HRMS-ESI+ m/z calculated for C14H18NO [M+H]
+: 216.1382, found 
216.1384. 
 
()-4-(4-Fluorophenyl)-N,N-dimethylbut-3-yn-2-amine, III-5g. 
 From ()-4-(4-fluorophenyl)but-3-yn-2-ol (1.0 g, 
6.1 mmol), following the general procedure described 
above, compound III-5g (959 mg, 5.0 mmol) was 
obtained in 82% yield as an orange oil. 
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1H NMR (300 MHz, CDCl3) δ 7.43 – 7.34 (m, 2H), 6.97 (t, J = 8.8 Hz, 
2H), 3.65 (q, J = 7.0 Hz, 1H), 2.31 (s, 6H), 1.38 (d, J = 7.0 Hz, 3H).13C 
NMR (75 MHz, CDCl3) δ 162.3 (d, JC-F = 249 Hz), 133.0 (d, JC-F = 8.25 
Hz), 119.4 (d, JC-F = 3.75 Hz), 115.4 (d, JC-F = 22.5 Hz), 87.4 (d, JC-F = 1.5 
Hz), 84.1, 52.7, 41.3, 19.9. HRMS-ESI+ m/z calculated for C12H15NF 
[M+H]+: 192.1183, found 192.1184. 
 
()-4-(4-Chlorophenyl)-N,N-dimethylbut-3-yn-2-amine, III-5h. 
From ()-4-(4-chlorophenyl)but-3-yn-2-ol (1.08 g, 
6.0 mmol), following the general procedure described 
above, compound III-5h (976 mg, 4.7 mmol) was 
obtained in 78% yield as an orange oil. 
1H NMR (300 MHz, CDCl3) 7.30 (d, J = 8.6 Hz, 2H), 7.20 (d, J = 8.6 
Hz, 2H), 3.63 (q, J = 7.0 Hz, 1H), 2.27 (s, 6H), 1.35 (d, J = 7.0 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 133.8, 132.8, 128.4, 121.8, 88.7, 84.1, 52.7, 
41.1, 19.8. HRMS-EI+ m/z calculated for C12H14NCl [M]
+: 207.0815, 
found 207.0810. 
 
(+)-(R)-4-(3-Bromophenyl)-N,N-dimethylbut-3-yn-2-amine, (R)-III-5i. 
From (S)-4-(3-bromophenyl)but-3-yn-2-ol (1.24 g, 
5.5 mmol), following the general procedure described 
above, compound (R)-III-5i (1.26 g, 5.0 mmol) was 
obtained in 91% yield as an orange oil. 
Compound (R)-III-5i was obtained in 99:1 enantiomeric ratio 
determined by GC on a Chirasil Dex-CB column (160 °C, hold 2 min, then 
→170 °C @ 0.3 °C/min, hold 5 min; then →180 °C @ 5 °C/min, hold 5 
min flow rate 1.0 mL/min.). major= 8.3 min, minor= 8.1 min. 1H NMR (300 
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MHz, CDCl3) 7.58 (m, 1H), 7.43 (d, J = 7.9 Hz, 1H), 7.35 (d, J = 7.9 Hz, 
1H), 7.16 (t, J = 7.9 Hz, 1H), 3.69 (q, J = 7.0 Hz, 1H), 2.32 (s, 6H), 1.39 (d, 
J = 7.0 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 134.7, 131.2, 130.4, 129.8, 
125.5, 122.2, 89.5, 84.0, 52.9, 41.5, 20.0. [α]20D= +35.2 (c = 1.0, CHCl3). 
HRMS-EI+ m/z calculated for C12H14NBr[M]
+: 251.0310, found 251.0298. 
 
()-4-(4-Methoxyphenyl)-N,N-dimethylbut-3-yn-2-amine, III-5j. 
From ()-4-(4-methoxyphenyl)but-3-yn-2-ol 
(790 mg, 4.5 mmol), following the general procedure 
described above, compound III-5j (608 mg, 3.0 
mmol) was obtained in 67% yield as an orange oil. 
1H NMR (300 MHz, CDCl3) δ 7.36 (d, J = 8.9 Hz, 2H), 6.82 (d, J = 8.9 Hz, 
2H), 3.80 (s, 3H), 3.67 (q, J = 7.0 Hz, 1H), 2.32 (s, 6H), 1.39 (d, J = 7.0 Hz, 
3H). 13C NMR (75 MHz, CDCl3) δ 159.5, 133.2, 115.6, 114.0, 86.2, 85.1, 
55.4, 52.9, 41.4, 20.2.  HRMS-ESI+ m/z calculated for C13H18NO [M+H]
+: 
204.1382, found 204.1383. 
 
(+)-(R)-4-(3-Methoxyphenyl)-N,N-dimethylbut-3-yn-2-amine, (R)-III-
5k. 
From (S)-4-(3-methoxyphenyl)but-3-yn-2-ol (900 
mg, 5.1 mmol), following the general procedure 
described above, compound (R)-III-5k (842 mg, 4.4 
mmol) was obtained in 87% yield as an orange oil. 
1H NMR (300 MHz, CDCl3) δ 7.19 (t, J = 7.9 Hz, 1H), 7.02 (dt, J = 7.6, 
1.2 Hz, 1H), 6.95 (m, 1H), 6.85 (dd, J = 8.3, 2.0 Hz, 1H), 3.79 (s, 3H), 3.68 
(q, J = 7.0 Hz, 1H), 2.33 (s, 6H), 1.40 (d, J = 7.0 Hz, 3H). 13C NMR (75 
Chapter 3 
 
276 
 
MHz, CDCl3) δ 159.4, 129.4, 124.4 (2C), 116.7, 114.5, 87.7, 85.2, 55.3, 
52.8, 41.4, 20.1.  [α]20D= +35.9 (c = 1.0, CHCl3). HRMS-ESI+ m/z 
calculated for C13H18NO [M+H]
+: 204.1382, found 204.1382. 
()-N,N-Dimethyl-4-(thiophen-2-yl)but-3-yn-2-amine, III-5l. 
From ()-4-(thiophen-2-yl)but-3-yn-2-ol (970 g, 6.4 
mmol), following the general procedure described 
above, compound III-5l (660 g, 3.7 mmol) was 
obtained in 58% yield as an orange oil. 
1H NMR (300 MHz, CDCl3) δ 7.18 – 7.12 (m, 2H), 6.91 (m, 1H), 3.67 
(q, J = 7.0 Hz, 1H), 2.29 (s, 6H), 1.36 (d, J = 7.0 Hz, 3H). 13C NMR (75 
MHz, CDCl3) δ 131.6, 126.9, 126.5, 123.3, 91.8, 78.4, 53.0, 41.3, 19.9. 
HRMS-EI+ m/z calculated for C10H13NS [M]
+: 179.0769, found 179.0762. 
 
()-N,N-Dimethyl-4-(trimethylsilyl)but-3-yn-2-amine, III-5m. 
From ()-4-(trimethylsilyl)-3-butyn-2-ol (1.5 g, 10.5 
mmol), following the general procedure described 
above, compound III-5m (1.68 g, 9.9 mmol) was 
obtained in 94% yield as a yellow oil. 
1H NMR, 13C NMR and MS data were consistent with literature values.94 
1H NMR (300 MHz, CDCl3) δ 3.47 (q, J = 7.0 Hz, 1H), 2.25 (s, 6H), 1.31 
(d, J = 7.1 Hz, 3H), 0.18 (s, 9H). 
 
 
94 Aguilar, D.; Contel, M.; Urriolabeitia, E. P. Chem. Eur. J. 2010, 16, 9287-9296. 
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 (+)-(R)-N,N-Dimethyl-6-phenylhex-3-yn-2-amine, (R)-III-5n. 
From (S)-6-phenylhex-3-yn-2-ol (800 mg, 4.6 
mmol), following the general procedure described 
above, compound (R)-III-5n (845 g, 4.2 mmol) was 
obtained in 91% yield as an orange oil. 
1H NMR (300 MHz, CDCl3) δ 7.39 – 7.14 (m, 5H), 3.45 (qt, J = 7.0, 
2.0 Hz, 1H), 2.86 (t, J = 7.5 Hz, 2H), 2.54 (td, J = 7.5, 2.0 Hz, 2H), 2.22 (s, 
6H), 1.29 (d, J = 7.0 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 141.0, 128.7, 
128.5, 126.4, 84.5, 78.9, 52.5, 41.3, 35.7, 21.0, 20.4. HRMS-EI+ m/z 
calculated for C14H19N [M]
+: 201.1517, found 201.1514. [α]20D= +18.4 (c = 
1.0, CHCl3). 
 
()-N,N-Dimethyl-1-phenylnon-1-yn-3-amine, III-5o. 
 From ()-1-phenylnon-1-yn-3-ol (1.37 g, 6.3 
mmol), following the general procedure described 
above, compound III-5o (810 g, 3.3 mmol) was 
obtained in 53% yield as an orange oil.  
1H NMR (300 MHz, CDCl3) δ 7.49 – 7.41 (m, 2H), 7.34 – 7.24 (m, 3H), 
3.52 (t, J = 7.3 Hz 1H), 2.33 (s, 6H), 1.73 – 1.64 (m, 2H), 1.57 – 1.41 (m, 
2H), 1.36 – 1.27 (m, 6H), 0.89 (t, J = 6.7 Hz, 3H). 13C NMR (75 MHz, 
CDCl3) δ 131.9, 128.4, 128.0, 123.6, 87.2, 86.1, 58.4, 41.6, 34.2, 31.9, 29.3, 
26.9, 22.8, 14.3. HRMS-ESI+ m/z calculated for C17H26N [M+H]
+: 
244.2059, found 244.2056. 
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()-N,N-Dimethyl-1,5-diphenylpent-1-yn-3-amine, III-5p. 
 From ()-1,5-diphenylpent-1-yn-3-ol (3.0 g, 
12.7 mmol), following the general procedure 
described above, compound III-5p (2.02 g, 7.6 
mmol) was obtained in 60% yield as an orange oil. 
 1H NMR (300 MHz, CDCl3) δ 7.61 – 7.47 (m, 2H), 7.45 – 7.23 (m, 
8H), 3.59 (t, J = 7.6 Hz, 1H), 3.03 – 2.77 (m, 2H), 2.41 (s, 6H), 2.10 (q, J 
= 7.7 Hz, 2H). 13C NMR (75 MHz, CDCl3) δ 141.9, 131.9, 128.7, 128.5, 
128.4, 128.0, 126.0, 123.5, 86.8, 86.5, 57.5, 41.6, 35.7, 32.9. HRMS-EI+ 
m/z calculated for C19H21N [M]
+: 263.1674, found 263.1661. 
 
()-N,N-Dimethyl-3-phenylprop-2-yn-1-amine, III-5q. 
 From 3-phenylprop-2-yn-1-ol (530 mg, 4 mmol), 
following the general procedure described above, 
compound III-5q (626 g, 3.9 mmol) was obtained in 98% 
yield as an orange oil. 
1H NMR, 13C NMR and MS data were consistent with literature values.95 
1H NMR (300 MHz, CDCl3) δ 7.40 – 7.33 (m, 2H), 7.25 – 7.20 (m, 3H), 
3.40 (s, 2H), 2.30 (s, 6H). 
 
 
95 West, T. H.; Daniels, D. S. B.; Slawin, A. M. Z.; Smith, A. D. J. Am. Chem. Soc. 2014, 
136, 4476-4479. 
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(−)-(R)-N,N-Dimethyl-1-(trimethylsilyl)hept-1-yn-3-amine, (R)-III-
5w. 
 From (S)-1-(trimethylsilyl)hept-1-yn-3-ol (1.0 g, 
5.4 mmol), following the general procedure described 
above, compound (R)-III-5w (700 mg, 3.3 mmol) was 
obtained in 61% yield as a yellow oil. 
 1H NMR (300 MHz, CDCl3) δ 3.27 (t, J = 7.5 Hz, 1H), 2.23 (s, 6H), 1.56 
(m, 2H), 1.37 (m, 4H), 0.91 (t, J = 7.0 Hz, 3H), 0.17 (s, 9H). 13C NMR (75 
MHz, CDCl3) δ 103.8, 89.8, 58.4, 41.4, 33.7, 28.9, 22.6, 14.1, 0.4. [α]20D= 
−5.7 (c = 1.0, CHCl3). HRMS-ESI+ m/z calculated for C12H26NSi [M+H]
+: 
212.1829, found 212.1829. 
 
3.6.1.5. Synthesis of propargylic ammonium triflates, 1. 
 
 
 
To a solution of the dimethylamine (1 equiv) in Et2O (2.0 mL/mmol of 
amine) was added methyl trifluoromethanesulfonate (1.1 equiv) at 0 ºC. 
The reaction was stirred for 30 min at 0 ºC and a white solid precipitated. 
The mixture was filtered through a fritted funnel and was washed with cold 
Et2O. The white solid was dried under vacuum for 16 h. 
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(+)-(R)-N,N,N-Trimethyl-4-phenylbut-3-yn-2-aminium 
trifluoromethanesulfonate, (R)-III-1a. 
 From (R)-III-5a (776 mg, 4.5 mmol), following 
the general procedure described above, compound 
(R)-III-1a (1.47 g, 4.35 mmol) was obtained in 97% 
yield as a white solid.  
1H NMR (300 MHz, CDCl3) δ 7.50 – 7.43 (m, 2H), 7.44 – 7.31 (m, 3H), 
4.81 (q, J = 6.8 Hz, 1H), 3.33 (s, 9H), 1.78 (d, J = 6.8 Hz, 3H). 13C NMR 
(75 MHz, CDCl3) δ 132.1, 130.1, 128.7, 120.8 (q, JC-F = 318 Hz), 120.2, 
91.4, 80.6, 63.9, 50.9, 16.3. [α]20D= +18.6 (c = 1.0, CHCl3). HRMS-FAB+ 
m/z calculated for C13H18N [M-OTf]
+: 188.1439, found 188.1436 
 
()-N,N,N-Trimethyl-4-(4-(trifluoromethyl)phenyl)but-3-yn-2-
aminium trifluoromethanesulfonate, III-1c. 
 From III-5c (1.00 g, 4.1 mmol), following 
the general procedure described above, compound 
III-1c (1.63 g, 4.0 mmol) was obtained in 97% 
yield as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.60 (s, 4H), 4.88 (q, J = 6.8 Hz, 1H), 3.31 
(s, 9H), 1.77 (d, J = 6.8 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 132.5, 131.6 
(q, JC-F = 32.9 Hz), 125.6 (q, JC-F = 3.7 Hz), 124.0, 123.7 (q, JC-F = 272.0 
Hz), 120.8 (q, JC-F = 318 Hz), 89.8, 82.7, 63.7, 51.0, 16.1. HRMS-FAB
+ 
m/z calculated for C14H17NF3 [M-OTf]
+: 256.1313, found 256.1315. 
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(+)-(R)-4-(4-(Methoxycarbonyl)phenyl)-N,N,N-trimethylbut-3-yn-2-
aminium trifluoromethanesulfonate, (R)-III-1d. 
 From methyl (R)-III-5d (347 mg, 1.5 
mmol), following the general procedure 
described above, compound (R)-III-1d (546 
mg, 1.4 mmol) was obtained in 92% yield as a 
white solid.  
1H NMR (300 MHz, CDCl3) δ 8.02 (d, J = 8.5 Hz, 2H), 7.53 (d, J = 8.5 Hz, 
2H), 4.87 (q, J = 6.8 Hz, 1H), 3.92 (s, 3H), 3.33 (s, 9H), 1.78 (d, J = 6.8 Hz, 
3H). 13C NMR (75 MHz, CDCl3) δ 166.2, 132.2, 131.4, 129.9, 124.6, 120.8 
(q, JC-F = 318 Hz), 90.7, 83.0, 64.0, 52.5, 51.2, 16.3. [α]20D= +24.8 (c = 1.0, 
CHCl3). HRMS-FAB+ m/z calculated for C15H20NO2 [M-OTf]
+: 246.1494, 
found 246.1490. 
 
()-4-(2-(Methoxycarbonyl)phenyl)-N,N,N-trimethylbut-3-yn-2-
aminium trifluoromethanesulfonate, III-1e. 
 From III-5e (600 mg, 2.6 mmol), following the 
general procedure described above, compound III-1e 
(946 mg, 2.4 mmol) was obtained in 94% yield as a 
white solid. 
1H NMR (300 MHz, CDCl3) δ 7.95 (d, J = 7.7 Hz, 1H), 7.50 (m, 2H), 7.40 
(t, J = 7.3 Hz, 1H), 4.83 (q, J = 6.7 Hz, 1H), 3.84 (s, 3H), 3.33 (s, 9H), 1.73 
(d, J = 6.7 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 165.6, 134.3, 132.3, 
131.4, 130.6, 129.4, 121.3, 120.8 (q, JC-F = 318 Hz), 89.4, 85.6, 63.8, 52.4, 
51.0, 16.0. HRMS-FAB+ m/z calculated for C15H20NO2 [M-OTf]
+: 
246.1488, found 246.1487. 
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(+)-(R)-4-(4-Acetylphenyl)-N,N,N-trimethylbut-3-yn-2-aminium 
trifluoromethanesulfonate, (R)-III-1f. 
 From (R)-III-5f (410 mg, 1.9 mmol), 
following the general procedure described 
above, compound (R)-III-1f (670 mg, 1.8 
mmol) was obtained in 93% yield as a white 
solid.  
1H NMR (300 MHz, CDCl3) δ 7.94 (d, J = 8.4 Hz, 2H), 7.58 (d, J = 8.4 Hz, 
2H), 4.91 (q, J = 6.7 Hz, 1H), 3.34 (s, 9H), 2.61 (s, 3H), 1.80 (d, J = 6.7 Hz, 
3H). 13C NMR (75 MHz, CDCl3) δ 197.3, 137.8, 132.4, 128.5, 124.8, 120.8 
(q, JC-F = 318 Hz), 90.6, 83.4, 63.9, 51.1, 26.8, 16.3. [α]20D= +24.8 (c = 1.0, 
CHCl3). HRMS-FAB+ m/z calculated for C15H20NO [M-OTf]
+: 230.1545, 
found 230.1543. 
 
()-4-(4-Fluorophenyl)-N,N,N-trimethylbut-3-yn-2-aminium 
trifluoromethanesulfonate, III-1g. 
 From III-5g (230 mg, 1.4 mmol), following 
the general procedure described above, compound 
III-1g (452 mg, 1.3 mmol) was obtained in 91% 
yield as a white solid.  
1H NMR (300 MHz, CDCl3) δ 7.47 (dd, J = 8.7, 5.3 Hz, 2H), 7.06 (t, J = 
8.6 Hz, 2H), 4.79 (q, J = 6.8 Hz, 1H), 3.31 (s, 9H), 1.76 (d, J = 6.8 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 163.4 (d, JC-F = 252 Hz), 134.2 (d, JC-F = 8.7 
Hz), 134.19, 120.8 (q, JC-F = 318 Hz), 116.3 (d, JC-F = 3.5 Hz), 116.0 (d, JC-
F = 22.3 Hz), 90.3, 80.3, 80.3, 63.8, 50.8, 16.1. HRMS-FAB
+ m/z 
calculated for C13H17FN [M-OTf]
+: 206.1340, found 206.1348. 
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()-4-(4-Chlorophenyl)-N,N,N-trimethylbut-3-yn-2-aminium 
trifluoromethanesulfonate, III-1h. 
 From III-5h (1.01 g, 4.7 mmol), following 
the general procedure described above, compound 
III-1h (1.73 g, 4.6 mmol) was obtained in 97% 
yield as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.40 (d, J = 8.6 Hz, 2H), 7.33 (d, J = 8.6 Hz, 
2H), 4.82 (q, J = 6.8 Hz, 1H), 3.30 (s, 9H), 1.76 (d, J = 6.8 Hz, 3H). 13C 
NMR (75 MHz, CDCl3) δ 136.3, 133.4, 129.1, 120.8 (q, JC-F = 318 Hz), 
118.7, 90.4, 81.5, 63.9, 51.0, 16.2. HRMS-FAB+ m/z calculated for C13
-
H17NCl [M-OTf]
+: 222.1044, found 222.1034. 
 
(+)-(R)-4-(3-Bromophenyl)-N,N,N-trimethylbut-3-yn-2-aminium 
trifluoromethanesulfonate, (R)-III-1i. 
 From (R)-III-5i (1.16 mg, 4.6 mmol), 
following the general procedure described above, 
compound (R)-III-1i (1.86 g, 4.5 mmol) was 
obtained in 97% yield as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.56 (s, 1H), 7.49 (d, J = 8.0 Hz, 1H), 7.38 
(d, J = 7.6 Hz, 1H), 7.19 (t, J = 7.9 Hz, 1H), 4.82 (q, J = 6.7 Hz, 1H), 3.26 
(s, 9H), 1.72 (d, J = 6.7 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 134.6, 
133.2, 130.7, 130.2, 120.8 (q, JC-F = 318 Hz), 122.3, 122.1, 89.7, 81.8, 63.7, 
50.9, 16.1. [α]20D= +19.6 (c = 1.0, CHCl3).  HRMS-FAB+ m/z calculated 
for C13H17NBr [M-OTf]
+: 266.0544, found 266.0548. 
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()-4-(4-Methoxyphenyl)-N,N,N-trimethylbut-3-yn-2-aminium 
trifluoromethanesulfonate, III-1j. 
 From III-5j (387 mg, 2.2 mmol), 
following the general procedure described 
above, compound III-1j (759 mg, 2.1 mmol) 
was obtained in 94% yield as a white solid.  
1H NMR (300 MHz, CDCl3) δ 7.39 (d, J = 8.9 Hz, 2H), 6.86 (d, J = 8.9 Hz, 
2H), 4.75 (q, J = 6.8 Hz, 1H), 3.82 (s, 3H), 3.29 (s, 9H), 1.74 (d, J = 6.8 Hz, 
3H). 13C NMR (75 MHz, CDCl3) δ 161.0, 133.9, 120.8 (q, JC-F = 318 Hz), 
114.4, 112.2, 91.8, 79.4, 64.3, 55.5, 50.9, 16.5. HRMS-FAB+ m/z 
calculated for C15H20NO [M-OTf]
+: 218.1545, found 218.1547. 
 
(+)-(R)-4-(3-Methoxyphenyl)-N,N,N-trimethylbut-3-yn-2-aminium 
trifluoromethanesulfonate, (R)-III-1k. 
 From (R)-III-5k (1.3 g, 6.5 mmol), following 
the general procedure described above, compound 
(R)-III-1k (2.2 g, 6.0 mmol) was obtained in 93% 
yield as a white solid.  
1H NMR (300 MHz, CDCl3) δ 7.55 (dd, J = 8.3, 7.2 Hz, 1H), 7.33 (d, J = 
7.6 Hz, 1H), 7.28 – 7.21 (m, 2H), 5.08 (q, J = 6.7 Hz, 1H), 4.10 (s, 3H), 
3.60 (s, 9H), 2.05 (d, J = 6.7 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 159.6, 
129.9, 124.6, 121.2, 120.8 (q, JC-F = 318 Hz), 116.9, 116.8, 91.5, 80.3, 64.0, 
55.5, 51.0, 16.4. [α]20D= +17.1 (c = 1.0, CHCl3). HRMS-ESI+ m/z 
calculated for C14H20NO [M-OTf]
+: 218.1539, found 218.1533. 
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()-N,N,N-Trimethyl-4-(thiophen-2-yl)but-3-yn-2-aminium 
trifluoromethanesulfonate, III-1l. 
 From III-5l (516 mg, 2.9 mmol), following the 
general procedure described above, compound III-
1l (950 mg, 2.8 mmol) was obtained in 96% yield as 
a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.35 (dd, J = 5.1, 0.9 Hz, 1H), 7.33 – 7.29 
(m, 1H), 6.99 (dd, J = 5.1, 3.7 Hz, 1H), 4.82 (q, J = 6.8 Hz, 1H), 3.24 (s, 
9H), 1.72 (d, J = 6.8 Hz, 3H).13C NMR (75 MHz, CDCl3) δ 134.7, 129.6, 
127.5, 120.8 (q, JC-F = 320.1 Hz), 119.7, 85.0, 84.4, 64.1, 50.9, 16.1. 
HRMS-FAB+ m/z calculated for C11H16NS [M-OTf]
+: 194.1003, found 
194.0996. 
 
()-N,N,N-Trimethyl-4-(trimethylsilyl)but-3-yn-2-aminium 
trifluoromethanesulfonate, III-1m. 
 From III-5m (1.24 g, 7.3 mmol), following the 
general procedure described above, compound III-1m 
(1.86 g, 5.6 mmol) was obtained in 77% yield as a 
white solid. 
1H NMR (300 MHz, CDCl3) δ 4.53 (q, J = 6.7 Hz, 1H), 3.22 (s, 9H), 1.64 
(d, J = 6.7 Hz, 3H), 0.19 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 120.8 (q, 
JC-F = 320.0 Hz), 98.3, 96.5, 63.8, 50.8, 16.2, −0.5. HRMS-FAB+ m/z 
calculated for C10H22NSi [M-OTf]
+: 184.1522, found 184.1522. 
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(+)-(R)-N,N,N-Trimethyl-6-phenylhex-3-yn-2-aminium 
trifluoromethanesulfonate, (R)-III-1n. 
 From (R)-III-5n (800 mg, 4.0 mmol), 
following the general procedure described above, 
compound (R)-III-1n (1.35 mg, 3.75 mmol) was 
obtained in 93% yield as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.38 – 7.28 (m, 2H), 7.28 – 7.18 (m, 
3H), 4.42 (qt, J = 6.6, 1.9 Hz, 1H), 3.04 (s, 9H), 2.87 (t, J = 7.1 Hz, 2H), 
2.71 – 2.54 (td, J = 7.1, 1.9 Hz, 2H), 1.57 (d, J = 6.6 Hz, 3H). 13C NMR 
(75 MHz, CDCl3) δ 139.7, 128.6, 128.4, 126.8, 120.7 (q, JC-F = 320.0 Hz), 
92.2, 73.5, 63.6, 50.5, 33.8, 20.4, 16.3. HRMS-FAB+ m/z calculated for 
C15H22N [M-OTf]
+: 216.1752, found 216.1754. [α]20D= +7.5 (c = 1.0, 
CHCl3). 
 
()-N,N,N-Trimethyl-1-phenylnon-1-yn-3-aminium 
trifluoromethanesulfonate, III-1o. 
 From III-5o (540 mg, 2.2 mmol), following the 
general procedure described above, compound III-1o 
(701 mg, 1.7 mmol) was obtained in 78% yield. In 
this case, a precipitate did not form upon addition of 
MeOTf. Instead, two distinct layers appeared. The top layer was decanted 
off. The bottom layer was washed with Et2O (2 x 10 mL) and then dried 
under vacuum to give salt III-1o as a light yellow tacky oil.  
1H NMR (300 MHz, CDCl3) δ 7.46 (dd, J = 7.9, 1.6 Hz, 2H), 7.44 – 7.30 
(m, 3H), 4.56 (dd, J = 11.5, 3.7 Hz, 1H), 3.31 (s, 9H), 2.08 (m, 1H), 1.85 – 
1.69 (m, 1H), 1.69 – 1.23 (m, 8H), 0.87 (t, J = 6.6 Hz, 3H). 13C NMR (75 
MHz, CDCl3) δ 132.2, 130.2, 128.8, 120.8 (q, JC-F = 318 Hz), 120.3, 92.6, 
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79.8, 68.9, 51.4, 31.6, 29.1, 28.7, 26.5, 22.5, 14.1. HRMS-ESI+ m/z 
calculated for C18H28N [M-OTf]
+: 258.2216, found 258.2204. 
 
()-N,N,N-Trimethyl-1,5-diphenylpent-1-yn-3-aminium 
trifluoromethanesulfonate, III-1p. 
 From III-5p (318 mg, 2.0 mmol), 
following the general procedure described 
above, compound III-1p (626 mg, 1.9 mmol) 
was obtained in 95% yield as white solid.  
1H NMR (300 MHz, CDCl3) δ 7.53 – 7.45 (m, 2H), 7.45 – 7.33 (m, 3H), 
7.32 – 7.22 (m, 4H), 7.18 (m, 1H), 4.57 (dd, J = 11.6, 3.5 Hz, 1H), 3.24 (s, 
9H), 2.99 (m, 1H), 2.85 (m, 1H), 2.42 (m, 1H), 2.08 (m, 1H). 13C NMR (75 
MHz, CDCl3) δ 139.3, 132.3, 130.2, 128.8, 128.8, 128.5, 126.8, 120.8 (q, 
JC-F = 320.1 Hz), 120.1, 93.2, 79.3, 68.2, 51.3, 32.3, 30.8. HRMS-FAB
+ 
m/z calculated for C20H24N [M-OTf]
+: 278.1903, found 278.1903. 
N,N,N-Trimethyl-3-phenylprop-2-yn-1-aminium 
trifluoromethanesulfonate, III-1q. 
From III-5q (318 mg, 2.0 mmol), following the 
general procedure described above, compound III-
1q (626 mg, 1.9 mmol) was obtained in 97% yield as 
a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.46 (d, J = 6.7 Hz, 2H), 7.42 – 7.29 (m, 
3H), 4.51 (s, 2H), 3.33 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 132.3, 130.2, 
128.8, 120.8 (q, JC-F = 319.8 Hz), 120.3, 92.4, 75.9, 57.5, 52.9. HRMS-
FAB+ m/z calculated for C12H16N [M-OTf]
+: 174.1283, found 174.1277. 
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N,N,N-Trimethyl-3-(trimethylsilyl)prop-2-yn-1-aminium 
trifluoromethanesulfonate, III-1r. 
From N,N-dimethyl-3-(trimethylsilyl)prop-2-yn-1-
amine (1.6 g, 10.3 mmol), following the general 
procedure described above, compound III-1r (3.23 g, 
10.1 mmol) was obtained in 98% yield as a white solid. 
1H NMR (300 MHz, CDCl3) δ 4.25 (s, 2H), 3.27 (s, 9H), 0.21 (s, 9H). 13C 
NMR (75 MHz, CDCl3) δ 120.7 (q, JC-F = 319.7 Hz), 99.7, 91.7, 57.4, 52.8, 
−0.5. HRMS-ESI+ m/z calculated for C9H20NSi [M-OTf]
+: 170.1359, 
found 170.1358. 
 
(−)-(R)-N,N,N-trimethyl-1-(trimethylsilyl)hept-1-yn-3-aminium 
trifluoromethanesulfonate, (R)-III-1w. 
From (R)-III-5w (400 mg, 1.9 mmol), 
following the general procedure described above, 
compound (R)-III-1w (628 mg, 1.7 mmol) was 
obtained in 88% yield as a white solid.  
1H NMR (300 MHz, CDCl3) δ 4.28 (dd, J = 11.6, 3.8 Hz, 1H), 3.26 (s, 9H), 
2.03 (m, 1H), 1.67 (m, 1H), 1.58 – 1.32 (m, 4H), 0.94 (t, J = 7.1 Hz, 3H), 
0.22 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 120.8 (q, JC-F = 320.1 Hz), 99.6, 
95.8, 68.6, 51.2, 28.5, 22.0, 13.9, −0.48. [α]20D= −18.1 (c = 1.0, CHCl3). 
HRMS-ESI+ m/z calculated for C13H28NSi [M-OTf]
+: 226.1985, found 
226.1993. 
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3.6.2. Copper-catalyzed reaction of propargylic ammonium triflates 
with aryl Grignard reagents. 
 
 
An oven-dried vial was charged with [Cu(CH3CN)4]PF6 (3.8 mg, 0.01 
mmol) and the corresponding ammonium salt (0.2 mmol) and sealed with 
a septum. The vial was connected to an argon-vacuum line, evacuated and 
backfilled with argon (x3). CH2Cl2 (2 mL) was added and the mixture was 
stirred for 5 min at room temperature. The reaction mixture was cooled to 
−40 ºC and an aryl magnesium bromide solution in THF (0.22 mmol) was 
added dropwise. The mixture was stirred at −40 ºC for 5 minutes. Water 
(0.1 mL) was added and the solution was filtered through a short pad of 
MgSO4 and rinsed with CH2Cl2. The solvent was removed under reduced 
pressure and the crude product was purified by flash column 
chromatography using n-hexane as eluent.  
 
(−)-(R)-1-Methoxy-4-(4-phenylbut-3-yn-2-yl)benzene, (R)-III-2a.  
From (R)-III-1a (67 mg, 0.2 mmol) and 4-
methoxyphenylmagnesium bromide (0.22 M in THF, 
0.22 mmol) following the general procedure described 
above, compound (R)-III-2a (43 mg, 0.18 mmol) was 
obtained in 90% yield as a yellow oil after flash column 
chromatography (hex/EtOAc, 95/5). From (±)-III-1a, 
following the same procedure, compound (±)-III-2a (42 mg, 0.18 mmol) 
was obtained in 88% yield. 
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Compound (R)-III-2a was obtained in 99:1 enantiomeric ratio 
determined by SFC using Chiralpak-ID column [CO2/MeOH (98:2)], 1.0 
mL/min, major= 10.9 min, minor= 12.4 min. 1H NMR (300 MHz, CDCl3) δ 
7.47 – 7.42 (m, 2H), 7.38 (d, J = 8.6 Hz, 2H), 7.33 – 7.27 (m, 3H), 6.90 (d, 
J = 8.6 Hz, 2H), 3.95 (q, J = 7.1 Hz, 1H), 3.81 (s, 3H), 1.57 (d, J = 7.1 Hz, 
3H). 13C NMR (75 MHz, CDCl3) δ 158.5, 135.6, 131.7, 128.3, 128.0, 
127.8, 123.9, 114.1, 93.1, 82.4, 55.4, 31.8, 24.7. [α]20D= −17.6 (c = 1.0, 
CHCl3). HRMS-EI+ m/z calculated for C17H16O [M]
+: 236.1195, found 
236.1183. 
 
(−)-(R)-But-1-yne-1,3-diyldibenzene, (R)-III-2b. 
From (R)-III-1a (67 mg, 0.2 mmol) and 
phenylmagnesium bromide (0.76M in THF, 0.22 mmol) 
following the general procedure described above, 
compound (R)-III-2b (39 mg, 0.19 mmol) was obtained in 
95% yield as a yellow oil. From (±)-III-1a, following the 
same procedure, compound (±)-III-2b (37 mg, 0.18 mmol) was obtained in 
91% yield. 
Compound (R)-III-2b was obtained in 99:1 enantiomeric ratio 
determined by SFC using Chiralpak-ID column [CO2], 1.0 mL/min, major= 
22.9 min, minor= 24.5 min.
 1H NMR, 13C NMR and MS data were consistent 
with literature values. 96 1H NMR (300 MHz, CDCl3) δ 7.45 (m, 4H), 7.32 
(m, 6H), 3.99 (q, J = 7.1 Hz, 1H), 1.59 (d, J = 7.0 Hz, 3H). [α]20D= −16.3 
(c = 1.0, CHCl3).  
 
 
96 García Ruano, J. L.; Marzo, L.; Marcos, V.; Alvarado, C.; Alemán, J. Chem. Eur. J. 
2012, 18, 9775-9779. 
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()-1-(3-Phenylbut-1-yn-1-yl)-4-(trifluoromethyl)benzene, III-2c. 
From III-1c (81 mg, 0.2 mmol) and 
phenylmagnesium bromide (0.76M in THF, 0.22 
mmol) following the general procedure described 
above, compound III-2c (46 mg, 0.17 mmol) was 
obtained in 84% yield as a yellow oil. 
 1H NMR (300 MHz, CDCl3) δ 7.55 (s, 4H), 7.44 (m, 2H), 7.41 – 7.32 (m, 
2H), 7.30 – 7.26 (m, 1H), 4.00 (q, J = 7.1 Hz, 1H), 1.60 (d, J = 7.1 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 143.0, 132.0, 129.7 (q, JC-F = 32.6 Hz), 128.8, 
127.8 (q, JC-F = 0.7 Hz), 127.1, 127.0, 125.3 (q, JC-F = 3.8 Hz), 124.2 (q, JC-
F = 272.0 Hz), 95.5, 81.4, 32.6, 24.4. HRMS-EI
+ m/z calculated for C17
-
H13F3 [M]
+: 274.0969, found 274.0979. 
 
(−)-Methyl (R)-4-(3-phenylbut-1-yn-1-yl)benzoate, (R)-III-2d. 
From (R)-III-1d (79 mg, 0.2 mmol) and 
phenylmagnesium bromide (0.76 M in THF, 0.22 
mmol) following the general procedure described 
above, compound (R)-III-2d (43 mg, 0.16 mmol) 
was obtained in 81% yield as a yellow oil after 
flash column chromatography (hex/EtOAc, 95/5). From (±)-III-1d, 
following the same procedure, compound (±)-III-2d (44 mg, 0.17 mmol) 
was obtained in 83% yield. 
Compound (R)-III-2d was obtained in 99:1 enantiomeric ratio determined 
by SFC using Chiralpak-ID column [CO2/MeOH (95:5)], 1.0 mL/min, 
major= 13.3 min, minor= 14.4 min. 1H NMR (300 MHz, CDCl3) δ 7.99 (d, J 
= 8.6 Hz, 2H), 7.51 (d, J = 8.6 Hz, 2H), 7.46 (d, J = 7.3 Hz, 2H), 7.37 (t, J 
= 7.3 Hz, 2H), 7.27 (m, 1H), 4.08 – 3.95 (m, 1H), 3.92 (s, 3H), 1.61 (d, J = 
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7.2 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 166.7, 142.9, 131.6, 129.4, 
129.1, 128.7, 128.6, 126.9, 126.9, 96.0, 81.9, 52.2, 32.6, 24.3. [α]20D= −12.5 
(c = 1.0, CHCl3). HRMS-EI+ m/z calculated for C18H16O2 [M]
+: 264.1150, 
found 264.1140.  
 
()-Methyl 2-(3-phenylbut-1-yn-1-yl)benzoate, III-2e. 
From III-1e (79 mg, 0.2 mmol) and 
phenylmagnesium bromide (0.76 M in THF, 0.22 mmol) 
following the general procedure described above, 
compound III-2e (31 mg, 0.12 mmol) was obtained in 
60% yield as a yellow oil after flash column 
chromatography (hex/ EtOAc, 95/5). 
 1H NMR (300 MHz, CDCl3) δ 7.92 (dd, J = 7.8, 1.4 Hz, 1H), 7.56 (dd, J = 
7.8, 1.3 Hz, 1H), 7.51 (d, J = 7.4 Hz, 2H), 7.44 (td, J = 7.6, 1.5 Hz, 1H), 
7.35 (d, J = 7.7 Hz, 2H), 7.30 – 7.23 (m, 1H), 4.06 (q, J = 7.1 Hz, 1H), 3.87 
(s, 3H), 1.63 (d, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 167.2, 
143.3, 134.2, 132.3, 131.6, 130.3, 128.7, 127.6, 127.1, 126.8, 124.1, 97.9, 
81.3, 52.1, 32.9, 24.5. HRMS-EI+ m/z calculated for C18H15O2 [M-1]
+: 
263.1072, found 263.1061. 
 
(−)-(R)-1-[4-(3-Phenylbut-1-yn-1-yl)phenyl]ethan-1-one, (R)-III-2f. 
From (R)-III-1f (73 mg, 0.2 mmol) and 
phenylmagnesium bromide (0.76 M in THF, 0.22 
mmol) following the general procedure described 
above, compound (R)-III-2f (26 mg, 0.10 mmol) 
was obtained in 52% yield as a yellow oil after flash 
column chromatography (hex/ EtOAc, 95:5). From (±)-III-1f, following 
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the same procedure, compound (±)-III-2f (26 mg, 0.10 mmol) was obtained 
in 52% yield. 
Compound (R)-III-2f was obtained in 98:2 enantiomeric ratio determined 
by SFC using Chiralpak-ID column [CO2/MeOH (98:2)], 1.0 mL/min, 
major= 26.3 min, minor= 24.6 min. 1H NMR (300 MHz, CDCl3) δ 7.86 (d, J 
= 8.4 Hz, 2H), 7.48 (d, J = 8.4 Hz, 2H), 7.41 (d, J = 7.3 Hz, 2H), 7.33 (t, J 
= 7.4 Hz, 2H), 7.24 (d, J = 7.6 Hz, 1H), 3.98 (q, J = 7.1 Hz, 1H), 2.56 (s, 
3H), 1.57 (d, J = 7.2 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 197.5, 143.0, 
136.1, 131.9, 128.9, 128.8, 128.3, 127.0, 127.0, 96.5, 82.0, 32.7, 26.7, 24.4. 
[α]20D= −35.7 (c = 1.0, CHCl3). HRMS-EI+ m/z calculated for C18H16O 
[M]+: 248.1201, found 248.1201. 
 
()-1-Fluoro-4-(3-phenylbut-1-yn-1-yl)benzene, III-2g. 
From III-1g (71 mg, 0.2 mmol) and 
phenylmagnesium bromide (0.76 M in THF, 0.22 
mmol) following the general procedure described 
above, compound III-2g (40 mg, 0.18 mmol) was 
obtained in 90% yield as a yellow oil. 
 1H NMR (300 MHz, CDCl3) δ 7.39 (m, 6H), 7.27 (m, 1H), 6.99 (t, J = 8.7 
Hz, 2H), 3.97 (q, J = 7.1 Hz, 1H), 1.58 (d, J = 7.1 Hz, 3H). 13C NMR (75 
MHz, CDCl3) δ 162.2 (d, JC-F = 248.4 Hz), 143.2, 133.5 (d, JC-F = 8.3 Hz), 
128.6, 126.9, 126.7, 119.8 (d, JC-F = 3.5 Hz), 115.4 (d, JC-F = 22.0 Hz), 92.3, 
81.4, 32.4, 24.5. HRMS-EI+ m/z calculated for C16H13F [M]
+: 224.1001, 
found 224.0996. 
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()-1-Chloro-4-(3-phenylbut-1-yn-1-yl)benzene, III-2h. 
From III-1h (74 mg, 0.2 mmol) and 
phenylmagnesium bromide (0.76 M in THF, 0.22 
mmol) following the general procedure described 
above, compound III-2h (46 mg, 0.19 mmol) was 
obtained in 96% yield as a yellow oil. The reaction 
was also carried out in gram scale, from III-1h (1.0 g, 2.7 mmol) and 
phenylmagnesium bromide (0.76 M in THF, 3.0 mmol) affording 
compound III-2h (604 mg, 2.51 mmol) in 93% yield as a yellow oil. 
 1H NMR (300 MHz, CDCl3) δ 7.42 (d, J = 7.5 Hz, 2H), 7.33 (m, 4H), 
7.25 (m, 3H), 3.95 (q, J = 7.1 Hz, 1H), 1.56 (d, J = 7.1 Hz, 3H). 13C NMR 
(75 MHz, CDCl3) δ 143.2, 133.8, 133.0, 128.7, 128.6, 127.0, 126.9, 122.4, 
93.8, 81.5, 32.6, 24.5. HRMS-EI+ m/z calculated for C16H13Cl [M]
+: 
240.0700, found 240.0692. 
 
()-1-Bromo-3-(3-phenylbut-1-yn-1-yl)benzene, III-2i. 
From III-1i (83 mg, 0.2 mmol) and 
phenylmagnesium bromide (0.76 M in THF, 0.22 
mmol) following the general procedure described 
above, compound III-2i (53 mg, 0.19 mmol) was 
obtained in 93% yield as a yellow oil. 
 1H NMR (300 MHz, CDCl3) δ 7.60 (t, J = 1.7 Hz, 1H), 7.46 – 7.39 (m, 
3H), 7.39 – 7.32 (m, 3H), 7.29 – 7.26 (m, 1H), 7.16 (t, J = 7.9 Hz, 1H), 3.98 
(q, J = 7.1 Hz, 1H), 1.58 (d, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) 
δ 143.0, 134.5, 131.0, 130.3, 129.8, 128.7, 127.0, 126.9, 125.9, 122.2, 94.3, 
81.1, 32.6, 24.4. HRMS-EI+ m/z calculated for C16H13Br [M]
+: 284.0201, 
found 284.0188.  
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()-1-Methoxy-4-(3-phenylbut-1-yn-1-yl)benzene, III-2j. 
From III-1j (74 mg, 0.2 mmol) and 
phenylmagnesium bromide (0.76 M in THF, 0.22 
mmol) following the general procedure described 
above, compound III-2j (45 mg, 0.19 mmol) was 
obtained in 94% yield as a yellow oil after flash 
column chromatography (hex/ EtOAc, 95/5). 
 1H NMR (300 MHz, CDCl3) δ 7.46 (d, J = 7.3 Hz, 2H), 7.36 (m, 4H), 7.30 
– 7.20 (m, 1H), 6.83 (d, J = 8.8 Hz, 2H), 3.98 (q, J = 7.1 Hz, 1H), 3.81 (s, 
3H), 1.58 (d, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 159.3, 143.7, 
133.1, 128.7, 127.1, 126.7, 116.0, 113.9, 91.2, 82.3, 55.4, 32.6, 24.7. 
HRMS-EI+ m/z calculated for C17H16O [M]
+: 236.1201, found 236.1195. 
 
(−)-(R)-1-Methoxy-3-(3-phenylbut-1-yn-1-yl)benzene, (R)-III-2k. 
From (R)-III-1k (73 mg, 0.2 mmol) and 
phenylmagnesium bromide (0.76 M in THF, 0.22 
mmol) following the general procedure described 
above, compound (R)-III-2k (46 mg, 0.19 mmol) 
was obtained in 97% yield as a yellow oil after flash 
column chromatography (hex/ EtOAc, 95/5). From (±)-III-1k, following 
the same procedure, compound (±)-III-2k (44 mg, 0.19 mmol) was 
obtained in 93% yield. 
Compound (R)-III-2k was obtained with a 98:2 enantiomeric ratio 
determined by SFC using Chiralpak-IB column [CO2/MeOH (99.5:0.5)], 
1.0 mL/min, major= 20.9 min, minor= 20.2 min. 1H NMR (300 MHz, CDCl3) 
δ 7.53 – 7.44 (m, 2H), 7.42 – 7.33 (m, 2H), 7.32 – 7.26 (m, 1H), 7.23 (m, 
1H), 7.07 (dt, J = 7.6, 1.1 Hz, 1H), 7.00 (m, 1H), 6.87 (ddd, J = 8.3, 2.6, 0.9 
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Hz, 1H), 4.01 (q, J = 7.1 Hz, 1H), 3.81 (s, 3H), 1.61 (d, J = 7.1 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 159.5, 143.4, 129.4, 128.7, 127.1, 126.8, 
124.9, 124.4, 116.6, 114.5, 92.6, 82.5, 55.4, 32.6, 24.6. [α]20D= −18.8 (c = 
1.0, CHCl3). HRMS-EI+ m/z calculated for C17H16O [M]
+: 236.1195, found 
236.1188. 
 
()-2-(3-Phenylbut-1-yn-1-yl)thiophene, III-2l. 
From III-1l (69 mg, 0.2 mmol) and 
phenylmagnesium bromide (0.76 M in THF, 0.22 mmol) 
following the general procedure described above, 
compound III-2l (34 mg, 0.16 mmol) was obtained in 
81% yield as a yellow oil. 
 1H NMR (300 MHz, CDCl3) δ 7.45 (d, J = 7.3 Hz, 2H), 7.36 (t, J = 7.4 Hz, 
2H), 7.28 (d, J = 7.1 Hz, 1H), 7.23 – 7.17 (m, 2H), 6.96 (dd, J = 5.1, 3.6 
Hz, 1H), 4.02 (q, J = 7.1 Hz, 1H), 1.60 (d, J = 7.2 Hz, 3H). 13C NMR (75 
MHz, CDCl3) δ 143.1, 131.4, 128.7, 127.1, 126.9, 126.9, 126.4, 124.0, 96.6, 
75.7, 32.9, 24.4. HRMS-EI+ m/z calculated for C14H12S [M]
+: 212.0654, 
found 212.0651. 
 
()-Trimethyl(3-phenylbut-1-yn-1-yl)silane, III-2m. 
From III-1m (67 mg, 0.2 mmol) and 
phenylmagnesium bromide (0.76 M in THF, 0.22 mmol) 
following the general procedure described above, 
compound III-2m (32 mg, 0.16 mmol) was obtained in 
80% yield as a yellow oil. 
 1H NMR (300 MHz, CDCl3) δ 7.43 – 7.29 (m, 4H), 7.26 (m, 1H), 3.80 
(q, J = 7.1 Hz, 1H), 1.50 (d, J = 7.2 Hz, 3H), 0.20 (s, 9H). 13C NMR (75 
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MHz, CDCl3) δ 143.20, 128.62, 127.02, 126.72, 109.63, 86.36, 32.95, 
24.79, 0.31. HRMS-EI+ m/z calculated for C13H18Si [M]
+: 202.1172, found 
202.1171. 
 
()-Hex-3-yne-1,5-diyldibenzene, III-2n. 
From III-1n (73 mg, 0.2 mmol) and 
phenylmagnesium bromide (0.76 M in THF, 0.22 
mmol) following the general procedure described 
above, compound III-2n (41 mg, 0.18 mmol) was 
obtained in 88% yield as a yellow oil. 
 1H NMR (300 MHz, CDCl3) δ 7.39 – 7.29 (m, 6H), 7.29 – 7.22 (m, 4H), 
3.76 (qt, J = 7.1, 2.1 Hz, 1H), 2.88 (t, J = 7.5 Hz, 2H), 2.56 (td, J = 7.5, 2.1 
Hz, 2H), 1.48 (d, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 143.9, 
141.0, 128.6, 128.5, 128.4, 126.9, 126.5, 126.2, 83.8, 81.6, 35.5, 32.0, 24.8, 
21.1. HRMS-EI+ m/z calculated for C18H18 [M]
+: 234.1409, found 
234.1396. 
 
()-Non-1-yne-1,3-diyldibenzene, III-2o. 
From III-1o (81 mg, 0.2 mmol) and 
phenylmagnesium bromide (0.76 M in THF, 0.22 
mmol) following the general procedure described 
above, compound III-2o (41 mg, 0.15 mmol) was 
obtained in 73% yield as a yellow oil. 
 1H NMR (300 MHz, CDCl3) δ 7.24 (m, 4H), 7.19 – 7.01 (m, 6H), 3.64 
(t, J = 7.2 Hz, 1H), 1.64 (m, 2H), 1.31 (m, 2H), 1.18 – 1.04 (m, 6H), 0.69 
(t, J = 6.6 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 142.4, 131.7, 128.5, 
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128.2, 127.7, 127.5, 126.6, 123.9, 91.8, 83.2, 38.7, 38.5, 31.8, 29.0, 27.4, 
22.6, 14.1. HRMS-EI+ m/z calculated for C21H24 [M]
+: 276.1872, found 
276.1870. 
 
()-Pent-1-yne-1,3,5-triyltribenzene, III-2p. 
From III-1p (86 mg, 0.2 mmol) and 
phenylmagnesium bromide (0.76 M in THF, 
0.22 mmol) following the general procedure 
described above, compound III-2p (48 mg, 0.16 
mmol) was obtained in 81% yield as a yellow oil. 
 1H NMR (300 MHz, CDCl3) δ 7.52 (m, 2H), 7.49 – 7.43 (m, 2H), 7.42 – 
7.19 (m, 11H), 3.98 – 3.83 (m, 1H), 2.99 – 2.78 (m, 2H), 2.26 – 2.07 (m, 
2H). 13C NMR (75 MHz, CDCl3) δ 142.0, 141.8, 131.9, 128.7, 128.6, 128.4, 
128.0, 127.7, 127.0, 126.1, 123.9, 91.4, 84.0, 40.3, 38.0, 33.8. HRMS-EI+ 
m/z calculated for C23H20 [M]
+: 296.1559, found 296.1552. 
 
Prop-1-yne-1,3-diyldibenzene, III-2q. 
From III-1q (65 mg, 0.2 mmol) and 
phenylmagnesium bromide (0.76 M in THF, 0.22 
mmol) following the general procedure described 
above, compound III-2q (20 mg, 0.10 mmol) was 
obtained in 50% yield as a yellow oil. 
1H NMR, 13C NMR and MS data were consistent with literature values.97 
1H NMR (300 MHz, CDCl3) δ, 7.44 (m, 4H), 7.30 (m, 6H), 3.85 (s, 2H). 
 
 
97 Martin, R.; Fustner, A. Angew. Chem. Int. Ed. 2004, 43, 3955. 
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Trimethyl(3-phenylprop-1-yn-1-yl)silane, III-2r. 
From III-1r (64 mg, 0.2 mmol) and 
phenylmagnesium bromide (0.76 M in THF, 0.22 mmol) 
following the general procedure described above, 
compound III-2r (26 mg, 0.14 mmol) was obtained in 
69% yield as a yellow oil. 
1H NMR, 13C NMR and MS data were consistent with literature values.97 
1H NMR (300 MHz, CDCl3) δ 7.17 – 7.02 (m, 5H), 3.47 (s, 2H), 0.03 – -
0.09 (m, 9H). 
 
()-1-(3-(4-Chlorophenyl)but-1-yn-1-yl)-3-methoxybenzene, III-2s. 
From III-1k (67 mg, 0.2 mmol) and 4-
chlorophenylmagnesium bromide (0.81 M in THF, 
0.22 mmol) following the general procedure 
described above, compound III-2s (52 mg, 0.19 
mmol) was obtained in 95% yield as a yellow oil after 
flash column chromatography (hex/ EtOAc, 95/5).  
 1H NMR (300 MHz, CDCl3) δ 7.30 (d, J = 8.5 Hz, 2H), 7.23 (d, J = 8.5 
Hz, 2H), 7.14 (dd, J = 15.2, 7.4 Hz, 1H), 6.99 – 6.92 (m, 1H), 6.91 – 6.86 
(m, 1H), 6.78 (ddd, J = 8.3, 2.6, 0.9 Hz, 1H), 3.88 (q, J = 7.1 Hz, 1H), 3.72 
(s, 3H), 1.48 (d, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 159.3, 
141.8, 132.4, 129.3, 128.7, 128.3, 124.5, 124.2, 116.5, 114.5, 91.8, 82.7, 
55.3, 31.9, 24.4. HRMS-EI+ m/z calculated for C17H15OCl [M]
+: 270.0811, 
found 270.0802.  
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()-1-[3-(4-Fluorophenyl)but-1-yn-1-yl]-3-methoxybenzene, III-2t. 
From III-1k (67 mg, 0.2 mmol) and 4-
fluorophenylmagnesium bromide (0.76 M in THF, 
0.22 mmol) following the general procedure described 
above, compound III-2t (49 mg, 0.19 mmol) was 
obtained in 93% yield as a yellow oil after flash 
column chromatography (n-hexane/ EtOAc 95/5). 
 1H NMR (300 MHz, CDCl3) δ 7.38 – 7.28 (m, 2H), 7.13 (dd, J = 14.6, 
6.6 Hz, 1H), 6.99 – 6.86 (m, 4H), 6.77 (ddd, J = 8.3, 2.6, 0.9 Hz, 1H), 3.88 
(q, J = 7.1 Hz, 1H), 3.71 (s, 3H), 1.48 (d, J = 7.1 Hz, 3H). 13C NMR (75 
MHz, CDCl3) δ 161.7 (d, JC-F = 244.6 Hz), 159.3, 139.0 (d, JC-F = 3.1 Hz), 
129.3, 128.4 (d, JC-F = 8.0 Hz), 124.6, 124.2, 116.5, 115.3 (d, JC-F = 21.4 
Hz), 114.5, 92.2, 82.6, 55.3, 31.8, 24.5. HRMS-EI+ m/z calculated for C17
-
H15OF [M]
+: 254.1107, found 254.1085.  
 
(−)-(R)-Methyl 4-[3-(4-methoxyphenyl)but-1-yn-1-yl]benzoate, (R)-
III-2u. 
From (R)-III-1d (79 mg, 0.2 mmol) and 4-
methoxyphenylmagnesium bromide (0.76 M in 
THF, 0.22 mmol) following the general procedure 
described above, compound (R)-III-2u (50 mg, 
0.17 mmol) was obtained in 84% yield as a yellow 
oil after flash column chromatography (n-
hexane/EtOAc 90/10). From (±)-III-1d, following the same procedure, 
compound (±)-III-2u (49 mg, 0.17 mmol) was obtained in 82% yield. 
Compound (R)-III-2u was obtained in 99:1 enantiomeric ratio determined 
by SFC using Chiralpak-ID column [CO2/MeOH (95:5)], 1.0 mL/min, 
major= 23.0 min, minor= 25.6 min. 1H NMR (300 MHz, CDCl3) δ 7.97 (d, J 
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= 8.5 Hz, 2H), 7.49 (d, J = 8.5 Hz, 2H), 7.35 (d, J = 8.7 Hz, 2H), 6.89 (d, J 
= 8.7 Hz, 2H), 3.96 (q, J = 7.1 Hz, 1H), 3.91 (s, 3H), 3.81 (s, 3H), 1.57 (d, 
J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 166.8, 158.6, 135.1, 131.7, 
129.5, 129.2, 128.7, 128.0, 114.2, 96.5, 81.8, 55.5, 52.3, 31.9, 24.5. [α]20D= 
−16.5 (c = 1.0, CHCl3). HRMS-EI+ m/z calculated for C19H18O3 [M]
+: 
294.1256, found 294.1253.  
 
(−)-(R)-1-Bromo-3-[3-(4-chlorophenyl)but-1-yn-1-yl]benzene, (R)-III-
2v. 
From (R)-III-1i (83 mg, 0.2 mmol) and 4-
chlorophenylmagnesium bromide (0.86 M in THF, 
0.22 mmol) following the general procedure described 
above, compound (R)-III-2v (48 mg, 0.16 mmol) was 
obtained in 79% yield as a yellow oil. From (±)-III-1i, 
following the same procedure, compound (±)-III-2v (52 mg, 0.17 mmol) 
was obtained in 83% yield. 
Compound (R)-III-2v was obtained in 99:1 enantiomeric ratio determined 
by SFC using Chiralpak-IA column [CO2/MeOH (99.5:0.5)], 1.0 mL/min, 
major= 28.0 min, minor= 26.4 min.  1H NMR (300 MHz, CDCl3) δ 7.59 (s, 
1H), 7.43 (d, J = 8.0 Hz, 1H), 7.39 – 7.29 (m, 5H), 7.17 (t, J = 7.9 Hz, 1H), 
3.95 (q, J = 7.1 Hz, 1H), 1.56 (d, J = 7.1 Hz, 3H). 13C NMR (75 MHz, 
CDCl3) δ 141.6, 134.5, 132.7, 131.2, 130.3, 129.8, 128.9, 128.4, 125.6, 
122.2, 93.6, 81.4, 32.0, 24.4. [α]20D= −25.1 (c = 1.0, CHCl3). HRMS-EI+ 
m/z calculated for C16H12BrCl [M]
+: 317.9811, found 317.9799.  
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(+)-(R)-Trimethyl(3-phenylhept-1-yn-1-yl)silane, (R)-III-2w. 
From (R)-III-1w (75 mg, 0.2 mmol) and 4-
methoxyphenylmagnesium bromide (0.76 M in 
THF, 0.22 mmol) following the general procedure 
described above, compound (R)-III-2w (45 mg, 0.18 
mmol) was obtained in 92% yield as a yellow oil 
after flash column chromatography. From (±)-III-1w, following the same 
procedure, compound (±)-III-2w (41 mg, 0.17 mmol) was obtained in 84% 
yield. 
Compound (R)-III-2w was obtained in 93:7 enantiomeric ratio determined 
by GC on a Chirasil Dex-CB column (100→130 °C @ 10 °C/min, hold 10 
min, then →170 °C @ 9 °C/min, hold 5 min; flow rate 1.0 mL/min.). major= 
17.0 min, minor= 16.9 min. 
1H NMR, 13C NMR and MS data were consistent 
with literature values.51 1H NMR (300 MHz, CDCl3) δ 7.43 – 7.21 (m, 
11H), 3.66 (t, J = 7.2 Hz, 2H), 1.85 – 1.68 (m, 4H), 1.56 – 1.24 (m, 8H), 
0.91 (t, J = 6.9 Hz, 6H), 0.21 (s, 17H). [α]20D= +13.8 (c = 1.0, CHCl3).  
 
(+)-(R)-(3-(4-Methoxyphenyl)hept-1-yn-1-yl)trimethylsilane, (R)-III-
2x. 
From (R)-III-1w (75 mg, 0.2 mmol) and 4-
methoxyphenylmagnesium bromide (0.76 M in THF, 
0.22 mmol) following the general procedure 
described above, compound (R)-III-2x (45 mg, 0.16 
mmol) was obtained in 82% yield as a yellow oil after 
flash column chromatography (hex/EtOAc, 98/2). From (±)-III-1w, 
following the same procedure, compound (±)-III-2x (49 mg, 0.18 mmol) 
was obtained in 89% yield. 
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1H NMR, 13C NMR and MS data were consistent with literature values. 
52 1H NMR (300 MHz, CDCl3) δ 7.26 (d, J = 8.6 Hz, 2H), 6.86 (d, J = 8.7 
Hz, 2H), 3.81 (d, J = 4.9 Hz, 3H), 3.59 (t, J = 7.2 Hz, 1H), 1.78 – 1.63 (m, 
2H), 1.46 – 1.23 (m, 4H), 0.89 (t, J = 7.1 Hz, 3H), 0.18 (s, 9H). [α]20D= +7.9 
(c = 1.0, CHCl3).  
Compound (R)-III-2x was transformed into (S)-III-7x through 
desilylation to determine the enantiomeric ratio (See compound (S)-III-7x, 
page SI-33). 
 
(+)-(R)-[3-(3-Methoxyphenyl)hept-1-yn-1-yl]trimethylsilane, (R)-III-
2y. 
From (R)-III-1w (75 mg, 0.2 mmol) and 3-
methoxyphenylmagnesium bromide (0.78 M in 
THF, 0.22 mmol) following the general procedure 
described above, compound (R)-III-2y (48 mg, 
0.17 mmol) was obtained in 87% yield as a yellow oil after flash column 
chromatography (hex/EtOAc, 98/2). From (±)-III-1w, following the same 
procedure, compound (±)-III-2y (45 mg, 0.16 mmol) was obtained in 82% 
yield. 
1H NMR, 13C NMR and MS data were consistent with literature values.52  
1H NMR (300 MHz, CDCl3) δ 7.23 – 7.18 (m, 1H), 6.92 (m, 2H), 6.77 (m, 
1H), 3.81 (s, 3H), 3.61 (t, J = 7.2 Hz, 1H), 1.72 (m, 2H), 1.49 – 1.24 (m, 
4H), 0.89 (t, J = 7.0 Hz, 3H), 0.18 (s, 9H). [α]20D= +8.2 (c = 1.0, CHCl3).  
Compound (R)-III-2y was transformed into (S)-III-7y through 
desilylation to determine the enantiomeric ratio (See compound (S)-III-7y). 
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3.6.3. Preparation of (4-Phenylbutyl)magnesium bromide solution 
An oven-dried flask was charged with magnesium (72 mg, 3 mmol, 1 
equiv) and a couple of crystals of iodine under Ar atmosphere. Dry THF (6 
mL) was added and the mixture was stirred for 2 min. (4-
bromobutyl)benzene was added dropwise to the mixture observing a gentle 
reflux. The mixture was stirred for 2h and then, it was allowed to rest for 
24h. The supernatant was filtered, and the solution was tritrated to 
determine its concentration (0,43M). 
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3.6.4. Copper-catalyzed reaction of propargylic ammonium triflates 
with alkyl Grignard reagents. 
3.6.4.1. General procedure for the reactions of (±)-propargylic ammonium 
salts (III-1) with alkylmagnesium halides. 
 
An oven-dried vial was charged with [Cu(CH3CN)4]PF6 (3.8 mg, 0.01 
mmol) and the correspondent ammonium salt III-1 (0.2 mmol) and sealed 
with a septum. The vial was connected to an argon-vacuum line, evacuated 
and backfilled with argon (x3). DCM (2 mL) was added and the mixture 
was stirred for 5 min at room temperature. The reaction mixture was cooled 
to -40 ºC and the alkyl magnesium bromide solution in THF (0.22 mmol) 
was added dropwise and the mixture was stirred at -40 ºC for 5 minutes. 
After total conversion observed by TLC (5 minutes), water (0.1 mL) was 
added and the solution was filtered through a short pad of MgSO4 and rinsed 
with DCM. Solvent was removed under reduced pressure and the crude 
product was purified by flash column chromatography.  
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3.6.4.2. General procedure for the reactions of enantiopure propargylic 
ammonium salts with alkylmagnesium halides. 
 
An oven-dried vial was charged with [Cu(CH3CN)4]PF6 (3.8 mg, 0.01 
mmol), Sphos (4.9 mg, 0.012 mmol) and the correspondent ammonium salt 
(0.2 mmol) and sealed with a septum. The vial was connected to an argon-
vacuum line, evacuated and backfilled with argon (x3). DCM (2 mL) was 
added and the mixture was stirred for 5 min at room temperature. The 
reaction mixture was cooled to -40 ºC and the alkyl magnesium bromide 
solution in THF (0.22 mmol) was added dropwise and the mixture was 
stirred at -40 ºC for 5 minutes. After total conversion observed by TLC (5 
minutes), water (0.1 mL) was added and the solution was filtered through a 
short pad of MgSO4 and rinsed with DCM. Solvent was removed under 
reduced pressure and the crude product was purified by flash column 
chromatography. 
 
(−)-(R)-2-(3-phenylhexa-3,4-dien-1-yl)-1,3-dioxane, (R)-III-3a. 
From (R)-III-1a (67 mg, 0.2 mmol) and (1,3-
Dioxan-2-ylethyl)magnesium bromide solution in THF 
(0.22 mmol) following the general procedure described 
above, compound (R)-III-3a (44 mg, 0.18 mmol) was 
obtained in 90% yield as a pale yellow oil, after 
purification by flash column chromatography 
(cyclohexane/EtOAc 95:5). From III-1a, following the same procedure 
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without Sphos, compound III-3a (42 mg, 0.17 mmol) was obtained in 86% 
yield. 
1H NMR, 13C NMR and MS data for III-3a were consistent with 
literature values.98 1H NMR (300 MHz, CDCl3) δ 7.43 – 7.14 (m, 5H), 5.50 
(qt, J = 6.9, 3.3 Hz, 1H), 4.63 (t, J = 5.2 Hz, 1H), 4.17 –  4.07 (m, 2H), 3.83 
– 3.71 (m, 2H), 2.59 – 2.40 (m, 2H), 2.19 – 2.01 (m, 1H), 1.90 – 1.81 (m, 
2H), 1.76 (d, J = 7.0 Hz, 3H), 1.40 – 1.31 (m, 1H). 
Compound (R)-III-3a was obtained in 98:2 enantiomeric ratio 
determined by SFC using Chiralpak-ID column [CO2/MeOH (98:2)], 1.0 
mL/min, major= 12.9 min, minor= 14.4 min.  [α]25D= −64.1 (c = 1.0, CHCl3). 
The reaction was also carried out in gram scale, from (R)-III-1a (1.0 
g, 2.96 mmol) and (1,3-dioxan-2-ylethyl)magnesium bromide solution in 
THF (3.3 mmol) affording compound (R)-III-3a (614 mg, 2.47 mmol) in 
85% yield as a yellow oil and enantiomeric ratio of 98:2. 
 
(±)-2-(3-(4-(Trifluoromethyl)phenyl)hexa-3,4-dien-1-yl)-1,3-dioxane, 
III-3c. 
 From III-1c (81 mg, 0.2 mmol) and (1,3-dioxan-2-
ylethyl)magnesium bromide solution in THF (0.22 
mmol) following the general procedure described above, 
compound III-3c (58 mg, 0.19 mmol) was obtained in 
93% yield as a pale yellow oil, after purification by flash 
column chromatography (hexane/AcOEt 95:5). 1H NMR, 
13C NMR and MS data were consistent with literature values.98  
 
98 Soler-Yanes, R.; Arribas-Álvarez, I.; Guisán-Ceinos, M.; Buñuel, E.; Cárdenas, D. J. 
Chem. Eur. J. 2017, 23, 1584. 
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1H NMR (300 MHz, CDCl3) δ 7.54 (d, J = 8.6 Hz, 2H), 7.48 (d, J = 8.5 Hz, 
2H), 5.56 (qt, J = 7.1, 3.3 Hz, 1H), 4.63 (t, J = 5.1 Hz, 1H), 4.19 – 4.07 (m, 
2H), 3.83 – 3.73 (m, 2H), 2.58 – 2.44 (m, 2H), 2.19 – 2.04 (m, 1H), 1.90 – 
1.80 (m, 2H), 1.77 (d, J = 7.1 Hz, 3H), 1.41 – 1.31 (m, 1H). 
 
(±)-Methyl 4-(1-(1,3-dioxan-2-yl)hexa-3,4-dien-3-yl)benzoate, III-3d. 
 From III-1d (79 mg, 0.2 mmol) and (1,3-
dioxan-2-ylethyl)magnesium bromide solution in 
THF (0.22 mmol) following the general procedure 
described above, compound III-3d (54 mg, 0.17 
mmol) was obtained in 89% yield as a pale yellow oil, 
after purification by flash column chromatography 
(pentane/Et2O 90:10). 
1H NMR, 13C NMR and MS data were consistent 
with literature values.98  
1H NMR (300 MHz, CDCl3) δ 7.98 – 7.92 (m, 2H), 7.49 – 7.41 (m, 2H), 
5.56 (qt, J = 7.0, 3.3 Hz, 1H), 4.63 (t, J = 5.1 Hz, 1H), 4.19 – 4.06 (m, 2H), 
3.90 (s, 3H), 3.84 – 3.72 (m, 2H), 2.58 – 2.44 (m, 2H), 2.18 – 2.06 (m, 1H), 
1.92 – 1.81 (m, 2H), 1.77 (d, J = 7.0 Hz, 3H), 1.40 – 1.30 (m, 1H). 
 
(±)-Methyl 2-(1-(1,3-dioxan-2-yl)hexa-3,4-dien-3-yl)benzoate, III-3e. 
 From III-1e (79 mg, 0.2 mmol) and (1,3-
dioxan-2-ylethyl)magnesium bromide solution in 
THF (0.22 mmol) following the general procedure 
described above, compound III-3e (30 mg, 0.10 
mmol) was obtained in 50% yield as a pale yellow 
oil, after purification by flash column 
chromatography (pentane/Et2O 90:10).  
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1H NMR (300 MHz, CDCl3) δ 7.67 (dd, J = 7.7, 1.5 Hz, 1H), 7.45 – 7.37 
(m, 1H), 7.33 – 7.26 (m, 2H), 5.25 (qt, J = 6.8, 3.2 Hz, 1H), 4.61 (t, J = 5.2 
Hz, 1H), 4.14 – 4.05 (m, 2H), 3.86 (s, 3H), 3.81 – 3.69 (m, 2H), 2.46 – 2.35 
(m, 2H), 2.14 – 2.00 (m, 1H), 1.85 – 1.77 (m, 2H), 1.66 (d, J = 7.0 Hz, 3H), 
1.37 – 1.28 (m, 1H). 13C NMR (75 MHz, CDCl3) δ 203.2, 168.8, 139.5, 
131.1, 130.8, 129.7, 129.28, 126.6, 104.5, 101.8, 87.8, 66.9, 52.0, 33.6, 
27.7, 25.9, 14.3. HRMS (EI) calculated for C18H22O4 [M]
+: 302.1518; 
Found: 302.1509. 
 
(±)-1-(4-(1-(1,3-Dioxan-2-yl)hexa-3,4-dien-3-yl)phenyl)ethenone, III-
3f. 
 From III-1f (76 mg, 0.2 mmol) and (1,3-dioxan-2-
ylethyl)magnesium bromide solution in THF (0.22 
mmol) following the general procedure described 
above (catalytic charge was changed to 0.02 mmol), 
compound III-3f (23 mg, 0.08 mmol) was obtained in 
40% yield as a pale yellow oil, after purification by 
flash column chromatography (pentane/Et2O 80:20).
 1H 
NMR, 13C NMR and MS data were consistent with literature values.¡Error! 
Marcador no definido. 
1H NMR (300 MHz, CDCl3) δ 7.92 – 7.85 (m, 2H), 7.51 – 7.45 (m, 2H), 
5.57 (qt, J = 6.9, 3.2 Hz, 1H), 4.63 (t, J = 5.1 Hz, 1H), 4.17 – 4.06 (m, 2H), 
3.85 – 3.71 (m, 2H), 2.58 (s, 3H), 2.56 – 2.46 (m, 2H), 2.19 – 2.01 (m, 1H), 
1.90 – 1.80 (m, 2H), 1.77 (d, J = 7.1 Hz, 3H), 1.40 – 1.31 (m, 1H). 
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(−)-(R)-2-(3-(4-fluorophenyl)hexa-3,4-dien-1-yl)-1,3-dioxane, (R)-III-
3g. 
From (R)-III-1g (71 mg, 0.2 mmol) and (1,3-
dioxan-2-ylethyl)magnesium bromide solution in THF 
(0.22 mmol) following the general procedure described 
above, compound (R)-III-3g (50 mg, 0.19 mmol) was 
obtained in 95% yield as a pale yellow oil, after 
purification by flash column chromatography 
(pentane/Et2O 97:3). From III-1g, following the same procedure without 
SPhos, compound III-3g (44 mg, 0.17 mmol) was obtained in 84% yield. 
 Compound (R)-III-3g was obtained in 97:3 enantiomeric ratio 
determined by SFC using Chiralpak-ID column [CO2/MeOH (99:1)], 1.0 
mL/min, major= 18.7 min, minor= 20.8 min.   1H NMR (300 MHz, CDCl3) δ 
7.40 – 7.30 (m, 2H), 7.03 – 6.92 (m, 2H), 5.49 (qt, J = 6.9, 3.2 Hz, 1H), 
4.62 (t, J = 5.1 Hz, 1H), 4.20 – 4.04 (m, 2H), 3.86 – 3.69 (m, 2H), 2.56 – 
2.35 (m, 2H), 2.19 – 2.00 (m, 1H), 1.88 – 1.80 (m, 2H), 1.75 (d, J = 7.0 Hz, 
3H), 1.40 – 1.30 (m, 1H). 13C NMR (75 MHz, CDCl3) δ 204.3 (d, JC-F = 2.0 
Hz), 161.8 (d, JC-F = 245.4 Hz), 133.4 (d, JC-F = 3.2 Hz), 127.6 (d, JC-F = 7.9 
Hz), 115.2 (d, JC-F = 21.4 Hz), 140.0, 101.9, 90.1, 67.1, 33.7, 26.0, 24.4, 
14.5. HRMS-(EI) calculated for C16H18FO2 [M-H]
+: 261.1291; Found: 
261.0887. [α]25D= −68.1 (c = 1.0, CHCl3). 
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(±)-2-(3-(4-chlorophenyl)hexa-3,4-dien-1-yl)-1,3-dioxane, III-3h. 
 From III-1h (74 mg, 0.2 mmol) and (1,3-dioxan-2-
ylethyl)magnesium bromide solution in THF (0.22 
mmol) following the general procedure described above, 
compound III-3h (50 mg, 0.18 mmol) was obtained in 
90% yield as a pale yellow oil, after purification by flash 
column chromatography (cyclohexane/Et2O 95:5). 
1H 
NMR, 13C NMR and MS data were consistent with literature values.98  
1H NMR (300 MHz, CDCl3) δ 7.35 – 7.28 (m, 2H), 7.28 – 7.22 (m, 2H), 
5.50 (qt, J = 6.9, 3.6 Hz, 1H), 4.61 (t, J = 5.1 Hz, 1H), 4.17 – 4.07 (m, 2H), 
3.83 – 3.71 (m, 2H), 2.54 – 2.39 (m, 2H), 2.20 – 2.03 (m, 1H), 1.89 – 1.79 
(m, 2H), 1.75 (d, J = 7.0 Hz, 3H), 1.40 – 1.31 (m, 1H). 
 
(±)-2-(3-(3-Bromophenyl)hexa-3,4-dien-1-yl)-1,3-dioxane, III-3i. 
From III-1i (83 mg, 0.2 mmol) and (1,3-
dioxan-2-ylethyl)magnesium bromide solution in THF 
(0.22 mmol) following the general procedure 
described above, compound III-3i (58 mg, 0.18 mmol) 
was obtained in 90% yield as a pale yellow oil, after 
purification by flash column chromatography 
(pentane/Et2O 95:5).  
1H NMR (300 MHz, CDCl3) δ 7.52 (t, J = 1.9 Hz, 1H), 7.30 (ddt, J = 8.0, 
5.1, 1.3 Hz, 2H), 7.15 (t, J = 7.9 Hz, 1H), 5.53 (qt, J = 7.0, 3.3 Hz, 1H), 
4.61 (t, J = 5.2 Hz, 1H), 4.19 – 4.07 (m, 2H), 3.84 – 3.71 (m, 2H), 2.55 – 
2.36 (m, 2H), 2.19 – 2.02 (m, 1H), 1.88 – 1.79 (m, 2H), 1.76 (d, J = 7.0 Hz, 
3H), 1.40 – 1.30 (m, 1H). 13C NMR (75 MHz, CDCl3) δ 204.7, 140.0, 
129.8, 129.4, 129.1, 124.6, 122.7, 104.0, 102.0, 90.5, 67.1, 33.7, 26.0, 24.0, 
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14.4. HRMS (EI) calculated for C16H19BrO2 [M]
+: 322.0568; Found: 
322.0552. 
(±)-2-(3-(4-Methoxyphenyl)hexa-3,4-dien-1-yl)-1,3-dioxane, III-3j. 
From III-1j (74 mg, 0.2 mmol) and (1,3-
dioxan-2-ylethyl)magnesium bromide solution in THF 
(0.22 mmol), following the general procedure 
described above, compound III-3j (33 mg, 0.12 mmol) 
was obtained in 60% yield as a pale yellow oil, after 
purification by flash column chromatography 
(pentane/Et2O 97:3).  
1H NMR (300 MHz, CDCl3) δ 7.35 – 7.29 (m, 2H), 6.88 – 6.82 (m, 2H), 
5.53 – 5.41 (m, 1H), 4.62 (t, J = 5.2 Hz, 1H), 4.19 – 4.06 (m, 2H), 3.81 – 
3.71 (m, 2H), 3.80 (s, 3H), 2.51 – 2.42 (m, 2H), 2.16 – 2.03 (m, 1H), 1.89 
– 1.80 (m, 2H), 1.74 (d, J = 7.0 Hz, 3H), 1.38 – 1.31 (m, 1H). 13C NMR 
(75 MHz, CDCl3) δ 204.0, 158.5, 129.8, 127.2, 113.9, 104.3, 102.1, 89.7, 
67.1, 55.4, 33.8, 26.0, 24.4, 14.7. HRMS-(EI) calculated for C17H21O3 
[M]+: 274.1491; Found 274.1495. 
 
(–)-(R)-2-(3-(3-methoxyphenyl)hexa-3,4-dien-1-yl)-1,3-dioxane, (R)-
III-3k. 
From (R)-III-1k (74 mg, 0.2 mmol) and (1,3-
dioxan-2-ylethyl)magnesium bromide solution in 
THF (0.22 mmol) following the general procedure 
described above, compound (R)-III-3k (51 mg, 0.19 
mmol) was obtained in 93% yield as a pale yellow 
oil, after purification by flash column 
chromatography (pentane/Et2O 97:3). From III-1k, following the same 
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procedure without SPhos, compound III-3k (51 mg, 0.19 mmol) was 
obtained in 93% yield. 
 1H NMR, 13C NMR and MS data for III-3k were consistent with 
literature values.98 1H NMR (300 MHz, CDCl3) δ 7.25 – 7.19 (m, 1H), 7.07 
– 6.90 (m, 2H), 6.77 – 6.71 (m, 1H), 5.49 (qt, J = 6.9, 3.3 Hz, 1H), 4.62 (t, 
J = 5.2 Hz, 1H), 4.17 – 4.08 (m, 2H), 3.82 – 3.72 (m, 2H), 3.80 (s, 3H), 
2.55 – 2.41 (m, 2H), 2.19 – 2.02 (m, 1H), 1.90 – 1.80 (m, 2H), 1.75 (d, J = 
7.0 Hz, 3H), 1.39 – 1.30 (m, 1H). 
Compound (R)-III-3k was obtained in 98:2 enantiomeric ratio 
determined by SFC using Chiralpak-IA column [CO2/MeOH (99:1)], 1.0 
mL/min, major= 25.5 min, minor= 27.3 min.   [α]25D= –66.7 (c = 1.0, CHCl3). 
 
(±)-2-(3-(Thiophen-2-yl)hexa-3,4-dien-1-yl)-1,3-dioxane, III-3l. 
  From III-1l (69 mg, 0.2 mmol) and (1,3-dioxan-
2-ylethyl)magnesium bromide solution in THF (0.22 
mmol) following the general procedure described above, 
compound III-3l  (40 mg, 0.16 mmol) was obtained in 
80% yield as a pale yellow oil, after purification by flash 
column chromatography (cyclohexane/EtOAc 95:5).  
1H NMR (300 MHz, CDCl3) δ 7.13 (dd, J = 5.0, 1.4 Hz, 1H), 7.00 – 6.90 
(m, 2H), 5.51 (qt, J = 6.9, 3.2 Hz, 1H), 4.62 (t, J = 5.2 Hz, 1H), 4.18 – 4.09 
(m, 2H), 3.83 – 3.73 (m, 2H), 2.54 – 2.44 (m, 2H), 2.16 – 2.03 (m, 1H), 
1.91 – 1.82 (m, 2H), 1.72 (d, J = 3.3 Hz, 3H), 1.40 – 1.31 (m, 1H). 13C 
NMR (75 MHz, CDCl3) δ 203.4, 143.0, 127.4, 124.1, 122.7, 101.9, 100.8, 
90.6, 67.1, 33.6, 26.0, 25.5, 14.6. HRMS (EI) calculated for C14H17O2S [M-
H]+: 249.0949; Found: 249.0553. 
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(±)-4-(1-(1,3-Dioxan-2-yl)hexa-3,4-dien-3-yl)benzonitrile, III-3m. 
 From III-1m (72 mg, 0.2 mmol) and (1,3-dioxan-
2-ylethyl)magnesium bromide solution in THF (0.22 
mmol) following the general procedure described above, 
compound III-3m (45 mg, 0.17 mmol) was obtained in 
84% yield as a pale yellow oil, after purification by flash 
column chromatography (pentane/Et2O 90:10).
 1H NMR, 
13C NMR and MS data were consistent with literature values.98  
1H NMR (300 MHz, CDCl3) δ 7.61 – 7.52 (m, 2H), 7.50 – 7.41 (m, 2H), 
5.58 (qt, J = 7.1, 3.3 Hz, 1H), 4.62 (t, J = 5.1 Hz, 1H), 4.19 – 4.06 (m, 2H), 
3.84 – 3.69 (m, 2H), 2.54 – 2.41 (m, 2H), 2.19 – 2.02 (m, 1H), 1.88 – 1.79 
(m, 2H), 1.77 (d, J = 7.0 Hz, 3H) 1.41 – 1.31 (m, 1H). 
 
(±)-2-(3-Phenethylhexa-3,4-dien-1-yl)-1,3-dioxane, III-3n. 
  From III-1n (73 mg, 0.2 mmol) and (1,3-dioxan-
2-ylethyl)magnesium bromide solution in THF (0.22 
mmol) following the general procedure described above 
(temperature was changed to rt), compound III-3n (33 mg, 
0.12 mmol) was obtained in 61% yield as a pale yellow oil, 
after purification by flash column chromatography 
(cyclohexane/EtOAc 95:5).  
1H NMR (300 MHz, CDCl3) δ 7.29 – 7.24 (m, 2H), 7.22 – 7.13 (m, 3H), 
5.08 (qt, J = 7.8, 3.4, 1H), 4.54 (t, J = 5.2 Hz, 1H), 4.16 – 4.05 (m, 2H), 
3.82 – 3.68 (m, 2H), 2.77 – 2.66 (m, 2H), 2.29 – 2.18 (m, 2H), 2.15 – 1.99 
(m, 3H), 1.79 – 1.68 (m, 2H), 1.55 (d, J = 7.1 Hz, 3H), 1.39 – 1.29 (m, 1H). 
13C NMR (75 MHz, CDCl3) δ 201.7, 142.5, 128.5, 128.31, 125.8, 102.8, 
102.1, 87.9, 67.1, 34.7, 34.2, 33.4, 27.0, 26.0, 15.0. HRMS (ESI) calculated 
for C18H24NaO2 [M+Na]
+: 295.1674; Found: 295.1665. 
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(–)-(R)-2-(3-Phenylundeca-3,4-dien-1-yl)-1,3-dioxane III-3o. 
From (R)-III-1o (82 mg, 0.2 mmol) and (1,3-
dioxan-2-ylethyl)magnesium bromide solution in THF 
(0.22 mmol) following the general procedure described 
above, compound (R)-III-3o (48 mg, 0.15 mmol) was 
obtained in 76% yield as a pale yellow oil, after 
purification by flash column chromatography 
(pentane/Et2O 95:5). From III-1o, following the same procedure without 
SPhos, compound III-3o (51 mg, 0.16 mmol) was obtained in 81% yield.  
Compound (R)-III-3o was obtained in 98:2 enantiomeric ratio 
determined by SFC using Chiralpak-IB column [CO2/MeOH (99:1)], 1.0 
mL/min, major= 28.3 min, minor= 27.7 min. 1H NMR (300 MHz, CDCl3) δ 
7.45 – 7.38 (m, 2H), 7.33 – 7.27 (m, 2H), 7.21 – 7.13 (m, 1H), 5.53 (tt, J = 
6.6, 3.3 Hz, 1H), 4.63 (t, J = 5.2 Hz, 1H), 4.20 – 4.05 (m, 2H), 3.83 – 3.68 
(m, 2H), 2.57 – 2.45 (m, 2H), 2.16 – 2.06 (m, 3H), 1.92 – 1.81 (m, 2H), 
1.56 – 1.21 (m, 10H), 0.96 – 0.82 (m, 3H). 13C NMR (76 MHz, CDCl3) δ 
203.6, 137.6, 128.4, 126.5, 126.0, 105.2, 102.1, 95.5, 67.1, 33.8, 31.8, 29.4, 
29.3, 29.1, 26.0, 24.2, 22.8, 14.2. HRMS (EI) calculated for C21H30O2 [M]
+: 
314.2246; Found: 314.2223. [α]25D= –78.2 (c = 1.0, CHCl3). 
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(±)-2-(7-(Methylthio)-3-phenethylhepta-3,4-dien-1-yl)-1,3-dioxane, 
III-3p. 
  From III-1p (85 mg, 0.2 mmol) and (1,3-
dioxan-2-ylethyl)magnesium bromide solution in THF 
(0.22 mmol) following the general procedure described 
above (temperature was changed to rt), compound III-
3p (48 mg, 0.14 mmol) was obtained in 72% yield as a 
pale yellow oil, after purification by flash column 
chromatography (cyclohexane/EtOAc 90:10).  
1H NMR (300 MHz, CDCl3) δ 7.31 – 7.22 (m, 2H), 7.22 – 7.13 (m, 3H), 
5.18 (qt, J = 6.2, 3.1 Hz, 1H), 4.54 (t, J = 5.1 Hz, 1H), 4.15 – 4.05 (m, 2H), 
3.83 – 3.67 (m, 2H), 2.74 (t, J = 7.9 Hz, 2H), 2.51 – 2.41 (m, 2H), 2.32 – 
2.01 (m, 10H), 1.79 – 1.68 (m, 2H), 1.38 – 1.29 (m, 1H). 13C NMR (75 
MHz, CDCl3) δ 201.0, 142.2, 128.5, 128.3, 125.8, 104.4, 102.0, 91.8, 67.0, 
34.6, 34.1, 33.8, 33.4, 29.3, 26.9, 26.0, 15.69. HRMS (EI) calculated for 
C20H28O2S [M]
+: 332.1810; Found: 332.1797. 
 
(±)-1-Bromo-3-(octa-2,3-dien-4-yl)benzene, III-3q. 
  From III-1i (83 mg, 0.2 mmol) and n-
butylmagnesium chloride solution in THF (0.22 mmol) 
following the general procedure described above, 
compound III-3q (30 mg, 0.11 mmol) was obtained in 
57% yield as a pale yellow oil, after purification by 
flash column chromatography (hexane/Et2O 98:2).  
1H NMR (300 MHz, CDCl3) δ 7.51 (t, J = 1.8 Hz, 1H), 7.34 – 7.27  (m, 
2H), 7.16 (dd, J = 8.3, 7.4 Hz, 1H), 5.49 (qt, J = 6.9, 3.1 Hz, 1H), 2.41 – 
2.31 (m, 2H), 1.76 (d, J = 0.7 Hz, 3H), 1.58 – 1.34 (m, 4H), 0.93 (t, J = 7.1 
Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 205.0, 140.3, 129.8, 129.3, 129.2, 
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124.6, 122.7, 104.3, 89.5, 30.1, 29.6, 22.5, 14.4, 14.1. HRMS (EI) 
calculated for C14H17Br [M]
+: 264.0514; Found: 264.0478. 
 
(±)-1-(Octa-2,3-dien-4-yl)-4-(trifluoromethyl)benzene, III-3r. 
  From III-1c (81 mg, 0.2 mmol) and n-
butylmagnesium bromide chloride solution in THF (0.22 
mmol) following the general procedure described above, 
compound III-3r (42 mg, 0.17 mmol) was obtained in 
83% yield as a pale yellow oil, after purification by flash 
column chromatography (pentane /Et2O 98:2).  
1H NMR (300 MHz, CDCl3) δ 7.54 (d, J = 8.4 Hz, 2H), 7.48 (d, J = 8.4 
Hz, 2H), 5.52 (qt, J = 6.8, 3.1 Hz, 1H), 2.45 – 2.35 (m, 2H), 1.78 (d, J = 7.0 
Hz, 3H), 1.58 – 1.35 (m, 5H), 0.94 (t, J = 7.2 Hz, 3H). 13C NMR (75 MHz, 
CDCl3) δ 205.6, 141.7, 128.4 (q, JC-F = 32.4 Hz), 126.3, 125.3 (q, JC-F = 3.9 
Hz), 124.5 (q, JC-F = 270.3 Hz), 104.5, 89.6, 30.2, 29.6, 22.5, 14.3, 14.1. 
HRMS (EI) calculated for C15H17F3 [M]
+: 254.1282; Found: 254.1279. 
 
(±)-1-Bromo-3-(1-phenylhexa-3,4-dien-3-yl)benzene, III-3s. 
  From III-3i (83 mg, 0.2 mmol) and 
phenethylmagnesium bromide solution in THF (0.22 
mmol) following the general procedure described 
above, compound III-3s (55 mg, 0.18 mmol) was 
obtained in 88% yield as a pale yellow oil, after 
purification by flash column chromatography 
(hexane/Et2O 98:2).  
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1H NMR (300 MHz, CDCl3) δ 7.52 (t, J = 1.9 Hz, 1H), 7.34 – 7.27 (m, 4H), 
7.24 – 7.14 (m, 4H), 5.51 (qt, J = 6.9, 3.1 Hz, 1H), 2.88 – 2.79 (m, 2H), 
2.74 – 2.59 (m, 2H), 1.69 (d, J = 7.0 Hz, 3H). 13C NMR (76 MHz, CDCl3) 
δ 205.1, 142.0, 139.9, 129.9, 129.5, 129.1, 128.6, 128.5, 126.0, 124.6, 
122.8, 103.8, 90.3, 34.2, 31.7, 14.3. HRMS (EI) calculated for C18H17Br 
[M]+: 312.0514; Found: 312.0485. 
 
(–)-(R)-1-Methoxy-3-(2-methylhexa-3,4-dien-3-yl)benzene, (R)-III-3t. 
From (R)-III-1k (75 mg, 0.2 mmol) and 
phenethylmagnesium bromide solution in THF (0.22 
mmol) following the general procedure described 
above, compound (R)-III-3t (50 mg, 0.19 mmol) was 
obtained in 95% yield as a pale yellow oil, after 
purification by flash column chromatography 
(pentane/Et2O 95:5). From III-1k, following the same procedure without 
SPhos, compound III-3t (52 mg, 0.20 mmol) was obtained in 97% yield.   
Compound (R)-III-3t was obtained in 96:4 enantiomeric ratio determined 
by SFC using Chiralpak-IB column [CO2/MeOH (99:1)], 1 mL/min, major= 
25.4 min, minor= 30.8 min. 1H NMR (300 MHz, CDCl3) δ 7.26 – 7.08 (m, 
7H), 6.96 – 6.87 (m, 2H), 6.68 (ddd, J = 8.2, 2.5, 1.1 Hz, 1H), 5.39 (qt, J = 
6.9, 3.0 Hz, 1H), 3.73 (d, J = 1.1 Hz, 3H), 2.77 (dd, J = 8.2, 5.8 Hz, 2H), 
2.69 – 2.57 (m, 2H), 1.61 (dd, J = 7.1, 1.1 Hz, 3H). 13C NMR (75 MHz, 
CDCl3) δ 205.0, 159.9, 142.3, 139.1, 129.4, 128.7, 128.4, 125.9, 118.7, 
112.1, 111.9, 104.7, 89.7, 55.4, 34.4, 31.9, 14.4. HRMS (EI) calculated for 
C19H20O [M]
+: 264.1514; Found: 264.1481. [α]25D= –52.0 (c = 1.0, CHCl3). 
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(–)-(R)-Octa-5,6-diene-1,5-diyldibenzene, (R)-III-3u. 
 From (R)-III-1a (75 mg, 0.2 mmol) and (4-
phenylbutyl)magnesium bromide solution in THF (0.22 
mmol) following the general procedure described above, 
compound (R)-III-3u (47 mg, 0.18 mmol) was obtained in 
90% yield as a pale-yellow oil, after purification by flash 
column chromatography (hexanes). From III-1a, 
following the same procedure, compound III-3u (46 mg, 0.18 mmol) was 
obtained in 88% yield. 
Compound (R)-III-3u was obtained in 98:2 enantiomeric ratio 
determined by SFC using Chiralpak-ID column [CO2/MeOH (99:1)], 1 
mL/min, major= 11.3 min, minor= 12.9 min. 
 1H NMR, 13C NMR and MS 
data were consistent with literature values.99 1H NMR (300 MHz, 
Chloroform-d) δ 7.44 – 7.38 (m, 2H), 7.36 – 7.25 (m, 4H), 7.22 – 7.18 (m, 
4H), 5.48 (qt, J = 6.8, 3.0 Hz, 1H), 2.73 – 2.63 (m, 2H), 2.54 – 2.41 (m, 
2H), 1.78 (d, J = 4.8 Hz, 3H), 1.75 – 1.58 (m, 4H). [α]25D= –54.0 (c = 1.0, 
CHCl3). 
 
(±)-1-Methoxy-4-(2-methylhexa-3,4-dien-3-yl)benzene, III-3v. 
  From III-1j (75 mg, 0.2 mmol) and 
isopropylmagnesium bromide solution in THF (0.22 
mmol) following the general procedure described 
above, compound III-3v (40 mg, 0.20 mmol) was 
obtained in 98% yield as a pale-yellow oil, after 
purification by flash column chromatography (cyclohexane/EtOAc 95:5).  
 
99 Uehling, M.R.; Marionni, S.T.; Lalic, G. Org. Lett., 2012, 14, 362. 
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1H NMR (300 MHz, CDCl3) δ 7.38 – 7.28 (m, 2H), 6.91 – 6.83 (m, 2H), 
5.47 (qd, J = 6.9, 2.4 Hz, 1H), 3.81 (s, 3H), 2.87 – 2.66 (m, 1H), 1.76 (dd, 
J = 6.9, 0.7 Hz, 3H), 1.13 (d, J = 5.8 Hz, 3H), 1.10 (d, J = 5.6 Hz, 3H). 13C 
NMR (75 MHz, CDCl3) δ 203.4, 158.4, 129.9, 127.7, 113.9, 112.1, 89.8, 
55.4, 28.2, 22.7, 22.3, 14.8. HRMS (EI) calculated for C14H18O [M]
+: 
202.1358; Found: 202.1354. 
 
(–)-(R)-1-Methoxy-3-(1-phenylhexa-3,4-dien-3-yl)benzene, (R)-III-
3w. 
From (R)-III-1k (75 mg, 0.2 mmol) and 
isopropylmagnesium bromide solution in THF (0.22 
mmol) following the general procedure described 
above, compound (R)-III-3w (33 mg, 0.16 mmol) 
was obtained in 82% yield as a pale yellow oil, after purification by flash 
column chromatography (pentane/Et2O 95:5). From III-1k, following the 
same procedure, compound III-3w (29 mg, 0.14 mmol) was obtained in 
71% yield. 
Compound (R)-III-3w was obtained in 97:3 enantiomeric ratio determined 
by SFC using Chiralpak-IB column [CO2/MeOH (99.5:0.5)], 0.5 mL/min, 
major= 26.3 min, minor= 24.5 min. 1H NMR (300 MHz, CDCl3) δ 7.23 (t, J 
= 7.8 Hz, 1H), 7.02 – 6.97 (m, 1H), 6.97 – 6.94 (m, 1H), 6.78 – 6.72 (m, 
1H), 5.49 (qd, J = 6.9, 2.3 Hz, 1H), 3.81 (s, 3H), 2.79 (pd, J = 6.7, 2.3 Hz, 
1H), 1.76 (d, J = 6.9 Hz, 3H), 1.13 (d, J = 5.3 Hz, 3H), 1.11 (d, J = 5.2 Hz, 
3H). 13C NMR (75 MHz, CDCl3) δ 203.9, 159.8, 139.3, 129.3, 119.2, 
112.7, 112.6, 111.6, 90.0, 55.3, 28.1, 22.7, 22.4, 14.6. HRMS (EI) 
calculated for C14H19O [M+H]
+: 204.1436; Found: 204.1427. [α]25D= –47.6 
(c = 1.0, CHCl3) 
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 (–)-(R)-Methyl 4-(2-methylhexa-3,4-dien-3-yl)benzoate, (R)-III-3x. 
From (R)-III-1d (79 mg, 0.2 mmol) and 
isopropylmagnesium bromide solution in THF (0.22 
mmol) following the general procedure described 
above, compound (R)-III-3x (39 mg, 0.17 mmol) 
was obtained in 85% yield as a pale yellow oil, after 
purification by flash column chromatography (pentane/Et2O 97:3). From 
III-1d, following the same procedure without SPhos, compound III-3x (44 
mg, 0.19 mmol) was obtained in 95% yield. 
  Compound (R)-III-3x was obtained in 97:3 enantiomeric ratio 
determined by SFC using Chiralpak-ID column [CO2/MeOH (99:1)], 1 
mL/min, major= 14.4 min, minor= 14.0 min. 
Using isopropylmagnesium chloride solution in THF (0.22 mmol) 
compound (R)-III-3x (41 mg, 0.18 mmol) was obtained in 89% yield and 
97:3 enantiomeric ratio as a pale yellow oil, after purification by flash 
column chromatography (pentane/Et2O 97:3). 
Using isopropylmagnesium chloride solution in Et2O (0.22 mmol) 
compound (R)-III-3x (12 mg, 0.05 mmol) was obtained in 26% yield and 
90:10 enantiomeric ratio as a pale yellow oil, after purification by flash 
column chromatography (pentane/Et2O 97:3). The low yield is attributed to 
the low solubility of the starting material in Et2O. 
 1H NMR (300 MHz, CDCl3) δ 8.02 – 7.89 (m, 2H), 7.49 – 7.38 
(m, 2H), 5.55 (qd, J = 7.0, 2.4 Hz, 1H), 3.90 (s, 3H), 2.82 (septd, J = 6.7, 
2.4 Hz, 1H), 1.78 (d, J = 7.0 Hz, 3H), 1.13 (d, J = 6.7 Hz, 3H), 1.11 (d, J = 
6.7 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 204.8, 167.2, 142.6, 129.7, 
127.9, 126.4, 112.3, 90.6, 52.1, 27.8, 22.6, 22.3, 14.4. HRMS (ESI) 
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calculated for C15H18NaO2 [M+Na]
+: 253.1204; Found: 253.1198. [α]25D= 
–83.7 (c = 1.0, CHCl3). 
 
(–)-(R)-1-bromo-3-(2,2-dimethylhexa-3,4-dien-3-yl)benzene (R)-III-
3y. 
From (R)-III-1i (83 mg, 0.2 mmol) and tert-
butylmagnesium chloride solution in THF (0.22 
mmol) following the general procedure described 
above, compound (R)-III-3y (43 mg, 0.16 mmol) was 
obtained in 81% yield as a pale yellow oil, after 
purification by flash column chromatography (pentane/Et2O 97:3). From 
III-1i, following the same procedure, compound III-3y (38 mg, 0.14 mmol) 
was obtained in 72% yield. 
Compound (R)-III-3x was obtained in 98:2 enantiomeric ratio 
determined by GC on a Chirasil Dex-CB column (60 ºC, hold 3 min, 
60→120 °C @ 10 °C/min, hold 2 min, then →160 °C @ 0.5 °C/min, then 
→180 °C @ 10 °C/min; flow rate 1.0 mL/min.). major= 27.6 min, minor= 
27.9 min. 1H NMR (300 MHz, CDCl3) δ 7.52 – 7.30 (m, 2H), 7.22 – 7.07 
(m, 2H), 5.20 (q, J = 6.9 Hz, 1H), 1.69 (d, J = 6.9 Hz, 3H), 1.12 (s, 9H). 13C 
NMR (75 MHz, CDCl3) δ   202.6, 140.6, 132.4, 129.5, 129.3, 128.1, 121.8, 
114.1, 86.8, 34.3, 30.0, 14.8. HRMS (APCI) calculated for C14H18Br 
[M+H]+: 265.0586; Found: 265.0585. [α]25D= –22.3 (c = 1.0, CHCl3). 
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(–)-(S)-(3-isopropylhexa-3,4-dien-1-yl)benzene, (S)-III-3z. 
From (R)-III-1n (73 mg, 0.2 mmol) and 
isopropylmagnesium chloride solution in THF (0.22 
mmol) following the general procedure described above, 
compound (S)-III-3z (35 mg, 0.18 mmol) was obtained in 
88% yield as a pale yellow oil, after purification by flash 
column chromatography (pentane/Et2O 97:3). From III-1n, following the 
same procedure, compound III-3z (33 mg, 0.17 mmol) was obtained in 
83% yield. 
Compound (S)-III-3z was obtained in 98:2 enantiomeric ratio 
determined by GC on a Chirasil Dex-CB column (60 ºC, hold 3 min, then 
60→80 °C @ 10 °C/min, hold 2 min, then →140 °C @ 0.5 °C/min, then 
→180 °C @ 10 °C/min, hold 3 min; flow rate 1.0 mL/min.). major= 68.5 
min, minor= 70.1 min. 1H NMR (300 MHz, CDCl3) δ7.24 – 7.04 (m, 5H), 
5.14 – 4.98 (m, 1H), 2.70 – 2.58 (m, 2H), 2.23 – 2.12 (m, 2H), 2.10 – 1.92 
(m, 1H), 1.52 (d, J = 6.8 Hz, 3H), 0.93 (dd, J = 6.8, 1.5 Hz, 6H).  13C NMR 
(75 MHz, CDCl3) δ 200.9, 142.8, 128.6, 128.3, 125.8, 110.0, 88.3, 34.5, 
32.7, 31.4, 22.0, 21.9, 15.2. HRMS (EI) calculated for C15H20 [M]
+: 
200.1565; Found: 200.1556. [α]25D= –8.4 (c = 1.0, CHCl3). 
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3.6.5. Derivatizations to determine the enantiomeric excess of (S)-
III-4w, (R)-III-2x and (R)-III-2y. 
3.6.5.1. Synthesis of (−)-(S)-hept-1-yn-3-yl benzoate, (S)-III-6w. 
 
 
 
K2CO3 (1.2 equiv) was added to a solution of (S)-III-4w (79 mg, 0.43 
mmol, 1 equiv) in MeOH/DCM (8:1, 4.5 mL). The reaction mixture was 
stirred overnight at room temperature and then quenched with H2O and 
extracted with DCM (x3). The combined organic phases were washed 
with brine, dried over Na2SO4, filtered and concentrated under vacuum to 
afford the terminal alkyne. The crude product was used in the next step 
without further purification. 
To a solution of crude product in CH2Cl2 (2 mL), 4-
dimethylaminopyridine (DMAP) (110 mg, 0.9 mmol, 2.1 equiv), 
triethylamine (180 µL, 1.3 mmol, 3 equiv) and benzoyl chloride (100 µL, 
0.86 mmol, 2.0 equiv) were added. The reaction mixture was stirred for 2 h 
at room temperature and then quenched with H2O. The aqueous layer was 
extracted with Et2O (x3) and the combined organic phases were washed 
with brine, dried over Na2SO4, filtered and concentrated under reduced 
pressure. The residue was purified by flash column chromatography over 
silica gel using hexane/EtOAc, 95:5 as eluent. Compound (S)-III-6w (74 
mg, 0.34 mmol) was obtained in 82% global yield as a colorless oil.  
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Compound (S)-III-6w was obtained in 93:7 enantiomeric ratio 
determined by SFC using Chiralpak-IA column [CO2/MeOH (99.5:0.5)], 
0.5 mL/min, major= 27.1 min, minor= 24.9 min.  [α]20D= -26.7 (c = 1.0, 
CHCl3). 1H NMR, 13C NMR and MS data were consistent with literature 
values.100 1H NMR (300 MHz, CDCl3) δ 8.12 – 8.01 (m, 2H), 7.62 – 7.52 
(m, 1H), 7.49 – 7.40 (m, 2H), 5.60 (td, J = 6.6, 2.1 Hz, 1H), 2.49 (d, J = 2.1 
Hz, 1H), 1.98 – 1.87 (m, 2H), 1.58 – 1.47 (m, 2H), 1.42 – 1.31 (m, 2H), 
0.94 (t, J = 7.2 Hz, 3H). 
 
3.6.5.2. General procedure for the deprotection of silylated alkynes 
 
 
K2CO3 (1.2 equiv) was added to a solution of the corresponding TMS-
protected alkyne (1 equiv) in MeOH/DCM (8:1, 1 mL/mmol of alkyne). 
The reaction mixture was stirred overnight at room temperature and then 
quenched with H2O and extracted with DCM (x3). The combined organic 
phases were washed with brine, dried over Na2SO4, filtered and 
concentrated under reduced pressure. The residue was purified by flash 
column chromatography over silica gel using hex/EtOAc, 98:2 as eluent. 
 
100 Nakamura, K.; Takenaka, K. Tetrahedron: Asymmetry, 2002, 13, 415. 
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(+)-(S)-1-(Hept-1-yn-3-yl)-4-methoxybenzene, (S)-III-7x. 
From (R)-III-2x (29 mg, 0.11 mmol) following the general 
procedure described above, compound (S)-III-7x (20 mg, 
0.10 mmol) was obtained in 89% yield as a yellow oil.  
Compound (S)-III-7x was obtained in 91:9 enantiomeric 
ratio determined by SFC using Chiralpak-IA column [CO2/MeOH 
(99.8:0.2)], 0.5 mL/min, major= 26.3 min, minor= 24.6 min.  1H NMR (300 
MHz, CDCl3) δ 7.28 (d, J = 8.7 Hz, 2H), 6.87 (d, J = 8.7 Hz, 2H), 3.80 (s, 
3H), 3.61 – 3.54 (m, 1H), 2.25 (d, J = 2.5 Hz, 1H), 1.80 – 1.68 (m, 2H), 
1.47 – 1.28 (m, 4H), 0.90 (t, J = 7.0 Hz, 3H). 13C NMR (75 MHz, CDCl3) 
δ 158.5, 134.0, 128.4, 114.0, 86.7, 70.6, 55.4, 38.2, 36.9, 29.5, 22.5, 14.1. 
[α]20D= +15.9 (c = 1.0, CHCl3). HRMS-EI+ m/z calculated for C14H19O 
[M+H]+: 203.1430, found 203.1425.  
 
(+)-(S)-1-(Hept-1-yn-3-yl)-3-methoxybenzene, (S)-III-7y. 
From (R)-III-2y (51 mg, 0.18 mmol) following the 
general procedure described above, compound (S)-III-
7y (32 mg, 0.16 mmol) was obtained in 87% yield as a 
yellow oil.  
Compound (S)-III-7y was obtained in 92:8 enantiomeric ratio determined 
by SFC using Chiralpak-IA column [CO2/MeOH (99.8:0.2)], 0.5 mL/min, 
major= 27.1 min, minor= 25.3 min.  1H NMR (300 MHz, CDCl3) 7.24 (m, 
1H), 6.94 (m, 2H), 6.82 – 6.75 (m, 1H), 3.82 (s, 3H), 3.63 – 3.55 (m, 1H), 
2.26 (d, J = 2.5 Hz, 1H), 1.76 (m, 2H), 1.51 – 1.28 (m, 4H), 0.89 (t, J = 7.1 
Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 159.9, 143.5, 129.6, 119.9, 113.4, 
112.1, 86.2, 71.0, 55.4, 38.1, 37.7, 29.6, 22.5, 14.1. [α]20D= +18.2 (c = 1.0, 
CHCl3). HRMS-EI+ m/z calculated for C14H19O [M+H]
+: 202.1430 found 
203.1429. 
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3.6.6. Competition experiment. 
 
 
An oven-dried vial was charged with [Cu(CH3CN)4]PF6 (3.8 mg, 0.01 
mmol) and both primary (0.2 mmol) and secondary ammonium salt (0.2 
mmol) and was sealed with a septum. The vial was connected to an argon-
vacuum line, evacuated and backfilled with argon (x3). CH2Cl2 (2 mL) was 
added and the mixture was stirred for 5 min at room temperature. The 
reaction mixture was cooled to −40 ºC and phenyl magnesium bromide 
solution in THF (0.76 M, 0.2 mmol) was added dropwise. The mixture was 
stirred at −40 ºC for 3 minutes. Water (0.1 mL) was added and the solution 
was filtered through a short pad of MgSO4 and rinsed with CH2Cl2. The 
solvent was removed under reduced pressure and toluene was added as 
internal standard. The 1H-NMR of the crude product showed compounds 
III-2a (65% yield) and III-2q (5% yield) and unreacted starting materials.  
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3.6.7. Assignment of the Absolute Configuration. 
The absolute configuration was stablished for compounds (R)-III-2b, 
(R)-III-2w, (R)-III-2x, (R)-III-2y and (R)-III-3u by comparison of the 
sign of the optical rotation with that of previously reported compounds. Our 
results indicate that the copper-catalyzed reaction proceeds with inversion 
of the configuration. We assumed the same stereochemical outcome for all 
the enantiomerically enriched compounds prepared.  
 
3.6.7.1. (−)-(R)-But-1-yne-1,3-diyldibenzene, (R)-III-2b.96 
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3.6.7.2. (+)-(R)-Trimethyl(3-phenylhept-1-yn-1-yl)silane, (R)-III-2w.51  
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3.6.7.3. (+)-(R)-(3-(4-Methoxyphenyl)hept-1-yn-1-yl)trimethylsilane, (R)-
III- 2x and (+)-(R)-[3-(3-Methoxyphenyl)hept-1-yn-1-
yl]trimethylsilane, (R)-III-2y.52  
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3.6.7.4. (–)-(R)-Octa-5,6-diene-1,5-diyldibenzene, (R)-III-3u.99 
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3.7. NMR Spectra. 
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3.8. SFC Chromatograms 
 
 
Chapter 3 
 
374 
 
 
 
 
Stereospecific Copper-Catalyzed Substitution Reaction Of Propargylic 
Ammonium Salts. 
 
375 
 
 
 
 
 
 
Chapter 3 
 
376 
 
 
 
 
 
 
Stereospecific Copper-Catalyzed Substitution Reaction Of Propargylic 
Ammonium Salts. 
 
377 
 
 
 
Chapter 3 
 
378 
 
 
 
 
 
 
Stereospecific Copper-Catalyzed Substitution Reaction Of Propargylic 
Ammonium Salts. 
 
379 
 
 
Chapter 3 
 
380 
 
 
 
 
 
 
 
Stereospecific Copper-Catalyzed Substitution Reaction Of Propargylic 
Ammonium Salts. 
 
381 
 
 
 
 
 
 
 
Chapter 3 
 
382 
 
 
 
 
 
 
Stereospecific Copper-Catalyzed Substitution Reaction Of Propargylic 
Ammonium Salts. 
 
383 
 
 
 
 
 
Chapter 3 
 
384 
 
 
 
 
 
Stereospecific Copper-Catalyzed Substitution Reaction Of Propargylic 
Ammonium Salts. 
 
385 
 
 
 
 
Chapter 3 
 
386 
 
 
 
 
 
 
 
Stereospecific Copper-Catalyzed Substitution Reaction Of Propargylic 
Ammonium Salts. 
 
387 
 
 
 
 
 
Chapter 3 
 
388 
 
 
 
 
 
Stereospecific Copper-Catalyzed Substitution Reaction Of Propargylic 
Ammonium Salts. 
 
389 
 
 
 
 
Chapter 3 
 
390 
 
 
3.9. GC-MS Chromatograms 
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4. STEREOSPECIFIC PALLADIUM-CATALYZED 
ALLYL-ALLYL CROSS-COUPLING OF ALLYLIC 
CARBONATES AND AMMONIUM SALTS. 
4.1. Background. 
4.1.1. Allyl-Allyl Cross-Coupling. 
1,5-dienes are a prevalent structure in many important biologically 
active molecules (Figure 4-1).1 As a common terpene structure, plays a key 
role in nature. 
 
 
Figure 4-1: Common natural products with 1,5-dienes in their 
structure. 
 
 
1 Breitmaier, E. Terpenes: Flavors, Fragrances, Pharmaca, Pheromones, Wiley-
VCH, Weinheim, 2006. 
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Moreover, 1,5-dienes are versatile synthetic intermediates that can be 
used for the preparation of a wide range of compounds. One of the  classical 
reaction involving 1,5-dienes is the Cope rearrangement.2 This 
transformation is a sigmatropic reaction which have been known for nearly 
eight decades and since its discovery, many variations have been reported  
(Scheme 4-1).3  
 
 
Scheme 4-1: Cope rearrangement. 
 
Other well-known transformations are the oxidative cyclization of 1,5-
dienes to obtain furanyl rings (Scheme 4-2, top),4 cycloisomerization 
 
2 Cope, A.C.; Hardy, E.M. J. Am. Chem. Soc. 1940, 62, 441-444. For a specific 
example see: Kawasaki, T.; Nonaka, Y.; Watanabe, K.; Ogawa, A.; Higuchi, K.; 
Terashima, R.; Masuda, K.; Sakamoto, M. J. Org. Chem. 2001, 66, 1200-1204. 
3 For a review see: Lutz, R.P. Chem. Rev. 1984, 3, 205-247. For more recent 
examples: a) Overman, L.E.; Knoll, F.M. J. Am. Chem. Soc. 1980, 102, 865-867. 
b) Felix, R.J.; Weber, D.; Gutierrez, O.; Tantillo, D.J.; Gagne, M.R. Nature 
Chemistry 2012, 4, 405-409. 
4 a) Antonsson, T.; Moberg, C.; Tottie, L. J. Org. Chem. 1989, 54, 4914-4929. c) 
Brown, R.C.D.; Keily, J.F. Angew. Chem. Int. Ed. 2001, 40, 4496-4498. d) 
Donohoe, T.J.; Butterworth, S.    
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reactions (Scheme 4-2, bottom)5 and the selective functionalization of both 
olefins. 
 
 
Scheme 4-2: Utility of 1,5-dienes. 
 
One of the most straightforward strategies to prepare 1,5-dienes is the 
metal-catalyzed allyl-allyl cross-coupling reaction between two different 
allylic partners. Different transition metals have been used to catalyze this 
transformation, including stereoselective variants. In those cases, the 
products are enantioenriched 1,5 dienes with one or more stereocenters.6 In 
 
5 a) Molander, G.A.; Hoberg, J.O. J. Am. Chem. Soc. 1992, 114, 3123-3125. b) 
Kisanga, P.; Goj, L.A.; Widenhoefer, R.A. J. Org. Chem. 2001, 66, 635-637. 
6 a) Trost, B.M.; Keinan, E. Tetrahedron Lett. 1980, 21, 2595-2598. b) 
Godschalx, J.; Stille, J.K. Tetrahedron Lett. 1980, 21, 2599-2602. c) Keinan, E.; 
Peretz, M. J. Org. Chem. 1983, 48, 5302-5309. d) Stille, J.K. Angew. Chem. Int. 
Ed. 1986, 25, 508-524. e) Sofia, A.; Karlstrom, E.; Backvall, J.E. Chem. Eur. J. 
2001, 7, 1981-1989. f) Mendez, M.; Cuerva, J.M.; Gomez-Bengoa, E.; Cardenas, 
D.J.; Echavarren, A.M. Chem. Eur. J. 2002, 8, 3620-3628. g) Mendez, M.; 
Echavarren, A.M.Eur. J. Org. Chem. 2002, 15-28. h) Porcel, S.; Lopez-Carrillo, 
V.; Garcia-Yebra, C.; Echavarren, A.M. Angew. Chem. Int. Ed. 2008, 47, 1883-
1886. i) Sumida, Y.; Hayashi, S.; Hirano, K.; Yorimitsu, H.; Oshima, K. Org. Lett.  
2008, 10, 1629-1632. 
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this section, selected examples of enantioselective and stereospecific allyl-
allyl cross-coupling will be discussed.  
 
4.1.2. Enantioselective Allyl-Allyl Cross-Coupling. 
In 2010, Morken and co-workers reported the first enantioselective allyl-
allyl cross-coupling between allylic carbonates and allyl boronates 
(Scheme 4-3).7 The branched product was formed as a single regioisomer 
with high levels of stereocontrol. They observed that regioselectivity was 
dependent of the bite angle of the ligand, being the best a chiral ligand with 
a small bite angle.8  
 
 
7 Zhang, P.; Brozek, L.A.; Morken, J.P. J. Am. Chem. Soc. 2010, 132, 10686-
10688. 
8 Ardolino, M.J.; Morken, J.P. Tetrahedron, 2015, 71, 6409-6413. 
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Scheme 4-3: Palladium-catalyzed enantioselective allyl-allyl cross-
coupling. 
 
Although the reaction might have occurred by an outer-sphere attack of 
the allylboronate to a η3-allyl palladium complex,9 based on mechanistic 
experiments, they proposed an inner-sphere 3,3-reductive elimination 
pathway for the reaction,10 as proposed by Echevarren11 and Espinet.12 First, 
 
9 a) Trost, B. M.; Keinan, E. Tetrahedron Lett. 1980, 21, 2595-2598. b) 
Godschalx, J.; Stille, J. K. Tetrahedron Lett. 1980, 21, 2599-2602. c) Flegeau, E. 
F.; Schneider, U.; Kobayashi, S. Chem. Eur. J. 2009, 15, 12247-12254. d) Jiminéz-
Aquino, A.; Flegeau, E. F.; Schneider, U.; Kobayashi, S. Chem. Commun. 2011, 
47, 9456-9458.  
10 Ardolino, M.J.; Morken, J.P. J. Am. Chem. Soc. 2014, 136, 7092-7100. 
11 a) Méndez, M.; Cuerva, J. M.; Gómez-Bengoa, E.; Cárdenas, D. J.; Echavarren, 
A. M. Chem. Eur. J. 2002, 8, 3620-3628. b) Cárdenas, D. J.; Echavarren, A. M. 
New J. Chem. 2004, 28, 338-347. 
12 a) Pérez-Rodríguez, M.; Braga, A. A. C.; Garcia-Melchor, M.; Pérez-
Temprano, M. H.; Casares, J. A.; Ujaque, G.; de Lera, A. R.; Maseras, F.; Álvarez, 
R.; Espinet, P. J. Am. Chem. Soc. 2009, 131, 3650-3657. b) Pérez-Rodríguez, M.; 
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there must be an oxidative addition of the carbonate to the palladium(0) 
complex to form a η3-allyl palladium complex, that would explain that the 
result was the same using either the branched or the linear allylic carbonate. 
Then, after the transmetalation step, the coordination of the small-bite 
bidentate phosphine would cause the two allyl group to adopt a η1 bonding 
mode that would favor the 3,3-reductive elimination pathway to produce 
the desired product (Scheme 4-4). 
 
 
Scheme 4-4: Proposed mechanism for the palladium-catalyzed allyl-
allyl cross-coupling via a 3,3-reductive elimination pathway. 
 
A year later, the same group reported a similar transformation, using 
tertiary allylic carbonates as starting allylic electrophiles.  Using the same 
 
Braga, A. A. C.; de Lera, A. R.; Maseras, F.; Álvarez, R.; Espinet, P. 
Organometallics 2010, 29, 4983-4991. 
Stereospecific Synthesis of 1,5-Dienes Through an Allyl-Allyl Cross-
Coupling Strategy. 
 
403 
 
chiral ligand as before, they prepared compounds with all-carbon 
quaternary centers from racemic substrates with excellent results (Scheme 
4-5).13 The transformation was not trivial, because an interconversion 
between the two possible π-allyl-palladium intermediates through a 
hindered tertiary η1-allylpalladium intermediate was needed. One of the 
drawbacks of this report was that a considerable amount of -hydride 
elimination product was formed in some cases. In the same year they 
reported a similar transformation using internal allylboronates with 
excellent diastereo- and enantioselectivities.14 
 
 
Scheme 4-5: Enantioselective allyl-allyl cross-coupling of quaternary 
carbonates. 
 
13 Zhang, P.; Kyne, R.E.; Morken, J.P. J. Am. Chem. Soc. 2011, 133, 9716-9719. 
14 Brozek, L.A.; Ardolino, M.J.; Morken, J.P. J. Am. Chem. Soc. 2011, 133, 
16778-16781. 
Chapter 4 
404 
 
In 2013, Feringa and co-workers reported the first copper-catalyzed 
allyl-allyl cross-coupling. They obtained high levels of regio- and 
enantioselectivity using a chiral phosphoramidite ligand along with a 
copper(I) salt (Scheme 4-6).15 They used readily available allyl bromides 
and allylmagnesium bromide to obtain enantiomerically enriched 1,5-
dienes. They proposed that the mechanism for this transformation was 
similar to the copper-catalyzed asymmetric allylic alkylation (Cu-AAA).16 
 
 
Scheme 4-6: Enantioselective copper-catalyzed allyl-allyl cross-
coupling. 
 
Carreira and co-workers added an elegant contribution to this field. They 
reported the enantioselective cross-coupling between unprotected allylic 
 
15 Hornillos, V.; Perez, M.; Fañanas-Mastral, M.; Feringa, B.L. J. Am. Chem. Soc. 
2013, 135, 2140-2143. 
16 Yoshikai, N.; Nakamura, E. Chem. Rev. 2012, 112, 2339-2372. 
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alcohols and allylsilanes catalyzed by iridium (Scheme 4-7).17 Chiral 
phosphoramidites were this time the ligand of choice. They applied their 
methodology to the synthesis of a pyrethroid insecticide. Later, Yang and 
coworkers reported a similar procedure using allylboronates as 
nucleophiles.18 
 
 
Scheme 4-7: Enantioselective iridium-catalyzed allyl-allyl cross-
coupling. 
 
In 2016, Sawamura and co-workers reported the cross coupling between 
(Z)-allylic phosphonates and allylboronates catalyzed by a Cu-NHC chiral 
 
17 Hamilton, J.Y.; Hauser, N.; Sarlah, D.; Carreira, E.M. Angew. Chem. Int. Ed. 
2014, 53, 10759-10762. 
18 Zheng, Y.; Yue, B.B.; Wei, K.; Yang, Y.R. Org. Lett. 2018, 20, 8035-8038. 
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complex. The reaction was completely -regioselective and the products 
were obtained with moderate to good stereoselectivities (Scheme 4-8).19 
 
 
Scheme 4-8: Copper-catalyzed enantioselective allyl-allyl cross-
coupling. 
 
Recently, Wang, Ding and co-workers reported a palladium-catalyzed 
allylic allylation of Morita-Baylis-Hillman adducts. Using a chiral 
spiroketal-based phosphine and allylic boronates as coupling partners, they 
obtained high regio- and enantioselectivities (Scheme 4-9).20 As Morken’s 
group, they proposed an inner-sphere 3,3’-reductive elimination as key step 
in the mechanism. 
 
19 Yasuda, Y.; Ohmiya, H.; Sawamura, M. Angew. Chem. Int. Ed. 2016, 55, 
10816-10820. 
20 Wang, X.; Wang, X.; Han, Z.; Wang, Z.; Ding, K. Angew. Chem. Int. Ed. 2017, 
56, 1116-1119. 
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Scheme 4-9: Enantioselective allyl-allyl cross-coupling of Morita-
Baylis-Hillman adducts. 
 
4.1.3. Stereospecific Allyl-Allyl Cross-Coupling. 
In a pioneering work, Hayashi and co-workers reported the reaction of 
enantiomerically enriched π-allylpalladium complex with various 
nucleophiles. One of the examples involved the stereospecific coupling 
with allylmagnesium chloride, which reacted with retention of the 
stereochemistry (Scheme 4-10).21 The chirality transfer for this 
transformation was only moderate and they proposed an inner-sphere 
mechanism for the reaction. 
 
 
21 Hayashi, T.; Konishi, M.; Kumada, M. J. Chem. Soc., Chem. Commun. 1984, 
107-108. 
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Scheme 4-10: Stereospecific reaction between π-allylpalladium 
complex and allylmagnesium chloride. 
 
The use of internal allyl electrophiles in stereospecific allyl-allyl cross-
coupling reactions is much less developed. In a pioneering work, Morken 
and co-workers reported the palladium-catalyzed allyl-allyl cross-coupling 
of internal allylic acetates with allylboronates (Scheme 4-11).22 They could 
not control the regioselectivity with disubstituted allyl acetates. Better 
regiocontrol was observed with trisubstituted allyl acetates.  
 
 
Scheme 4-11: Allyl-allyl cross-coupling of internal allylic acetates. 
 
They studied the chirality transfer starting from enantioenriched allylic 
acetates. The catalyst loading had an influence in both the stereospecificity 
 
22 Le, H.; Batten, A.; Morken, J.P. Org. Lett. 2014, 16, 2096-2099. 
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and the regioselectivity, with opposite effects. Low catalyst loading 
afforded excellent stereospecificity but low regioselectivity. On the other 
hand, higher catalyst loading control the regioselectivity, but is detrimental 
for the chirality transfer (Scheme 4-12). In all cases they isolated the 
product along an unknown quantities of -hydride elimination product. 
 
 
Scheme 4-12: Stereospecific allyl-allyl cross-coupling. 
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4.2. Stereospecific Synthesis of 1,5-Dienes Through an Allyl-
Allyl Cross-Coupling Strategy. 
4.2.1. Introduction and Objectives. 
At the beginning of this project, there was only two examples of 
stereospecific allyl-allyl cross-coupling reactions.21,22 We thought that a 
strategy involving the stereospecific synthesis of 1,5-dienes from 
enantiomerically enriched internal allylic compounds would be desirable. 
We got inspired by Morken’s work and we decided to use palladium as our 
catalyst. However, Morken’s work showed us that this reaction could have 
many problems. We envisioned that choosing the appropriate ligand should 
be critical for the transformation we wanted to perform. But not only the 
choice of the ligand in this transformation is crucial. We have learnt that 
the correct choice of the leaving group is also important for cross-coupling 
reactions. The objectives of this chapter include: 
- Choose the appropriate catalytic system and leaving group to control 
the regioselectivity and stereospecificity of the reaction. 
-  Find the optimal condition to minimize the amount of -hydride 
elimination product formed. 
- Functionalize selectively both different double bonds in the 1,5-
diene. 
 
 
Scheme 4-13: Objectives of this chapter. 
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4.2.2. Synthesis of Starting Materials. 
To study the proposed transformation, we prepared a series of allylic 
carbonates IV-1 and ammonium salts IV-2  (Figure 4-2 and Figure 4-3), 
following different procedures described below.   
 
 
Figure 4-2: Enantiomerically enriched allylic carbonates.  
 
Chapter 4 
412 
 
 
Figure 4-3: Enantiomerically enriched allylic ammonium salts. 
 
The synthetic sequence to prepare allylic carbonates IV-1a-j started 
with the synthesis of the corresponding - unsaturated ketones IV-6 by a 
Wittig reaction, to obtain the E-alkenes selectively. Then, 1,2-reduction of 
the corresponding - unsaturated ketones IV-6, afford racemic alcohols 
(±)-IV-7. Then, a kinetic resolution using Amano lipase from Pseudomones 
Fluorescens, provided enantiomerically enriched alcohols IV-7. Finally, 
carbonates IV-1 were prepared by treatment of the alcohols with methyl 
chloroformiate (Scheme 4-14). The yields showed in the scheme are global 
yields. It is important to note that the maximum yield in the kinetic 
resolution is 50%. 
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Scheme 4-14: Synthesis of allylic carbonates IV-1a-j. 
 
Racemic alcohol (±)-IV-7k was prepared by addition of ethyl 
magnesium bromide to cinnamaldehyde. From here, kinetic resolution 
followed by treatment of the alcohol with methyl chloroformate afforded 
enantiomerically enriched allylic carbonate IV-1k (Scheme 4-15). 
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Scheme 4-15: Synthesis of IV-1k. 
 
Allylic ammonium salts IV-2 were synthesized from enantiomerically 
enriched allylic alcohols IV-7. Acetylation, followed by a stereospecific 
palladium catalyzed Tsuji-Trost reaction, provided dimethylamines IV-9. 
Finally, allylic ammonium salts IV-2 were obtained upon treatment of 
amines IV-9 with methyl triflate (Scheme 4-16). The yields showed in the 
scheme are global yields.  
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Scheme 4-16: Synthesis of allylic ammonium salts IV-2. 
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4.2.3. Palladium-Catalyzed Allyl-Allyl Cross-Coupling of Allylic 
Carbonates. Screening of Conditions. 
Motivated by the possibilities of this reaction, we tried the previously 
reported conditions by Morken (Scheme 4-17, top), using allylic carbonates 
instead of acetates. As catalyst, we used [Pd(allyl)Cl]2 and dppbenzene as 
ligand. We obtained the desired product in 47%, but as a mixture of the 
three possible products. The stereospecificity of the reaction was great, but 
we did not achieve good regioselectivity and we found -hydride 
elimination product in low amount (Scheme 4-17, mid). Decreasing the 
amount of cesium fluoride to 3 equivalents and the amount of allylBpin to 
2 equivalents improve the yield of the reaction to 95%, but the 
regioselectivity was still unsatisfactory and the amount of -hydride 
elimination product increase (Scheme 4-17, bottom), so we decided to look 
for the optimal conditions for this cross-coupling reaction. 
 
Scheme 4-17: Palladium-catalyzed allyl-allyl cross-coupling of allylic 
carbonates. 
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We started our screening by changing the ligand to dppf, and 
surprisingly only IV-3a was obtained, but with a considerable amount of -
hydride elimination product IV-5a and in 32% yield (Table 4-1, entry 2). 
Using dppp or dppe did not improve the results of the reaction (Table 4-1, 
entries 3 and 4), but it is important to note that only regiosiomer IV-3a was 
observed. Triphenylphosphine gave similar results (Table 4-1, entry 5) and 
tri-tert-butylphosphine, a very bulky and electron-rich phosphine gave IV-
3a in only 30% yield but no diene IV-5a was detected (Table 4-1, entry 6). 
It was CataCXium ABn, another bulky and electron-rich phosphine with 
two adamantly and one benzyl substituents, the one that gave the best result 
in this reaction. We obtained the desired product IV-3a with 87% isolated 
yield, excellent stereospecificity and only 8% of -hydride elimination 
product was detected (Table 4-1, entry 7). Finally, using Johnphos as ligand 
did not achieve any conversion and we recover the starting material (Table 
4-1, entry 9). We did not observe any conversion in the absence of cesium 
fluoride (Table 4-1, entry 10), ligand (Table 4-1, entry 11) or catalyst 
(Table 4-1, entry 12).  
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Table 4-1: Influence of the ligand. 
 
Entry L (4 mol%) Yield[a] 
Ratio 
3:4:5[a] 
es (%)[c] 
1 DPPBz 32 32:49:19 99% 
2 DPPF 42 69:00:31 99% 
3 DPPP 13 34:00:66 99% 
4 DPPE 25 54:00:46 99% 
5 PPh3 21 58:00:42 99% 
6 P(t-Bu)3 30 100:00:00 99% 
7 CataCXiumABn 87[b] 92:00:08 99% 
8 Xphos 29 55:00:45 99% 
9 JohnPhos 0 - 0 
10[d] CataCXiumABn 0 - 0 
11[e] - 0 - 0 
12[f] CataCXiumABn 0 - 0 
Reaction conditions: IV-1a (0.2 mmol, 1.0 equiv), AllylBpin (2.0 equiv), 
[Pd(allyl)Cl]2 (2 mol%), Ligand (4 mol%), CsF (3.0 equiv), H2O (15.0 
equiv), THF (0.14 M), rt, 16h, unless otherwise noted. aYield and ratio of 
the product determined by 1H-NMR using quinoline as internal standard. 
Yields corrected based on of the amount of diene formed. bIsolated yield 
after column chromatography. cDetermined by chiral GC-MS. dNo base was 
used. eNo ligand was used. fNo palladium was used.  
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With the optimal conditions in hand, we briefly studied the influence of 
the leaving group in the transformation. We were glad to see that trimethyl 
ammonium salts gave also excellent results in the allyl-allyl cross-coupling 
and yielded the desired product with 82% yield and perfect stereospecificity 
(Table 4-2, entry 2). Surprisingly, the corresponding allylic acetate 
previously used by Morken, afforded IV-3a in only 9% yield and with 
complete loss of the chirality transfer (Table 4-2, entry 3). A primary allylic 
amine and the dimethyl amine derivative, previously used as electrophiles 
in Tsuji-Trost type reactions,23 did not react under the optimized conditions 
(Table 4-2, entries 4 and 5). 
 
Table 4-2: Influence of the leaving group. 
 
Entry Leaving Group Yield (3:4:5)[a], [b] es (%)[c] 
1 OCO2Me 87 (92:00:08)[d] 99% 
2 NMe3OTf 82 (94:00:6)[d] 99% 
3 OAc 9 (90:00:10) 0% 
4 NH2 0 0 
5 NMe2 0 0 
Reaction conditions: Allylic compound (0.2 mmol, 1.0 equiv), AllylBpin (2.0 equiv), 
[Pd(allyl)Cl]2 (2 mol%), CataCXium ABn (4 mol%), CsF (3.0 equiv), H2O (15.0 
equiv), THF (0.14 M), rt, 16h, unless otherwise noted. aIsolated yield after column 
chromatography. bRatio of the product determined by 1H-NMR using quinoline as 
internal standard. cDetermined by chiral GC-MS. dYields corrected based on the 
amount of diene formed. 
 
23 Li, M. B.; Wang, Y.; Tian, S. K. Angew. Chem. Int. Ed. 2012, 51, 2968-2971. 
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To gain insight into the Pd(II) precatalyst involved in the reaction we 
mixed one equivalent of [Pd(allyl)Cl]2 and two equivalents of cataCXium 
ABn to obtain IV-10 as a white solid. This solid was recrystallized from 
dichloromethane to provide suitable crystals for X-ray diffraction (Scheme 
4-18).24  
 
 
Scheme 4-18: Synthesis and characterization of IV-10. 
 
When we used 1 mol% of the preformed catalyst IV-10 under the 
optimized conditions, diene IV-3a was obtained in 75% yield, as a single 
regioisomer and with excellent stereospecificity. Along the desired product, 
we obtained 6% of diene (Scheme 4-19). 
 
 
24 CCDC 1953214 contains the supplementary crystallographic data. These data can be 
obtained free of charge at www.ccdc.cam.ac.uk/conts/retrieving.html  
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Scheme 4-19: Model reaction using the preformed Pd(II) catalyst. 
 
4.2.4. Scope of the Reaction. 
With the optimal conditions in hand, we next tested the enantiomerically 
enriched allylic carbonates prepared previously (Figure 4-2) to determine 
the structural scope of the reaction (Scheme 4-20). Enantiomeric ratios 
were determined by chiral GC-MS. The ratios between the product and the 
undesired diene were measured by 1H-NMR. We were not able to separate 
them by silica chromatography but it was possible to get rid of the diene by 
a simple Diels-Alder reaction with maleic anhydride.22 Yields were 
corrected based on the amount of diene in the mixture. 
Electron-donating groups in the para-position worked really good under 
the optimal conditions. Using carbonate IV-1b, with a Boc-protected indol, 
gave the product IV-3b with no trace of the -hydride elimination product. 
Sulfur atoms were also compatible with the reaction conditions, obtaining 
product IV-3c with 91% yield and only 7% of diene. Trifluoromethyl 
substituent at the para position, as starting material gave the desired 
coupled product IV-3d with 58% yield and only 9% of diene. Esters were 
compatible with the reaction conditions and IV-1e gave the desired product 
IV-3e in good yield and only 11% of diene. Methyl substituents were 
compatible in both the orto and meta position. The results using IV-1f as 
starting material was especially good, and it gave IV-3f with 97% yield 
without any appreciable amount of diene. 
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Fluorine and chlorine substituted allylic carbonates IV-1h and IV-1i 
yielded the desired products with good results, however the amount of diene 
was higher in the case of IV-3i, going up to 19% (with a chlorine 
substituent). The result when we used IV-1j, with the trifluoromethyl group 
at the meta position was similar to that of IV-3i and the amount of diene 
went up to 25%. Finally, changing the methyl substituent in the allylic 
position with an ethyl moiety (IV-1k) increased the amount of diene to 
28%. 
It is important to highlight that in all cases the enantiomeric information 
was preserved almost completely. In addition, no trace of the other 
regioisomer was detected in any of the product.  
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Scheme 4-20: Scope of the stereospecific allyl-allyl cross-coupling 
reaction. 
 
We also tried the reaction using the Z-allylic compound (Z)-IV-1a and 
we obtained IV-3a with 50% conversion but only 41% of stereospecificity.  
This result could indicate that a -allyl palladium complex is indeed 
formed. The loss of enantiomeric information could be due to the attack of 
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Pd(0) to the -allyl complex. The results showed in Scheme 4-21 are the 
average of three experiments. 
 
 
Scheme 4-21: Allyl-allyl cross-coupling reaction using Z-allylic 
carbonate. 
  
Stereospecific Synthesis of 1,5-Dienes Through an Allyl-Allyl Cross-
Coupling Strategy. 
 
425 
 
4.2.5. Palladium-Catalyzed Allyl-Allyl Cross-Coupling of Allylic 
Ammonium Salts. Scope of the Reaction. 
As described in Table 4-2, allylic ammonium salt IV-2a underwent the 
Pd catalyzed allyl-allyl cross coupling with similar efficiency to that shown 
for the carbonate derivative. This result prompted us to briefly investigate 
if this was a general trend and to compare the reactivity between allylic 
acetates, carbonates and ammonium salts in this transformation (Table 
4-2). 
With the optimal conditions in hand, we tested the enantiomerically 
enriched allylic ammonium salts prepared previously (Figure 4-3) to 
determine the structural scope of the reaction (Scheme 4-22). Enantiomeric 
ratios were determined by chiral GC-MS. The ratios between the product 
and the undesired diene were measured by 1H-NMR. We were not able to 
separate them by silica chromatography but it was possible to get rid of the 
diene by a simple Diels-Alder reaction with maleic anhydride.22 Yields 
were corrected based on the amount of diene in the mixture. 
Using ammonium salt IV-2d, with a trifluoromethyl substituent at the 
para position, as starting material yielded the desired 1,5 diene IV-3d with 
good yield and 14% of diene. Methyl substituents are compatible in both 
the orto and meta position. Again, the results using IV-2f as starting 
material was better, and it gave IV-3f with 82% yield with only 4% of 
diene.  
Chlorine substituted allylic ammonium salt IV-2i yielded the desired 
product IV-3i with good results. However, when we used IV-2j, with the 
trifluoromethyl group at the meta position, the yield decreased, but we did 
not observe any formation of the -hydride elimination product.  
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It is important to highlight that in all cases the enantiomeric information 
was preserved almost completely. In addition, no trace of the other possible 
regioisomer was detected in any of the products.  
 
 
Scheme 4-22: Scope of the stereospecific allyl-allyl cross-coupling 
reaction using allylic ammonium salts. 
 
4.2.6. Competition Experiments. 
To test the different reactivity between allylic carbonates and 
ammonium salts we did a series of competition experiments. First, we tested 
the reactivity of the carbonate IV-3a against allylic acetate IV-8a (Scheme 
4-23). We put 0.2 mmol of each compound (IV-1a and IV-8a) under the 
reaction conditions. Surprisingly, we observed that only 10% of the starting 
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carbonate IV-1a was converted. In the case of the acetate, we also observed 
10% of conversion.  
 
 
Scheme 4-23: Competition experiment between allylic carbonates and 
acetates. 
 
We next tested the reactivity of the ammonium salt IV-2a against allylic 
acetate IV-8a using the same procedure (Scheme 4-24). In this case, we 
observed total conversion of the ammonium salt and only 11% conversion 
of the acetate. 
 
 
Scheme 4-24: Competition experiment between allylic ammonium 
salts and acetates. 
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Finally, we tested differences between both compounds (Scheme 4-25). 
We put 0.2 mmol of each compound (IV-1a and IV-2a) under the reaction 
conditions. We observed total conversion of the ammonium salt IV-2a and 
43% conversion of IV-1a.  
 
 
Scheme 4-25: Competition experiment between allylic carbonates and 
ammonium salts. 
 
These results could mean that ammonium salts are more reactive than 
the corresponding carbonates under the reaction conditions. Also, it seemed 
as the acetates would shut down the catalytic system when they reacted. 
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4.2.7. Selective functionalization of the alkenes in the 1,5-dienes. 
Tu further demonstrate the utility of the synthetized 1,5-dienes we 
designed a series of transformations, in order to take advantage of the 
different stereoelectronic properties of both alkenes. 
We started trying to functionalize the terminal olefin. Our first attempts 
using OsO4 and -AD-mix gave us complex mixtures of products. We 
found out that treating IV-3a with 9-BBN as borylating agent and 
subsequent oxidation with sodium perborate gave us the terminal alcohol 
IV-11a (Scheme 4-26). 
 
 
Scheme 4-26: Selective hydroboration/oxidation of compound IV-3a. 
 
Next, we planned to transform IV-3a into the rose oxide derivative 
Doremox®.25 This derivative was first reported in 1993 by Firmenich, and 
it increased the substantivity of rose scent in the skin. We envisioned that 
Doremox® could be obtained by a simple cycloisomerization from the 
alcohol (Scheme 4-27, first step). This alcohol could be obtained from the 
corresponding diol coming from diborylate IV-3a (Scheme 4-27). 
 
25 a) Brenna, E.; Fuganti, C.; Ronzani, S.; Serra, S. Can. J. Chem. 2002, 80, 714-
723. b) Coulombel, L.; Weiwer, M.; Duñach, E. Eur. J. Org. Chem. 2009, 5788-
5795. 
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Scheme 4-27: Retrosynthetic analysis of Doremox®. 
 
We decided to attempt the synthesis of this compound. We started the 
synthesis by a metal-free diborylation reaction in the terminal olefin,26 
followed by oxidation of the resulting crude mixture to obtain a 
diastereomeric mixture of diol IV-12 with excellent yield. We continued 
the synthesis by the oxidative cleavage of the diol with NaIO4, followed by 
reduction of the formed aldehyde to obtain alcohol IV-13 (Scheme 4-28).  
 
 
26 Bonet, A.; Pubill-Ulldemolins, C.; Bo, C.; Gulyas, H.; Fernandez, E. Angew. 
Chem. Int. Ed. 2011, 50, 7158-7161. 
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Scheme 4-28: Synthesis of alcohol IV-13. 
 
Finally, by an Al(OTf)3 catalyzed cycloisomerization, we obtained the 
desired product with excellent yield and a diastereomeric ratio of 94:6 
(Scheme 4-29). 
 
 
Scheme 4-29: Synthesis of the rose oxide derivative Doremox®. 
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To functionalize the internal olefin, we selected an epoxidation using m-
CPBA, obtaining a diastereomeric mixture of epoxides. Then, 
regioselective opening of the epoxide by treatment with DIBAL-H, 
followed by oxidation with Dess-Martin periodinane afforded ketone IV-
14 with a global yield of 43% (Scheme 4-30). 
 
 
Scheme 4-30: Synthesis of ketone IV-14. 
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4.3. Conclusions. 
In this chapter we have described the regioselective and stereospecific 
palladium-catalyzed allyl-allyl cross-coupling between allylic carbonates 
or ammonium salts and allyl boronates leading to the corresponding 1,5-
dienes. We have solved some of the remnant problems in this kind of 
reactions as the regioselectivity and the stereospecificity. Also, we have 
minimized the amount of b-hydride elimination product formed in the 
reaction (Scheme 4-31). 
The nature of the leaving group and the ligand used in the reaction are 
key factors to control the regioselectivity and the stereospecificity of the 
reaction. The use of carbonates or ammonium salts along an electron rich 
and bulky monodentate ligand was crucial to control the outcome of the 
reaction.  
Furthermore, taking advantage of the two different olefins formed in the 
reaction, we have selectively functionalized both of them to access valuable 
compounds as the cyclic ether Doremox®. 
  
 
Scheme 4-31: Palladium-catalyzed allyl-allyl cross-coupling between 
allylic carbonates or ammonium salts and allylic boronates. 
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4.4. Conclusions. 
En este capítulo, se ha descrito el acoplamiento cruzado alilo-alilo entre 
carbonatos alílicos o sales de amonio alílicas y boronatos alílicos para la 
síntesis de 1,5-dienos de manera regioselectiva y estereoespecífica. Con 
esta metodología, hemos solventado los problemas de regioselectividad y 
estereoespecifidad que acarrean este tipo de reacciones. También, hemos 
conseguido minimizar la cantidad de producto de -eliminación de hidruro 
formado durante la reacción (Esquema 4-32). 
La naturaleza del grupo saliente y del ligando son factores importantes 
para el control de la regioselectividad y la estereoespecificidad. El uso de 
carbonatos alílicos o sales de amonio alílicas junto a un ligando rico, con 
gran impedimento estérico y monodentado fue crucial para controlar el 
resultado de la reacción.  
Además, aprovechando que durante la reacción se forman dos olefinas 
con diferentes propiedades estéricas y electrónicas, hemos funcionalizado 
selectivamente ambos dobles enlaces llegando a productos de gran valor, 
como el éter cíclico Doremox®.  
  
 
Esquema 4-32: Acoplamiento cruzado alilo-alilo catalizado por 
paladio entre carbonatos alílicos o sales de amonio alílicas y boronatos 
alílicos. 
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4.5. Supplementary Data. 
Tetrahydrofuran and dichloromethane were purified by passing through 
a Pure Solv™ column drying system from Innovative Technology, Inc. 
Additionally, Tetrahydrofuran and dichloromethane were degassed passing 
Argon through them for 15 min. Diethyl ether was dried using activated 4Å 
molecular sieves and stored under argon. Unless indicated otherwise, all 
reactions were conducted under an argon atmosphere using flame-dried 
glassware with standard vacuum-line techniques. NMR spectra were 
acquired on a Bruker 300 spectrometer, running at 300, and 75 MHz for 1H 
and 13C NMR respectively. Chemical shifts (δ) are reported in ppm relative 
to residual solvent signals (CDCl3, 7.26 ppm for 
1H NMR and 77.2 ppm for 
13C NMR respectively). 13C NMR spectra were acquired on a broad band 
decoupled mode. The following abbreviations are used to describe peak 
patterns when appropriate: s (singlet), d (doublet), t (triplet), q (quartet), 
quint (quintet), sex (sextet), hept (septuplet), m (multiplet), br (broad). 
Analytical thin layer chromatography (TLC) was performed using pre-
coated aluminum-backed plates (Merck Kieselgel 60 F254) and visualized 
by ultraviolet irradiation or phosphomolybdic acid dip or potassium 
permanganate dip. Purification of reaction mixtures was carried out by flash 
chromatography (FC) using silica gel Merck-60. Optical rotations were 
measured on a Perkin-Elmer 241 polarimeter. The enantiomeric ratio (e.r.) 
of the products was determined by stationary phase SFC, HPLC or GC-MS 
using chiral columns. Mass Spectrometry (MS) and High Resolution Mass 
Spectrometry (HRMS) were registered in a spectrometer GCT Agilent 
Technologies 6890N using Electronic Impact (E.I.) techniques at 70 eV, 
Fast Atom Bombardment and electrospray (ESI+ or ESI-).  
All ligands, metal complexes, allylboronic acid pinacol ester and Amano 
Lipase from Pseudomonas fluorescens were acquired from commercial 
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sources and were used without further purification. Cinnamyl alcohol, 4-
Phenyl-3-buten-2-one were purchased from Sigma Aldrich and were used 
without purification. 
4.5.1. Synthesis of starting materials. 
4.5.1.1. Synthesis of ,-unsaturated ketones IV-6. 
 
 
To an oven-dried round bottom flask was added the corresponding 
aromatic aldehyde (1.0 equiv), 1-(triphenylphosphoranylidene)-2-
propanone (1.2 equiv) and toluene (2 mL/mmol of aldehyde). The reaction 
mixture was stirred for 16 h at reflux. Silica gel was added to the mixture 
and the solvent was removed under reduced pressure. The crude product 
was purified by flash column chromatography using the appropriate 
mixture of solvents. 
tert-Butyl (E)-5-(3-oxobut-1-en-1-yl)-1H-indole-1-carboxylate, IV-6b. 
From tert-butyl 5-formyl-1H-indole-1-carboxylate 
(8.5 g, 34.7 mmol), following the general procedure 
described above, compound IV-6b (8.41 g, 29.5 
mmol) was obtained in 85% yield as a yellow solid 
after flash column chromatography (Cy/EtOAc, 90/10). 
1H NMR, 13C NMR and MS data were consistent with literature 
values.27 1H NMR (300 MHz, CDCl3) δ 8.17 (d, J = 8.6 Hz, 1H), 7.76-7.59 
 
27 Zhang, H.; Han, M.; Chen, T.; Xu, L.; Yu, L. RSC Adv. 2017, 7, 48214-48221. 
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(m, 4H), 6.76 (dd, J = 16.3, 1.9 Hz, 1H), 6.60 (s, 1H), 2.41 (s, 3H), 1.69 (s, 
9H). 
(E)-4-(4-(Methylthio)phenyl)but-3-en-2-one, IV-6c. 
From 4-(methylthio)benzaldehyde (4.6 g, 30.0 
mmol), following the general procedure described 
above, compound IV-6c (5.76 g, 30.0 mmol) was 
obtained in 99% yield as a white solid after flash 
column chromatography (Cy/EtOAc, 90/10). 
1H NMR, 13C NMR and MS data were consistent with literature 
values.28 1H NMR (300 MHz, CDCl3) δ 7.46 (m, 3H), 7.26 – 7.19 (m, 2H), 
6.67 (d, J = 16.3 Hz, 1H), 2.50 (s, 3H), 2.37 (s, 3H). 
 
(E)-4-(4-(Trifluoromethyl)phenyl)but-3-en-2-one, IV-6d. 
From 4-(trifluoromethyl)benzaldehyde (7.80 g, 
45.0 mmol), following the general procedure 
described above, compound IV-6d (9.78 g, 45.0 
mmol) was obtained in 99% yield as a yellow solid 
after flash column chromatography (Cy/EtOAc, 90/10). 
1H NMR, 13C NMR and MS data were consistent with literature 
values.29 1H NMR (300 MHz, CDCl3) δ 7.65 (s, 4H), 7.52 (d, J = 16.3 Hz, 
1H), 6.77 (d, J = 16.3 Hz, 1H), 2.40 (s, 3H). 
 
 
 
28 Antiñolo, A.; Carrillo-Hermosilla, F.; Cadierno, V.; Garcia-Alvarez, J.; Otero, 
A. ChemCatChem 2012, 4, 123-128. 
29 Zhang, S.-L.; Deng, Z.-Q. Org. Biomol. Chem. 2016, 14, 7282-7294. 
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Methyl (E)-4-(3-oxobut-1-en-1-yl)benzoate, IV-6e. 
From methyl 4-formylbenzoate (4.9 g, 30.0 
mmol), following the general procedure described 
above, compound IV-6e (5.49 g, 27.0 mmol) was 
obtained in 90% yield as a white solid after flash 
column chromatography (Cy/EtOAc, 90/10). 
1H NMR, 13C NMR and MS data were consistent with literature 
values.29 1H NMR (300 MHz, CDCl3) δ 8.06 (d, J = 8.4 Hz, 2H), 7.60 (d, J 
= 8.3 Hz, 2H), 7.52 (d, J = 16.3 Hz, 1H), 6.78 (d, J = 16.3 Hz, 1H), 3.93 (s, 
3H), 2.40 (s, 3H). 
 
(E)-4-(o-Tolyl)but-3-en-2-one, IV-6f. 
From 2-methylbenzaldehyde (2.4 g, 20.0 mmol), 
following the general procedure described above, 
compound IV-6f (2.69 g, 16.8 mmol) was obtained in 
84% yield as a yellow oil after flash column 
chromatography (Cy/EtOAc, 90/10). 
1H NMR, 13C NMR and MS data were consistent with literature 
values.29 1H NMR (300 MHz, CDCl3) δ 7.83 (d, J = 16.1 Hz), 7.57 (d, J = 
7.2 Hz, 1H), 7.32-7.20 (m, 3H), 6.66 (d, J = 16.0 Hz, 1H), 2.46 (s, 3H), 2.39 
(s, 3H). 
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(E)-4-(m-Tolyl)but-3-en-2-one, IV-6g. 
From 3-methylbenzaldehyde (2.4 g, 20.0 mmol), 
following the general procedure described above, 
compound IV-6g (2.98 g, 18.6 mmol) was obtained in 
93% yield as a yellow oil after flash column 
chromatography (Cy/EtOAc, 90/10). 
1H NMR, 13C NMR and MS data were consistent with literature 
values.30 1H NMR (300 MHz, CDCl3) δ 7.50 (d, J = 16.3 Hz, 1H), 7.40 – 
7.19 (m, 4H), 6.72 (d, J = 16.3 Hz, 1H), 2.39 (s, 6H). 
 
(E)-4-(3-Fluorophenyl)but-3-en-2-one, IV-6h. 
From 3-fluorobenzaldehyde (3.7 g, 30.0 mmol), 
following the general procedure described above, 
compound IV-6h (4.72 g, 28.8 mmol) was obtained in 
96% yield as a yellow oil after flash column 
chromatography (Cy/EtOAc, 90/10). 
1H NMR, 13C NMR and MS data were consistent with literature 
values.31 1H NMR (300 MHz, CDCl3) δ 7.48 (d, J = 16.3 Hz, 1H), 7.36 (m, 
2H), 7.26 (m, 1H), 7.12 (m, 1H), 6.72 (d, J = 16.3 Hz, 1H), 2.40 (s, 3H). 
 
(E)-4-(3-Chlorophenyl)but-3-en-2-one, IV-6i. 
From 3-chlorobenzaldehyde (2.8 g, 20.0 mmol), 
following the general procedure described above, 
compound IV-6i (3.40 g, 18.8 mmol) was obtained in 
94% yield as a yellow oil after flash column 
chromatography (Cy/EtOAc, 90/10). 
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1H NMR, 13C NMR and MS data were consistent with literature 
values.30 1H NMR (300 MHz, CDCl3) δ 7.52–7.30 (m, 5H), 6.71 (d, J = 
15.8 Hz, 1H), 2.38 (s, 3H). 
 
(E)-4-(3-(Trifluoromethyl)phenyl)but-3-en-2-one, IV-6j. 
From 3-(trifluoromethyl)benzaldehyde (5.0 g, 28.7 
mmol), following the general procedure described above, 
compound IV-6j (5.71 g, 26.7 mmol) was obtained in 
93% yield as a yellow solid after flash column 
chromatography (Cy/EtOAc, 90/10). 
1H NMR, 13C NMR and MS data were consistent with literature 
values.31 1H NMR (300 MHz, CDCl3) δ 7.79 (s, 1H), 7.72 (d, J = 8.0 Hz, 
1H), 7.62 (d, J = 8.0 Hz, 1H), 7.56-7.50 (m, 2H), 6.78 (d, J = 16.0 Hz, 1H), 
2.40 (s, 3H). 
 
4.5.1.2. Synthesis of allylic alcohols, IV-7. 
 
 
To an oven-dried round bottom flask was added the corresponding 
ketone (1 equiv) in methanol (0.3M) and cooled to 0 ºC. To this solution, 
 
30 Pan, G.-F.; Zhu, X.-Q.; Guo, R.-L.; Gao, Y.-R.; Wang, Y.-Q. Adv. Synth. Catal. 
2018, 360, 4774-4783. 
 
31 Liu, J.; Zhu, X.-R.; Ren, J.; Chen, W.-D.; Zeng, B.-B. Synlett, 2013, 24, 2740-
2742. 
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sodium borohydride (1.45 equiv) in H2O was added dropwise and the 
reaction mixture was stirred for 1 h at 0 ºC. Then, the mixture was warmed 
to room temperature and stirred overnight. The reaction mixture was 
quenched with saturated aqueous solution of ammonium chloride and 
extracted with Et2O (3x), dried over MgSO4 and the solvent was removed 
under reduced pressure. The crude product was purified by flash column 
chromatography on silica gel using the appropriate mixture of solvents. 
The enantiopure allylic alcohols were obtained by kinetic resolution 
using Amano Lipase from Pseudomonas fluorescens following the reported 
procedure.32 
 
 
 
To an oven-dried round bottom flask was added the racemic alcohol (±)-
IV-7 (1 equiv), molecular sieves (50 % w/w) and Amano Lipase from 
Pseudomonas fluorescens (50 % w/w). The flask was connected to an 
argon-vacuum line, evacuated and backfilled with argon (x3). n-Hexane 
(150 mL) was added, followed by vinyl acetate (3 equiv) and the reaction 
mixture was stirred at room temperature for 24 h. After completion 
(checked by chiral SFC or HPLC) the reaction was filtered, and the solvent 
was removed under reduced pressure. The product is purified by flash 
column chromatography on silica gel using the appropriate mixture of 
solvents. 
 
32 Li, Z.; Parr, B. T.; Davies, H. M. L. J. Am. Chem. Soc. 2012, 184, 10942. 
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(−)-(S,E)-4-Phenylbut-3-en-2-ol, IV-7a. 
From (E)-4-phenylbut-3-en-2-one (5.0 g, 34.2 mmol), 
following the general procedure described above, 
compound (±)-IV-7a (4.7 g, 31.5 mmol) was obtained in 
92% yield as a pale yellow oil after flash column chromatography 
(Cy/EtOAc, 90/10). 
1H NMR, 13C NMR and MS data were consistent with literature values. 
33  1H-NMR (300 MHz, CDCl3): δ 7.41-7.24 (m, 5H), 6.56 (d, J = 15.8 Hz, 
1H), 6.27 (d, J = 15.8, 6.4 HZ, 1H), 4.51 (quint, J = 6.3 Hz, 1H), 1.92 (s 
broad, 1H), 1.38 (d, J = 6.5 Hz, 3H). 
From (±)-IV-7a (4.0 g, 27 mmol), following the general procedure 
described above, compound IV-7a (1.6 g, 10.8 mmol) was obtained in 40% 
yield as a pale yellow oil after flash column chromatography (Cy/EtOAc, 
90/10). Compound IV-7a was obtained in 99:1 enantiomeric ratio 
determined by HPLC using Chiralpak-IC column [Hexane/iPrOH (99:1)], 
1.0 mL/min, major = 11.8 min, minor = 10.5 min. [α]20D = −28.8 (c = 1.0, 
CHCl3). We assigned the absolute configuration by comparison of the 
optical rotation with that of the previously reported compound.33  
(−)-tert-Butyl-(S,E)-5-(3-hydroxybut-1-en-1-yl)-1H-indole-1-
carboxylate, IV-7b.  
 From tert-butyl (E)-5-(3-oxobut-1-en-1-yl)-1H-
indole-1-carboxylate (9.88 g, 34.6 mmol), following 
the general procedure described above, compound 
(±)-IV-7b  (32.9 mmol) was obtained in 95% yield as 
a pale yellow oil after flash column chromatography (Cy/EtOAc, 85/15). 
 
33 Inagaki, T.; Ito, A.; Ito, J.; Nishiyama, H. Angew. Chem. Int. Ed. 2010, 49, 
9384-9387. 
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1H-RMN (300 MHz, CDCl3): δ 7.96 (d, J = 8.7 Hz, 1H), 7.45 (d, J = 3.6 
Hz, 1H), 7.35 (s broad, 1H), 7.25 (d, J = 8.7 Hz, 1H), 6.52 (d, J = 16.2 Hz, 
1H), 6.39 (d, J = 3.5 Hz, 1H), 6.11 (dd, J = 15.8, 6.4 Hz, 1H), 4.37 (quint, 
J = 6.4 Hz, 1H), 2.24 (s broad, 1H), 1.54 (s, 9H), 1.27 (d, J = 6.4 Hz, 3H). 
13C NMR (75 MHz, CDCl3): δ 149.6, 134.7, 132.4, 131.5, 130.8, 129.6, 
126.3, 122.6, 118.9, 115.1, 107.4, 83.7, 68.9, 28.1, 23.5. HRMS-ESI+ m/z 
calculated for C17H21NO3Na [M+Na]
+: 310.1413, found 310.1427. 
From (±)-IV-7b (3.5 g, 16.2 mmol), following the general procedure 
described above, compound IV-7b (1.4 g, 6.5 mmol) was obtained in 40% 
yield as a pale yellow oil after flash column chromatography (Cy/EtOAc, 
85/15). Compound IV-7b was obtained in 99:1 enantiomeric ratio 
determined by HPLC using Chiralpak-IA column [Hexane/iPrOH (98:2)], 
1.0 mL/min, major = 8.8 min, minor = 12.0 min. [α]20D = −21.6 (c = 1.0, 
CHCl3). 
 
(−)-(S,E)-4-(4-(Methylthio)phenyl)but-3-en-2-ol, IV-7c.  
From methyl (E)-4-(4-(methylthio)phenyl)but-3-
en-2-one (5.76 g, 30.0 mmol), following the general 
procedure described above, compound IV-7c was 
obtained in 85% yield as a white solid after flash 
column chromatography (Cy/EtOAc, 70/30). 
1H NMR, 13C NMR and MS data were consistent with literature 
values.34 1H-NMR (300 MHz, CDCl3): δ 7.30 (d, J = 8.4 Hz, 2H), 7.20 (d, 
J = 8.4 Hz, 2H), 6.52 (d, J = 15.9 Hz, 1H), 6.22 (dd, J = 15.9, 6.4 Hz, 1H), 
4.48 (quint, J = 7.1, 6.6 Hz, 1H), 2.48 (s, 3H), 1.37 (d, J = 6.4 Hz, 3H). 
 
34 Zhou, Q.; Srinivas, H. D.; Zhang, S.; Watson, M. P. J. Am. Chem. Soc. 2016, 
138, 11989. 
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From (±)-IV-7c (2.0 g, 10.3 mmol), following the general procedure 
described above, compound IV-7c (0.95 g, 4.9 mmol) was obtained in 47% 
yield as a pale yellow oil after flash column chromatography (Cy/EtOAc, 
90/10). Compound IV-7c was obtained in 99:1 enantiomeric ratio 
determined by HPLC using Chiralpak-IC column [Hexane/iPrOH (95:5)], 
1.0 mL/min, major = 11.4 min, minor = 9.7 min. [α]20D = −33.8 (c = 1.0, 
CHCl3). 
 
(−)-(S,E)-4-(4-(Trifluoromethyl)phenyl)but-3-en-2-ol, IV-7d. 
 From (E)-4-(4-(trifluoromethyl)phenyl)but-3-en-
2-one (3.76 g, 17.5 mmol), following the general 
procedure described above, compound (±)-IV-7d (3.7 
g, 17.3 mmol) was obtained in 99% yield as a pale 
yellow oil after flash column chromatography (Cy/EtOAc, 90/10). 
1H NMR, 13C NMR and MS data were consistent with literature 
values.35 1H-NMR (300 MHz, CDCl3): δ 7.56 (d, J = 7.9 Hz, 2H), 7.45 (d, 
J = 7.9 Hz, 2H), 6.60 (d, J = 15.7 Hz, 1H), 6.35 (dd, J = 15.2, 5.8 Hz, 1H), 
4.52 (quint, J = 7.7 Hz, 1H), 1.93 (s broad, 1H), 1.39 (d, J = 6.4 Hz, 3H). 
From (±)-IV-7d (3.2 g, 14.8 mmol), following the general procedure 
described above, compound IV-7d (1.2 g, 5.3 mmol) was obtained in 36% 
yield as a pale yellow oil after flash column chromatography (Cy/EtOAc, 
90/10). Compound IV-7d was obtained in 99:1 enantiomeric ratio 
determined by HPLC using Chiralpak-IA column [Hexane/iPrOH (99:1)], 
1.0 mL/min, major = 12.1 min, minor = 10.9 min. [α]20D = −13.4 (c = 1.0, 
CHCl3). 
 
35 Zhang, Z.; Lee, S. D.; Fisher, A. S.; Widenhoefer, R. A. Tetrahedron, 2009, 
65, 1794. 
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(−)-Methyl (S,E)-4-(3-hydroxybut-1-en-1-yl)benzoate, IV-7e.  
From methyl (E)-4-(3-oxobut-1-en-1-yl)benzoate 
(5.49 g, 27.0 mmol), following the general procedure 
described above, compound IV-7e was obtained in 
88% yield as a pale yellow oil after flash column 
chromatography (Cy/EtOAc, 70/30). 
1H NMR, 13C NMR and MS data were consistent with literature 
values.36 1H-NMR (300 MHz, CDCl3): δ 7.97 (d, J = 8.4 Hz, 2H), 7.41 (d, 
J = 8.3 Hz, 2H), 6.60 (d, J = 16.0 Hz, 1H), 6.37 (dd, J = 15.9, 6.0 Hz, 1H), 
4.51 (quint, J = 6.4 Hz, 1H), 3.90 (s, 3H), 1.38 (d, J = 6.4 Hz, 3H). 
From (±)-IV-7e (2.0 g, 9.7 mmol), following the general procedure 
described above, compound IV-7e (0.93 g, 4.5 mmol) was obtained in 46% 
yield as a pale yellow oil after flash column chromatography (Cy/EtOAc, 
90/10). Compound IV-7e was obtained in 99:1 enantiomeric ratio 
determined by HPLC using Chiralpak-IA column [Hexane/iPrOH (95:5)], 
1.0 mL/min, major = 12.9 min, minor = 15.7 min. [α]20D = −30.4 (c = 1.0, 
CHCl3). 
 
(−)-(S,E)-4-(o-Tolyl)but-3-en-2-ol, IV-7f.  
 From (E)-4-(o-tolyl)but-3-en-2-one (2.60 g, 16.2 
mmol), following the general procedure described above, 
compound (±)-IV-7f (1.7 g, 10.2 mmol) was obtained in 
63% yield as a pale yellow oil after flash column 
chromatography (Cy/EtOAc, 90/10). 
 
36 Chen, F.; Zhang, Y.; Yu, L.; Zhu, S. Angew. Chem. Int. Ed. 2017, 56, 2022. 
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1H NMR, 13C NMR and MS data were consistent with literature 
values.37 1H-NMR (300 MHz, CDCl3): δ 7.45-7.43 (m, 1H), 7.18-7.15 (m, 
3H), 6.79 (d, J = 16.3, 1H), 6.16 (dd, J = 16.2, 6.7 Hz, 1H), 4.51 (quint, J = 
6.4 Hz, 1H), 2.35 (s, 3H), 1.39 (d, J = 6.3 Hz, 3H). 
From (±)-IV-7f (2.2 g, 13.5 mmol), following the general procedure 
described above, compound IV-7f (0.9 g, 5.7 mmol) was obtained in 42% 
yield as a pale yellow oil after flash column chromatography (Cy/EtOAc, 
90/10). Compound IV-7f was obtained in 99:1 enantiomeric ratio 
determined by HPLC using Chiralpak-IG column [Hexane/iPrOH (99:1)], 
1.0 mL/min, major = 12.1 min, minor = 10.8 min. [α]20D = −15.7 (c = 1.0, 
CHCl3). 
 
(−)-(S,E)-4-(m-Tolyl)but-3-en-2-ol, IV-7g.  
 From (E)-4-(m-tolyl)but-3-en-2-one (4.37 g, 27.3 
mmol), following the general procedure described above, 
compound IV-7g was obtained in 82% yield as a pale 
yellow oil after flash column chromatography (Cy/EtOAc, 
90/10). 
1H NMR, 13C NMR and MS data were consistent with literature 
values.37 1H-NMR (300 MHz, CDCl3): δ 7.28-7.19 (m, 3H), 7.07 (d, J = 
6.1 Hz, 1H), 6.53 (d, J = 16.1, 1H), 6.25 (dd, J = 15.8, 6.5 Hz, 1H), 4.50 
(sext, J = 6.1 Hz, 1H), 2.36 (s, 3H), 1.57 (d, J = 4.2 Hz, 1H), 1.38 (d, J = 
6.3 Hz, 3H). 
From (±)-IV-7g (2 g, 12.3 mmol), following the general procedure 
described above, compound IV-7g (0.88 g, 5.4 mmol) was obtained in 44% 
yield as a pale yellow oil after flash column chromatography (Cy/EtOAc, 
90/10). Compound IV-7g was obtained in 99:1 enantiomeric ratio 
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determined by HPLC using Chiralpak-IBN column [Hexane/iPrOH (99:1)], 
1.0 mL/min, major = 21.1 min, minor = 13.4 min. [α]20D = −27.8 (c = 1.0, 
CHCl3). 
 
(−)-(S,E)-4-(3-Fluorophenyl)but-3-en-2-ol, IV-7h.  
From (E)-4-(3-(fluoromethyl)phenyl)but-3-en-2-one 
(4.92 g, 30 mmol), following the general procedure 
described above, compound (±)-IV-7h was obtained in 
93% yield as a pale yellow oil after flash column 
chromatography (Cy/EtOAc, 80/20). 
1H-NMR (300 MHz, CDCl3): δ 7.33 – 7.21 (m, 1H), 7.17 – 7.04 (m, 
2H), 6.94 (m, 1H), 6.55 (d, J = 15.9 Hz, 1H), 6.27 (dd, J = 15.9, 6.1 Hz, 
1H), 4.50 (quintd, J = 6.3, 1.3 Hz, 1H), 1.79 (s, 1H), 1.38 (d, J = 6.4 Hz, 
3H). 13C-NMR (76 MHz, CDCl3) δ 163.2 (d, JC-F = 245 Hz), 139.3 (d, JC-F 
= 8 Hz) 135.10, 130.1(d, JC-F = 8 Hz), 128.3 (d, JC-F = 3 Hz), 122.5 (d, JC-F 
= 3 Hz), 114.5 (d, JC-F = 21 Hz), 113.0 (d, JC-F = 22 Hz), 68.76, 23.52. 
HRMS-EI+ m/z calculated for C10H11OF [M]
+: 166.0794, found 166.0790.  
From (±)-IV-7h (1.7 g, 10.3 mmol), following the general procedure 
described above, compound IV-7h (0.75 g, 4.5 mmol) was obtained in 44% 
yield as a pale yellow oil after flash column chromatography (Cy/EtOAc, 
90/10). Compound IV-7h was obtained in 99:1 enantiomeric ratio 
determined by HPLC using Chiralpak-IBN column [Hexane/iPrOH (95:5)], 
1.0 mL/min, major = 8.5 min, minor = 6.3 min. [α]20D = −19.0 (c = 1.0, 
CHCl3). 
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(−)-(S,E)-4-(3-Chlorophenyl)but-3-en-2-ol, IV-7i.  
From (E)-4-(3-chlorophenyl)but-3-en-2-one (3.15 g, 
17.4 mmol), following the general procedure described 
above, compound (±)-IV-7i was obtained in 92% yield as 
a pale yellow oil after flash column chromatography 
(Cy/EtOAc, 90/10). 
1H NMR, 13C NMR and MS data were consistent with literature 
values.37 1H-NMR (300 MHz, CDCl3): δ 7.36 (s broad, 1H), 7.27-7.19 (m, 
3H), 6.52 (dd, J = 15.9, 1.3 Hz, 1H), 6.27 (dd, J = 15.9, 6.3 Hz, 1H), 4.54-
4.45 (quint, J = 6.5, 1.2 Hz, 1H), 1.74 (s broad, 1H), 1.38 (d, J = 6.5 Hz,  
3H). 
From (±)-IV-7i (2.8 g, 15.3 mmol), following the general procedure 
described above, compound IV-7i (1.1 g, 5.8 mmol) was obtained in 38% 
yield as a pale yellow oil after flash column chromatography (Cy/EtOAc, 
90/10). Compound IV-7i was obtained in 99:1 enantiomeric ratio 
determined by HPLC using Chiralpak-IBN column [Hexane/iPrOH (98:2)], 
1.0 mL/min, major = 25.0 min, minor = 12.3 min. [α]20D = −17.3 (c = 1.0, 
CHCl3). 
 
(−)-(S,E)-4-(3-(Trifluoromethyl)phenyl)but-3-en-2-ol, IV-7j. 
From (E)-4-(3-(trifluoromethyl)phenyl)but-3-en-2-one 
(5.73 g, 26.7 mmol), following the general procedure 
described above, compound (±)-IV-7j (5.6 g, 25.9 mmol) 
was obtained in 97% yield as a pale yellow oil after flash 
column chromatography (Cy/EtOAc, 90/10). 
 
37 Li, X.; Li, L.; Tang, Y.; Zhong, L.; Cun, L.; Zhu, J.; Liao, J.; Deng, J. J. Org. 
Chem. 2010, 75, 2981. 
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1H NMR, 13C NMR and MS data were consistent with literature 
values.38 1H-NMR (300 MHz, CDCl3): δ 7.62 (s, 1H), 7.56-7.40 (m, 3H), 
6.62 (d, J = 15.8, 1H), 6.35 (dd, J = 15.8, 6.2 Hz, 1H), 4.53 (s broad, 1H), 
1.39 (d, J = 6.2 Hz, 3H). 
From (±)-IV-7j (3.5 g, 16.2 mmol), following the general procedure 
described above, compound IV-7j (1.4 g, 6.5 mmol) was obtained in 40% 
yield as a pale yellow oil after flash column chromatography (Cy/EtOAc, 
90/10). Compound IV-7j was obtained in 99:1 enantiomeric ratio 
determined by HPLC using Chiralpak-IA column [Hexane/iPrOH (99:1)], 
1.0 mL/min, major = 8.7 min, minor = 8.1 min. [α]20D = −19.0 (c = 1.0, 
CHCl3). 
 
4.5.1.3. Synthesis of (−)-(S,E)-1-phenylpent-1-en-3-ol, IV-7k.  
 
To a solution of cinnamaldehyde (6.61 g, 30.0 mmol, 1 equiv) in THF 
(90 mL) at 0 ºC, was added dropwise a solution of ethylmagnesium bromide 
(36 mmol, 1.2 equiv, 1M in THF). The reaction was stirred at 0 ºC for 2 h 
and then was allowed to warm to room temperature and stirred overnight. 
The reaction mixture was quenched with water and extracted with diethyl 
ether for three times, dried over MgSO4 and the solvent was removed under 
reduced pressure. The crude product was purified by flash column 
chromatography on silica gel. Compound (±)-IV-7k was obtained in 92% 
 
38 Sgalla, S.; Fabrizi, G.; Cirilli, R.; Macone, A.; Bonamore, A.; Boffic, A.; 
Cacchia, S. Tetrahedron: Asymmetry, 2007, 18, 2791. 
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yield as a yellowish oil after flash column chromatography (Cy/EtOAc, 
80/20). 
1H NMR, 13C NMR and MS data were consistent with literature 
values.37 1H-RMN (300 MHz, CDCl3): δ 7.42-7.24 (m, 5H), 6.58 (d, J = 
16.3, 1H), 6.23 (dd, J = 15.9, 6.6 Hz, 1H), 4.23 (m, 1H), 1.69 (m, 3H), 1.00 
(t, J = 7.4 Hz, 3H). 
The enantiopure allylic alcohol was obtained from the kinetic resolution 
using Amano Lipase from Pseudomonas fluorescens following the previous 
procedure.32 
From (±)-IV-7k (2.0 g, 12.3 mmol), following the general procedure 
described above, compound IV-7k (0.99 g, 5.0 mmol) was obtained in 50% 
yield as a pale yellow oil after flash column chromatography (Cy/EtOAc, 
95/5). Compound IV-7k was obtained in 99:1 enantiomeric ratio 
determined by HPLC using Chiralpak-IC column [Hexane/iPrOH (95:5)], 
1.0 mL/min, major = 5.8 min, minor = 5.1 min. [α]20D = −32.7 (c = 1.0, 
CHCl3). 
 
4.5.1.4. Synthesis of allylic carbonates, IV-1. 
 
 
To a solution of the corresponding alcohol IV-7 (1 equiv) and pyridine 
(3 equiv) in CH2Cl2 (0.2M) at 0 ºC was added dropwise methyl 
chloroformate (2 equiv). The reaction mixture was allowed to warm to 
room temperature and stirred overnight. The reaction was quenched by 
addition of 1M HCl aqueous solution and extracted three times with Et2O, 
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dried over MgSO4, filtered and the solvent was removed under reduced 
pressure. The crude product was purified by flash column chromatography 
on silica gel using the appropriate mixture of solvents.39 
 
(−)-(S,E)-Methyl (4-phenylbut-3-en-2-yl) carbonate, IV-1a. 
From (S,E)-4-phenylbut-3-en-2-ol (1.51 g, 10.2 
mmol), following the general procedure described 
above, compound IV-1a (1.9 g, 9.4 mmol) was 
obtained in 92% yield as a colorless oil after flash 
column chromatography (Cy/EtOAc, 90/10). 
1H NMR, 13C NMR and MS data were consistent with literature 
values.40 1H-NMR (300 MHz, CDCl3): δ 7.45-7.28 (m, 5H), 6.67 (d, J = 
15.9 Hz, 1H), 6.23 (d, J = 16.0, 7.1 Hz, 1H), 5.43 (quint, J = 6.2 Hz, 1H), 
3.83 (s, 3H), 1.51 (d, J = 6.5 Hz, 3H). 
Compound IV-1a was obtained in 99:1 enantiomeric ratio determined 
by HPLC using Chiralpak-IA column [Hexane/iPrOH (99:1)], 1.0 mL/min, 
major = 3.5 min, minor = 3.1 min. [α]20D = −117.4 (c = 1.0, CHCl3). 
 
(−)-tert-Butyl-(S,E)-5-(3-((methoxycarbonyl)oxy)but-1-en-1-yl)-1H-
indole-1-carboxylate, IV-1b. 
 From tert-butyl (S,E)-5-(3-hydroxybut-1-
en-1-yl)-1H-indole-1-carboxylate (0.7 g, 2.5 
mmol), following the general procedure 
described above, compound IV-1b was 
 
39 Li, C.; Breit, B. Chem. Eur.J. 2016, 22, 14655. 
40 Trost, B. M.; Richardson, J.; Yong, K. J. Am. Chem. Soc. 2006, 128, 2540. 
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obtained in 91% yield as a pale yellow oil after flash column 
chromatography (Cy/EtOAc, 90/10). 
1H-NMR (300 MHz, CDCl3): δ 8.07 (d, J = 8.5 Hz, 1H), 7.57 (m, 2H), 
7.38 (d, J = 8.5 Hz, 1H), 6.73 (d, J = 15.8 Hz, 1H), 6.55 (d, J = 3.7 Hz, 1H), 
6.20 (dd, J = 15.9, 7.1 Hz, 1H), 5.42 (quint, J = 6.5 Hz, 1H), 3.81 (s, 3H), 
1.69 (s, 9H), 1.50 (d, J = 6.2 Hz, 3H). 13C-NMR (75 MHz, CDCl3): δ 155.2, 
149.5, 135.1, 132.8, 130.9, 130.8, 126.8, 126.4, 122.9, 119.4, 115.2, 107.3, 
83.7, 75.6, 54.5, 28.1, 20.5. HRMS-ESI+ m/z calculated for C19H23NO5Na 
[M+Na]+: 368.1492, found 368.1483. 
Compound IV-1b was obtained in 97:3 enantiomeric ratio determined 
by HPLC using Chiralpak-IA column [Hexane/iPrOH (99:1)], 1.0 mL/min, 
major = 6.0 min, minor = 5.3 min. [α]20D = −79.6 (c = 1.0, CHCl3). 
 
(−)-(S,E)-Methyl (4-(4-(methylthio)phenyl)but-3-en-2-yl) carbonate, 
IV-1c. 
 From (S,E)-4-(4-(methylthio)phenyl)but-3-
en-2-ol (693 mg, 3.6 mmol), following the 
general procedure described above, compound 
IV-1c was obtained in 52% yield as a pale yellow 
oil after flash column chromatography (Cy/EtOAc, 90/10). 
1H-NMR (300 MHz, CDCl3): δ 7.30 (d, J = 8.4 Hz, 2H), 7.19 (d, J = 8.4 
Hz, 2H), 6.59 (d, J = 16.0 Hz, 1H), 6.15 (dd, J = 15.9, 7.0 Hz, 1H), 5.36 
(m, 1H), 3.78 (s, 3H), 2.48 (s, 3H), 1.46 (d, J = 6.5 Hz, 3H). 13C-NMR (75 
MHz, CDCl3): δ 155.3, 138.6, 133.2, 131.8, 127.6, 127.2, 126.7, 75.5, 54.8, 
20.6, 15.9. HRMS-ESI+ m/z calculated for C13H16O3SNa [M+Na]
+: 
275.0712, found 275.0717. 
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Compound IV-1c was obtained in 99:1 enantiomeric ratio determined 
by HPLC using Chiralpak-IC column [Hexane/iPrOH (99:1)], 1.0 mL/min, 
major = 5.6 min, minor = 5.2 min. [α]20D = −105.3 (c = 1.0, CHCl3). 
 
(−)-(S,E)-4-(4-Trifluorophenyl)but-3-en-2-yl methyl carbonate, IV-1d. 
 From (S,E)-4-(3-fluorophenyl)but-3-en-2-ol 
(780 mg, 3.6 mmol), following the general 
procedure described above, compound IV-1d 
was obtained in 76% yield as a pale yellow oil 
after flash column chromatography (Cy/EtOAc, 95/5). 
1H-NMR (300 MHz, CDCl3): δ 7.26 – 7.15 (m, 1H), 7.12 – 6.96 (m, 
2H), 6.92 – 6.82 (m, 1H), 6.54 (d, J = 16.0 Hz, 1H), 6.13 (dd, J = 16.0, 6.8 
Hz, 1H), 5.29 (m, 1H), 3.72 (s, 3H), 1.40 (d, J = 6.5, 3H). 13C-NMR  (75 
MHz, CDCl3): δ 155.1, 139.7 (q, JC-F = 1 Hz), 130.8, 130.6, 129.8 (q, JC-F = 
32 Hz), 126.8, 124.1 (q, JC-F = 271 Hz), 125.5 (q, JC-F = 4 Hz), 74.7, 54.7, 
20.3. HRMS-ESI+ m/z calculated for C13H13O3F3Na [M+Na]
+: 297.0709, 
found 297.0715. 
Compound IV-1d was obtained in 99:1 enantiomeric ratio determined 
by HPLC using Chiralpak-IA column [Hexane/iPrOH (99:1)], 1.0 mL/min, 
major = 4.4 min, minor = 3.4 min. [α]20D = −132.7 (c = 1.0, CHCl3). 
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(−)-Methyl (S,E)-4-(3-((methoxycarbonyl)oxy)but-1-en-1-yl)benzoate, 
IV-1e. 
 From methyl (S,E)-4-(3-hydroxybut-1-en-
1-yl)benzoate (850 mg, 4.1 mmol), following 
the general procedure described above, 
compound IV-1e was obtained in 67% yield as 
a pale yellow oil after flash column chromatography (Cy/EtOAc, 90/10). 
1H-NMR (300 MHz, CDCl3): δ 7.99 (d, J = 8.4 Hz, 2H), 7.44 (d, J = 8.1 
Hz, 2H), 6.68 (d, J = 16.3 Hz, 1H), 6.31 (dd, J = 16.0, 6.7 Hz, 1H), 5.39 
(quintd, J = 6.5, 1.2 Hz, 1H), 3.92 (s, 3H), 3.80 (s, 3H), 1.49 (d, J = 6.5 Hz, 
3H). 13C-NMR (75 MHz, CDCl3): δ 166.9, 155.2, 140.8, 131.2, 130.9, 
130.1, 129.6, 126.7, 75.0, 54.8, 52.2, 20.5. HRMS-ESI+ m/z calculated for 
C14H16O5Na [M+Na]
+: 287.0889, found 287.0903. 
Compound IV-1e was obtained in 99:1 enantiomeric ratio determined 
by HPLC using Chiralpak-IBN column [Hexane/iPrOH (99:1)], 1.0 
mL/min, major = 7.9 min, minor = 6.7 min. [α]20D = −89.4 (c = 1.0, CHCl3). 
 
(−)-(S,E)-Methyl (4-(o-tolyl)but-3-en-2-yl) carbonate, IV-1f. 
 From (S,E)-4-(o-tolyl)but-3-en-2-ol (0.2 g, 1.2 
mmol), following the general procedure described 
above, compound IV-1f (0.26 g, 1.2 mmol) was 
obtained in 99% yield as a colorless oil after flash 
column chromatography (Cy/EtOAc, 90/10). 
1H-NMR (300 MHz, CDCl3): δ 7.42 (s broad, 1H), 7.15 (m, 2H), 6.85 
(d, J = 16.0 Hz, 1H), 6.06 (dd, J = 16.1, 6.7 Hz, 1H), 6.39 (m, 1H), 3.79 (s, 
3H), 2.35 (s, 3H), 1.47 (d, J = 6.9 Hz, 3H). 13C-NMR (75 MHz, CDCl3): δ 
155.2, 135.8, 135.3, 130.3, 130.2, 129.5, 127.9, 126.1, 125.8, 75.5, 54.5, 
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20.5, 19.7. HRMS-ESI+ m/z calculated for C13H16O3Na [M+Na]
+: 
243.0991, found 243.0997. 
Compound IV-1f was obtained in 99:1 enantiomeric ratio determined 
by HPLC using Chiralpak-IG column [Hexane/iPrOH (99:1)], 1.0 mL/min, 
major = 3.3 min, minor = 3.1 min. [α]20D = −93.2 (c = 1.0, CHCl3). 
 
(−)-(S,E)-Methyl (4-(m-tolyl)but-3-en-2-yl) carbonate, IV-1g. 
 From (S,E)-4-(m-tolyl)but-3-en-2-ol (400 mg, 
2.5 mmol), following the general procedure 
described above, compound IV-1g (312 mg, 1.4 
mmol)  was obtained in 57% yield as a pale yellow 
oil after flash column chromatography (Cy/EtOAc, 95/5). 
1H-NMR (300 MHz, CDCl3): δ 7.24 – 7.16 (m, 3H), 7.13 – 7.02 (m, 
1H), 6.62 (dd, J = 15.9, 1.1 Hz, 1H), 6.19 (dd, J = 15.9, 7.0 Hz, 1H), 5.45 
– 5.28 (m, 1H), 3.78 (s, 3H), 2.34 (s, 3H), 1.47 (d, J = 6.4 Hz, 3H).13C-
NMR  (75 MHz, CDCl3): δ 155.3 138.3, 136.3, 132.5, 129.0, 128.6, 128.0, 
127.5, 124.0, 77.6, 77.2, 76.7, 75.5, 54.7, 21.5, 20.6. HRMS-ESI+ m/z 
calculated for C13H16O3Na [M+Na]
+: 243.0991, found 243.1001. 
Compound IV-1g was obtained in 99:1 enantiomeric ratio determined 
by HPLC using Chiralpak-IG column [Hexane/iPrOH (99.5:0.5)], 1.0 
mL/min, major = 7.2 min, minor = 6.9 min. [α]20D = −96.2 (c = 1.0, CHCl3). 
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(−)-(S,E)-4-(3-fluorophenyl)but-3-en-2-yl methyl carbonate, IV-1h. 
 From (S,E)-4-(3-fluorophenyl)but-3-en-2-ol (598 
g, 3.6 mmol), following the general procedure 
described above, compound IV-1h was obtained in 
73% yield as a pale yellow oil after flash column 
chromatography (Cy/EtOAc, 95/5). 
1H-NMR (300 MHz, CDCl3): δ 7.26 – 7.15 (m, 1H), 7.12 – 6.96 (m, 
2H), 6.92 – 6.82 (m, 1H), 6.54 (d, J = 16.0 Hz, 1H), 6.13 (dd, J = 16.0, 6.8 
Hz, 1H), 5.29 (m, 1H), 3.72 (s, 3H), 1.40 (d, J = 6.5, 3H). 13C-NMR  (75 
MHz, CDCl3): δ 163.2 (d, JC-F = 245 Hz), 155.24, 138.7 (d, JC-F = 8 Hz), 
131.1 (d, JC-F = 2 Hz), 130.2 (d, JC-F = 3 Hz), 129.66, 122.7 (d, JC-F = 3 Hz), 
115.0 (d, JC-F = 21 Hz), 113.2 (d, JC-F = 21 Hz), 75.02, 54.78, 20.52. HRMS-
ESI+ m/z calculated for C12H13O3FNa [M+Na]
+: 247.0740, found 
247.0747. 
Compound IV-1h was obtained in 99:1 enantiomeric ratio determined 
by HPLC using Chiralpak-IA column [Hexane/iPrOH (99:1)], 1.0 mL/min, 
major = 3.8 min, minor = 3.2 min. [α]20D = −92.6 (c = 1.0, CHCl3). 
 
(−)-(S,E)-4-(3-Chlorophenyl)but-3-en-2-yl methyl carbonate, IV-1i. 
 From (S,E)-4-(3-chlorophenyl)but-3-en-2-ol (0.2 
g, 1.3 mmol), following the general procedure 
described above, compound IV-1i was obtained in 
63% yield as a pale yellow oil after flash column 
chromatography (Cy/EtOAc, 90/10).  
1H-NMR (300 MHz, CDCl3): δ 7.39 (s broad, 1H), 7.26 (m, 3H), 6.58 
(d, J = 16.0 Hz, 1H), 6.21 (d, J = 16.0, 6.6 Hz, 1H), 5.38 (quint, J = 6.5 Hz, 
1H), 3.81 (s, 3H), 1.47 (d, J = 6.5 Hz, 3H). 13C-NMR (75 MHz, CDCl3): δ 
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155.1, 138.1, 134.6, 130.4, 129.8, 129.7, 127.9 126.5, 124.9, 74.8, 54.6, 
20.4. HRMS-ESI+ m/z calculated for C12H13O3ClNa [M+Na]
+: 247.0496, 
found 247.0498. 
Compound IV-1i was obtained in 99:1 enantiomeric ratio determined by 
HPLC using Chiralpak-IA column [Hexane/iPrOH (99:1)], 1.0 mL/min, 
major = 3.9 min, minor = 3.2 min. [α]20D = −119.0 (c = 1.0, CHCl3). 
 
(−)-(S,E)-Methyl (4-(3-(trifluoromethyl)phenyl)but-3-en-2-yl) 
carbonate, IV-1j. 
 From (S,E)-4-(3-(trifluoromethyl)phenyl)but-3-
en-2-ol (0.4 g, 1.8 mmol), following the general 
procedure described above, compound IV-1j (0.47 
g, 1.71 mmol) was obtained in 95% yield as a 
colorless oil after flash column chromatography (Cy/EtOAc, 90/10). 
1H-NMR (300 MHz, CDCl3): δ 7.65 (s, 1H), 7.51 (m, 3H), 6.65 (d, J = 
16.0 Hz, 1H), 6.27 (dd, J = 15.8, 6.6 Hz, 1H), 5.40 (quint, J = 6.6 Hz, 1H), 
3.81 (s, 3H), 1.49 (d, J = 6.5 Hz, 3H). 13C-NMR  (75 MHz, CDCl3): δ 155.2, 
137.1, 131.2 (q, JC-F = 32.4 Hz), 130.7, 130.2, 129.9, 129.2, 125.9 (q, JC-F = 
272.6 Hz), 124.6 (q, JC-F = 3.9 Hz), 123.4 (q, J = 3.9 Hz), 74.9, 54.7, 20.4. 
HRMS-ESI+ m/z calculated for C13H13O3F3Na [M+Na]
+: 297.0709, found 
297.0720. 
Compound IV-1j was obtained in 99:1 enantiomeric ratio determined 
by HPLC using Chiralpak-IA column [Hexane/iPrOH (99:1)], 1.0 mL/min, 
major = 3.4 min, minor = 2.9 min. [α]20D = −82.5 (c = 1.0, CHCl3). 
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(−)-(S,E)-Methyl (1-phenylpent-1-en-3-yl) carbonate, IV-1k. 
 From (S,E)-1-phenylpent-1-en-3-ol (1.5 g, 9.2 
mmol), following the general procedure described 
above, compound IV-1k was obtained in 74% yield 
as a pale yellow oil after flash column 
chromatography (Cy/EtOAc, 95/5). 
1H NMR, 13C NMR and MS data were consistent with literature 
values.41 1H-RMN (300 MHz, CDCl3): δ 7.43-7.26 (m, 5H), 6.65 (d, J = 
16.6 Hz, 1H), 6.14 (dd, J = 16.2, 7.6 Hz, 1H), 5.17 (q, J = 6.7 Hz, 1H), 3.80 
(s, 3H), 1.81 (m, 2H), 0.99 (t, J = 7.3 Hz, 3H). 
Compound IV-1k was obtained in 99:1 enantiomeric ratio determined 
by HPLC using Chiralpak-IA column [Hexane/iPrOH (99:1)], 1.0 mL/min, 
major = 3.5 min, minor = 3.2 min. [α]20D= −113.1 (c = 1.0, CHCl3). 
 
4.5.1.5. Synthesis of allylic acetates IV-8. 
 
 
The enantiopure allylic acetates were prepared following the described 
procedure starting from the corresponding alcohols IV-7.42 Alcohol IV-7 
(1 equiv) was combined with THF (7 mL/mmol alcohol), acetic anhydride 
(1.20 equiv), triethylamine (1.80 equiv), and DMAP (2 mol%) at 0 °C. The 
reaction mixture was maintained at 0 °C for 1 h and then was allowed to 
 
41 Yamada, Y. M. A.; Sarkar, S. M.; Uozumi, Y. J. Am. Chem.Soc. 2012, 134, 
3190. 
42 Onaran, M. B.; Seto, C. T. J. Org. Chem. 2003, 68, 8136. 
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stir at room temperature overnight. The solvent was removed by rotary 
evaporation, and the resulting material was washed with water, brine and 
dried over MgSO4. Purification by flash column chromatography gave the 
desired product. 
 
(−)-(S,E)-4-Phenylbut-3-en-2-yl acetate, IV-8a. 
 From (S,E)-4-(phenyl)but-3-en-2-ol (0.84 g, 5.7 
mmol), following the general procedure described above, 
compound IV-8a (0.81 g, 4.3 mmol) was obtained in 75% 
yield as a pale yellow oil after flash column 
chromatography (Cy/AcOEt, 90/10). 
1H NMR, 13C NMR and MS data were consistent with literature 
values.22 1H-NMR (300 MHz, CDCl3): δ 7.46 – 7.40 (m, 2H), 7.40 – 7.33 
(m, 2H), 7.33 – 7.28 (m, 1H), 6.65 (d, J = 16.0 Hz, 1H), 6.23 (dd, J = 16.0, 
6.7 Hz, 1H), 5.57 (quint, J = 6.5 Hz, 1H), 2.12 (s, 3H), 1.45 (d, J = 6.5 Hz, 
3H). 
Compound IV-8a was obtained in 99:1 enantiomeric ratio determined 
by HPLC using Chiralpak-IC column [Hexane/iPrOH (99.5:0.5)], 1.0 
mL/min, major = 8.2 min, minor = 6.0 min. [α]20D = −169.6 (c = 1.0, CHCl3). 
 
(−)-(S,E)-4-(4-(Trifluoromethyl)phenyl)but-3-en-2-yl acetate, IV-8d.  
 From (S,E)-4-(4-(trifluoromethyl)phenyl)but-3-
en-2-ol (0.6 g, 2.83 mmol), following the general 
procedure described above, compound IV-8d (0.69 
g, 2.68 mmol) was obtained in 95% yield as a pale 
yellow oil after flash column chromatography (Cy/AcOEt, 90/10). 
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1H-NMR (300 MHz, CDCl3): δ 7.56 (d, J = 8.3 Hz, 2H), 7.47 (d, J = 8.3 
Hz, 2H), 6.62 (d, J = 16.0 Hz, 1H), 6.28 (dd, J = 16.0, 6.5 Hz, 1H), 5.54 
(quint, J = 6.5 Hz, 1H), 2.09 (s, 3H), 1.42 (d, J = 6.5 Hz, 3H).13C-NMR  
(75 MHz, CDCl3): δ 170.4, 140.0 (q, JC-F = 1.5 Hz), 131.7, 130.1, 129.9 (q, 
JC-F = 32.5 Hz), 126.9, 125.7 (q, JC-F = 4.8 Hz),  124.3 (q, JC-F = 247 Hz), 
70.7, 21.5, 20.4. HRMS-EI+ m/z calculated for C13H13O2F3 [M]
+: 
258.0868, found 258.0871. 
Compound IV-8d was obtained in 99:1 enantiomeric ratio determined 
by HPLC using Chiralpak-IA column [Hexane/iPrOH (99.5:0.5)], 1.0 
mL/min, major = 5.3 min, minor = 4.0 min. [α]20D = −135.7 (c = 1.0, CHCl3). 
 
(−)-(S,E)-4-(o-Tolyl)but-3-en-2-yl acetate, IV-8f. 
 From (S,E)-4-(o-tolyl)but-3-en-2-ol (1.0 g, 6.2 
mmol), following the general procedure described 
above, compound IV-8f (1.1 g, 5.4 mmol) was obtained 
in 87% yield as a pale yellow oil after flash column 
chromatography (Cy/AcOEt, 90/10). 
1H-NMR (300 MHz, CDCl3): δ 1H NMR (300 MHz, Chloroform-d) δ 
7.42 (m, 1H), 7.16 (m, 3H), 6.83 (d, J = 15.8 Hz, 1H), 6.07 (dd, J = 15.8, 
6.8 Hz, 1H), 5.55 (quint, J = 6.2 Hz, 1H), 2.35 (s, 3H), 2.08 (s, 3H), 1.43 
(d, J = 6.5 Hz, 3H). 13C-NMR (75 MHz, CDCl3): δ 170.5, 135.8, 135.6, 
130.4, 130.3, 129.6, 127.9, 126.2, 125.8, 71.4, 21.5, 20.6, 19.9. HRMS-
GCEI+ m/z calculated for C13H16O2 [M]
+: 204.1150, found 204.1144. 
Compound IV-8f was obtained in 99:1 enantiomeric ratio determined 
by HPLC using Chiralpak-IBN column [Hexane/iPrOH (99.5:0.5)], 1.0 
mL/min, major = 5.8 min, minor = 5.3 min. [α]20D = −83.6 (c = 1.0, CHCl3). 
 
Stereospecific Synthesis of 1,5-Dienes Through an Allyl-Allyl Cross-
Coupling Strategy. 
 
461 
 
(−)-(S,E)-4-(m-Tolyl)but-3-en-2-yl acetate, IV-8g. 
 From (S,E)-4-(m-tolyl)but-3-en-2-ol (0.40 g, 2.5 
mmol), following the general procedure described 
above, compound IV-8g (0.46 g, 2.25 mmol) was 
obtained in 92% yield as a pale yellow oil after flash 
column chromatography (Cy/AcOEt, 90/10). 
1H-NMR (300 MHz, CDCl3) δ 7.11 (m, 3H), 6.98 (d, J = 6.7 Hz, 1H), 
6.49 (d, J = 16.0 Hz, 1H), 6.09 (dd, J = 16.0, 6.7 Hz, 1H), 5.44 (quint, J = 
6.5 Hz, 1H), 2.26 (s, 3H), 1.99 (s, 3H), 1.33 (d, J = 6.5 Hz, 3H). 13C-NMR 
(76 MHz, CDCl3) δ 170.4, 138.2, 136.4, 131.8, 128.8, 128.8, 128.6, 127.4, 
123.9, 71.2, 21.5, 21.5, 20.5. HRMS-GCEI+ m/z calculated for C13H16O2 
[M]+: 204.1150, found 204.1142. 
Compound IV-8g was obtained in 99:1 enantiomeric ratio determined 
by HPLC using Chiralpak-IC column [Hexane/iPrOH (99.5:0.5)], 1.0 
mL/min, major = 9.2 min, minor = 6.3 min. [α]20D = −122.7 (c = 1.0, CHCl3). 
 
(−)-(S,E)-4-(3-Chlorophenyl)but-3-en-2-yl acetate, IV-8i. 
 From (S,E)-4-(3-chlorophenyl)but-3-en-2-ol (0.50 g, 
2.7 mmol), following the general procedure described 
above, compound IV-8i (0.38 g, 1.7 mmol) was obtained 
in 62% yield as a pale yellow oil after flash column 
chromatography (Cy/AcOEt, 90/10). 
1H-NMR (300 MHz, CDCl3) δ 7.37 (m, 1H), 7.26 – 7.18 (m, 3H), 6.53 
(dd, J = 16.0, 0.8 Hz, 1H), 6.19 (dd, J = 16.0, 6.6 Hz, 1H), 5.59 – 5.42 (m, 
1H), 2.08 (s, 3H), 1.40 (d, J = 6.5 Hz, 3H). 13C-NMR (76 MHz, CDCl3) δ 
170.4, 138.3, 134.6, 130.5, 130.2, 129.9, 127.9, 126.5, 125.0, 70.8, 21.5, 
Chapter 4 
462 
 
20.4. HRMS-EI+ m/z calculated for C12H13O2Cl [M]
+: 224.0604, found 
224.0594. 
Compound IV-8i was obtained in 99:1 enantiomeric ratio determined by 
HPLC using Chiralpak-IC column [Hexane/iPrOH (99.5:0.5)], 1.0 mL/min, 
major = 5.6 min, minor = 4.4 min. [α]20D = −95.3 (c = 1.0, CHCl3). 
 
(−)-(S,E)-4-(3-(Trifluoromethyl)phenyl)but-3-en-2-yl acetate, IV-8j. 
 From (S,E)-4-(3-(trifluoromethyl)phenyl)but-3-en-2-
ol (2.0 g, 9.3 mmol), following the general procedure 
described above, compound IV-8j (2.2 g, 8.5 mmol) was 
obtained in 92% yield as a pale yellow oil after flash 
column chromatography (Cy/AcOEt, 90/10). 
1H-NMR (300 MHz, CDCl3): δ 7.60 – 7.52 (m, 1H), 7.47 – 7.38 (m, 
2H), 7.38 – 7.30 (m, 1H), 6.54 (d, J = 16.0 Hz, 1H), 6.18 (dd, J = 16.0, 6.5 
Hz, 1H), 5.45 (quintd, J = 6.5, 1.0 Hz, 1H), 2.00 (s, 3H), 1.34 (d, J = 6.5 
Hz, 3H). 13C NMR (76 MHz, CDCl3) δ 170.4, 137.3, 131.2 (q, JC-F = 31.6 
Hz), 131.1, 130.1, 129.9 (q, JC-F = 1.7 Hz), 129.2, 124.5 (q, JC-F = 3.8 Hz), 
124.2 (q, JC-F = 271.3 Hz), 123.3 (q, JC-F = 3.8 Hz), 70.7, 31.0, 21.4, 20.4. 
HRMS-EI+ m/z calculated for C13H13O2F3 [M]
+: 258.0868, found 
258.0873. 
Compound IV-8j was obtained in 99:1 enantiomeric ratio determined 
by HPLC using Chiralpak-IBN column [Hexane/iPrOH (99.5:0.5)], 1.0 
mL/min, major = 3.8 min, minor = 3.3 min. [α]20D = −135.5 (c = 1.0, CHCl3). 
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4.5.1.6. Synthesis of allylic amines IV-9.  
 
 
To a stirred solution of allylic acetate (1 equiv), Pd(PPh3)4 (0.03 equiv) 
and PPh3 (0.04 equiv) in THF (2 mL/mmol) was added dimethylamine (2M 
THF, 2 equiv) under argon atmosphere at room temperature. The reaction 
mixture was stirred overnight at 45 ºC. The mixture was extracted with HCl 
1M (5x). The aqueous phase was taken to basic pH using NaOH 2M and 
extracted with DCM (5x). The combined organic layers were dried over 
MgSO4 and the solvent was evaporated. The crude reaction was purified by 
flash column chromatography using AcOEt/MeOH (100:0 to 80:20) as 
eluent. 
 
(−)-(S,E)-N,N-Dimethyl-4-phenylbut-3-en-2-amine, IV-9a. 
 From (S,E)-4-phenylbut-3-en-2-yl acetate (834 mg, 
4.4 mmol), following the general procedure described 
above, compound IV-9a (555 mg, 3.2 mmol) was 
obtained in 72% yield as a pale yellow oil after flash 
column chromatography (AcOEt/MeOH, 70/30). 
1H-NMR (300 MHz, CDCl3): δ 7.42-7.22 (m, 5H), 6.46 (d, J = 16.0 Hz, 
1H), 6.22 (dd, J = 16.0, 8.0 Hz, 1H), 3.05 (quint, J = 6.8 Hz, 1H), 2.32 (s, 
6H), 1.26 (d, J = 6.5 Hz, 3H). 13C-NMR (75 MHz, CDCl3): δ 137.2, 132.3, 
130.7, 128.6, 127.3, 126.3, 62.9, 42.2, 18.1. HRMS-ESI+ m/z calculated 
for C12H18N [M+H]
+: 176.1433, found 176.1440. 
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Compound IV-9a was obtained in 96:4 enantiomeric ratio determined 
by chiral GC-MS using CP-Chirasil Dex CB (60→110 °C @ 10 °C/min, 
hold 2 min, then →130 °C @ 1 °C/min, then →180 °C @ 10 °C/min; flow 
rate 1.0 mL/min.). major = 22.0 min, minor = 21.9 min. [α]20D = −60.5 (c = 
1.0, CHCl3). 
 
(−)-(S,E)-N,N-Dimethyl-4-(4-(trifluoromethyl)phenyl)but-3-en-2-
amine, IV-9d. 
 From (S,E)-4-(4-(trifluoromethyl)phenyl)but-3-
en-2-yl acetate (0.8 g, 3.29 mmol), following the 
general procedure described above, compound IV-
9d (707 mg, 2.9 mmol) was obtained in 89% yield 
as a pale yellow oil after flash column chromatography (AcOEt/MeOH, 
70/30). 
1H-NMR (300 MHz, CDCl3): δ 7.53 (d, J = 8.3 Hz, 2H), 7.45 (d, J = 8.3 
Hz, 2H), 6.52 (d, J = 116.5 Hz, 1H), 6.30 (dd, J = 15.9, 7.5 Hz, 1H), 3.26-
3.17 (m, 1H), 2.33 (s, 6H), 1.28 (d, J = 6.7 Hz, 3H). 13C-NMR (75 MHz, 
CDCl3): δ 140.8, 135.4, 129.5, 129.3 (q, JC-F = 32.0 Hz), 126.5, 125.6 (q, 
JC-F = 4.3 Hz), 124.4 (q, JC-F = 272.2 Hz), 62.84, 42.31, 17.81. HRMS-ESI
+ 
m/z calculated for C13H17NF3 [M+H]
+: 244.1307, found 244.1315. [α]20D= 
−135.7 (c = 1.0, CHCl3). 
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(−)-(S,E)-N,N-Dimethyl-4-(o-tolyl)but-3-en-2-amine, IV-9f. 
 From (S,E)-4-(o-tolyl)but-3-en-2-yl acetate (0.9 g, 
4.50 mmol), following the general procedure described 
above, compound IV-9f (596 mg, 3.2 mmol) was 
obtained in 70% yield as a pale yellow oil after flash 
column chromatography (AcOEt/MeOH, 70/30). 
1H-NMR (300 MHz, CDCl3): δ 7.45-7.42 (m, 1H), 7.18-7.11 (m, 3H), 
6.65 (d, J = 15.6 Hz, 1H), 6.06 (dd, J = 15.8, 8.0 Hz, 1H), 3.11-3.02 (quint, 
J = 7.1 Hz, 1H), 2.35 (s, 3H), 2.31 (s, 6H), 1.26 (d, J = 6.7 Hz, 3H). 13C-
NMR (75 MHz, CDCl3): δ 136.5, 135.4, 133.5, 130.4, 129.0, 127.4, 126.2, 
125.9, 63.3, 42.3, 31.1, 20.0, 18.5. HRMS-EI+ m/z calculated for C13H19N 
[M]+: 189.1517, found 189.1514.  
Compound IV-9f was obtained in 97:3 enantiomeric ratio determined 
by GC-MS using CP-Chirasil Dex CB. major = 29.0 min, minor = 28.8 min. 
[α]20D= −35.1 (c = 1.0, CHCl3). 
 
(−)-(S,E)-N,N-Dimethyl-4-(m-tolyl)but-3-en-2-amine, IV-9g. 
 From (S,E)-4-(m-tolyl)but-3-en-2-yl acetate (0.4 g, 
2.1 mmol), following the general procedure described 
above, compound IV-9g (167 mg, 0.9 mmol) was 
obtained in 41% yield as a pale yellow oil after flash 
column chromatography (AcOEt/MeOH, 70/30). 
1H-NMR (300 MHz, CDCl3): δ 7.14 (m, 4H), 6.44 (d, J = 15.9 Hz, 1H), 
6.22 (dd, J = 15.9 Hz, 7.8 Hz, 1H), 3.04 (m, 1H), 2.36 (s, 3H), 2.30 (s, 6H), 
1.25 (d, J = 6.2 Hz, 3H). 13C-NMR (75 MHz, CDCl3) δ 138.2, 137.1, 131.5, 
131.3, 128.6, 128.3, 127.1, 123.6, 63.1, 42.1, 21.5, 18.1. HRMS-EI+ m/z 
calculated for C13H19N [M]
+: 189.1517, found 189.1512. 
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Compound IV-9g was obtained in 97:3 enantiomeric ratio determined 
by GC-MS using CP-Chirasil Dex CB (60→110 °C @ 10 °C/min, hold 2 
min, then →130 °C @ 1 °C/min, then →180 °C @ 10 °C/min; flow rate 1.0 
mL/min.). major = 31.2 min, minor = 31.0 min. [α]20D = −51.2 (c = 1.0, 
CHCl3). 
 
(−)-(S,E)-4-(3-Chlorophenyl)-N,N-dimethylbut-3-en-2-amine, IV-9i. 
 From (S,E)-4-(3-chlorophenyl)but-3-en-2-yl acetate 
(0.3 g, 1.3 mmol), following the general procedure 
described above, compound IV-9i  (136 mg, 0.7 mmol) 
was obtained in 49% yield as a pale yellow oil after flash 
column chromatography (AcOEt/MeOH, 70/30). 
1H-NMR (300 MHz, CDCl3): δ 7.39 (s broad, 1H), 7.32-7.20 (m, 3H), 
6.45 (d, J = 16.0 Hz, 1H), 6.26 (dd, J = 16.1, 8.2 Hz, 1H), 3.09 (quint, J = 
7.0 Hz, 1H), 2.33 (s, 6H), 1.27 (d, J = 6.5 Hz, 3H). 13C-NMR (75 MHz, 
CDCl3): δ 139.0, 134.4, 133.7, 129.7, 129.4, 127,2, 126.2, 124.4, 62.6, 42.0, 
17.7. HRMS-ESI+ m/z calculated for C12H17NCl [M+H]
+: 210.1044, found 
210.1049. [α]20D= −41.3 (c = 1.0, CHCl3).  
 
(−)-(S,E)-N,N-Dimethyl-4-(3-(trifluoromethyl)phenyl)but-3-en-2-
amine, IV-9j. 
 From (S,E)-4-(3-(trifluoromethyl)phenyl)but-3-en-2-
yl acetate (2.2 g, 8.3 mmol), following the general 
procedure described above, compound IV-9j (1.3 g, 5.2 
mmol) was obtained in 62% yield as a pale yellow oil 
after flash column chromatography (AcOEt/MeOH, 70/30). 
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1H-NMR (300 MHz, CDCl3): δ 7.60 (s, 1H), 7.54 (d, J = 7.4 Hz, 1H), 
7.44 (m, 2H), 6.50 (d, J = 16.0 Hz, 1H), 6.28 (dd, J = 16.0, 7.8 Hz, 1H), 
3.10 (quint, J = 7.0, 6.6 Hz, 1H), 2.31 (s, 6H), 1.26 (d, J = 6.6 Hz, 3H).13C-
NMR (75 MHz, CDCl3) δ 138.0, 134.1, 131.2 (q, JC-F = 31.6 Hz), 129.8, 
129.5 (q, JC-F = 1.2 Hz), 129.2, 124.3 (q, JC-F = 271.3 Hz), 124.1(q, JC-F = 
3.7 Hz), 123.2 (q, JC-F = 3.7 Hz), 62.8, 42.1, 17.8. HRMS-ESI
+ m/z 
calculated for C13H17NF3 [M+H]
+: 244.1307, found 244.1312. 
Compound IV-9j was obtained in 99:1 enantiomeric ratio determined 
by GC-MS using CP-Chirasil Dex CB (60→110 °C @ 10 °C/min, hold 2 
min, then →130 °C @ 1 °C/min, then →180 °C @ 10 °C/min; flow rate 1.0 
mL/min.). major = 25.0 min, minor = 24.7 min. [α]20D = −77.4 (c = 1.0, 
CHCl3). 
 
4.5.1.7. Synthesis of allylic ammonium salts IV-2. 
 
 
To a solution of the allylic amine (1 equiv) in Et2O (2 mL/mmol of 
amine) was added methyl trifluoromethanesulfonate (1.1 equiv) dropwise 
at 0 ºC. The reaction mixture was stirred at 0 ºC for 30 minutes. The crude 
was concentrated under reduced pressure and purified by flash column 
chromatography using AcOEt/MeOH (from 90:10 to 50:50) as eluent. 
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(−)-(S,E)-N,N,N-Trimethyl-4-phenylbut-3-en-2-aminium 
trifluoromethanesulfonate, IV-2a. 
From (S,E)-N,N-dimethyl-4-phenylbut-3-en-2-
amine (1.1 g, 6.27 mmol), following the general 
procedure described above, compound IV-2a (2.0 g, 
5.96 mmol) was obtained in 95% yield as a white solid. 
1H-NMR (300 MHz, CDCl3): δ 7.44 (m, 2H), 7.34 (m, 3H), 6.99 (d, J = 
15.5 Hz, 1H), 6.09 (dd, J = 15.4, 9.2 Hz, 1H), 4.37 (quint, J = 6.9 Hz, 1H), 
3.14 (s, 9H), 1.59 (d, J = 6.6 Hz, 3H). 13C-NMR (75 MHz, CDCl3): δ 140.8, 
134.6, 129.5, 128.9, 127.3, 123.0 [q, JC-F = 318.0 Hz], 120.0, 73.2, 50.8, 
15.3. HRMS-ESI+ m/z calculated for C13H20N [M−OTf]+: 190.1590, found 
190.1590. [α]20D = −53.6 (c = 1.0, CHCl3). 
 
(−)-(S,E)-N,N,N-Trimethyl-4-(4-(trifluoromethyl)phenyl)but-3-en-2-
aminium trifluoromethanesulfonate, IV-2d. 
 From (S,E)-N,N-dimethyl-4-(4-
(trifluoromethyl)phenyl)but-3-en-2-amine (0.4 
g, 1.64 mmol), following the general procedure 
described above, compound IV-2d (0.6 g, 1.54 
mmol) was obtained in 93% yield as a colorless oil after flash column 
chromatography (AcOEt/MeOH from 90:10 to 50:50). 
1H-NMR (300 MHz, Acetone-d6): δ 7.77 (d, J = 8.1 Hz, 2H), 7.65 (d,  J 
= 8.1 Hz, 2H), 7.14 (d, J = 16.0 Hz, 1H), 6.71 (dd, J = 15.7, 9.4 Hz, 1H), 
4.52 (m, 1H), 3.25 (s, 9H), 2.23 (s, 3H), 1.64 (m, 3H). 13C-NMR (75 MHz, 
Acetone-d6): δ 140.2, 138.4, 130.7 (q, JC-F = 32.3 Hz), 128.7, 126.9 (q, JC-F 
= 269.9 Hz), 126.6 (q, JC-F = 3.8 Hz), 125.8, 123.9 (q, JC-F = 320.7 Hz), 
73.4, 51.3, 15.5. HRMS-ESI+ m/z calculated for C14H19NF3 [M−OTf]+: 
258.1464, found 258.1471. [α]20D = −171.2 (c = 1.0, CHCl3). 
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(−)-(S,E)-N,N,N-Trimethyl-4-(o-tolyl)but-3-en-2-aminium 
trifluoromethanesulfonate, IV-2f. 
 From (S,E)-N,N-dimethyl-4-(o-tolyl)but-3-en-2-
amine (0.6 g, 3.17 mmol), following the general 
procedure described above, compound IV-2f (0.5 g, 
1.52 mmol) was obtained in 48% yield as a colorless 
oil after flash column chromatography (AcOEt/MeOH from 90:10 to 
50:50). 
1H-NMR (300 MHz, CDCl3): δ 7.38 (m, 1H), 7.19-7.07 (m, 4H), 5.89 
(dd, J = 15.3, 9.5 Hz, 1H), 4.34 (m, 1H), 3.07 (s, 9H), 2.28 (s, 3H), 1.50 (d, 
J = 6.4 Hz, 3H). 13C-NMR (75 MHz, CDCl3): δ 139.2, 136.7, 133.8, 130.8, 
129.5, 126.5, 126.1, 122.9 (q, JC-F = 321.5 Hz), 121.2, 73.5, 51.0, 19.6, 15.2. 
HRMS-ESI+ m/z calculated for C14H22N [M−OTf]+: 204.1746, found 
204.1743. [α]20D = −75.8 (c = 1.0, CHCl3). 
 
(−)-(S,E)-N,N,N-Trimethyl-4-(m-tolyl)but-3-en-2-aminium 
trifluoromethanesulfonate, IV-2g. 
 From (S,E)-N,N-dimethyl-4-(m-tolyl)but-3-en-
2-amine (0.25 g, 1.34 mmol), following the general 
procedure described above, compound IV-2g (0.4 g, 
1.1 mmol) was obtained in 84% yield as a colorless 
oil after flash column chromatography (AcOEt/MeOH from 90:10 to 
50:50). 
1H-NMR (300 MHz, CDCl3): δ 7.14 (m, 3H), 7.03 (m, 1H), 6.83 (d, J = 
15.7 Hz, 1H), 6.02 (dd, J = 15.5, 9.4 Hz, 1H), 4.23 (quint, J = 6.6 Hz, 1H), 
3.00 (s, 9H), 2.23 (s, 3H), 1.47 (d, J = 6.5 Hz, 3H). 13C-NMR (75 MHz, 
CDCl3): δ 140.8, 138.5, 134.5, 130.1, 128.7, 127.7, 124.5, 122.8 (q, JC-F = 
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320.1 Hz),119.8, 73.2, 50.6, 21.1, 15.1. HRMS-ESI+ m/z calculated for 
C14H22N [M−OTf]+: 204.1746, found 204.1745. [α]20D = −12.3 (c = 1.0, 
CHCl3). 
 
(−)-(S,E)-4-(3-Chlorophenyl)-N,N,N-trimethylbut-3-en-2-aminium 
trifluoromethanesulfonate, IV-2i. 
 From (S,E)-4-(3-chlorophenyl)-N,N-dimethylbut-
3-en-2-amine (0.6 g, 2.76 mmol), following the 
general procedure described above, compound IV-2i 
(0.93 g, 2.5 mmol) was obtained in 90% yield as a 
colorless oil after flash column chromatography 
(AcOEt/MeOH from 90:10 to 50:50). 
1H-NMR (300 MHz, CDCl3): δ 7.35 (s broad, 1H), 7.28 (m, 1H), 7.19 
(m, 2H), 6.83 (d, J = 15.8 Hz, 1H), 6.06 (dd, J = 15.5, 9.5 Hz, 1H), 4.32 
(quint, J = 6.8 Hz, 1H), 3.06 (s, 9H), 1.51 (d, J = 6.7 Hz, 3H). 13C-NMR 
(75 MHz, CDCl3): δ 139.6, 136.5, 134.8, 130.3, 129.4, 127.1, 125.7, 122.9 
(q, JC-F = 320.7 Hz),121.5, 73.0, 50.9, 15.3. HRMS-ESI
+ m/z calculated for 
C13H19NCl [M−OTf]+: 224.1200, found 224.1197. [α]20D = −67.8 (c = 1.0, 
CHCl3). 
 
(−)-(S,E)-4-(3-(Trifluoromethyl)phenyl)-N,N,N-trimethylbut-3-en-2-
aminium trifluoromethanesulfonate, IV-2j. 
 From (S,E)-4-(3-chlorophenyl)-N,N-
dimethylbut-3-en-2-amine (0.75 g, 3.08 mmol), 
following the general procedure described above, 
compound IV-2j (0.53 g, 1.3 mmol) was obtained in 
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42% yield as a colorless oil after flash column chromatography 
(AcOEt/MeOH from 90:10 to 50:50). 
1H-NMR (300 MHz, (CD3)2CO): δ 7.86 (m, 2H), 7.69 – 7.55 (m, 2H), 
7.14 (d, J = 15.8 Hz, 1H), 6.73 (dd, J = 15.8, 9.4 Hz, 1H), 4.54 (m, 1H), 
3.30 (s, 9H), 1.74 – 1.64 (m, 3H). 13C-NMR (75 MHz, CDCl3): δ 138.6, 
137.6, 132.0, 131.4 (q, JC-F = 28.0 Hz), 130.56, 129.1 (q, JC-F = 316.7 Hz), 
126.1 (q, JC-F = 4.3 Hz), 125.1, 124.5 (q, JC-F = 4.3 Hz), 121.7 (q, JC-F = 
252.5 Hz), 73.8, 51.59, 51.53, 51.48, 15.6. HRMS-ESI+ m/z calculated for 
C14H19NF3 [M−OTf]+: 258.1464, found 258.1469. [α]20D= −89.2(c = 1.0, 
CHCl3). 
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4.5.2. Palladium-catalyzed allyl-allyl cross-coupling reaction of 
allylic carbonates. 
 
 
 
In a 1 dram vial provided with a PTFE septa cap were weighted 
[Pd(allyl)Cl]2 (0.7 mg, 0.002 mmol, 1 mol%) and the ligand di(1-
adamantyl)benzylphosphine (CataCXiumABn) (1.6 mg, 0.004 mmol, 2 
mol%). The vial was introduced to a glove box under nitrogen atmosphere 
and THF (0.2 mL) was added. The mixture was stirred 10 minutes at rt.  To 
this solution, the allylic carbonate (0.2 mmol) in THF (1.2 mL) was added 
and then, the allyl pinacol boronic ester (2 equiv), CsF (3 equiv) were added 
subsequently. Finally, the vial was taken out of the glove box and H2O (15 
equiv) was added. The reaction mixture was stirred overnight at rt. The 
reaction was filtered through a short pad of celite and rinsed with DCM. 
The solvent was evaporated under reduced pressure and the crude product 
purified by flash column chromatography using hexane as eluent. The ratio 
of IV-3 and IV-5 was determined by 1H-RMN. Yields are corrected based 
on the amount of elimination product isolated with the desired product. 
 
(+)-(S,E)-(3-Methylhexa-1,5-dien-1-yl)benzene, IV-3a. 
 From (S,E)-methyl (4-phenylbut-3-en-2-yl) 
carbonate (41 mg, 0.2 mmol) following the general 
procedure described above, compound IV-3a (30 mg, 
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0.17 mmol) was obtained in 87% yield as a colorless oil after flash column 
chromatography in hexane along with 8% of elimination product. 
1H-RMN (300 MHz, CDCl3): δ 7.42-7.22 (m, 5H), 6.39 (d, J = 15.5 Hz, 
1H), 6.22 (dd, J = 16.1, 7.4 Hz, 1H), 5.86 (m, 1H), 5.08 (m, 2H), 2.46 (quint, 
J = 6.6 Hz, 1H), 2.22 (m, 2H), 1.16 (t, J = 6.8 Hz, 3H). 13C-RMN (300 
MHz, CDCl3): δ 137.9, 137.1, 136.2, 128.6, 128.3, 127.0, 126.1, 116.1, 
41.4, 37.0, 20.0. 
Compound IV-3a was obtained in 98:2 enantiomeric ratio determined 
by chiral GC-MS on a Chirasil Dex-CB column (60→110 °C @ 10 °C/min, 
hold 2 min, then →130 °C @ 1 °C/min, then →180 °C @ 10 °C/min; flow 
rate 1.0 mL/min.). major = 21.7 min, minor = 22.1 min. [α]20D = +44.5 (c = 
1.0, CHCl3). The absolute configuration was stablished by comparison with 
the previously reported compound.21 
 
(+)-(S,E)-tert-Butyl-5-(3-methylhexa-1,5-dien-1-yl)-1H-indole-1-
carboxylate, IV-3b. 
 From tert-butyl-(E)-5-(3-((methoxycarbonyl) 
oxy)but-1-en-1-yl)-1H-indole-1-carboxylate (69.1 
mg, 0.2 mmol), following the general procedure 
described above, compound IV-3b (58 mg, 0.19 
mmol) was obtained in 93% yield as a colorless oil after flash column 
chromatography in hexane. 
1H-RMN (300 MHz, CDCl3): δ 8.09 (d, J = 8.2 Hz, 1H), 7.59 (d, J = 3.3 
Hz, 1H), 7.53 (s broad, 1H), 7.39 (d, J = 8.5 Hz, 1H), 6.55 (d, J = 3.5 Hz, 
1H), 6.50 (d, J = 15.8 Hz, 1H), 6.19 (dd, J = 15.7, 7.3 Hz, 1H), 5.88 (m, 
1H), 5.03 (m, 2H), 2.45 (quint, J = 6.8 Hz, 1H), 2.21 (m, 2H), 1.70 (s, 9H), 
1.15 (t, J = 6.8 Hz, 3H). 13C-RMN (300 MHz, CDCl3): δ 149.9, 137.3, 
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135.0, 134.6, 132.9, 131.1, 128.6, 126.4, 122.7, 118.5, 116.1, 115.2, 107.5, 
83.8, 41.7, 37.1, 28.4, 20.2. HRMS-ESI+ m/z calculated for C20H25NO2Na 
[M+Na]+: 334.1777, found 334.1792. [α]20D= +14.4 (c = 1.0, CHCl3).  
Compound IV-3b was derivatized into the corresponding tert-butyl 
(S,E)-5-(6-hydroxy-3-methylhex-1-en-1-yl)-1H-indole-1-carboxylate to 
determinate its enantiomeric ratio (See compound IV-11b).  
 
(+)-(S,E)-Methyl(4-(3-methylhexa-1,5-dien-1-yl)phenyl)sulfane, IV-
3c. 
 From (S,E)-methyl(4-(4-(methylthio)phenyl) 
but-3-en-2-yl) carbonate (52.9 mg, 0.2 mmol), 
following the general procedure described above, 
compound IV-3c (40 mg, 0.18 mmol) was obtained 
in 91% yield as a colorless oil after flash column chromatography in hexane 
along with 7% of elimination product. 
1H-RMN (300 MHz, CDCl3): δ 7.19 (d, J = 8.4 Hz, 2H), 7.11 (d, J = 8.5 
Hz, 2H), 6.23 (d, J = 15.9 Hz, 1H), 6.03 (dd, J = 15.9, 7.3 Hz, 1H), 5.80 – 
5.61 (m, 1H), 5.02 – 4.88 (m, 2H), 2.39 (s, 3H), 2.31 (m, 1H), 2.18 – 1.98 
(m, 2H), 1.01 (d, J = 6.7 Hz, 3H). 13C-RMN (300 MHz, CDCl3): δ 137.0, 
136.8, 135.8, 135.1, 127.7, 127.1, 126.6, 116.1, 41.5, 37.0, 20.0, 16.3. 
HRMS-EI+ m/z calculated for C14H19S [M]
+: 219.1207, found 219.1186.  
Compound IV-3c was obtained in 95:5 enantiomeric ratio determined 
by HPLC using Chiralpak-IG column [Hexane/iPrOH (100:0 to 99.5:0.5 in 
30 min)], 0.5 mL/min, major = 14.2 min, minor = 15.87 min. [α]20D = +22.1 
(c = 1.0, CHCl3). 
 
Stereospecific Synthesis of 1,5-Dienes Through an Allyl-Allyl Cross-
Coupling Strategy. 
 
475 
 
(+)-(S,E)-1-(3-Methylhexa-1,5-dien-1-yl)-4-(trifluoromethyl)benzene, 
IV-3d. 
 From (S,E)-4-(4-trifluorophenyl)but-3-en-2-yl 
methyl carbonate (54.8 mg, 0.2 mmol), following the 
general procedure described above, compound IV-
3d (28 mg, 0.12 mmol) was obtained in 58% yield 
after flash column chromatography in hexane along with 9% of elimination 
product. 
1H-RMN (300 MHz, CDCl3): δ 7.54 (d, J = 8.2 Hz, 2H), 7.43 (d, J = 8.2 
Hz, 2H), 6.39 (d, J = 16.0 Hz, 1H), 6.25 (dd, J = 15.9, 7.2 Hz, 1H), 5.80 
(m, 1H), 5.13 – 4.97 (m, 2H), 2.44 (hept, J = 6.9 Hz, 1H), 2.29 – 2.07 (m, 
2H), 1.12 (d, J = 6.7 Hz, 3H). 13C-RMN (300 MHz, CDCl3): 141.5, 139.0, 
136.8, 128.8 (q, JC-F = 32.5 Hz), 127.2, 126.3, 125.6 (q, JC-F = 3.8 Hz), 124.4 
(q, JC-F = 272 Hz), 116.4, 41.3, 37.1, 19.9. HRMS-EI
+ m/z calculated for 
C14H15F3 [M]
+: 240.1126, found 240.1117. 
Compound IV-3d was obtained in 97:3 enantiomeric ratio determined 
by chiral GC-MS using CP-Chirasil Dex CB column (60→110 °C @ 10 
°C/min, hold 2 min, then →130 °C @ 1 °C/min, then →180 °C @ 10 
°C/min; flow rate 1.0 mL/min.). major = 22.3 min, minor = 22.2 min. [α]20D = 
+1.5 (c = 1.0, CHCl3). 
 
(+)-Methyl (S,E)-4-(3-methylhexa-1,5-dien-1-yl)benzoate, IV-3e. 
From methyl (S,E)-4-(3-((methoxycarbonyl) 
oxy)but-1-en-1-yl)benzoate (52.9 mg, 0.2 mmol), 
following the general procedure described above, 
compound IV-3e (33 mg, 0.14 mmol) was obtained 
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in 72% yield as a colorless oil after flash column chromatography in hexane 
along with 11% of elimination product. 
1H-RMN (300 MHz, CDCl3): δ 7.88 (d, J = 8.4 Hz, 2H), 7.31 (d, J = 8.3 
Hz, 2H), 6.32 (d, J = 16.0 Hz, 1H), 6.20 (dd, J = 15.9, 7.1 Hz, 1H), 5.72 
(m, 1H), 5.06 – 4.84 (m, 2H), 3.82 (s, 3H), 2.35 (hept, J = 6.7 Hz, 1H), 2.20 
– 1.97 (m, 2H), 1.03 (d, J = 6.7 Hz, 3H).13C-RMN (300 MHz, CDCl3): δ 
167.1, 142.5, 139.1, 136.8, 130.0, 128.5, 127.7, 126.0, 116.4, 52.1, 41.3, 
37.2, 19.9. HRMS-GCEI+ m/z calculated for C15H19O2 [M]
+: 231.1385, 
found 231.1376. 
Compound IV-3e was obtained in 98:2 enantiomeric ratio determined 
by HPLC using Chiralpak-IG column [Hexane/iPrOH (99.7:0.3)], 0.5 
mL/min, major = 20.1 min, minor = 19.8 min. [α]20D = +40.7 (c = 1.0, CHCl3). 
 
(+)-(S,E)-1-Methyl-2-(3-methylhexa-1,5-dien-1-yl)benzene, IV-3f. 
 From (S,E)-methyl (4-(o-tolyl)but-3-en-2-yl) 
carbonate (44.1 mg, 0.2 mmol), following the general 
procedure described above, compound IV-3f (36 mg, 
0.19 mmol) was obtained in 97% yield as a colorless oil 
after flash column chromatography in hexane. 
1H-RMN (300 MHz, CDCl3): δ 7.39 (d, J = 6.3 Hz, 1H), 7.13 (m, 3H), 
6.52 (d, J = 15.5 Hz, 1H), 5.99 (dd, J = 15.6, 7.4 Hz, 1H), 5.82 (m, 1H), 
5.04 (m, 2H), 2.43 (quint, J = 6.7 Hz, 1H), 2.33 (s, 3H),  2.19 (m, 2H), 1.10 
(t, J = 6.8 Hz, 3H). 13C-RMN (300 MHz, CDCl3): δ 137.6, 137.1, 135.1, 
130.2, 126.9, 126.2, 126.1, 125.6, 116.0, 41.6, 37.3, 20.2, 19.9. HRMS-EI+ 
m/z calculated for C14H18 [M]
+: 186.1409, found 186.1412. 
Compound IV-3f was obtained in 99:1 enantiomeric ratio determined 
by chiral GC-MS using CP-Chirasil Dex CB (60→110 °C @ 10 °C/min, 
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hold 2 min, then →130 °C @ 1 °C/min, then →180 °C @ 10 °C/min; flow 
rate 1.0 mL/min.). major = 25.4 min, minor = 25.3 min. [α]20D = +28.4 (c = 
1.0, CHCl3).  
 
(+)-(S,E)-1-Methyl-3-(3-methylhexa-1,5-dien-1-yl)benzene, IV-3g. 
 From (S,E)-methyl (4-(m-tolyl)but-3-en-2-yl) 
carbonate (44.1 mg, 0.2 mmol), following the general 
procedure described above, compound IV-3g (34 mg, 
0.18 mmol) was obtained in 91% yield as a colorless oil 
after flash column chromatography in hexane along with 6% of elimination 
product. 
1H-RMN (300 MHz, CDCl3): δ 7.15-7.05 (m, 3H), 6.94 (s broad, 1H), 
6.28 (d, J = 15.5 Hz, 1H), 6.04 (dd, J = 15.9, 7.4 Hz, 1H), 5.72 (m, 1H), 
4.95 (m, 2H), 2.31 (quint, J = 6.7 Hz, 1H), 2.25 (s, 3H), 2.06 (m, 2H), 1.02 
(t, J = 6.7 Hz, 3H). 13C-RMN (300 MHz, CDCl3): δ 138.1, 137.9, 137.1, 
136.0, 128.5, 128.4, 127.8, 126.8, 123.3, 116.0, 41.5, 37.0, 21.5, 20.1. 
HRMS-EI+ m/z calculated for C14H18 [M]
+: 186.1409, found 186.1407. 
Compound IV-3g was obtained in 97:3 enantiomeric ratio determined 
by chiral GC-MS on a Chirasil Dex-CB column (60→110 °C @ 10 °C/min, 
hold 2 min, then →130 °C @ 1 °C/min, then →180 °C @ 10 °C/min; flow 
rate 1.0 mL/min.). major = 25.1 min, minor = 25.0 min. [α]20D = +27.6 (c = 
1.0, CHCl3). 
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(+)-(S,E)-1-Fluoro-3-(3-methylhexa-1,5-dien-1-yl)benzene, IV-3h. 
 From (S,E)-4-(3-fluorophenyl)but-3-en-2-yl methyl 
carbonate (45.0 mg, 0.2 mmol), following the general 
procedure described above, compound IV-3h (27 mg, 
0.14 mmol) was obtained in 70% yield as a colorless oil 
after flash column chromatography in hexane along with 10% of 
elimination product. 
1H-RMN (300 MHz, CDCl3): δ 7.30 – 7.18 (m, 1H), 7.14 – 6.99 (m, 
2H), 6.88 (td, J = 8.7, 2.5 Hz, 1H), 6.33 (d, J = 15.9 Hz, 1H), 6.16 (dd, J = 
15.9, 7.3 Hz, 1H), 5.80 (m, 1H), 5.13 – 4.95 (m, 2H), 2.51 – 2.31 (m, 1H), 
2.29 – 2.04 (m, 2H), 1.10 (d, J = 6.7 Hz, 3H). 13C-RMN (300 MHz, CDCl3): 
δ 163.3 (d, JC-F = 245 Hz), 140.4 (d, JC-F = 7.8 Hz), 137.3 (d, JC-F = 57 Hz), 
130.0 (d, JC-F = 8.1 Hz), 127.4 (d, JC-F = 3.7 Hz), 122.1 (d, JC-F = 3.7 Hz), 
116.3, 113.8 (d, JC-F = 21.5 Hz), 112.6 (d, JC-F = 21.5 Hz), 41.4, 37.0, 19.9. 
HRMS-GCEI+ m/z calculated for C13H16F [M]
+: 191.1236, found 
191.1195.  
Compound IV-3h was obtained in 98:2 enantiomeric ratio determined 
by chiral GC-MS using CP-Chirasil Dex CB (60→110 °C @ 10 °C/min, 
then →140°C @ 1 °C/min, then →180 °C @ 20 °C/min; flow rate 1.0 
mL/min.). major = 20.6 min, minor = 20.4 min. [α]20D = +13.3 (c = 1.0, 
CHCl3). 
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(+)-(S,E)-1-Chloro-3-(3-methylhexa-1,5-dien-1-yl)benzene, IV-3i. 
 From (S,E)-4-(3-chlorophenyl)but-3-en-2-yl methyl 
carbonate (48.1 mg, 0.2 mmol), following the general 
procedure described above, compound IV-3i (28 mg, 
0.14 mmol) was obtained in 68% yield as a colorless oil 
after flash column chromatography in hexane along with 19% of 
elimination product. 
1H-RMN (300 MHz, CDCl3): δ 7.25 (s broad, 1H), 7.14-7.06 (m, 3H), 
6.19 (d, J = 15.9 Hz, 1H), 6.06 (dd, J = 15.9, 7.2 Hz, 1H), 5.71 (m, 1H), 
4.96 (m, 2H), 2.32 (quint, J = 6.6 Hz, 1H), 2.07 (m, 2H), 1.01 (t, J = 6.7 
Hz, 3H). 13C-RMN (300 MHz, CDCl3): δ 139.8, 137.7, 136.8, 134.5, 129.8, 
127.1, 126.9, 126.0, 124.3, 116.3, 41.3, 37.0, 19.9. HRMS-EI+ m/z 
calculated for C13H15Cl [M]
+: 206.0862, found 206.0867. 
Compound IV-3i was obtained in 99:1 enantiomeric ratio determined by 
chiral GC-MS on a Chirasil Dex-CB column (60→110 °C @ 10 °C/min, 
hold 2 min, then →130 °C @ 1 °C/min, then →180 °C @ 10 °C/min; flow 
rate 1.0 mL/min.). major = 33.1 min, minor = 33.3 min.  [α]20D = +24.1 (c = 
1.0, CHCl3).  
 
(+)-(S,E)-1-(3-Methylhexa-1,5-dien-1-yl)-3-(trifluoromethyl)benzene, 
IV-3j. 
 From (S,E)-methyl (4-(3-
(trifluoromethyl)phenyl)but-3-en-2-yl) carbonate (54.8 
mg, 0.2 mmol), following the general procedure 
described above, compound IV-3j (36 mg, 0.15 mmol) 
was obtained in 75% yield as a colorless oil after flash column 
chromatography in hexane along with 25% of elimination product. 
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1H-RMN (300 MHz, CDCl3): δ 7.59 (s broad, 1H), 7.52-7.37 (m, 3H), 
6.37 (d, J = 16.1 Hz, 1H), 6.21 (dd, J = 16.2, 7.5 Hz, 1H), 5.80 (m, 1H), 
5.05 (m, 2H), 2.43 (quint, J = 6.7 Hz, 1H), 2.17 (m, 2H), 1.13 (t, J = 6.7 
Hz, 3H). 13C-RMN (300 MHz, CDCl3): δ 138.7, 138.2, 136.8, 131.2 (q, JC-
F = 31.6 Hz), 129.3, 129.0, 127.2, 126.1 (q, JC-F = 272.4 Hz), 123.5 (q, JC-F 
= 3.6 Hz), 122.8 (q, JC-F = 3.6 Hz), 116.3, 41.3, 37.0, 19.9. HRMS-EI
+ m/z 
calculated for C14H15F3 [M]
+: 240.1126, found 240.1119. 
Compound IV-3j was obtained in 97:3 enantiomeric ratio determined 
by chiral GC-MS using CP-Chirasil Dex CB (60→110 °C @ 10 °C/min, 
hold 2 min, then →180 °C @ 0.5 °C/min, flow rate 1.0 mL/min.). major = 
82.8 min, minor = 81.1 min. [α]20D = +21.7 (c = 1.0, CHCl3). 
 
(+)-(S,E)-(3-Ethylhexa-1,5-dien-1-yl)benzene, IV-3k. 
From (S,E)-methyl (1-phenylpent-1-en-3-yl) 
carbonate (44.1 mg, 0.2 mmol), following the general 
procedure described above but modifying the 
temperature to 35 ºC, compound IV-3k (26 mg, 0.14 
mmol) was obtained in 70% yield as a colorless oil after flash column 
chromatography in hexane along with 28% of elimination product. The 
byproduct was removed by treating the mixture with maleic anhydride in 
THF at 60 ºC for 3 h.22 
1H-RMN (300 MHz, CDCl3): δ 7.38-7.17 (m, 5H), 6.39 (d, J = 15.9 Hz, 
1H), 6.03 (dd, J = 15.9, 7.9 Hz, 1H), 5.80 (m, 1H), 2.19 (m, 3H), 1.37 (m, 
2H), 0.91 (t, J = 7.3 Hz, 3H), 0.87 (m, 2H). 13C-RMN (300 MHz, CDCl3): 
δ 138.0, 137.1, 134.7, 129.9, 128.6, 126.9, 126.1, 115.9, 44.9, 39.5, 27.6, 
11.8. HRMS-GCEI+ m/z calculated for C14H19 [M]
+: 187.1487, found 
187.1465. 
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Compound IV-3k was obtained in 99:1 enantiomeric ratio determined 
by chiral GC-MS using CP-Chirasil Dex CB (60→120 °C @ 10 °C/min, 
then →145 °C @ 0.5 °C/min, then →180 °C @ 20 °C/min; flow rate 1.0 
mL/min.). major = 35.2 min, minor = 35.0 min. [α]20D = +13.6 (c = 1.0, 
CHCl3). 
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4.5.3. Palladium-catalyzed allyl-allyl cross-coupling reaction of 
allylic ammonium salts. 
 
In a 1 dram vial provided with a PTFE septa cap were weighted 
[Pd(allyl)Cl]2 (0.7 mg, 0.002 mmol, 1 mol%) and the ligand di(1-
adamantyl)benzylphosphine (CataCXiumABn) (1.6 mg, 0.004 mmol, 2 
mol%). The vial was introduced to a glove box under nitrogen atmosphere 
and THF (0.2 mL) was added. The mixture was stirred 10 minutes at rt.  To 
this solution, the ammonium salt IV-2 (0.2 mmol) in THF (1.2 mL) was 
added and then, the allyl pinacol boronic ester (2 equiv), CsF (3 equiv), 
were added subsequently. Finally, the vial was taken out of the glove box 
and H2O (15 equiv) was added. The reaction mixture was stirred overnight 
at rt. The reaction was filtered through a short pad of celite and rinsed with 
DCM. The solvent was evaporated under reduced pressure and the crude 
product purified by flash column chromatography using hexane as eluent. 
The ratio of IV-3 and IV-5 was determined by 1H-RMN. Yields are 
corrected based on the amount of elimination product isolated with the 
desired product. 
 
(+)-(S,E)-(3-Methylhexa-1,5-dien-1-yl)benzene, IV-3a. 
From (S,E)-N,N,N-trimethyl-4-phenylbut-3-en-2-
aminium trifluoromethanesulfonate (67.8 mg, 0.2 
mmol), following the general procedure described 
above, compound IV-3a (28 mg, 0.16 mmol) was obtained in 82% yield as 
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a colorless oil after flash column chromatography in hexane along with 6% 
of elimination product. 
1H-RMN (300 MHz, CDCl3): δ 7.42-7.22 (m, 5H), 6.39 (d, J = 15.5 Hz, 
1H), 6.22 (dd, J = 16.1, 7.4 Hz, 1H), 5.86 (m, 1H), 5.08 (m, 2H), 2.46 (quint, 
J = 6.6 Hz, 1H), 2.22 (m, 2H), 1.16 (t, J = 6.8 Hz, 3H). 13C-RMN (300 
MHz, CDCl3): δ 137.9, 137.1, 136.2, 128.6, 128.3, 127.0, 126.1, 116.1, 
41.4, 37.0, 20.0. 
Compound IV-3a was obtained in 96:4 enantiomeric ratio determined 
by chiral GC-MS using CP-Chirasil Dex CB (60→110 °C @ 10 °C/min, 
hold 2 min, then →130 °C @ 1 °C/min, then →180 °C @ 10 °C/min; flow 
rate 1.0 mL/min.). major = 21.8 min, minor = 22.2 min. [α]20D = +38.7 (c = 
1.0, CHCl3). 
 
(+)-(S,E)-1-(3-Methylhexa-1,5-dien-1-yl)-4-(trifluoromethyl)benzene, 
IV-3d. 
From (S,E)-N,N,N-trimethyl-4-(4-
(trifluoromethyl)phenyl)but-3-en-2-aminium 
trifluoromethanesulfonate (81.4 mg, 0.2 mmol), 
following the general procedure described above, 
compound IV-3d (34 mg, 0.14 mmol) was obtained in 70% yield as a 
colorless oil after flash column chromatography in hexane along with 14% 
of elimination product. 
1H-RMN (300 MHz, CDCl3): δ 7.54 (d, J = 8.2 Hz, 2H), 7.43 (d, J = 8.2 
Hz, 2H), 6.39 (d, J = 16.0 Hz, 1H), 6.25 (dd, J = 15.9, 7.2 Hz, 1H), 5.80 
(m, 1H), 5.13 – 4.97 (m, 2H), 2.44 (hept, J = 6.9 Hz, 1H), 2.29 – 2.07 (m, 
2H), 1.12 (d, J = 6.7 Hz, 3H). 13C-RMN (300 MHz, CDCl3): 141.5, 139.0, 
136.8, 128.8 (q, JC-F = 32.5 Hz), 127.2, 126.3, 125.6 (q, JC-F = 3.8 Hz), 124.4 
Chapter 4 
484 
 
(q, JC-F = 272 Hz), 116.4, 41.3, 37.1, 19.9. HRMS-EI
+ m/z calculated for 
C14H15F3 [M]
+: 240.1126, found 240.1117. 
Compound IV-3d was obtained in 97:3 enantiomeric ratio determined 
by chiral GC-MS using CP-Chirasil Dex CB (60→110 °C @ 10 °C/min, 
hold 2 min, then →130 °C @ 1 °C/min, then →180 °C @ 10 °C/min; flow 
rate 1.0 mL/min.). major = 25.5 min, minor = 25.4 min. [α]20D = +11.5 (c = 
1.0, CHCl3). 
 
(+)-(S,E)-1-Methyl-2-(3-methylhexa-1,5-dien-1-yl)benzene, IV-3f. 
From ammonium salt (S,E)-N,N,N-trimethyl-4-(o-
tolyl)but-3-en-2-aminium trifluoromethanesulfonate 
(70.7 mg, 0.2 mmol), following the general procedure 
described above, compound IV-3f (31 mg, 0.16 mmol) 
was obtained in 82% yield as a colorless oil after flash column 
chromatography in hexane along with 4% of elimination product. 
1H-RMN (300 MHz, CDCl3): δ 7.39 (d, J = 6.3 Hz, 1H), 7.13 (m, 3H), 
6.52 (d, J = 15.5 Hz, 1H), 5.99 (dd, J = 15.6, 7.4 Hz, 1H), 5.82 (m, 1H), 
5.04 (m, 2H), 2.43 (quint, J = 6.7 Hz, 1H), 2.33 (s, 3H),  2.19 (m, 2H), 1.10 
(t, J = 6.8 Hz, 3H). 13C-RMN (300 MHz, CDCl3): δ 137.6, 137.1, 135.1, 
130.2, 126.9, 126.2, 126.1, 125.6, 116.0, 41.6, 37.3, 20.2, 19.9. HRMS-EI+ 
m/z calculated for C14H18 [M]
+: 186.1409, found 186.1412. 
Compound IV-3f was obtained in 96:4 enantiomeric ratio determined 
by chiral GC-MS using CP-Chirasil Dex CB., major = 25.5 min, minor = 25.1 
min. [α]20D = +28.4 (c = 1.0, CHCl3).  
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(+)-(S,E)-1-Methyl-3-(3-methylhexa-1,5-dien-1-yl)benzene, IV-3g. 
From ammonium salt (S,E)-N,N,N-trimethyl-4-(m-
tolyl)but-3-en-2-aminium trifluoromethanesulfonate 
(70.6 mg, 0.2 mmol), following the general procedure 
described above, compound IV-3g (31 mg, 0.17 mmol) 
was obtained in 84% yield as a colorless oil after flash column 
chromatography in hexane along with 9% of elimination product. 
1H-RMN (300 MHz, CDCl3): δ 7.15-7.05 (m, 3H), 6.94 (s broad, 1H), 
6.28 (d, J = 15.5 Hz, 1H), 6.04 (dd, J = 15.9, 7.4 Hz, 1H), 5.72 (m, 1H), 
4.95 (m, 2H), 2.31 (quint, J = 6.7 Hz, 1H), 2.25 (s, 3H), 2.06 (m, 2H), 1.02 
(t, J = 6.7 Hz, 3H). 13C-RMN (300 MHz, CDCl3): δ 138.1, 137.9, 137.1, 
136.0, 128.5, 128.4, 127.8, 126.8, 123.3, 116.0, 41.5, 37.0, 21.5, 20.1. 
HRMS-EI+ m/z calculated for C14H18 [M]
+: 186.1409, found 186.1407. 
Compound IV-3g was obtained in 97:3 enantiomeric ratio determined 
by chiral GC-MS using CP-Chirasil Dex CB(60→110 °C @ 10 °C/min, 
hold 2 min, then →130 °C @ 1 °C/min, then →180 °C @ 10 °C/min; flow 
rate 1.0 mL/min.). major = 25.5 min, minor = 25.3 min. [α]20D = +27.6. 
 
(+)-(S,E)-1-Chloro-3-(3-methylhexa-1,5-dien-1-yl)benzene, IV-3i. 
From (S,E)-4-(3-chlorophenyl)-N,N,N-trimethylbut-
3-en-2-aminium trifluoromethanesulfonate (74.7 mg, 
0.2 mmol), following the general procedure described 
above, compound IV-3i (38 mg, 0.18 mmol) was 
obtained in 92% yield as a colorless oil after flash column chromatography 
in hexane along with 7% of elimination product. 
1H-RMN (300 MHz, CDCl3): δ 7.25 (s broad, 1H), 7.14-7.06 (m, 3H), 
6.19 (d, J = 15.9 Hz, 1H), 6.06 (dd, J = 15.9, 7.2 Hz, 1H), 5.71 (m, 1H), 
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4.96 (m, 2H), 2.32 (quint, J = 6.6 Hz, 1H), 2.07 (m, 2H), 1.01 (t, J = 6.7 
Hz, 3H). 13C-RMN (300 MHz, CDCl3): δ 139.8, 137.7, 136.8, 134.5, 129.8, 
127.1, 126.9, 126.0, 124.3, 116.3, 41.3, 37.0, 19.9. HRMS-EI+ m/z 
calculated for C13H15Cl [M]
+: 206.0862, found 206.0867. 
Compound IV-3i was obtained in 99:1 enantiomeric ratio determined by 
chiral GC-MS using CP-Chirasil Dex CB (60→110 °C @ 10 °C/min, hold 
2 min, then →130 °C @ 1 °C/min, then →180 °C @ 10 °C/min; flow rate 
1.0 mL/min.). major = 33.1 min, minor = 33.3 min. [α]20D = +24.1 (c = 1.0, 
CHCl3).  
 
(+)-(S,E)-1-(3-Methylhexa-1,5-dien-1-yl)-3-(trifluoromethyl)benzene, 
IV-3j. 
 From (S,E)-4-(3-(Trifluoromethyl)phenyl)-N,N,N-
trimethylbut-3-en-2-aminium trifluoromethanesulfonate 
(81.4 mg, 0.2 mmol), following the general procedure 
described above, compound IV-3j (22 mg, 0.09 mmol) 
was obtained in 46% yield as a colorless oil after flash column 
chromatography in hexane. 
1H-RMN (300 MHz, CDCl3): δ 7.59 (s broad, 1H), 7.52-7.37 (m, 3H), 
6.37 (d, J = 16.1 Hz, 1H), 6.21 (dd, J = 16.2, 7.5 Hz, 1H), 5.80 (m, 1H), 
5.05 (m, 2H), 2.43 (quint, J = 6.7 Hz, 1H), 2.17 (m, 2H), 1.13 (t, J = 6.7 
Hz, 3H). 13C-RMN (300 MHz, CDCl3): δ 138.7, 138.2, 136.8, 131.2 (q, JC-
F = 31.6 Hz), 129.3, 129.0, 127.2, 126.1 (q, JC-F = 272.4 Hz), 123.5 (q, JC-F 
= 3.6 Hz), 122.8 (q, JC-F = 3.6 Hz), 116.3, 41.3, 37.0, 19.9. HRMS-EI
+ m/z 
calculated for C14H15F3 [M]
+: 240.1126, found 240.1119. 
Compound IV-3j was obtained in 96:4 enantiomeric ratio determined 
by chiral GC-MS using CP-Chirasil Dex CB (60→110 °C @ 10 °C/min, 
hold 2 min, then →130 °C @ 1 °C/min, then →180 °C @ 10 °C/min; flow 
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rate 1.0 mL/min.), major = 22.1 min, minor = 21.7 min. [α]20D = +21.7 (c = 
1.0, CHCl3). 
 
4.5.4. Synthesis of precatalyst IV-10. 
 
 
 
Inside the glovebox, [Pd(allyl)Cl]2 (25 mg, 0.068 mmol) and cataCXium 
ABn (53.6 mg, 0.068 mmol) were added to an oven dried 1-dram vial with 
a stir bar. Dichloromethane (2 mL) was added to the mixture and it was left 
stirring at room temperature for 18 h. After 18 h, the solid was filtered and 
re-crystallized from dichloromethane, obtaining product IV-10 (18 mg, 
0.031 mmol) in 46% yield as a yellowish crystalline solid. 
1H NMR (300 MHz, CDCl3) δ 7.72 (d, J = 7.4 Hz, 2H), 7.17 (dt, J = 
14.4, 7.2 Hz, 3H), 5.51 – 5.31 (m, 1H), 4.81 (td, J = 7.1, 2.4 Hz, 1H), 3.94 
(d, J = 6.6 Hz, 1H), 3.82 – 3.68 (m, 1H), 3.68 – 3.45 (m, 2H), 2.72 (d, J = 
11.9 Hz, 1H), 2.31 – 2.17 (m, 2H), 2.17 – 1.96 (m, 6H), 1.97 – 1.82 (m, 
10H), 1.72 – 1.52 (m, 12H). 13C NMR (76 MHz, CDCl3) δ 136.7, 136.6, 
131.0, 130.9, 127.9, 126.2, 126.2, 115.0, 114.9, 82.2, 81.9, 52.4, 52.4, 41.0, 
40.8, 40.6, 40.5, 40.2, 40.01, 39.98, 36.5, 28.7, 28.64, 28.61, 28.5, 24.6, 
24.4. 
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4.5.5. General procedure for the selective hydroboration of dienes 
IV-3. 
 
To an oven-dried 1 dram vial with a stir bar was added 9-BBN dimer (1 
equiv) and THF (5 mL/mmol) under N2. The solution was cooled to 0 ºC 
and a solution of diene IV-3 (1 equiv) in THF (5 mL/mmol) was added 
slowly. The solution was warmed to rt and left stirring for 16 h. After full 
conversion (checked by 1H-NMR), water (10 mL/mmol) was added, 
followed by NaBO3·4H2O and the mixture was stirred for 3 h. The reaction 
mixture was extracted with Et2O (3x) and the combined organic layers were 
washed with brine, dried over MgSO4 and the solvent evaporated. The 
crude reaction was purified by flash column chromatography using n-
hexane/AcOEt (9:1) as eluent. 
 
(+)-(S,E)-4-Methyl-6-phenylhex-5-en-1-ol, IV-11a. 
 From (S,E)-(3-methylhexa-1,5-dien-1-
yl)benzene (34.5 mg, 0.2 mmol), following the 
general procedure described above, compound IV-
11a (31 mg, 0.16 mmol) was obtained in 82% yield 
as a colorless oil after flash column chromatography. 
1H-RMN (300 MHz, CDCl3): δ 7.32 – 7.17 (m, 4H), 7.17 – 7.05 (m, 
1H), 6.28 (d, J = 15.9 Hz, 1H), 6.01 (dd, J = 15.9, 8.0 Hz, 1H), 3.57 (t, J = 
6.5 Hz, 2H), 2.24 (hept, J = 6.7 Hz, 1H), 1.53 (m, 2H), 1.38 (m, 2H), 1.03 
(d, J = 6.7 Hz, 3H). 13C-RMN (300 MHz, CDCl3): δ 137.8, 136.4, 128.5, 
128.5, 126.9, 126.0, 63.1, 37.2, 33.1, 30.7, 20.7. HRMS-GCEI+ m/z 
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calculated for C13H18O [M]
+: 190.1358, found 190.1356. [α]20D = +43.3 (c 
= 1.0, CHCl3). 
 
(+)-tert-Butyl-(S,E)-5-(6-hydroxy-3-methylhex-1-en-1-yl)-1H-indole-
1-carboxylate, IV-11b. 
 From (S,E)-tert-butyl-5-(3-methylhexa-1,5-
dien-1-yl)-1H-indole-1-carboxylate (62.3 mg, 
0.2 mmol), following the general procedure 
described above, compound IV-11b (49 mg, 
0.15 mmol) was obtained in 74% yield as a yellow oil after flash column 
chromatography. 
1H-RMN (300 MHz, CDCl3): δ 8.04 (d, J = 8.6 Hz, 1H), 7.55 (d, J = 3.8 
Hz, 1H), 7.50 (d, J = 1.7 Hz, 1H), 7.33 (dd, J = 8.6, 1.8 Hz, 1H), 6.52 (dd, 
J = 3.7, 0.8 Hz, 1H), 6.44 (d, J = 15.7 Hz, 1H), 6.08 (dd, J = 15.8, 8.0 Hz, 
1H), 3.66 (t, J = 6.5 Hz, 2H), 2.33 (hept, J = 6.9 Hz, 1H), 1.67 (s, 10H), 
1.62 (m, 2H), 1.48 (m, 2H), 1.12 (d, J = 6.7 Hz, 3H). 13C-RMN (300 MHz, 
CDCl3): δ 149.7, 135.2, 134.4, 132.6, 130.9, 128.7, 126.2, 122.5, 118.3, 
115.1, 107.4, 83.6, 63.2, 37.2, 33.2, 30.7, 28.2, 20.8. HRMS-ESI+ m/z 
calculated for C20H27NO3Na [M+Na]
+: 352.1883, found 352.1889. 
Compound IV-11b was obtained in 95:5 enantiomeric ratio determined 
by chiral HPLC using Chiralpak-IA column [Hexane/iPrOH (98:2)], 1.0 
mL/min, major = 19.3 min, minor = 18.0 min. [α]20D = +13.1 (c = 1.0, CHCl3). 
 
 
 
Chapter 4 
490 
 
4.5.6. Synthesis of Doremox®. 
 
 
To an oven-dried 1-dram vial with a stir bar was added MeONa (25.6 
mg, 0.48 mmol, 0.6 equiv) and B2pin2 (464 mg, 1.6 mmol, 2 equiv) and 
solved in THF (2 mL) under N2. The solution was cooled to 0 ºC and a 
solution of IV-3a (138 mg, 0.8 mmol, 1 equiv) in THF (2 mL) was added 
slowly. The solution was warmed to 60 ºC and left stirring for 16 h at that 
temperature. After full conversion (1H-NMR), water was added, and the 
reaction mixture was extracted with Et2O (3x) and the combined organic 
layers were washed with brine, dried over MgSO4 and the solvent 
evaporated. The crude product was used without further purification in the 
next step. 
To an oven-dried flask with a stir bar, diborylated product was added (1 
equiv) and solved in THF (3.2 mL). At this point, the mixture was cooled 
to 0 ºC and NaOH 1M (1.6 ml, 2 equiv) and H2O2 30% (0.32 mL). The 
solution was warmed to room temperature and left stirring for 2 h at that 
temperature. After full conversion (TLC), water was added, and the reaction 
mixture was extracted with Et2O (3x) and the combined organic layers were 
washed with brine, dried over MgSO4 and the solvent evaporated. The 
crude product was used without further purification in the next step. 
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To an oven-dried flask with a stir bar, the diol was added (1 equiv) and 
solved in DCM (1.2 mL). At this point the mixture was cooled to 0 ºC and 
NaIO4 (344 mg, 0.8 mmol, 2 equiv) and saturated NHCO3 solution (80 µL) 
were added. The solution was warmed to room temperature and left stirring 
for 16 h at that temperature. After full conversion (TLC), water was added, 
and the reaction mixture was extracted with DCM (3x) and the combined 
organic layers were washed with brine, dried over MgSO4 and the solvent 
evaporated. The crude product was used without further purification in the 
next step. 
To an oven-dried round bottom flask was added the aldehyde (1 equiv) 
in methanol (0.3M) and cooled to 0 ºC. To this solution, sodium 
borohydride (44 mg, 1.16 mmol, 1.45 equiv) was added portionwise and 
the reaction mixture was stirred for 1 h at 0 ºC. Then, the mixture was 
warmed until room temperature and stirred until full conversion. The 
reaction mixture was quenched with ammonium chloride saturated aqueous 
solution and extracted with diethyl ether for three times, dried over MgSO4 
and the solvent was removed under reduced pressure. The crude product 
was purified by flash column chromatography on silica gel using n-
hexane/AcOEt (9:1) as eluent. Alcohol IV-13 (90 mg, 0.52 mmol) was 
obtained in 50% yield after 4 steps as a colorless oil. 
1H NMR, 13C NMR and MS data were consistent with literature 
values.43 1H-RMN (300 MHz, CDCl3): δ 7.32-7.15 (m, 5H), 6.32 (d, J = 
15.9 Hz, 1H), 6.02 (dd, J = 15.8, 7.2 Hz, 1H), 3.63 (t, J = 6.5 Hz, 2H), 2.42 
(hept, J = 7.2 Hz, 1H), 1.66-1.45 (m, 2H), 1.05 (d, J = 7.2 Hz, 3H). 
 
 
43 Coulombel, L.; Weïwer, M.; Duñach, E. Eur. J.  Org. Chem., 2009, 33, 5788. 
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Over a solution of IV-13 (52.9 mg, 0.3 mmol) in DCE (3 mL), Al(OTf)3 
(7.1 mg, 0.015 mmol, 0.05 equiv) was added and the reaction was stirred at 
85 ºC for 3 h. After full conversion (GC-MS), the reaction was cooled to 0 
ºC and HCl 1N was added. The reaction mixture was extracted with diethyl 
ether for three times, dried over MgSO4 and the solvent was removed under 
reduced pressure. The crude product was purified by flash column 
chromatography on silica gel using n-pentane/Et2O (9:1) as eluent. 
Doremox® (44 mg, 0.25 mmol) was obtained in 84% yield and d.r. = 94:6 
as a colorless oil. 
1H-RMN (300 MHz, CDCl3): δ 7.30-7.14 (m, 5H), 4.24 (dd, J = 11.3 
Hz, 2.1 Hz, 1H), 4.14-4.03 (ddd, J = 11.3, 4.8, 1.5 Hz, 1H), 3.60-3.46 (ddd, 
J = 12.3, 12.2, 2.3 Hz, 1H), 1.83-1.54 (m, 3H), 1.37-1.06 (m, 2H), 0.93 (d, 
J = 6.8 Hz, 3H). 13C-RMN (75 MHz, CDCl3): δ 143.2, 128.3, 127.3, 126.1, 
125.8, 79.8, 68.5, 42.7, 34.4, 30.81, 22.3. HRMS-EI+ m/z calculated for 
C12H16O [M]
+: 176.1193, found 176.1201. [α]20D= +44.8 (c = 1.0, CHCl3). 
The absolute configuration was stablished by comparison with the 
previously reported compound.25 
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4.5.7. Synthesis of (+)-(S)-3-methyl-1-phenylhex-5-en-2-one, IV-
14. 
 
 
To an oven-dried round flask was added a solution of IV-3a (35 mg, 0.2 
mmol) in DCM (3 mL). The mixture was cooled to 0 ºC and a solution of 
m-CPBA (44.6 mg, 0.2 mmol) in DCM (3 mL) was added slowly. Then, 
potassium carbonate (27.8 mg, 0.2 mg) was added and the mixture was 
slowly warmed to rt. The reaction was stirred for 16 h and then a solution 
of Na2SO3 was added to the mixture. The phases were separated, and the 
aqueous phase was extracted with Et2O (3x). The combined organic phases 
were washed with NaHCO3 (2x), brine, dried over MgSO4 and the solvent 
evaporated. The crude mixture was filtered through a short pad of silica (n-
hexane/EtOAc 99:1) and the desired epoxide was obtained as a 1:1 mixture 
of diastereoisomers, which was used in the next step of synthesis without 
further purification. 
Over a solution of the epoxide (55 mg, 0.3 mmol) in DCM (2 mL) at -
40 ºC, was added DIBAL-H (0.9 mL, 0.9 mmol). The reaction was stirred 
at rt until full conversion (TLC). Then, water was added slowly, and the 
phases were separated. The aqueous phase was extracted with Et2O (3x) 
and the combined organic phases were washed with NaHCO3 (2x), brine, 
dried over MgSO4 and the solvent evaporated. The crude mixture was 
filtered through a short pad of silica (n-hexane/EtOAc 95:5) and the desired 
alcohol was obtained as a 1:1 mixture of diastereoisomers, which was used 
in the next step of synthesis without further purification. 
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To an oven-dried round flask was added a solution of the alcohol (39 
mg, 0.2 mmol) in DCM (2 mL). The mixture was cooled to 0 ºC and DMP 
(110 mg, 0.3 mmol) was added slowly. The mixture was slowly warmed to 
rt and left stirred for 16 h. Then a solution of Na2S2O3 was added to the 
mixture. The phases were separated, and the aqueous phase was extracted 
with Et2O (3x). The combined organic phases were washed with NaHCO3 
(2x), brine, dried over MgSO4 and the solvent evaporated. The crude 
reaction was purified by flash column chromatography using n-
hexane/AcOEt (95:5) as eluent. Compound IV-14 (37 mg, 0.19 mmol) was 
obtained in 82% yield (3 steps) as a colorless oil. 
1H-RMN (300 MHz, CDCl3): δ 7.30-7.07 (m, 5H), 5.75-5.42 (m, 1H), 
4.99-4.88 (m, 2H), 3.66 (s, 2H) 2.65 (hept, J = 6.9 Hz, 1H), 2.32 (m, 1H), 
2.03 (m, 1H), 1.01 (d, J = 6.9 Hz, 3H). 13C-RMN (300 MHz, CDCl3): δ 
210.9, 135.5, 134.1, 129.5, 128.6, 126.9, 116.8, 77.4, 77.2, 76.6, 48.6, 45.1, 
37.1, 16.2. HRMS-EI+ m/z calculated for C13H16O [M]
+: 188.1204, found 
188.1201. [α]20D= +19.4 (c = 1.0, CHCl3). 
 
4.5.8. Assignment of the Absolute Configuration. 
The absolute configuration was stablished for compounds, IV-3a and 
Doremox® by comparison of the sign of the optical rotation with that of 
previously reported compounds. Our results indicate that the palladium 
catalyzed cross-coupling reaction proceeds with inversion of the 
configuration. We assumed the same stereochemical outcome for all the 
enantiomerically enriched compounds prepared.  
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4.5.8.1. (S,E)-(3-methylhexa-1,5-dien-1-yl)benzene, IV-3a.21 
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4.5.8.2. (2R,4S)-4-methyl-2-phenyltetrahydro-2H-pyran, Doremox®.25 
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4.6. NMR spectra. 
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4.7. HPLC Chromatograms. 
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4.8. SFC Chromatograms. 
4.8.1. 1,5-dienes IV-3 from IV-1. 
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4.8.2. 1,5-dienes IV-3 from IV-2. 
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